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Tecnologia no âmbito do projeto 
«PTDC/SAU-NMC/111980/2009»; por 
Fundos da FCT e do programa 
POPH/FSE no âmbito bolsa individual 
«SFRH/BD/ 78507/2011»; e pelo 
Instituto de Biomedicina – iBiMED 
«UID/BIM/04501/2013». 
 
 
  
  
  
 
 
 
Dedico este trabalho às minhas sobrinhas Francisca e Clara. 
 
 
  
  
 
 
 
 
 
 
o júri   
 
presidente Professor Doutor Luís António Ferreira Martins Dias Carlos 
professor catedrático do Departamento de Física da Universidade de Aveiro 
  
 
 Doutor Uwe Konietzko 
investigador sénior do Instituto de Medicina Regenerativa (IREM), Universidade de Zurique, Suíça 
  
 
 Doutora Cláudia Guimas de Almeida Gomes 
investigadora auxiliar do Centro de Estudos de Doenças Crónicas (CEDOC), Faculdade de 
Ciências Médicas da Universidade Nova de Lisboa 
  
 
 Professora Doutora Ana Gabriela da Silva Cavaleiro Henriques 
professora auxiliar convidada do Departamento de Ciências Médicas da Universidade de Aveiro 
  
 
 Professora Doutora Sandra Isabel Moreira Pinto Vieira 
professora auxiliar convidada do Departamento de Ciências Médicas da Universidade de Aveiro 
  
   
  
 
  
  
 
  
 
 
 
 
  
  
  
 
agradecimentos 
 
Aos meus pais, por todos os sacríficos que fizeram para que pudesse usufruir 
de educação superior.  
À Professora Sandra Vieira e à Professora Odete da Cruz e Silva pela 
oportunidade de trabalhar neste projeto e pela orientação científica. 
À Joana Vieira, amiga e colega de casa de tantos anos, e ao Miguel por 
evitarem que eu enlouquecesse a formatar este documento. Fico eternamente 
grata. 
Aos meus colegas de trabalho desde o CBC ao iBiMED, a grande recompensa 
deste doutoramento. Um especial agradecimento aos meus colegas de 
doutoramento Filipa Martins, Joana Oliveira, e Roberto Dias. Ao Igor pelo 
suporte aos dramas informáticos. Aos alunos de mestrado que acompanhei 
mais de perto Regina, Lili, Páti, Ana, Luísa, Catarina, Soraia, Joana, Marlene, 
e Patrícia. Às colegas e vizinhas que nunca recusaram ajuda, Juliana e Maria. 
Aos colegas mais velhos pela partilha de conhecimentos, especialmente à 
Mariana. À minha (ex)“work wife” Sara. 
To Uwe Konietzko and his team members Sarina, Sabine, and Sonja for their 
warm welcome and generosity. 
Aos colegas de faculdade que me acompanharam mais de perto neste 
percurso Carina, Sofia, Ritinha, e Guida. 
Às minhas amigas Sofia, Beatriz, Joana, Andreia, Ana. Num mundo dominado 
por aparências e materialismo, obrigada por me proporcionarem o prazer de 
uma longa e verdadeira amizade! 
Ao Luís, o meu melhor amigo, por acreditar em mim mesmo quando eu própria 
duvidei.  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
  
palavras-chave 
 
proteína precursora de amilóide de Alzheimer, fosforilação (S655), células SH-
SY5Y, diferenciação neuronal, via do factor de crescimento epidermal, 
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resumo 
 
 
A Proteína Precursora de Amilóide (APP) é uma proteína membranar mais 
conhecida por ser precursora do péptido Amilóide β, tendo por isso um papel 
central na doença de Alzheimer. Não obstante, a APP tem sido reconhecida 
como neuromodulador do sistema nervoso central. Alterações nos níveis ou na 
atividade da APP e seus fragmentos estão implicadas em diferentes doenças 
neurológicas. As relações entre o seu transporte intracelular, modificações 
pós-traducionais, corte proteolítico, e proteínas com as quais interage são 
complexas e multifacetadas. Talvez por isso, estudos focados no papel 
fisiológico da APP apresentem resultados contraditórios e muitas questões em 
aberto. O objetivo deste trabalho consistiu na caracterização do papel 
fisiológico da APP na diferenciação neuronal. Particularmente, focámo-nos nos 
mecanismos mediados pela APP e fragmento sAPP, e a fosforilação da APP 
no resíduo serina 655.  
Inicialmente, caracterizámos a proteína APP ao longo da diferenciação de 
células SH-SY5Y com ácido retinóico (RA). A análise sistemática deste modelo 
permitiu delimitar uma resposta bifásica: na primeira fase (D0-D4), um pico de 
sAPP/APP acompanha o aparecimento de novos processos e o crescimento a 
neurites; na segunda fase (D4-D8) o aumento nos níveis da APP suporta o 
crescimento e manutenção das neurites.  
Caracterizámos posteriormente a relação entre a APP e a via de sinalização 
EGF-EGFR-ERK na diferenciação neuronal. Demonstrámos, pela primeira vez, 
que a APP interage com o proEGF, e confirmámos a sua ligação ao EGFR. 
Adicionalmente, observámos que a APP e o EGF têm um efeito sinérgico na 
diferenciação tipo-neuronal e aumento da ativação da ERK1/2, e que a APP 
afeta os níveis e transporte do EGFR. Estes mecanismos são modulados pela 
fosforilação da APP na S655, que favorece a dendritogénese em neurónios 
corticais de ratinho.  
Por último, focámo-nos na identificação de proteínas interatoras da APP 
dependentes da fosforilação em S655 e com função na diferenciação neuronal. 
Usando células SH-SY5Y diferenciadas e a sobrexpressar a APPWt ou 
fosfomutantes da S655, imunoprecipitámos as diferentes APPs e seus 
interatores, posteriormente identificados por espectrometria de massa. O 
interatoma da APP desfosforilada é enriquecido em funções associadas à 
organização do citoesqueleto, levando a uma maior reorganização da actina. O 
interatoma da APP fosforilada incluí proteínas envolvidas na regulação de 
sobrevivência e diferenciação, e em várias vias de sinalização, o que se 
correlaciona com o favorecimento de neurites nestas células.  
Com este trabalho esperamos ter contribuído para uma melhor compreensão 
do papel neurotrófico da APP e dos mecanismos subjacentes a este. 
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abstract 
 
The Amyloid Precursor Protein (APP) is a type 1 membrane glycoprotein, 
mainly known as the precursor of the amyloid β-peptide, a central player in 
Alzheimer’s disease. Nevertheless, APP has been established as a 
neuromodulator of developing and mature nervous system. Alterations in the 
level or activity of APP and APP fragments seem to play a critical role in 
several neurodegenerative and neurodevelopment disorders. APP is a complex 
molecule due to the intricate relationships between its intracellular trafficking, 
posttranslational modifications, proteolytic cleavages, and multiple protein 
interactors. Various studies currently address the physiological roles of APP 
and its fragments, but there are contradictory results and missing pieces that 
need further work. The main objective of this thesis was to contribute to the 
characterization of the role of APP in neuronal differentiation. Particularly, we 
focused on mechanisms mediated by APP, its fragment sAPP, and APP 
phosphorylation at serine 655.  
First, we characterized the APP protein in Retinoic Acid (RA)-induced SH-
SY5Y cell differentiation. The comprehensive analysis of this model exposed a 
biphasic temporal response: a first early phase (D0-D4), where a sAPP/APP 
peak assists the emergence of new processes and their elongation into 
neurites; and a second phase (D4-D8) when increased holoAPP protein levels 
are necessary to sustain neuritic elongation and stabilization.  
In line with our main aim, we subsequently characterized the relationship 
between APP and the neurotrophic EGF-EGFR-ERK signaling pathway. We 
showed, for the first time, that APP interacts with proEGF, and confirmed the 
interaction with EGFR. Furthermore, we showed that combined APP and EGF 
have a synergistic effect on neuronal-like differentiation, related to enhanced 
ERK1/2 activation, and observed that APP modulates EGFR expression levels 
and trafficking. Both ERK1/2 activation and EGFR seem to be modulated by 
the APP S655 phosphorylation state, and phosphorylation at this residue 
favours dendritogenesis in mice cortical neurons.  
Finally, we focused on discovering APP protein interactors dependent on S655 
phosphorylation and with a role in neuronal differentiation. SH-SY5Y 
differentiated cells, overexpressing APPWt or S655 phosphomutants, were 
used to immunoprecipitate the specific APP proteins and their respective 
interacting partners, later identified by mass spectrometry. The 
dephosphoS655 APP interactome was enriched in functions associated with 
cytoskeleton organization, and these cells were particularly associated with 
actin remodeling. The phosphoS655 APP interactome included proteins 
involved in the regulation of survival and differentiation, and in various signaling 
pathways, correlating well with an enhanced neurite outgrowth displayed by 
these cells. 
We hope that the knowledge here gathered can contribute to a better 
comprehension of APP-driven neurotrophic roles and underlying mechanisms. 
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1.!Nervous system development 
We all start as a single cell – the fertilized egg. After some rounds of cell division and 
rearrangements, the embryoblast (future embryo) forms two monolayers of cells: the top layer 
(dorsal position) on the side of the amniotic cavity is the ectoderm, and the bottom layer (ventral 
position) is the endoderm [1]. In the vertebrates, the nervous system is derived from the embryonic 
ectoderm (that also generates the skin). Around the embryonic day 14, specialized regions on the 
midline ectoderm (caudal end of the embryo) – the primitive streak and primitive node – originate 
a third layer of cells between the ectoderm and endoderm – the mesoderm. These new cells, 
migrate rostrally along the midline to form the notochordal process, later the notochord. The 
notochordal cells have the ability to secrete factors (like the sonic hedgehog protein, Shh) that 
diffuse dorsally to induce changes in the ectoderm. Namely, the ectoderm starts to differentiate into 
a central, thicker, spoon-shape neural ectoderm – the neural plate, and separates from a peripheral 
ectoderm that will form the skin [1]. 
During neurulation, the neural plate invaginates into the mesodermal layer to originate the neural 
tube [1]. Closure of the neural tube separates the ventricular system from the amniotic fluid [2]. 
After the completely closure of the neural tube (embryonic day 30 in humans), three vesicles can 
be distinguished: the primary forebrain vesicle (prosencephalon), the primary midbrain vesicle 
(mesencephalon), and the primary hindbrain vesicle (rhombencephalon). In the caudal half lies the 
presumptive spinal cord. Later, neural tube regions are further divided to form a five vesicles-stage 
neural tube. The primary hindbrain forms, rostrally, the secondary hindbrain (epenchephalon) and, 
caudally, the after brain (metencephalon). The primary forebrain gives rise to the endbrain 
(telencephalon) and the interbrain (diencephalon) [1]. 
Between the neural plate/neural tube and the somatic ectoderm there is a transition zone – the 
neural crest – that will form most of the ganglia of the peripheral nervous system. The neural crest 
migrates ventrally into the developing body to form sensory and motor neurons. Other sensory 
neurons are derived from “isolated” placodes (specially differentiated somatic ectoderm) [1]. 
At the point of the five vesicles-stage neural tube plus the spinal cord segment, the neuroepithelium 
is still a monolayer of stem cells. However, the neuroepithelium displays a layered appearance 
because the nuclei of neuroepithelial cells migrate up and down the apical–basal axis during the 
cell cycle (a phenomenon named interkinetic nuclear movement). Furthermore, neuroepithelial 
cells (NEC) are highly polarized along their apical-basal axis, presenting tight junctions and 
adherens junctions at the most apical end of the plasma membrane (PM) [3]. NEC undergo 
symmetric proliferative divisions increasing the pool of stem cells, and these proliferative cells 
form the ventricular zone (VZ) [3, 4].  
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1.1.!Neurogenesis and development of the cerebral cortex 
Neurogenesis begins soon after neural tube closure, and occurs throughout the entire neural tube 
following specific and spatial patterns and rates along the caudal-rostral, ventral-dorsal, and lateral-
medial body axes, originating a series of longitudinal grooves in the inner surface of the wall of the 
neural tube [1, 5]. Neurogenesis specific events will be here described based on the example of the 
mammalian cerebral cortex development, in other words corticogenesis, and specifically cortical 
projection neurons development. 
The mature cerebral neocortex is comprised of six layers along the radial axis, with areal and 
columnar subdivisions along the tangential axis [6]. Cortical neurons can be divided in two major 
types: excitatory projection neurons (pyramidal neurons) and inhibitory interneurons. All cortical 
pyramidal neurons are derived from neural progenitors in the dorsal telencephalon VZ and 
subventricular zone (SVZ, described below) [7]. Some evidences show that the VZ generates the 
projection neurons of the deeper layers of the neocortex whereas the SVZ produces those of the 
more superficial layers [4, 7]. Inhibitory interneurons derive from radial glial cells (RGC) in the 
medial and caudal ganglionic eminences of the ventral telencephalon and from dorsal 
telencephalon SVZ. These neurons migrate first tangentially to reach the dorsal telencephalon and 
then radially within the different cortical layers (not detailed here) [2, 7].  
At the point of neurogenesis, many asymmetric, self-renewing division occur that originate a 
daughter stem cell and a more differentiated cell [3, 4]. The second cell can be a non-stem-cell 
progenitor (commonly named intermediate progenitor) or a neuron. In parallel, NEC lose some 
epithelial features (like tight junctions) and transform into RGC [3]. This seems to be induced by a 
set of genes that includes forkhead box G1 (FOXG1), LIM homeobox 2 (LHX2), paired box 6 
(PAX6) and empty spiracles homologue 2 (EMX2) [4]. RGC possess both properties of 
neuroepithelial and astroglial cells. Like NEC, these cells express nestin, present an apical surface, 
important features of apical-basal polarity (like apical centrosomes and the transmembrane protein 
prominin-1), adherens junction, and establish contact with the basal lamina. They also show 
interkinetic nuclear migration, although with some small differences comparing to NEC. The 
characteristics that completely distinguishing RGC from NEC are the astroglial properties like the 
presence of glycogen granules, and astrocyte molecules (GLAST, S100Beta, GFAP, vimentin and 
BLBP) [3]. Furthermore, there is differentially expression of some genes from region to region [4]. 
The transitions from NEC to RGC correlates with the onset of neurogenesis in almost all regions of 
the developing CNS (around E10 and E12 in mice, ~E33 in Humans) [3, 4]. 
Symmetric proliferative divisions of NEC, and of apical RGC, cause the lateral (tangential) 
expansion of the VZ. At the same time, both type of cells can increase their basolateral-to-apical 
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plasma membrane ratio and thus become more elongated inducing growth in the radial dimension 
[5]. The existence of a distinct population of apical intermediate progenitors was described - short 
neural precursors - that generally divide just once to produce postmitotic neurons [4]. So, within 
the VZ at least three different classes of neural precursors seem to cohabit: NECs, (apical) RGCs, 
and the short neural precursors (see Figure  A.1, top image). Additionally, bipolar RGC and 
unipolar progenitor cells can be found in the basal VZ (subapical progenitors) [4, 5].  
With time, dividing cells generated from the asymmetrical division of RGC, namely the resulting 
non-RGC daughter, migrate away from the ventricle, round up, and start to accumulate at the basal 
border of the VZ in a new compartment – SVZ. These intermediate or “basal” progenitors are also 
neurogenic, but contrarily to NEC and RGC, are not attached to the ventricular surface and do not 
display interkinetic nuclear movement [4]. Intermediate precursors express the transcription factors 
TBR2, neurogenin 2 (NGN2), cut-like homeobox 1 (CUX1) and CUX2, and the non-coding RNA 
SVET1 [3, 4]. Basal progenitors contribute to neurogenesis by undergoing symmetric, neurogenic 
cell divisions that generate two neuronal daughter cells. Additional neural progenitors can be found 
within the SVZ, namely basal RGC (originated from the subapical bipolar RGC) and transit 
amplifying progenitors (see Figure 1, bottom image) [5]. 
 
 
Figure  A.1 - Ventricular and Subventricular zone resident neural progenitor cells. In the ventricular zone, during 
neurogenesis, neuroepithelial cells lose some epithelial features and transform into (apical) radial glial cells. When these 
cells perform asymmetric, self-renewing divisions they can originate a daughter stem cell and a more differentiated cell 
(upper image). The latter can be an intermediate progenitor or a neuron. In the basal ventricular zone bipolar radial glial 
cells and unipolar progenitors can also be found, collectively named subapical progenitors. With time, neural progenitors 
originated from basal radial glial divisions migrate away from the ventricle and accumulate in a new compartment – the 
subventricular zone (lower image). PP, preplate. Adapted from reference [4].!
 
Asymmetric self-renewing divisions of NEC and apical RGC are the primary basis of neocortex 
expansion in the radial dimension. Animals with higher encephalization have more expanded SVZ, 
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with higher numbers and diversity of intermediate progenitors, which in turn correlates with 
increased number of neurons and thicker cortical layers [5, 8]. The mode of stem and progenitor 
cell division, cell fate choice, and programmed cell death plays a crucial role in establishing the 
correct number and organization (radial and tangential) of the cortex. Dysregulation of these 
processes might result in different development disorders, like microcephaly [9]. Several 
molecules, including transcription factors (TFs) regulate and coordinate cell fate and the 
appropriate mode of cell division. For instance, the anti-proliferative gene Tis21 is selectively 
expressed in essentially all NEC that are about to undergo a neurogenic division, but not in the 
proliferating ones. Also the TF factor PAX6 promotes asymmetric, neurogenic cell divisions, while 
the TF EMX2 appears to promote symmetric proliferative divisions [3, 10]. 
One aspect that seems fundamental in the determination of the proportion of symmetric, 
proliferative versus asymmetric, neurogenic divisions in NEC and RGC is the orientation of the 
mitotic spindle (and consequently the cleavage-plane orientation) that will establish, in turn, the 
symmetric versus asymmetric inheritance of specific subcellular components and molecules.  
Namely, it appears that the presence or absence of the apical PM (primarily defined by the position 
of the mitotic spindle), determines which daughter cell will be able to divide again and which will 
become a neuron, respectively. In order to follow a symmetric division there is to be fusion of the 
basal membrane with the apical membrane, which normally occurs via heterophilic fusion of the 
basal v-SNARE and the apical t-SNARE. This process allows that both cells keep portions of the 
apical PM. By the other hand, asymmetric/neurogenic division depends on hemophilic fusions 
between basal v-SNARE and lateral (tight-junction) t-SNARE. Such events suggest that there must 
be a signal(s) for proliferation that is transmitted through the apical membrane [3]. The apical 
membrane faces the ventricle which is filled with the cerebrospinal fluid (CSF). The CSF 
composition is dynamically regulated during development, and is rich in growth factors like the 
fibroblast growth factor (FGF), insulin-like growth factor (IGF), Shh, bone morphogenetic proteins 
(BMPs), and Wnts. Several receptors for these molecules were found in the apical PM, for example 
the glycoprotein megalin whose ligands include both BMPs and Shh; and the protein prominin-1 
[5]. 
Furthermore, junctional components (cadherins and catenins, concentrated beneath the apical PM) 
have been reported to be asymmetrically partitioned during mitosis. For instance, β-catenin is an 
important downstream target of the Wnt pathway. Upon Wnt pathway activation there is 
accumulation of β-catenin (because its degradation complex GSK-3/APC/CK1 is inhibited) and its 
subsequent translocation to the nucleus, where it regulates proliferation and differentiation genes. 
During early developmental stages of the neocortex, active β-catenin might be necessary for cell 
cycle re-entry and increased progenitor proliferation. Nevertheless, activation of the Wnt signaling 
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has been implicated in NEC/apical RGC expansion, as well as in differentiation of basal 
progenitors [11]. The small GTPases RhoA, and Rac1 are associated with the tight-junctions, and 
link apical-basal polarity to cytoskeleton remodelling. These proteins were shown to affect 
progenitor proliferation (with region-specific differences) and cell fate [12]. In general, RhoA 
deletion leads to hyperproliferation of the progenitor pool, while Rac1 loss is associated with a 
decrease in proliferation and premature differentiation [13]. The atypical GTPase Rnd3 specifically 
controls the proliferation of basal progenitors, and is necessary for the maintenance of cleavage 
plain vertical orientation during RGC divisions [12, 13]. 
The differential inheritance of the primary cilium (including the centrosome and the ciliary 
membrane) also seems to correlate with cell fate and to have a specific role in neurogenesis, a fact 
stressed by the CNS defects observed in ciliopathies [5]. Inheritance of the basal process of NEC 
and RGC that extend towards the basal lamina is also considered important in determining 
daughter-cell fate. The cell that maintains the basal process normally maintains the proliferative 
abilities [3]. In early stages of development, the basal process is split between both daughter cells, 
but in mid- and late neurogenesis, the basal process is no longer split, resulting in its asymmetric 
inheritance. The basal endfoot may lead to alterations in the proliferative capacities of cortical 
stem/progenitor cells and gyrification via interaction with extracellular matrix components. In line 
with this, integrin manipulations affect neural stem and progenitor cell behaviour [14], and the 
basal process is the cell component that senses the Reelin gradients secreted by the Cajal-Retzius 
cells (discussed below) [5]. Other important neural progenitor cell-fate determining protein is 
Numb. Accordingly, Numb is segregated asymmetrically into the daughter cells, in a way that 
during mitosis the daughter cells with Numb will remain progenitors while the daughter cells 
without Numb assume a neuronal fate. Nevertheless, Numb is also required for neuronal survival 
and differentiation and its expression quickly rises in the neuronal daughter cells [5, 15]. 
Cell-cycle length also seems to have a role in the transition of NEC and RGC from proliferative to 
neurogenic divisions. In fact, neurogenic progenitors show a significantly longer cell cycle (mainly 
longer G1 phase) than the proliferating cells. The main hypothesis is that longer cell cycles give 
time for the cell to respond to cell cycle determinant molecules (ex: differentiation factor). In this 
view, if the cell cycle is long enough that the cell fate determinant is able to induce differentiation 
in both daughter cells, they will adopt a symmetric fate [3]. 
Of note, the existence of dividing neurogenic cells outside the classical proliferative VZ and SVZ 
was described in the rodent and human cortex [4]. 
The newly generated neurons will then migrate from the SVZ and VZ, and their postmitotic 
differentiation leads to the formation of new structures (some transient), until reaching their “final” 
destination – the cortical plate (CP) [2]. Shortly before the formation of the cortical plate, different 
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types of neurons (some of which migrating from extra-cortical sites) settle in a layer under the pial 
surface, forming the preplate (Figure  A.2, second image from the left). The preplate is a dynamic 
and largely-transient structure that will further divide into two compartments. The compartment in 
the superficial sub-pial position is formed by the reelin-secreting Cajal-Retzius cells (CR). Reelin 
stops neuronal migration and will establish the upper boundary of the CP. The second compartment 
that extends to the SVZ has different types of cells, and will later originate the subplate (SP) [4]. 
The main role of SP cells is to guide thalamic axons to the CP [6]. In the boundary of the SP and 
above the SVZ another compartment seems to develop, the intermediate zone (IZ, very difficult to 
distinguish from the SP itself in early stages in humans) (Figure  A.2, third and last image from the 
left). At later stages, after the invasion of large numbers of cortical fibres and the beginning of 
myelination this layer transforms into the white matter [4]. 
Additionally, after emergence of the CP, part of the preplate transforms in a cell-sparse layer 
formed by the subpial processes of ventricular cells and tangential migratory neurons – the 
marginal zone (MZ) (Figure  A.2, third and last image from the left). Later this compartment 
becomes the layer 1 which contains few neurons and is largely filled with arborizations of apical 
dendrites and intrinsic tangential axons [4]. 
 
 
Figure  A.2 - Cortical layers during neurogenesis. The preplate (PP) forms shortly before the formation of the cortical 
plate (CP), which will later divide into two compartments. One, in a sub-pial position, is formed by the reelin-secreting 
Cajal-Retzius cells, and the other extending to the subventricular zone (SVZ) that later originates the subplate (SP). In the 
boundary of the SP and above the SVZ another compartment seems to develop, the intermediate zone (IZ). After 
emergence of the CP, part of the PP, formed by the subpial processes of ventricular cells and tangential migratory 
neurons, transforms in the marginal zone (MZ). The subpial granular layer (SG), is a transient layer, part of the MZ, 
occupied by tangentially migrating small granular neurons (potential source of cortical interneurons and Cajal-Retzius 
cells). E, indicates embryonic day; GW, indicates gestational week. Adapted from [4].!
 !
Right after the formation of the preplate, RGCs begin to produce layer projection neurons [6]. The 
migration of newly born projection neurons to their final laminar position in the emerging CP 
occurs in a precise inside-first, outside-last gradient [2]. First neural progenitors shift their 
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“assembly line” from CR cell production to deep layer projection neurons production, and then a 
transition from deep layer projection neurons production to upper layer projection neurons 
production. In humans, CP appears first in the most lateral part of the rostral telencephalic wall, at 
E50. Peak migratory activity is thought to occur between the third and fifth months of gestation, 
and migration is completed during the third trimester [4]. Each layer of neurons arises from the VZ 
and SVZ progenitors and moves radially toward the pial surface via multi-step guided migration 
processes (Figure  A.3). On the way, newborn neurons have to move along the SVZ, IZ, and the 
developing CP. The exact mechanism of migration adopted by a neuron and the molecules that 
induce or regulate such mechanism appear to depend on the subtype of neuron and migration 
distance. In the VZ, the proliferative cells resulting from asymmetric divisions of RGC adopt a 
long ascending process and rapidly migrate to the SVZ/IZ layers by somal translocation. On the 
other end, the RGC progeny resultant of a final division, migrate slowly and tend to accumulate in 
the lower part of the SVZ presenting a characteristic multipolar morphology (this zone is 
commonly named multipolar cell accumulation zone, MAZ). These cells extend and retract 
multiple processes while advancing slowly toward the cortical plate – multipolar migration (Figure  
A.3, step 2). Although the first type of cells mentioned enter the SVZ/IZ earlier, they still have to 
divide, and thus multipolar cells transform into locomotion cells and enter the CP earlier [16]. Very 
interestingly, after the acquisition of multipolar morphology it has been described a step of 
retrograde migration toward the ventricle. After contacting the ventricle this cells, similar to 
newborn neurons generated in the SVZ, assume bipolar morphology and travel by RGC-guided 
locomotion toward the cortical plate [17]. 
  !!
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Figure  A.3 - Differentiation of layer projection neurons. Each layer of neurons arises from ventricular zone (VZ) and 
subventricular zone (SVZ) progenitors that move radially toward the pial surface. In the VZ, the proliferative cells 
resulting from asymmetric divisions of apical radial glial cells (aRG), adopt a long ascending process and rapidly migrate 
to the SVZ/IZ layers by somal translocation. Non-dividing neural progenitors migrate slowly and tend to accumulate in 
the lower part of the SVZ - multipolar cell accumulation zone (MAZ) - presenting a characteristic multipolar 
morphology. Multipolar cells transform into bipolar locomotion cells and travel by RGC-guided locomotion toward the 
cortical plate. Neuronal polarization starts during this process, with the extension of the trailing process (ventricle 
oriented), and one selected neurite turning in a thick leading process (pia oriented). After reaching the CP, newborn 
neurons stop migrate, detach from the RG fibers, and anchor to the MZ for terminal translocation. Dendrites start to 
differentiate from the leading process branching out to generate an apical tuft. CR, Cajal-Retzius cell; EN, early born 
neuron; INM, interkinetic nuclear migration; PCZ, primitive cortical zone; SP, sub-plate neuron. Reproduced from 
reference [18].!
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The multipolar to bipolar (MP to BP) cell transition is crucial for radial migration, and appears to 
happen after delamination of cells from the apical surface of the VZ via suppression of E-cadherin 
[18]. Neuronal polarization starts during this process, with the extension of the trailing process 
(ventricle oriented), and one selected neurite turning into a thick leading process (pia oriented) [17, 
18]. Thus, neuronal polarization/axon guidance events are coupled to neuronal migration, and both 
processes are commonly induced and regulated via the same cues and signals [19]. Axon extension 
is first detected in the lower IZ, and depends, at least in part, on homophilic interactions between 
surface TAG1 molecules present in the corticofugal axons that define the IZ and in the axons of 
newly-born projection neurons. Downstream signal events include Src family kinase Lyn and small 
GTPase Rac1 [20]. Neurotrophin receptors TrkB and TrkC and ligands brain-derived neurotrophic 
factor (BDNF) and neurotrophin (NT)-3 also regulate axon induction and radial migration in vivo 
[19]. Other crucial signalling, comprehends the Semaphorin protein family. Sema3A is secreted at 
the top of the CP originating a gradient through the cortex. This molecule, through its receptors 
Plexin and Neuropilin, is responsible for the growth of dendrites towards the pia (attractive cue), 
and axon growth towards the ventricle (repulsive cue). Downstream signalling might involve RhoA 
stimulation. In addition, Sema3A may provide a directional signal for radial migration [19, 21]. 
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The kinase LKB1 (the mammalian ortholog of Par4) is activated via STRADalpha at the trailing 
process of newborn migrating neurons, which in turn activates SAD-A and SAD-B leading to tau 
phosphorylation and axon formation. LKB1 also regulates the transition from MP to BP and 
neuronal migration [22]. 
Migrating neurons express the Reelin receptors very low density lipoprotein receptor (VLDLR) 
and apolipoprotein E receptor type 2 (ApoER2), and the Reelin-Dab1 signalling pathway is critical 
for neuronal migration (glia-independent) and lamination [23]. Additional, MP exit and MP-BP 
transitions seems to require modulation of the activity of the Netrin receptor DCC by its co-
receptor Unc5D [19]. ArfGEF2 and Filamin A gene mutations are associated with neuronal 
migration defects leading to human cortical malformations (for example, Periventricular 
heterotopia). By regulating vesicle trafficking and actin cytoskeleton, respectively, these proteins 
influence MP-BP transition [18]. Lissencephaly-1 (LIS1) gene mutations are also linked to human 
disorders resulting from incomplete and/or abnormal neuronal migration and abnormal cortical 
organization. It codes a MT- and MT organizing center-associated protein, and forms a protein 
complex with NDE1/NDEL1 and cytoplasmic dynein [9, 18]. LIS1 protein has been implicated in 
INM, axon extension, and MP-BP transition. Doublecortin (DCX) gene mutations produce similar 
phenotypes to LIS1 mutations. DCX is also an MT-associated protein, additional associated with 
vesicle trafficking, regulation of cell adhesion, and MT-actin crosstalk [9]. In line with the role of 
the centrosome position for MP-BP transition, it was found that the centrosomal protein 
SDCCAG8 regulates this transition step via interaction with PCM1. 
After converting to a BP shape, neurons are able to migrate via RGC-guided locomotion (Figure  
A.3, step 3). This migratory mechanism involves nuclear translocation and forward movement of 
the cell body, and imply cytoskeleton coordination, endocytosis, and cell adhesion processes [18]. 
On the molecular level, RGC-guided locomotion depends on surface N-cadherin, regulated through 
Rab5-dependent endocytosis and Rab11-dependent recycling pathways and Reelin-Rap1-RalA 
signalling [24]. N-cadherin not only senses direction signals for radial migration but it is also 
involved in the earlier MP-BP transition. Recently, it was shown that N-cadherin mediates leading 
process formation at the RGC-neuron contact site via RhoA activation, and through Rac1 
activation on the opposite site leads to axon formation [25].  The CDK5-Rap1-N-cadherin 
signalling is critical for exit from the MP phase. The Gap junction proteins Connexin 43 and 
Connexin 26 display cell adhesive properties and ensure the stabilization of the neurons’ leading 
process along RGC and, consequently, neuronal migration [26]. 
Three distinct behaviours mark the end of migration once neurons reach their final destination: 
locomotion termination, detachment from the RG fibers, and anchoring to the MZ for terminal 
translocation (Figure  A.3, step 4). Migrating neurons respond to a stop signal from the pia’s 
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basement membrane. One of the most well described molecular mechanisms involves the GPCR 
GPR56. Collagen III binding to GPR56 leads to RhoA activation, a signal fundamental for pia 
basement integrity and to prevent neuronal over-migration. Interactions of this receptor with 
alpha3beta1 integrin produce a proper stop signal. The extracellular matrix with anti-adhesive 
properties, SC1, is involved in the detachment of neurons from the RGC, and Reelin-Dab1 
signalling plays an essential role in terminal translocation [18]. Of note, in addition to migrate to 
their radial positions, projection neurons have to assume their correct cortical columnar areas by 
tangential dispersion, and their specific cortical area [21]. Neuron organization across tangential 
dimensions seems to be regulated, in general, by the Ephrin receptor and its ligands Ephrin A 
(stimulation) and Ephrin B1 (inhibition). However, other subtype-specific mechanism were already 
described, like translational regulation of NOS1 by FMRP for layer 5 neurons, and reelin signalling 
for Stab2-positive upper layer neurons [6, 19]. 
Upon arriving at the CP, neurons are instructed to stop migrating and continue to differentiate. 
Most differentiation processes, such as the extension and elaboration of dendrites and the formation 
of synaptic connections, take place mainly after neurons have assumed their final position in the 
CP [2]. The period after gestational week 22 is the most significant time for differentiation of the 
CP [4]. In pyramidal cortical neurons, the first dendrite derives from the leading process. This 
dendrite is oriented to the apical side and branches out generating an apical tuft. The guidance of 
axon and dendrite to opposite directions appears to be mediated, in part, by the same molecular 
gradient but different signalling pathways [27]. Later, basal dendrites and additional side branches 
from the apical shaft start to develop. Extensive (secondary and tertiary) branching events are 
necessary to efficiently cover the target field [28]. After this, there has to be growth restriction to 
define dendritic borders and avoid the overlap between dendrites of the same neuron type (a 
mechanism referred as self-avoidance), and coordination of the dendritic growth (defined as 
dendritic tiling).  Neuronal maturation is marked by the (over-)development of dendritic spines, 
followed by dendrite pruning and post-synaptic differentiation. The final neuronal morphology will 
vary largely depending on which layer neurons are located [27, 28].  
Distinct transcription factors may positively or negatively regulate dendrite arborization, and some 
transcription factors are further regulated by calcium signalling and neuronal activity. The bHLH 
transcription factor neurigenin 2, for instance, is involved in the specification of a unipolar apical 
dendrite in cortical pyramidal neurons. The mammalian Cut-like 1 and 2 (Cux1 and Cux2) appear 
to have specific functions in dendrite morphogenesis. In cortical pyramidal neurons, Cux1 appears 
to reduce dendritic complexity via RhoA modulation. The SYT-related nuclear protein calcium-
responsive transactivator (CREST) responds to neuronal activity to elaborate dendrites. This 
molecule is part of a neuron-specific chromatin remodelling complex that controls the expression 
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of genes determinant for morphogenesis like GAP43, Stm2, Rap1a, Gprin1 and Ephexin1 [10, 28]. 
The small GTPase RhoA is associated with the restriction of dendrite growth, what might be 
important to define the correct innervation bondaries, whereas Rac1 and Cdc42 appear to drive 
dendrite elaboration [12, 28]. The Hippo family members and PI3K-mTor signalling play an 
important role in the correct definition of the target receptive fields and self-avoidance mechanisms 
[28].  
Axon and dendrite outgrowth, and synaptogenesis are long events that extend into early childhood. 
The size of pyramidal neurons and length of dendrites increase greatly during the first postnatal 
year, and continue until the fifth postnatal year, although at a smaller extent. The first synapses in 
the CP appear around the 18th embryonic week, but the peak of neocortical synaptogenesis only 
occurs later in prenatal development and early postnatal development [2]. After this there is the 
refinement of synaptic connections and dendritic pruning, a process that can last until the 3rd 
decade of life [29, 30]. The latest transition in corticogenesis is the switch from upper layer 
neurons to gliogenesis, and the timing of this transition determines the overall number of neurons 
in the neocortex [6]. 
1.1.1.!Experimental in vitro models of neuronal differentiation 
In vitro dissociated neuronal cultures, either from CNS or PNS neurons, are a very useful 
experimental system to study the molecular and cell biology of neuronal differentiation.   
Simpler model organism like Drosophila melanogaster, Caenorhabditis elegans, Xenopus laevis, 
Danio rerio are very attractive, but to study mammalian neuronal differentiation Mus musculus and 
Rattus norvegicus are most commonly used. 
Dissociated rodent hippocampal neurons are a typical and well establish model system to study 
neuronal polarization and differentiation. Hippocampus is a widely adopted source for in vitro 
neuronal cultures because it has a relatively homogeneous population of neurons (80-95% are 
pyramidal neurons), and the hippocampal pyramidal neurons present a well-defined shape with a 
single axon and several dendrites (a single long apical dendrite and several shorter basilar 
dendrites). Furthermore, embryonic hippocampal neurons in culture acquire their characteristic 
polarized morphology during five well characterized distinct stages, as first described by [31] 
(Figure  A.4). Most cortical neurons establish axon-dendrite polarization via events similar, to 
some extent, to that observed in cultured hippocampal neurons, for instance polarity formation 
primarily occurs in highly dynamic multipolar cells [32]. 
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Figure  A.4 - Differentiation stages of hippocampal neurons in vitro. Dissociated rodent hippocampal neurons are 
commonly used as models to study neuronal polarization and differentiation. In culture these neurons acquire their 
characteristic polarized morphology during five stages. The red circle indicates the growth cone. IV, in vitro; DIV, days 
in vitro. Adapted from reference [33]. 
 
The main event in stage 1 hippocampal neurons is the formation of lamellipodia, which develop 
around the periphery of the cell soon after the cells attach to the substrate. Changes in these 
structures were correlated to the formation of neurites, as lamellipodia break up into discrete motile 
patches that will become the neuritic growth cones. In stage 2 the lamellipodia are transformed into 
minor processes (typically 4 to 6) that extend to a length of 15-30 µm. Once they reach this length, 
there is no net elongation, but the processes still display a dynamic growth with cycles of extension 
and retraction. The cells maintain a symmetric appearance. The stage 3 is marked by the formation 
and growth of the axon. One of the minor processes begins to grow at a much more rapid rate 
(about 5-10 times greater than the other processes) and becomes the future axon, while the other 
neurites remain quiescent. As a result, stage 3 neurons have a single axon and several short 
neurites, which implies that the cell has become polarized [31, 33, 34]. Stage 4 comprehends the 
growth of dendrites that, similar to the axon, develop from the minor processes that appear during 
the first day in culture. Besides starting later than the axon growth, dendrites grow more slowly 
than axons. Additionally, unlike axons, several dendrites grow at the same time [31, 33, 34]. 
Eventually, after seven days in culture, dendritic arbors become more elaborated and branched. 
Neurons form large number of synaptic contacts, develop dendritic spines, and spontaneous 
electrical activity propagates throughout the neuronal network – stage 5 [31, 33, 34]. 
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1.2.!Cytoskeleton dynamics in neuronal polarization and axon/dendrite outgrowth 
As explained above, in vivo, cortical projection neurons start to differentiate while migrating to 
their final location (Figure  A.3). Specifically, these neurons acquire their polarity from the 
emergence of a leading process and a trailing process that will become the future dendrites and 
axon, respectively. The extensive stereotypical changes that neurons suffer from a round-shape 
stage right after division, to the intermediary multipolar stage and the bipolar stage during 
migration, until final dendrite morphogenesis and maturation, are extremely dependent on 
cytoskeleton dynamics and rearrangements. 
The cytoskeleton both establishes and maintains polarity in neurons, and rearrangements of the 
actin cytoskeleton and microtubules are crucial for the initial establishment of polarity (see Figure  
A.5) [35]. Of central importance for neuronal polarity and neuritogenesis is the growth cone 
(schematic representation in Figure  A.5) which is a highly motile cellular compartment at the tips 
of growing neurites that has the ability to sense extracellular cues and transducing those signals to 
the cytoskeleton. The growth cone is a broad flat expansion, with many long microspikes or 
filopodia that are protrusions of F-actin, and some veil-like sheets of branched actin, the 
lamellipodia [36, 37]. 
!
Figure  A.5 - Cytoskeleton dynamics during neuronal polarization. Unpolarized neurons display several equal 
neurites. Axon polarization is marked by actin instability and increased microtubule stability. Kinesin motors induce 
unidirectional membrane trafficking towards the forming axon allowing its rapid elongation. Highlighted is a schematic 
representation of the growth-cone. Actin dominates the periphery of the growth-cone, forming filopodia and 
lamellipodia. Microtubules are distributed along the axonal shaft and protrude in the central region of the growth cone. 
Adapted from reference [35]. 
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The basis of the actin cytoskeleton growth is the polymerization of ATP-bound globular actin (G-
actin) into helical actin filaments (F-actin) [35, 36]. Barbed (plus)-ends of F-actin where actin 
monomers are continuously incorporated face the edges of the growth cone, while pointed (minus)-
ends are oriented towards the base. The continuous F-actin disassembly at the pointed-ends and the 
F-actin assembly at the barbed-end is named F-actin treadmilling. F-actin treadmilling is 
responsible for the protrusion of lamelipodia and filopodia, and is an event essential for neurite 
outgrowth [38, 39]. The filopodia attach to the substrate and exert a force that pulls the rest of the 
cell forward, allowing it to move by elongation [38]. In stage 2 neurons (see previous section and 
Figure  A.4), the future axon shows enhanced growth cone dynamics and, thereby, actin turnover, 
whereas the future dendrites, quiescent at that moment, have a static growth cone with a rigid actin 
cytoskeleton. Local actin instability, in the future axon, may cause reduced obstruction to the 
protrusion of microtubules (MT; mainly stable at this point) and, consequently, allows neurite 
outgrowth [36]. 
Current knowledge places actin-based processes as the central event in neuritogenesis, with a 
required balance between actin assembly and disassembly. Actin dynamics is regulated by several 
actin-binding proteins, like actin nucleator, severing, branching, and bundling proteins. Nucleation-
promoting factors, such as WASP and WAVE, promote neurite growth by regulating actin 
polymerization via Arp 2/3 and profillin. The Arp2/3 complex initiates actin filaments branching in 
lamellipodia. Formins and fascin mediate bundling of actin filaments, and are involved in filopodia 
formation [38]. The alterations initiated by actin nucleators may be sufficient to induce neurite 
initiation once the correct dynamics is maintained after nucleation.  
Cofilin has the ability to increase actin dynamics by filament severing and depolymerization, an 
event essential for neurite initiation. This protein promotes actin depolymerization by adding actin-
ADP to the pointed (minus)-end of actin filaments, by promoting ATPase activity, and by 
increasing the rate of phosphate release and monomer loss. Its activity results in a general increase 
in the rate of actin treadmilling creating a pool of actin monomers free to bind actin filaments 
barbed (plus)-end. Cofilin is highly active in the growing axonal growth cones [36, 39]. Other actin 
severing protein is gelsolin, which binds actin barbed-ends and mediates calcium-dependent actin 
severing [37]. The released G-actin is sequestered, for example, by profillin. Profillin, in turn, will 
enhance the incorporation of ATP-actin monomers into actin barbed (plus)-ends. On the other end, 
beta-thymosin is a G-actin sequester protein that attenuates actin polymerization and delays neurite 
outgrowth. Nevertheless, its action seems crucial, for instance, during the response to extracellular 
cues. In this way, G-actin sequesters prevent spontaneous actin nucleation and control actin 
polymerization [36, 37]. Capping proteins such as CapZ prevent filament elongation. On the 
contrary, anti-capping proteins, as the proteins from the Ena/VASP family, prevent the binding of 
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capping proteins, allowing filament elongation. In addition, the Ena/VAPS proteins prevent actin 
branching and bundling [35, 36]. 
Axonal MT show increased stability with neuronal polarization. Stabilization of MT can be 
achieved by active stabilization of existing microtubules, increased polymerization, reduction of 
microtubule destabilization, and possibly by microtubule bundling.  
Neuronal microtubule-associated proteins (MAPs: MAP2, tau, and MAP1B) are MT stabilizing 
proteins and are extensively involved in neurite formation [40]. By binding directly to MT, these 
proteins might also affect the binding of other proteins and might function as scaffolds. Plus-end 
tracking proteins (+TIPs) are MT-associated proteins that, as their name implies, bind MT plus-end 
and modify MT assembly and disassembly. This group includes the growth promoting factors, 
CLIPs (Cytoplasmic Linker Proteins); the stabilizing proteins, CLASPs (CLIP-associated proteins); 
core element proteins that regulate binding of other proteins, like the End-binding family members 
EB1-3; and the LIS1 and DCX proteins. These proteins mainly favor MT elongation [38]. MT 
destabilizing proteins such as Op18/Stathmin also have a role in neuronal polarity [36]. On the 
other hand, the MT stabilizing protein CRMP-2 binds to alpha/beta-tubulin dimers and promotes 
their binding to MT plus-ends. CRMP-2 is described to accumulate in the neurite that will originate 
the axon [41]. The inhibition of the microtubule destabilizer Stathmin via DOCK7 also increases 
microtubule stability [35]. The MT motors – kynesins and dynein - are equally important players in 
the events of neuronal differentiation, not only because of their function as long-range transporter 
and as the obvious link to the cell body, but also by their ability to modify the position and 
organization of MT, to contribute to MT stability, and to link MT to actin cytoskeleton. 
Actin cytoskeleton and microtubules dynamics are not isolated events in neuritogenesis. Not only 
extracellular cues and intracellular signaling events will have the ability to induce rearrangements 
in both structures, but also these structures can physically interact and modulate each other. 
Kinesins and dynein link MT to the actin cytoskeleton and might promote MT movement and cell 
membrane protrusion using actin as scaffold [40]. The EB3 protein binds and forms a complex 
with the actin-binding protein drebrin. This complex seems to be involved in microtubule 
penetration into filopodia during neurite outgrowth [38]. MAP2 and MAP1B have the ability to 
bind F-actin and alter actin dynamics [40]. CRMP-2 regulates kinesin-mediated transport of the 
WAVE complex into the axon contributing to actin nucleation [41]. 
The progression through the different neuronal differentiation stages (from neuritogenesis to 
synaptogenesis) requires remodeling and a significant increase in cell size and plasma membrane 
surface area [34, 42]. Thus, regulated membrane trafficking events, including newly synthesized 
membrane from the exocytic secretory pathway (Tran-Golgi network-derived) and membrane 
recycling after endocytosis, will be tightly connected to the signaling pathways orchestrating 
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neuronal differentiation. The endocytic pathway (early endosome, the late endosome, recycling 
endosome, and the lysosome) will have a dual function during neuronal morphogenesis: to allow 
selective/polarized plasma membrane remodeling, as well as activation of intracellular signaling 
pathways that further enhance neuronal morphology. In this way, the structural constituents and 
regulators of membrane trafficking events will be crucial players during neuronal development and 
growth. Important examples include the SNARE complex proteins (vamp-2 and vamp-7, snap-25, -
29, -47, and syntaxin and Sec22b) and their regulators (e.g. Munc18 family), the vesicle tethering 
proteins of the exocyst complex, the large family of Rab and ARF GTPases, and the motor proteins 
(e.g. Kynesin superfamily members) [42, 43]. 
1.3.!Signaling events in neuronal differentiation 
In vivo, neuronal polarity and differentiation derives from a complex interaction between 
extracellular cues and intrinsic properties. Gradients of physiological extracellular cues and cell-
autonomous signaling cascades allow neurons to determine axon and dendrites. Maintenance of 
neuronal polarity depends on the maintenance of asymmetric distribution of signaling molecules 
what implies a precise spatial regulation of protein expression. Such regulation is accomplished 
through mechanisms of regulation of local protein synthesis, protein trafficking, and selective 
protein degradation. Of note, different neuron subtypes present differences in intrinsic signaling 
pathways what dictates different responses to a same extracellular cue. 
1.3.1.!Extracellular cues 
Numerous extracellular ligands/cues act through distinct receptors existing in the plasma 
membrane of neurons and will promote localized changes in signaling pathways. 
•! Netrin. Bifunctional molecule, capable of attracting some axons and repelling others. By 
binding to DCC receptors netrin works as an attractive cue, while via UNC5 receptors 
netrin exerts repulsive effects [21]. This molecule is described to exert long-range and 
short-range effects [21]. 
•! Slits bind receptors of the Robo family. It has been described as an axon repulsive cue, and 
as a branching factor for axons and dendrites [21, 27].  
•! Semaphorins. The semaphorins protein family includes secreted and transmembrane 
guidance cues. Binding to either semaphoring receptors Plexins or to co-receptors 
Neuropilin, induces active holoreceptor complexes and initiates intracellular signaling 
events. This extracellular cue has been implicated in several neuronal differentiation events 
including axon guidance, projection pruning, and synaptogenesis. In vivo, the best 
described member is Sema3A. Sema3A is present at high levels in the cortical plate and 
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mediates both the attraction of the pyramidal neurons’ apical dendrites and the repulsion of 
the axon. This polarized response is a result of the presence of soluble guanylate cyclase 
(sGC) specifically in the dendrites [27, 44].  
•! Ephrins family. Comprehends two different classes of cell-surface molecules, which 
function in clusters as short-range cues. Bind the tyrosine kinase receptors Eph. These 
molecules have several roles in neuronal differentiation: attractive/repellent axon guidance 
properties, regulate axonal branching, regulate dendrite morphology and synaptogenesis 
[21].    
•! Wnt and respective frizzled family of seven transmembrane receptors [43]. Wnt 
comprehends a large family of secreted proteins (19 genes described in mice). Although 
initially described as an embryonic morphogen, Wnt and its highly conserved signaling 
components are now implicated in different aspects of neurite development (axon 
outgrowth, axon branching guidance and remodeling, dendritic arborization, and 
synaptogenesis). After binding to its receptor, there is activation of the adaptor protein 
disheveled (Dvl). Downstream Wnt signaling pathways include the canonical Wnt/β-
catenin, and the planar cell polarity (PCP) pathways. The former induces the inhibition of 
GSK-3β (by disassembly of the complex formed by axin, adenomatous polyposis coli 
(APC), and GSK-3β), and consequently the promotion of the β-catenin-induced gene 
transactivation. The PCP pathway, by activation of the Rho GTPase and the c-Jun (N)-
terminal kinase (JNK), generates signaling events that culminate in the reorganization of 
actin and microtubules [45].  
•! Neurotrophins belong to a family of extracellular molecules that has complex influences 
on neuronal development, and is composed by the nerve growth factor (NGF), the BDNF, 
the NT-3, and the NT-4. Neurotrophins mediate their effects by binding to two types of cell 
surface receptors, the tyrosine kinase receptors (Trk receptors: NGF binds to TrkA, BDNF 
and NT-4 bind to TrkB, and NT-3 binds to TrkC) and the p75 neurotrophin receptor 
(p75NTR). In general, Trk receptors transmit positive signals, while the p75NTR transmits 
both positive and negative signals. Neurotrophins are mainly associated with increases in 
the dendritic complexity of pyramidal neurons. BDNF was also shown to play an 
instructive role in axon specification, being this effect dependent on the activation of 
cAMP-dependent protein kinase (PKA) and phosphorylation of LKB1 by PKA [46, 47]. 
•! Other growth factors: Transforming growth factor beta (TGFβ). Presents a graded 
expression in the developing cortex initiated at the VZ, and has a role in neuronal 
polarization. Downstream effectors include the Par6-Par3-aPKC complex – Rac1 
activation [48, 49]; the basic fibroblast growth factor (bFGF), which accelerates the 
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outgrowth of both axons and dendrites in hippocampal neurons [50]; insulin-like growth 
factor-1 (IGF-1) regulates neurite growth in developing brain and affects dendritic growth 
and branching of post-natal layer 2 cortical neurons [33]. 
•! Extracellular matrix and cell adhesion molecules – Direct cell-cell or cell-matrix 
interactions mediated by membrane-associated receptors, ensure the coupling of 
extracellular signals to the cytoskeleton via distinct adaptor proteins. This allows site-
directed cytoskeletal rearrangements and consequently proper growth cone motility. 
Adhesion receptors include the integrins (involved in cell-matrix interactions), the 
cadherins, and the immunoglobulin superfamily of cell adhesion molecules (IgCAMs). The 
two last receptors are mainly involved in cell-cell interactions [43]. In the nervous system 
examples of extracellular matrix molecules include laminins, tenascins, fibronectin, and 
chondroitin sulfate or heparin sulfate proteoglycans. These ECM molecules will present 
strategic and dynamic distributions during brain development (like the proliferative zone of 
the telencephalon or the preplate), and will bind transmembrane integrins and trigger 
integrin signaling pathways. Regulation of integrin activity is a recognized fundamental 
mechanism that controls neuritogenesis and neurite outgrowth, and integrin signaling 
pathways with roles in such processes include the focal adhesion kinase (FAK), the 
integrin linked kinase (ILK), and the adaptor paxillin [51]. Growth factors commonly 
cooperate with adhesion molecules to promote neuronal differentiation [43]. 
1.3.2.!Intracellular signaling pathways 
Intracellular signaling cascades, extracellular signal-induced and cell-autonomous ones, orchestrate 
the sequential events of neuronal differentiation. Several signaling networks operating in 
differentiation will culminate in the regulation of actin and/or microtubule dynamics, but also in the 
regulation of protein secretory, endocytic and degradation pathways. Of note, arrows bellow 
indicate activation of the molecules that follow. 
•! LKB1 + Strad ! SAD-A/B. LKB1 is activated by its co-activator Strad and by 
phosphorylation at S431 (by PKA or p90RSK). This specific phosphorylation is induced 
by some extracellular cues, like Sema3A, neurotrophins and FGF. After activation, LKB1 
phosphorylates and activates SAD-A/B and MARK kinases, which in turn target several 
MAPs (such as Tau and DCX) reducing their MT binding affinity [13, 52]. Clearly 
involved in the development of polarity of cortical neurons in vivo [36]. 
•! PI3K ! PtdIns (3,4,5)3 (PIP3). The polarized activation of PI3K and the accumulation of 
PIP3 at the tip of a single minor neurite (future axon) are required for axon specification. It 
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is a well described event during axon formation in vitro, but there is sparse evidence for its 
role in vivo. 
o! PI3K ! local increases in PIP3 ! PKD or ILK ! Akt ! GSK3β. Pathway 
described to be activated following neurotrophins-induced activation of Trk 
receptors. Its role in vivo is still questionable [41].  
o! PI3K ! local increases in PIP3 ! PKD or ILK ! mTor. Signaling event 
described to promote dendrite growth downstream of Reelin [41]. 
o! (TrkA) ! PI3K ! RAP1B ! Cdc42 and Par complex. Accumulation of 
RAP1B in the tips of the future axons precedes the accumulation of cdc42 and the 
PAR complex [41]. 
•! GSK3 (α and β) is a central molecule involved in the regulation of MT dynamics during 
neuronal differentiation, and appears to be a common link between several intracellular 
signaling pathways. This constitutively active kinase phosphorylates MAPs and contributes 
to MT instability. Its inactivation, following exposure to neurotrophins for instance, is 
necessary to MT stability. Described to be inactive at the growing axon and active at the 
dendrites, and to be one of the “control” signaling preventing dendrites to transform in 
axons [13]. However, its significance in vivo is still controversial. GSK3 main targets are: 
o! Tau, and MAP1B. 
o! APC phosphorylation, preventing APC binding to the MT plus end. 
o! CRMP2, which in turn targets: tubulin heterodimers – to assist MT 
polymerization [41]; Numb-mediated endocytosis of neuronal cell-adhesion 
protein L1 (an IgCAM) [41]; Sra-1 – WAVE, regulators of the actin cytoskeleton 
[41]. Furthermore, CRMP2 is a mediator of semaphorin-induced growth cone 
collapse. 
•! Ras, is activated downstream several growth factor receptors. This pathway seems to 
regulate axonal cytoskeleton via phosphorylation of several MAPS, and also regulates a 
broad range of transcription factors, including Serum Response Factor [53]. Downstream 
of Ras, two main signaling pathways can be activated [54]: 
o! PI3K (described above); 
o! Raf ! MEK ! Erk1/2. Haploinsufficiency of the MAPK1/ERK2 gene in 
humans results in microcephaly, neurodevelopmental deficits and learning 
disabilities. Furthermore, mutations in upstream or downstream signaling 
components of the ERK cascade are associated with a variety of neurodevelopment 
syndromes (characterized by developmental delay and mental retardation) [55]. 
For instance, in the developing cortex, ERK signalling is described to regulate the 
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proliferation of neural progenitors and, consequently, the progenitor pool size, by 
keeping the correct balance between proliferative and neurogenic divisions through 
downstream effectors p27Kip1 and cyclin D1 [56]. On the other hand, the 
conditional inactivation of ERK2 within neural progenitors at the beginning of the 
neurogenic period results in fewer neurons populating the cortex, and increased 
number of astrocytes. Indicating that ERK2 is responsible to suppress glial fate and 
promoting neurogenesis in the developing cortex. In addition this molecule plays 
critical roles in learning and memory [57]. 
•! Rho-family of small GTPases. Growing evidence indicates that neurite initiation does not 
depend simply on constitutively activation or inactivation of small GTPases, but rather in a 
specific local and temporal cycling between activation and inactivation states [40]. 
Furthermore, different family members can be differentially activated by a particular 
signal. For instance, following neurotrophin treatment, local increases in PIP3 are 
associated with increases in the activation of cdc42 and Rac, but decreases in RhoA 
signaling [58]. 
o! Cdc42 regulates actin dynamics, more specifically is involved in fillopodia 
formation and growth cone morphology [36]. In vivo studies strongly support its 
involvement in axon polarity initiation and growth. Major effectors: Cdc42 ! 
WASP; Cdc42 ! PAK! Cofilin ! actin; Cdc42 ! STEF/Tiam ! Rac1 [12].  
o! Rac1 and Cdc42 might converge on a common signaling pathway to induce 
dendrite elaboration in immature cortical neurons: activation of the 
serine/threonine kinase Pak1. May also activate the Arp2/3 complex. During 
dendrite morphogenesis the activity of these proteins is regulated by neuronal 
depolarization by NMDA and glutamate receptors [28]. 
o! Rac1 role in actin cytoskeleton dynamics is mainly associated to its role in 
lamellipodia formation [36]. Rac1 is a well described positive regulator of axon 
guidance in vivo [12]:  Rac1 ! PAK; Rac1 ! WAVE. This small GTPase also 
controls MT dynamics via stathmin inactivation [58]. 
o! RhoA ! ROCK ! profilin II and myosin II: induces destabilization of actin 
cytoskeleton and neurite retraction. ROCK can also modulate MT. Contrarily to 
Rac and Cdc42, RhoA appears to associate with repulsive cues and growth-cone 
collapse, but there is a lack of in vivo studies [58]. 
•! Par complex (Par3 and Par6) ! atypical PKC. Might be regulated downstream of PI3K. 
It is transported to the axon terminals by kinesin 2 motor. 
o! Cdc42 ! STEF or TIAM1 GEFs ! Rac1 
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o! MARK2. The Par complex via aPKC inhibits MARK2 and thus MAP 
phosphorylation at the axon tips. MARK2 overexpression inhibits axon formation, 
and its downregulation induces supernumerary neurons [59]. 
•! Local calcium and cAMP/cGMP gradients can mediate filopodia formation and neurite 
growth. Calcium is key mediator of neurite outgrowth in almost all types of neurons. It can 
act directly, or through the activation of various calcium-binding proteins to modulate the 
state of polymerization of actin filaments and microtubules [50, 53]. For instance it 
activates the actin severing protein gelsolin. 
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2.!The Amyloid Precursor Protein 
Amyloid Precursor Protein (APP; also known as Amyloid beta A4 protein) is a ubiquitously 
expressed type 1 membrane glycoprotein that suffers proteolytic cleavages and, as its name 
implies, is the precursor protein of the amyloid β-peptide (Aβ). Aβ is the main component of the 
senile plaques present in the brain of patients with Alzheimer’s disease (AD), the most common 
age-related neurodegenerative disorder, first described in 1906 by Alois Alzheimer. AD is a 
multifactorial illness of insidious onset and progressive decline in cognitive (including memory 
loss) and functional abilities, including as well, behavioral and psychiatric symptoms. Ultimately, it 
leads to a vegetative state and death [60, 61]. 
Although APP was initially mainly studied because of its association to AD, this protein is widely 
expressed on the cell surface, particularly in neurons, and has been implicated in physiological 
roles such as cell adherence, survival, migration and differentiation. Recently, it is being 
established as a neuromodulator of developing and mature nervous system. 
2.1.!APP characterization: gene family, isoforms and functional domains 
In 1984, Aβ was isolated from deposits found in blood vessels of AD brains and Down’s syndrome 
(DS) brains, which provided a partial sequence of this peptide [62, 63]. A year later, Aβ was 
identified as the main component of neuritic plaques in AD brain [64], and shortly thereafter, the 
gene encoding APP was identified, and found to be located on the DS region of the chromosome 
21 (21q21.2-3) [65-67]. The human APP gene contains 19 exons (with more than 170 kb) and is 
expressed in many cell and tissue types including endothelial cells, glia and neurons of the brain 
[68]. APP is one of three members of a small gene family that, in humans, includes APLP1 and 
APLP2. APP and APLP1 are suggested to result from an earlier duplication event, and APLP2 
from a later gene duplication event [69]. The redundancy of APP and APLPs is reflected in an 
analogous protein domain structure: all encode type 1 integral membrane glycoproteins with a large 
extracellular domain and a short cytoplasmic region, and undergo a similar proteolytic processing. 
These three related proteins are well conserved in evolution and share similar functions, but only 
APP contains the Aβ domain, encoded by parts of exons 16 and 17 [69, 70]. 
APP-like cDNAs were found in Drosophila melanogaster and C. elegans, the APPL and APL-1 
respectively. Both species only have one member of the APP gene, and APL-1 is predicted to be 
the closest to the ancestral protein. Curiously, APLP1 and D. melanogaster APPL are only 
expressed in the nervous system, much like the APP695 isoform (see bellow) [69, 70].  
APP gene mutations are reported to be associated with familial, early-onset AD, however these 
account for a very small portion of AD cases (~16%) [71]. In general, such mutations are localized 
University of Aveiro  35!
close to the beta-secretase or gamma-secretase cleavage sites. Examples include the V717I, V717F, 
V717G, and the Swedish double mutation K670N and M671L substitutions. In addition, APP 
mutations comprising amino acid substitutions within residues 21-34 of the Aβ domain are linked 
to cerebral amyloid arteriopathy (like the Dutch variant E693Q, the Flemish variant A692G, and 
the Artic variant E693G, among others). On the other hand, APP genetic variations in its core 
promoter and in its 5-prime upstream regulatory region might be correlated with late-onset AD [72, 
73]. The importance of APP in the etiology of AD, namely the robust effect of the dose for APP, is 
also notorious by the fact that virtually all individuals with DS (who overexpress APP due to 
chromosome 21 trisomy) develop age-related cognitive decline and AD-related pathology, and 
duplications in the APP locus are described to be sufficient to cause early-onset AD. The APP-
A673T coding mutation was shown to correlate with protection against AD and against cognitive 
decline in (Icelandic) elderly without AD [74]. 
APP gene transcripts suffer alternative splicing of exon 7, 8, and 15 to produce several protein 
isoforms. Main transcripts include the APP695 (exons 1-6, 9-18, not 13a) which is preferentially 
expressed in neuronal tissues; the APP751 (exons 1-7, 9-18, not 13a); and the APP770 (exons 1-18, 
not 13a). APP751 and APP770 contain the exon 7, which encodes a serine protease inhibitor (also 
called Kunitz proteinase inhibitor, KPI) domain, missing in APP655. APP770 contains, in addition, 
the exon 8 that encodes a domain with homology to the MRC OX-2 antigen found on the surface of 
neurons and certain immune cells such as thymocytes. The preceding isoforms are expressed 
mainly in non-neuronal cells. Other alternatively generated splice variants (the ‘L-‘ isoforms) lack 
exon 15 (encoding 18 amino acids), and are found in peripheral leukocytes and in microglia cells 
[75-77]. 
APP structure can be generally divided in a large extracellular amino-terminal domain, a single 
transmembrane spanning domain, and a small intracellular cytoplasmic domain. Structural data, 
suggests that the domains of a single APP molecule have a linear extended conformation without 
any strong interaction between them, so APP displays a conformation resembling "balls on a 
string" [78, 79]. In Figure  A.6 is depicted the overall structure of APP and the relative position of 
its main functional domains. 
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Figure  A.6 - APP functional domains. APP has a large extracellular domain, a transmembrane domain (TM), and a 
small cytoplasmic domain comprising the protein C-Terminal (CT). The extracellular domain includes a 17 amino-acid 
signal peptide (SP), the E1 domain, the E2 domain, and a juxtamembrane region (JMR) that holds the Aβ sequence. The 
E1 domain contains a cysteine-rich growth factor-like domain (GFLD) with heparin binding properties (HBD), followed 
by zinc and copper binding domains (Zn/Cu-BD). The E2 domain includes an additional GFLD with an HBD and a 
RERMS, and a carbohydrate sub-domain containing the Collagen binding domain (CBD) and the N-glycosylation sites 
(N-Glyco) of the ectodomain. The KPI domain is only present in APP770 and APP751 isoforms, and the OX2 domain in 
APP770. On the bottom, the sequence of the CT is represented, and the sorting YTSI and YENPTY motifs are 
highlighted. In lighter grey is the binding site to the Gαo protein. ‘P’, indicate phosphorylation sites. The β-secretase (β 
and β’) and α-secretase (α) cleavage sites are also represented. 
 
The extracellular domain starts with a 17-residue signal peptide, and is organized in two N-terminal 
folded domains, the E1 and E2 domains, linked by a highly flexible and negatively charged 
subdomain – termed acidic domain (AcD). Before the AcD and uniquely present in APP, there is a 
small extension (sub)domain (ED) that holds at least two phosphorylation sites. In between E1 and 
E2 domains, APP770 and APP751 isoforms, display a KPI and an OX2 domains [75, 76].  
The E1 domain contains a cysteine-rich growth factor-like domain (GFLD) with heparin binding 
properties (HBD), followed by zinc and copper binding domains (Zn/Cu-BD) [76]. The HBD is not 
present in APLP1, APPL or APL, the Cu-BD (142-151) is somehow less efficient in APLP2 and is 
not present in APLP1, while the Zn-BD (179-188 – BxxExxCC) is present in all elements of the 
APP superfamily. Binding of zinc II alters the ability of APP to bind heparin, when present the 
affinity for heparin increases [66, 67]. The E1 domain appears to provide APP family members the 
ability to form both homo- and hetero- dimers, cis- and trans- directed, promoting cell adhesion 
[76, 77]. 
The 56-amino acid long KPI, present in APP and APLP2, is suggested to influence the processing 
of APP770 and 751 isoforms, and is thought to affect cell adhesion by regulation of the time APP 
or sAPP is available to bind extracellular substrates before degradation. The OX-2 domain is a 
novel feature of APP, present in the APP770 isoform, and might affect the protease inhibitory 
aspects of the KPI domain [66, 75]. 
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The E2 (mainly flexible alpha-helices) region includes an additional HBD/GFLD (370-393) present 
in all APP family, with the RERMS motif found only in APP. This main domain also includes the 
carbohydrate (sub)domain containing the N-glycosylation sites of the ectodomain, and the 
Collagen binding domain (CBD, 448-465) completely present in APP and APLP2. Furthermore, 
the E2 was recently found to bear a novel metal binding site (for Cu or Zn) [66, 75].  
The Chondroitin sulphate attachment site is formed by alternative splice exclusion of exon 15 in 
human APP (a similar event occurs in APLP2 by alternative splice of exon 14) [66]. 
The juxtamembrane region (JMR) is the highly flexible region that connects the entire ectodomain 
to the sigle TM helix. The sites of β- and α-secretase cleavage are within or at the C-terminus of 
this segment, and the 16 amino acids that are contained in sAPPα, but not in sAPPβ, belong to the 
JMR [75, 76]. 
The Aβ domain comprises the 28 residues just outside the membrane plus the first 12-14 residues 
of the transmembrane domain (TM), and is a novel feature of APP conserved between species. 
The TM contains three consecutive glycine-xxx-glycine (GxxxG) motifs, including one embedded 
within the Aβ sequence. In general, GxxxG motifs are involved in dimerization of transmembrane 
proteins. In fact, it has been shown that glycine to alanine substitutions within such motifs attenuate 
TM dimerization and reduce APP processing, including to toxic Aβ42 [77, 78]. 
The cytoplasmic region of APP contains a 682YENPTY687 motif containing an NPXpY 
internalization signal for membrane proteins, and that is found in the entire APP superfamily [79, 
80]. This motif mediates the interaction of APP with different binding partners via their 
phosphotyrosine interaction domains [81]. APP C-terminal also hold a 653YTSI656 basolateral 
sorting domain described to bind PAT1 (or APPBP2), and AP-1, and AP-3. Besides function as 
basolateral sorting signals, canonical Yxxθ motifs have roles in endocytosis, lysosomal sorting, and 
retrograde sorting to the Golgi [80, 82, 83]. Near the YTSI motif, there is a Go binding site (H657-
K676 of APP695) equally present in APP, APLP1 and APLP2 [66, 84]. 
2.2.!APP cellular localization and intracellular trafficking 
APP is an transmembrane protein that is dynamically sorted through the membranes of intracellular 
organelles and the plasma membrane (Figure  A.7) [88]. In general, total cellular APP has a short-
half life (30-60 min), but some results suggest the existence of a stable pool of membrane-tethered 
APP. 
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Figure  A.7 - Intracellular trafficking of APP. After synthesis, APP is transported through the constitutive secretory 
pathway to the cell surface (1). After this, APP suffers internalization and is delivered to the endosomes - retrograde 
transport (2). From the endocytic pathway, APP is either recycled by transport vesicles to the trans-Golgi network and to 
the plasma membrane (3), or transported to lysosomes. Reproduced from reference [89]. 
 
APP is cotranslationally translocated into the endoplasmic reticulum (ER) via its signal peptide, 
and then post-translationally modified (“matured”) through the secretory pathway. Acquisition of 
N- and O-linked sugars occurs rapidly after biosynthesis [60]. N-glycosylation localizes to the ER 
and early Golgi – immature APP, not cleaved by secretases – and O-glycosylation occurs during 
Golgi trafficking – mature APP that, from the TGN, enters into the late secretory pathway [84]. 
Only a small fraction of nascent APP molecules reach the PM (estimated to be ~10%), whereas the 
majority of APP at steady-state localizes to the Golgi apparatus and trans-Golgi network (TGN) 
[89]. After arrival at the cell surface, the APP that is not shed by alpha-secretase suffers 
internalization, via its YENPTY motif, being delivered to the endosomes - retrograde transport. 
From the late endosomes, APP is either transported to lysosomes, or recycled by transport vesicles 
to the TGN and to the cell surface [90]. In addition, APP is described to locate to the ER/nuclear 
envelop and to the ER-mitochondria [91]. Of note, during trafficking through the endocytic 
pathway, APP can undergo a variety of proteolytic cleavages, specified in the next topic.   
In neurons, APP is subjected to the constitutive secretory pathway and undergoes fast axonal 
transport to presynaptic terminals. Some authors show evidences that the axonal transport of APP 
is mediated by the direct binding of APP to the kinesin light chain subunit of kinesin I [92], but 
such results are controversial [93]. APP is not only transported to axons, but also to dendrites, and 
axonal APP and dendritic APP can follow different fates [94] (discussed in the following topic).  
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The main coat complexes described to be involved in APP transport include the clathrin and the 
retromer. The clathrin coat complex is involved in two main sorting routes: the endocytic pathway, 
connecting the cell surface to the endosome, and the pathway connecting the TGN to the 
endosome. The targeting of APP to clathrin-coated vesicles is mediated by the NPXY amino acid 
motif. A number of clathrin adaptor proteins have been found to mediate the binding of the APP’s 
NPXY motif to clathrin coats and therefore serve as regulators of APP endocytosis: autosomal-
recessive hypercholesterolemia (ARH) protein, disable family member (Dab) 1, c-Jun N-terminal 
kinase interaction (Jip1b) protein, members of the Fe65, and members of the X11 families, in 
particular X11a [88]. The retromer is the second coat complex implicated in the rapid transport of 
APP (and of its β-secretase BACE) from the endosomes to the TGN. It is a coat complex composed 
of vacuolar protein sorting (VPS) 35, VPS26, VPS29, VSP5, and VPS17. VPS35 represents the 
core of the retromer complex and has been described to bind the cytoplasmic tail of the 
transmembrane protein cargo that is being sorted, including APP [95]. In addition, retromer 
binding to cargo proteins might also occur via its VPS10-containing sorting receptor proteins, such 
as SorLA and Sortilin. Both proteins were associated with APP trafficking and processing, and 
seem to mediate sAPP internalization. In hippocampal neurons SorLA, which binds to APP E2 
domain, mainly colocalizes with APP in the soma, where it seems to protect APP from proteolytic 
processing, while Sortilin mainly interacts with APP in neurites and promotes its cleavage by the α-
secretase. Sortilin mediated-sAPP internalization might facilitate lysosomal degradation of this 
fragment. SorLa colocalizes with sAPP in paranuclear regions [96]. 
In addition, to the already mentioned, multiple other signals and protein interactors can modulate 
APP trafficking. Estrogen (17-beta-estradiol) treatment is associated with accelerated APP 
trafficking through the TGN and reduced Aβ production [97]. The microtubule-interacting protein 
PAT1a (or APBP2) binds to the basolateral sorting domain of APP affecting APP surface levels 
and amyloidogenic metabolism [98, 99]. Clearance of Aβ from the brain across the blood brain 
barrier is mediated by the low density lipoprotein receptor-related protein-1 (LRP1), that binds Aβ 
directly, or via chaperone molecules like the proteinase inhibitor alpha-2-macroglobulin. LRP1 is 
also coupled to APP internalization and processing, with Fe65 and/or RanBP9 function as linkers 
[89]. In opposition to its clearance role, APP interaction with LRP1 accelerates APP endocytosis 
and is associated with increased processing to Aβ [100]. RanBP9 is described to increase APP 
localization to lipid rafts and enhances the association of LRP1, APP, and BACE1, to increase Aβ 
generation [101].  
The fusion of transport vesicles to the membrane of the targeted organelle completes the process of 
transmembrane protein sorting. The fusion event is governed by three main families of proteins: 
SNAREs, Rabs, and Sec1/Munc18. The SNAREs expressed in the membrane of the transport 
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vesicle interact with a single SNARE protein in the membrane of the organelle, with Rab and 
Sec1/Munc18 mediating this interaction [88].  
2.3.!APP proteolytic processing 
As described above, part of the newly synthesized APP undergoes anterograde transport and is 
targeted as a full-length protein to the plasma membrane, after which it may be cleaved to sAPP or 
reinternalized into the endocytic pathway. During this trafficking APP undergoes endoproteolytic 
cleavages by proteases, releasing biologically active peptides (Figure  A.8). 
Two main proteolytic cleavage sites have been identified close to the TM domain, and one site 
occurs within the TM domain. Starting from the amino terminus of the protein, these are termed β- 
(between residues Met596 and Asp597 of APP695), α- (between residues Lys612 and leu613 of 
APP695) and γ- (multiple sites, as described later) cleavage sites. Each cleavage is catalysed by 
separate enzymes: β-, α- and γ-secretases, respectively [102]. The α- and β-cleavages are mutually 
exclusive events, with APP undergoing two post-translational processing pathways. In the non-
amyloidogenic pathway (Figure  A.8 upper part, right side), APP is cleaved within the Aβ region 
by the α-secretase, liberating a large soluble extracellular N-terminal fragment - sAPPα.  The 
carboxy-terminal fragment (CTF), named C83 or CTFα, remains tethered to the membrane, and is 
subsequently subjected to a transmembrane cleavage by γ-secretase, producing a non-pathogenic 
p3 peptide and the cytoplasmic APP intracellular C-terminal domain, AICD. In the alternative, 
amyloidogenic pathway (Figure  A.8 upper part, left side), APP is first cleaved by β-secretase, 
generating the large soluble sAPPβ peptide and the CTFβ, C99. This is subsequently processed by 
γ-secretase, producing the Aβ peptide associated with Alzheimer’s disease, and the intracellular 
AICD fragment. There is a second β-secretase cleavage site (β′, between Tyr606 and Glu697 of 
APP695) that is 10 amino acids towards the C-terminus from the β site, yielding CTF89 [61, 102]. 
 
University of Aveiro  41!
!
Figure  A.8 - APP proteolytic processing. A. Main described cleavage pathways. In the non-amyloidogenic pathway, 
cleavage by α-secretase enables the secretion of the sAPPα and the preservation of the C83 fragment in the membrane. 
The C83 can undergo cleavage by γ-secretase to release the p3 and AICD (right side). Alternatively, in the 
amyloidogenic pathway, β-secretase cleavage results in the secretion of the slightly truncated sAPPβ and the membrane 
retention of a C99 or a C89 (depending on the cleavage site). The resulting C-terminal fragments can also undergo 
cleavage by γ-secretase to release the Aβ and AICD (on the left). B. Additional cleavage events. Caspase can also cleave 
APP to release C-terminal fragments: ‘C31’ when it cleaves APP full-length, or ‘Jcasp’ if there is also a cleavage event 
by γ-secretase (right side). During the η-secretase pathway, truncated soluble ectodomains and higher molecular mass C-
terminal fragments (CTFη) are originated. CTFη can be further cleaved by the α-secretase or β-secretase to release Aηα 
or Aηβ (left side). 
 
α-secretases: several membrane-bound disintregrin and zinc metalloproteinases including 
ADAM10, ADAM17 (or TACE), ADAM9 and MDC-9 have been identified has having α-
secretase-like activity [103]. In neurons, the major functional (constitutively cleaving) α-secretase 
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activity is mediated by ADAM10. But α-secretase cleavage can be stimulated above its constitutive 
level - regulated α-secretase cleavage, which is thought to be mediated by ADAM17 [104]. 
Unregulated α-secretase cleavage of APP has been shown to occur at the cell surface [89]. 
However, α-secretase cleavage was shown to also occur intracellularly, in a late compartment of 
the default secretory pathway, and a large amount of sAPPα is already generated within the Golgi 
compartment long before it reaches the cell surface. The α-secretase proteins are synthesized as 
preproproteins, and to become active their prodomain is cleaved in the late Golgi by proprotein 
convertases (PPCs). Interestingly, these enzymes apparently can act at the same cell surface, or 
perform trans-cleavage of substrates located in neighbor cells [104]. The β-site APP-cleavage 
enzyme (BACE) 2 has also been identified as a α-secretase, as it can cleave APP in the middle of 
the Aβ domain (between Phe19 and Phe20). Importantly, PKC phosphorylation, either via 
treatment with phorbol esters or via activation of growth factor receptors, increases α-site cleavage 
of APP while decreases Aβ generation, an effect that can both depend on direct APP 
phosphorylation and on phosphorylation of APP-cleaving enzymes [105].  
β-secretases: β-cleavage is attributed to the aspartyl protease BACE1. BACE1 is produced as a 
pro-enzyme in the ER and the in the nuclear envelop, and its prodomain is cleaved by furin or other 
PPCs just before trafficking through the Golgi [61, 102]. Mature BACE is mainly found in the 
endosome, but can also be found in lower levels in the Golgi, TGN, and at the cell surface. 
Nevertheless, “convenient” acidic environment for its optimal active form appears to be only found 
in the late Golgi, endosomes and lysosomes. Lipid rafts have also appeared as potential sites for 
BACE1 activity [89]. The zinc metalloprotease Meprinβ has been proposed as a candidate β-
secretase acting at the cell surface [102]. 
γ-secretases: γ-secretase is a multimeric complex, made of four essential subunits: Presenilin-1 or -
2 (PS1 and PS2), Nicastrin, APH-1, and PEN-2 [106]. Each subunit has been found to be necessary 
for the enzymatic activity of the complex, which is dramatically impaired when any of the 
components are deficient. Although still under debate, the work of many labs indicate that mature 
active γ-secretase is mainly localized at the PM and in the endosomal/lysosomal system, including 
phagosomes and autophagosomes (and not in ER, Golgi, or post-Golgi transport vesicles as 
previously thought) [89, 91]. The complex acts in multiple sites within the APP TM domain, 
cleaving the remaining APP CTFs inside the membrane. APP-CTFα (or CTF83) cleavage yields 
AICD and p3 fragment production, and βCTFs (CTF99 or 89) processing results in different Aβ 
forms and AICD. βCTFs are processed by γ-secretase first at the epsilon-site (Leu645-val646 bond, 
APP695 numbering), what releases AICD to the cytosol. Subsequent cleavage at the zeta-site of the 
membrane retained Aβ49 (between Val642 and Ile643) generates Aβ46 and, finally, cleavage at 
multiple γ-sites produces two main combinations of Aβ peptides: the predominantly Aβ49-Aβ46-
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Aβ43-Aβ40-Aβ37 set from which Aβ40 is the principal end product, and the Aβ48-Aβ45-Aβ42-
Aβ38 set that gives rise to the pathogenic Aβ42 and the Aβ38 in comparable amounts [104, 105]. 
Curiously, although most Aβ species were abolished in PS1/PS2 -/- cells, the production of 
intracellular Aβ42 generated in the ER/intermediate compartment was unaffected by the absence of 
these proteins (either singly or in combination). Therefore, another γ-secretase activity must be 
responsible for APP cleavage within the early secretory compartments [107]. 
Recent work presented evidences that PS1 and PS2 take different paths in the cell. PS2 (by 
association with AP-1), but not PS1, resides in late endosomes and lysosomes. PS1 was spread 
across multiple cellular fractions, and nearly 10% of PS1 was detected in the plasma membrane, 
where PS2 is practically absent. In neurons, PS2-containing vesicles congregated in dendrites 
rather than axons or cell bodies, and cells expressing only PS2 contained higher amounts of 
intracellular Aβ (a higher ratio of Aβ42 to Aβ40) and secreted less Aβ than did cells expressing 
only PS1 [108, 109]. 
The γ-secretase complex acts through a mechanism known as regulated intramembrane proteolysis 
(RIP) that, besides a proteolytic process, comprises a transcriptional regulation event following 
AICD translocation to the nucleus [110]. This event has been reported (but still under discussion) 
to depend on AICD stabilization by Fe65 interaction, translocation of the protein complex to the 
nucleus, and association with Tip60. Such AICD-Fe65-Tip60 (AFT)-complexes were demonstrated 
to correspond to transcription factories [111]. On the contrary, association of RanBP9 with AICD 
recruits AICD to Tip60-enriched nuclear speckles, preventing AFT-complex formation and AICD-
mediated nuclear signaling [112]. Very interestingly, it has been suggested that the origin of APP-
CTFs, either from the β- or α-secretase processing, may determine the affinity of γ-secretase to the 
CTFs [110]. For example, it was demonstrated that the AICD produced following β-secretase 
cleavage is transported to the nucleus and binds to the neprilysin gene promoter, whereas that 
produced following α-secretase cleavage is rapidly degraded in the cytosol by insulin-degrading 
enzyme [102]. Nuclear signaling of AICD was also shown to occur predominantly through the 
neuronal 695 isoform [113]. 
Of note, recent evidence indicates that ADAM10 and γ-secretase physically interact and form a 
functional complex to sequentially cleave APP. This complex is further stabilized by members of 
the tetraspanin family of scaffold proteins (namely tetraspanin 12 and 17). There is also some data 
indicated a physical interaction between BACE1 and γ-secretase, and the existence of a distinct 
complex comprising these two secretases [114]. 
In addition to the aforementioned classic APP cleavage pathways, other proteolytic processing 
events have been described for APP, and several APP NTFs of unknown proteolytic origin have 
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also been reported in human and rodent tissues [91, 115]. The APP cytoplasmic domain can be 
directly cleaved by caspases, predominantly caspase-3 (cleaves APP695 between Asp664 and 
Ala665). This event generates two fragments, C31 and Jcasp, which might be linked to neuronal 
apoptotic events (Figure  A.8 lower part, right side) [116, 117]. Another physiologic APP 
processing pathway, mediated by membrane-bound matrix metalloproteinases (such as MT5-
MMP), was termed η-secretase and generates proteolytic fragments capable of inhibiting neuronal 
activity within the hippocampus (Figure  A.8 lower part, left side). This secretase activity (mainly 
at amino acids 504-505 of APP695) releases a truncated soluble ectodomain (~80-95 kDa) and 
generates higher molecular mass CTFs - CTFη. CTFη is further processed by ADAM10 and 
BACE1 to release long and short Aη peptides (termed Aηα and Aηβ). CTFs produced by η-
secretase are enriched in dystrophic neurites in an AD mouse model and in human AD brains 
[118].! A δ-secretase event, mediated by an asparagine endopeptidase, cleaves APP at two different 
ectodomain sites (between N373-E374 and N585-I586) generating 3 soluble APP fragments 
(sAPP1-373, sAPP1-585, and sAPP374-585) and CTFs. The lysosomal cysteine protease 
Cathepsin B was associated with enhanced production of N-terminally truncated pyro-glutamate 
forms of Aβ which have highly propensity to aggregate and consequently might be more toxic 
[102].!
Several efforts have been made to understand where the different APP fragments are generated, as 
well as their transport and final destination. As previously mentioned, axonal APP and dendritic 
APP can follow different fates. A study using primary hippocampal neurons transduced with APP 
chimeras selectively targeted to the axonal or the dendritic compartment, in combination with 
mutations that render the respective mutants secretase-resistant, showed interesting results 
regarding APP processing and APP fragments’ origin in neurons. Surface APP is mainly APP full-
length and is preferentially polarized to the axonal surface. Although β- and γ-secretases cleave 
APP either in the pre- or post-synaptic compartments, more Aβ peptides seem to be released from 
dendrites [94]. A subsequent study confirmed that the majority of APP is processed in the neuronal 
soma (as already suggested [119]), but local processing in axons/synapses can still occur, a 
mechanism that might be more significant in human neurons than in mouse neurons [120]. This is 
concordant with previously reports of endocytosis-dependent Aβ release following synaptic 
activity [121]. The authors report higher amounts of Aβ40 than Aβ42 in both the soma and axonal 
compartments of human brains, and higher amounts of sAPPα than sAPPβ. The transport of APP 
products generated in the soma depend on endocytosis, but at least APP full-length might enter the 
axons independently of endocytosis [120]. In fact, it was shown that APP can be transported 
independently of any sorting signal to the axonal and dendritic compartment [122]. Other studies 
add that the APP cleavage products are sorted into distinct vesicles before entering the axon. NTFs 
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display a perinuclear distribution and preferentially associate with acetylated microtubules and 
neurofilaments in neurons. CTFs are preferentially present in a compact region in the soma. A 
significant larger fraction of the CTFs is retained in the cell body, while NTFs appear to be 
massively exported from the soma into neurites and neurite terminals [119, 123]. 
Above it was described several factors that modulate APP trafficking and, consequently, APP 
proteolytic processing. In addition, γ-secretase is influenced by signal transduction pathways, 
namely by PDGF, Src, Rac1, and Ras. Activation of β2-adrenergic receptors and activation of the 
opioid receptor OPRD1 also stimulate γ -secretase activity and Aβ production. One important 
player in APP processing is its interaction partner PIN1, a peptidyl-prolyl cis/trans isomerase. PIN1 
overexpression reduces Aβ secretion, and knockout of Pin1 increases its secretion. The 
mechanisms seems to involve PIN1 binding to the phosphorylated T(668)-P motif in APP and 
consequent prolyl isomerization [124]. 
2.4.!Post-translational modifications – APP phosphorylation 
As previously described, after biosynthesis APP suffers posttranslational glycosylation – termed as 
maturation – during its trafficking through the secretory pathway. This includes the acquisition of 
N- and O-linked sugars. APP N-glycosylation starts at the ER and further proceeds in the cis-Golgi. 
APP has two potential N-glycosylation sites, but only the one located at N467 was proved in vitro 
and in vivo. N-glycosylation was shown to affect the intracellular sorting and secretion of APP, 
including axonal sorting [125]. APP maturation by O-glycosylation occurs during trafficking 
through the TGN. APP has several O-glycosylation sites (for example T291, T292, T576 of 
APP695), and APP O-glycosylation is suggested to be necessary for the APP processing by 
secretases [125]. Secretory trafficking through the TGN also involves APP tyrosine sulfation [126]. 
In addition to glycosylation, APP might be modulated by phosphorylation events, acetylation, 
neddylation, sumoylation, and ubiquitination (as specified at PhosphoSite [127]). 
Direct phosphorylation of the APP molecule is associated with important roles in the regulation of 
APP binding, traffic and processing. Indeed, APP is a phosphoprotein with several putative 
phosphorylation sites. Within the small ED domain (located between the E1 domain and the AcD 
domain) at least two phosphorylation sites were described, namely at Ser198, and Ser206 [126]. In 
addition, the APP cytoplasmic tail comprises at least three Tyr residues and five Ser/Thr putative 
phosphorylation sites: Tyr653, Thr654, Ser655, Thr668, Ser675, Tyr682, Thr686 and Tyr687, most of which 
are located within three functional motifs: 653YTSI656, 667VTPEER672, and 682YENPTY687; and their 
phosphorylated forms were detected in post-mortem brain tissue of AD patients (except for the 
T654; See Figure  A.6) [105, 128]. In spite of this, there is still some controversy concerning their 
functional value and in vivo validity. Of note, phosphorylation does not seem to be specific of the 
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APP full-length molecule, but some CTFs and AICD fragments are also detected as 
phosphorylated.   
Threonine 668 is the APP phosphorylation residue most extensively studied, followed by Tyrosine 
682. In fact, some level of interaction between these two phosphorylation residues was shown to 
exist and to modulate the APP interactome [129]. For example, the Shc and Grb2 protein adaptors 
only bind APP when this is phosphorylated at Y682, and the interaction is further increased by 
additional T688 phosphorylation. Nevertheless, the effect of APP phosphorylation at T668 in APP 
processing is still contradictory, but there is reports associating its phosphorylation to Aβ 
production [128], and to a decrease in APP cleavage by caspases. Importantly, APP 
phosphorylation at T668 appears to be important for APP binding to PIN1, and to Fe65 (or 
APBB1). Phosphorylation at T688 creates a recognition site for Pin1, but inhibits Fe65 binding.  
Phosphorylation of S655, that has been observed to occur in mature APP molecules in vitro and in 
vivo, may be a pivotal regulatory process for APP trafficking and proteolysis, since this residue is 
located in the basolateral sorting motif, 653YTSI656, and it is the only APP Ser/Thr residue 
phosphorylated by PKC [128, 130, 131]. Additionally, NMR analysis showed that APP 
phosphorylation at S655 induces significant local conformational changes in the APP C-terminus at 
and downstream the 653YTSI656 motif [132]. Besides PKC, S655 may be phosphorylated by 
calmodulin-dependent protein kinase II (CaMKII) [130], and by APP kinase I [131]. APP 
phosphorylated at S655 is an active molecule, crucial in the regulation of the APP subcellular 
trafficking. Through the use of APP S655 phosphomutants - serine 655 to alanine (S655A), and 
serine 655 to glutamate (S655E), mimicking dephosphorylated and phosphorylated APP, 
respectively – evidence was gather that S655 phosphorylation of mature APP molecules is a signal 
for APP traffic via the secretory pathway, facilitating its incorporation into TGN vesicles and Golgi 
exit. S655A is thus highly retained at the Golgi, exhibiting delayed incorporation into secretory 
post-TGN vesicles and delayed sAPPα medium secretion. In contrast, S655E appears to have 
facilitated Golgi exit, enhanced traffic between the Golgi and the PM, as well as a higher rate of 
sAPPα secretion. In addition, the APP S655 phosphomimetic mutant displayed enhanced half-life 
and recycling via increased binding to the retromer complex and consequent facilitated retromer-
mediated retrieval to the TGN [95, 133]. More recently, the S655 phosphomimetic mutant was 
associated to a decrease in APP trafficking to lysosomes and decreased Aβ42 production, 
potentially via disruption of the APP interaction with AP-3 [134]. This raises the hypothesis that 
part of the mature APP population is phosphorylated at S655 when it is necessary to target APP for 
a more dynamic TGN-to-PM trafficking, and sAPPα generation, what may occur through the 
catalytic action of PKC [133]. 
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3.!APP interactors – evidence for an APP role in nervous system 
development and function 
The complexity of APP derives not only from its elaborate intracellular trafficking, 
posttranslational modifications and proteolytic cleavage, but also from the existence of multiple 
protein interactors. A search in the expert curated human protein-protein interaction database 
‘HIPPIE’ retrieved more than 2000 protein partners for APP (accessed on June 27, 2016) [135]. 
APP protein interactions will depend on APP intracellular localization, posttranslational 
modifications and proteolytic cleavage. On the other hand, different APP partners will modulate 
the protein cellular “behavior” and will guide APP to specific functions (and dysfunction). 
Previously, some APP interactors that could modulate APP intracellular trafficking and proteolytic 
cleavage were mentioned, namely Fe65, SorLA, Sortilin, RanBP9, PAT1a, and PIN1. It was also 
mentioned that the phosphorylation status of the APP YENPTY motif modulates different APP 
protein-protein interactions. This C-terminal motif has been associated to several other important 
APP partners, as X11α/mint1, JIP, Dab1, and Numb, which have also been described to modulate 
the APP “life-cycle”. 
X11α/Mint1 binds to APP, independently of the APP phosphorylation status, and this interaction 
appears to modulate several aspects of APP trafficking and metabolism, including reduction of Aβ 
levels [136, 137]. In addition, Mint proteins are critical players in regulating activity-dependent 
APP endocytosis and insertion, which, in turn, affects Aβ generation. Upon synaptic activity, Mint 
mediates the convergence of APP/PS1 co-localization [138]. 
JIP scaffold proteins, JIP1 and JIP2, are structurally related proteins proposed to assembly 
functional JNK modules (binding MLK3, MKK7, and JNK) supporting the activation of the JNK 
signaling pathway. Both proteins are described to bind APP, which is suggested to mediate the 
APP binding to JNK, and in turn APP T688 phosphorylation. JIP1b seems to modulate the 
processing of APP (decreases intracellular CTFα, and sAPPα and Aβ secretion), while JIP-2 
apparently has no effect on APP processing [139, 140]. Furthermore, the JIP1 and JIP2 proteins, 
similar to APP, can bind the light chain of Kinesin-1 and are transported via MT to growth cones in 
cultured neurons [141]. The binding of JIP proteins to Kinesin-1 might be involved in the 
activation of Kinesin-1 and cargo release [142], and JIP1 (and to some extent JIP2) is reported to 
modulate the transport of T668-phosphorylated APP into neurites by Kinesin-1 [143, 144]. 
Dab1 is an adaptor protein involved in the Reelin signaling pathway, whose binding to APP is 
associated with increased levels of surface APP and α-secretase cleavage. In addition, Dab1 
overexpression seems to increase APP/CTFβ levels as well as Aβ secretion [145, 146]. Numb is a 
negative regulator of Notch, and has four alternatively spliced variants, described in mammals, that 
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differ in the length of their PTB and proline-rich region. Neural cells expressing short Numb 
isoforms (that lack inserts in the PTB domain) exhibited marked accumulation of APP in early 
endosomes and recycling compartments, and increased levels of APP-CTFs. On the other hand, 
cells expressing long Numb isoforms (with the insertion in the PTB domain) exhibited reduced 
amounts of cellular APP and its fragments. The expression of short Numb isoforms, and 
consequently increased amyloidogenic processing of APP, appear to be favored during trophic 
factor deprivation in primary cortical neurons [147]. 
Since the majority of the mentioned APP interactors bind to the same C-terminal motif in APP, 
some of which have opposing effects on APP cell fate, it is feasible that APP interactors have to 
compete for APP binding and that this competition will determine different APP fates in different 
cellular physiologic and pathologic contexts. Competition for APP binding has been described, for 
instance, for Dab1 and X11 [145], for Dab1 and Fe65 [148], and for X11 (β isoform) and Fe65 
[149]. Complementarily, the phosphorylation status of APP and APP proteolytic processing might 
dictate the identity of APP binding partners in the different contexts. Some interactions will depend 
on the phosphorylation status of specific residues, as already mentioned through the text, and some 
interactions might depend on the cleavage status of APP (full length protein versus APP cleavage 
products). For example, RanBP9 has been shown to interact more strongly with AICD than with 
the APP full-length protein, and ShcA preferentially interacts with C99 [112, 150]. 
The extracellular domain of APP also mediates several APP protein interactions, a fraction of 
which are secreted proteins that could function as APP ligands and place APP as a potential 
receptor. Reported potential APP ligands include: TAG-1 [151], F-spondin [152], contactins [153], 
Reelin [146, 154], and pancortins [155]. Curiously, the described ligands and their relation to APP 
are commonly associated with neurodevelopment. APP interaction with Reelin has effects on both 
proteins. On one hand, APP interaction with Reelin may be important to maintain normal Reelin 
levels in the brain. On the other hand, Reelin increases surface APP by decreasing APP 
internalization, increases APP α-cleavage, and decreases Aβ production. Importantly, APP and 
Reelin functionally interact to promote dendritic complexity and length, in vitro and in vivo, and 
apparently this effect might further involve β1-integrin [154]. Previous studies, had already shown 
that in rat hippocampal neurons, cell surface APP co-localized selectively with α1β1 and α5β1 
integrin heterodimers at characteristic segmental locations in the axonal membrane [156]. The role 
of pancortins in the regulation of neural precursors’ migration into the cortical plate might depend, 
at least in part, on their action as extracellular ligands of APP [155]. In addition, the extracellular 
region of membrane bound APP has been shown to interact with various extracellular matrix 
components (like heparin, collagen type I, and laminin), and other cell adhesion molecules (NCAM 
and NgCAM) suggesting a role for APP in cell-matrix and cell-cell adhesion [157]. 
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If we look at the known APP protein interactors retrieved by the HIPPIE database, select the 
interactors with the higher confidence scores (Supplementary Table A.1), and perform the Panther 
overrepresentation test [158], we can appreciate which functions might be enriched in this APP 
interactome and know which APP partners might be involved in each function. In the Panther 
overrepresentation test, analysis results are sorted accordingly to the hierarchy system established 
by the Gene Ontology Consortium[159] based on the interrelatedness of enriched functional terms - 
parent-child method. Focusing on gene ontology terms related to nervous system function, we can 
organize the APP known protein interactors into four functional groups of specific interest (Table 
A.1; for the complete list of selected gene ontology terms see Supplementary Table A.2). 
 
Table A.1 - APP known protein interactors are implicated in functions related to nervous system development and 
synapse function. In the panther overrepresentation test, here used, analysis results are sorted accordingly to a hierarchy 
system based on the interrelatedness of enriched functional terms (parent-child method). “Parent terms” were used to 
organize the APP known protein interactors into three functional groups of specific interest: Nervous system 
development group, Synapse function group, and Neuron death group. A fourth group includes additional gene ontology 
terms corresponding to functions tightly associated with brain development, function and organization. GO Biological 
process, indicates significantly enriched biological processes corresponding to more specific (child) terms. F. 
Enrichment, the fold enrichment of the genes observed in the APP protein interactors list over the expected based on the 
reference list (the human genome). A number greater than 1, indicates that the category is overrepresented. pvalue, 
calculated pvalue with Bonferroni correction. Only pvalues higher than 0.05 were considered. 
 GO Biological process F. Enrichment pvalue 
N
er
vo
us
 sy
st
em
 
de
ve
lo
pm
en
t 
cerebral cortex development 11.64 1.76E-04 
glial cell differentiation 9.07 1.74E-03 
limbic system development 9.76 1.71E-02 
negative regulation of neuron projection development 8.99 7.62E-03 
regulation of axonogenesis 8.36 9.50E-04 
axonogenesis 7.56 1.08E-07 
positive regulation of neuron projection development 5.89 2.79E-02 
Sy
na
ps
e 
Fu
nc
tio
n 
regulation of synaptic vesicle transport 24.56 1.77E-03 
regulation of neuronal synaptic plasticity 18.13 1.30E-03 
neuron-neuron synaptic transmission 15.86 3.15E-03 
chemical synaptic transmission, postsynaptic 13.88 7.62E-03 
presynaptic process involved in synaptic transmission 10.88 1.59E-03 
synapse organization 10.43 2.23E-05 
positive regulation of synaptic transmission 10.38 2.34E-03 
regulation of neurotransmitter levels 8.41 2.32E-04 
N
eu
ro
n 
de
at
h Neuron apoptotic process 24.68 1.63E-04 
positive regulation of neuron apoptotic process 24.30 1.69E-06 
negative regulation of neuron apoptotic process 11.20 1.02E-05 
ot
he
rs
 
Learning or memory 8.04 2.77E-05 
Extracellular matrix organization 8.27 6.09E-09 
Regulation of cell adhesion 4.38 6.54E-05 
Cell migration 4.18 1.41E-05 
Cytoskeleton organization 4.09 4.56E-06 
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The two major functional groups obtained, presenting more gene ontology terms and higher 
number of proteins associated were Nervous system development with 31 terms associated, and 
Synapse function (including synaptic signaling and synapse organization) with 15 terms, see Table 
A.1 and Table A.2. Analysis of such APP protein interactors can give us more clues about APP 
physiological function in the nervous system. 
 
Table A.2 - APP protein interactors associated with Nervous system development, Synapse function, Neuron death, and 
other related functions. The proteins are here represented by the gene symbol. ECM, extracellular matrix. 
 APP protein interactors (by gene name) 
Nervous system 
development 
UCHL1; NUMB; RANBP9; NOTCH1; SHC1; YWHAG; GSN; SORL1; NEFL; RAB3A; 
CALR; CFL1; NF1; GSK3B; HSP90AA1; KLK6; DLG4; ITM2A; CASP3; GFAP; STXBP1; 
MAPT; TNFRSF21; ACTB; LRP1; CAV1; TGFB2; RNF2; UBB; COL25A1; TGFB1; 
APBB2; APOE; GSK3A; APBA1; AKT2; ACHE; CLU; ABL1; PIN1; CDK5; GNAO1; 
APOA1; MBP; APBB1; DAB1; FLOT1; PARK2; PSEN1; SPTAN1; SHC3; MAPK8IP2; 
NGFR; CUL7; FOS; EGFR; APBA2; TMEM30A; APLP1 
Synapse 
function 
RAB3A; NF1; GSK3B; DLG4; SNCA; STXBP1; CHRNA7; SNCB; APBA3; HSPA8; 
DNM1; APOE; GSK3A; APBA1; ACHE; CDK5; KIF1B; MBP; PARK2; PSEN1; SHC3; 
MAPK8IP2; APBA2; YWHAG; GFAP; CLSTN1; FLOT1; NGFR; PIN1 
Neuron death 
KLK6; CASP3; TNFRSF21; GAPDH; CDK5; PSEN1; NAE1; SORL1; NEFL; SNCA; 
STXBP1; SNCB; LRP1; SET; NGFR; NF1; GSK3B; MAP3K5; UBE2M; TGFB2; CLU; 
ABL1. 
Learning and 
memory 
NF1; DLG4; CASP3; CHRNA7; PRNP; CDK5; PARK2; PSEN1; SHC3; MAPK8IP2; FOS; 
EGFR 
ECM 
organization 
A2M; GSN; NF1; FBLN1; SNCA; GFAP; HSPG2; TGFB2; COL4A6; TGFB1; APBB2; 
TTR; FLOT1; BGN; NOTCH1; HSPA8; ABL1 
Regulation of 
cell adhesion 
NOTCH1; GSN; CALR; NF1; GSK3B; HSPD1; FBLN1; CASP3; TNFRSF21; CAV1; 
TGM2; TGFB2; PRNP; TGFB1; ABL1; APOA1; DAB1; FLOT1 
Cell migration NUMB; MAPRE1; NOTCH1; GSN; SORL1; CALR; NF1; GSK3B; FBLN1; LRP1; TGFB2; TGFB1; APOE; AKT2; TIRAP; CDK5; DAB2; EGFR; ADAM17 
Cytoskeleton 
organization 
RANBP9; SHC1; MYH9; GSN; QRICH1; NEFL; CALR; EPB41; CFL1; CRYAB; NF1; 
GFAP; MAPT; DNAH1; CAV1; GAPDH; APOE; MAST1; ABL1; CDK5; SPTAN1; CUL7; 
TUBB; ARRB1 
 
Interestingly, the APP protein interactors in the three main functional groups shown in Table A.1 
and table A.2 (‘Nervous system development’, ‘Synapse function’, and ‘Neuron death’) seem to be 
highly interconnected, has demonstrated in Figure  A.9. Some of the interactors here represented 
were already mentioned due to their effect on APP, namely APBB1 (or Fe65), APBA1 (or X11α, 
or Mint1), MAPK8IP2 (or JIP2), Dab1, Sorl1 (or SorLA), RanBP9, LRP1, Shc, Numb, Pin1. 
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Figure  A.9 - Protein-protein interaction network of the APP interactors attributed to the Nervous system development, 
Synapse function, and Neuron death functional groups. The network was constructed using the Cytoscape software 
(version 3.4.0). Information about how the APP partners interact between each other was retrieved from the International 
Molecular Exchange (IMEx) consortium partners only. Red outlined circles represent proteins that are brain 
specific/enriched as indicated in the Human Protein Atlas database. Network nodes are configured by size accordingly to 
node degree (low values to small sizes) and by color accordingly to the functional group (‘Nervous system development’, 
green; ‘Synapse function’, purple; and ‘Neuron death’, blue)!
 
Based on simple topological parameters like node degree (number of interactors) and betweenness 
centrality (a measure of node’s centrality, that is, how frequent a node represents the shortest-path 
between other nodes), one of the highlighted nodes is EGFR (Figure  A.9). APP interaction with 
EGFR was detected in a screen of integral membrane protein-protein interactions using a variation 
of a membrane yeast two-hybrid assay. In the study, the interaction seems to be stronger with a 
constitutive kinase active EGFR mutant [160]. The EGFR (and its ligands) are expressed in various 
regions of the CNS, and their expression pattern is suggestive of a role in neurodevelopment. In 
addition, EGFR signaling has been implicated in several neurological disorders including in 
Alzheimer’s disease.  Interestingly, a study using single-cell RNA-seq to characterize DCX-
expressing immature neurons during neurogenesis in the hippocampus of adult mammals, showed 
that the progression from early, stem-like stage, to the more mature neuronal stage is marked by an 
up-regulation of genes enriched for interactions with EGFR along with synapse and dendrite 
localization, cellular transport, nitric oxide signaling and long-term potentiation [161]. 
52  University of Aveiro!
APP and Fe65 (APBB1) colocalize and interact at two type of mobile membranes namely, integrin-
based focal complexes characteristic of extending lamellipodia [162] and growth cones of 
developing neurons [163]. The interaction between APP and Fe65 accelerates cell migration during 
a wound-healing assay, an effect that is thought to also involve the Fe65 protein interactor Mena, 
an actin-binding cytoskeletal protein that regulates lamellipodia dynamics [162]. Additional 
studies, showed that disruption of APP and Fe65 interaction in cultured hippocampal neurons 
results in aberrant axonal branching, again with indications of the involvement of a third protein 
that binds to the WW domain of FE65 [164]. The phenotypes displayed by Fe65 KO mice (either 
single or Fe65/Fe65l1 double KO), which have several similarities to APP family members triple 
KO mice, further implicate Fe65 in cortical development [165], and in central and peripheral 
synapses modulation [166]. Curiously, Fe65 (and Fe65L/APBB2) also binds EGFR (see Figure  
A.9). 
In Figure  A.9, we can see that APP shares another interesting protein interactor with EGFR, the 
protein Numb. Numb inhibition of Notch1 signaling pathways, an important signaling in cell fate 
decisions during central nervous system development and maturation [167], is thought to depend 
on its function as an endocytic adapter protein that mediates the internalization of receptors. 
Conditional mouse mutants with deletion of numb in developing sensory ganglia show reduced 
endocytosis, a significant increase in nuclear Notch1, and a severe reduction in axonal arborization 
in afferent fibers. Contrarily, overexpression of Numb induces accumulation of Notch1 in 
markedly enlarged endocytic-lysosomal vesicles, reduced nuclear Notch1, and aberrant axonal 
arborization [168]. Other studies also implicated Numb in neuronal differentiation and neurite 
outgrowth [169, 170]. Curiously, enhanced EGFR signaling has been described to reduce Notch1 
expression through Numb, mediating the expansion of the neural progenitor cells pool and 
decreasing neural stem cells number and self-renewal in the subventricular zone [171]. Apparently, 
binding of APP to Numb prevents Numb from inhibiting Notch, and increases Notch activity [172]. 
Ectopic expression of human APP-family members induced Notch gain-of-function phenotypes in 
the mechano-sensory organs (MSOs) of Drosophila, and expression of high levels of APP (and 
APLP2) suppresses the abnormal phenotypes in drosophila development induced by Numb 
overexpression [173]. Noteworthy, in the mentioned work, Dab was also shown to play a role in 
the fly phenotypes induced by APP, as Dab also binds Notch, authors propose it could be also 
mediating the interaction between APP and Notch [173]. Dab1 is an important mediator of Reelin 
signaling crucial not only for neuronal migration and positioning, but also for dendritogenesis 
during neocortex development [174]. In utero electroporation of Dab1 RNA interference in a 
subset of migrating neurons at E16, resulted in  simplified leading processes that are less likely to 
contact the marginal zone at E20 (even in the presence of Reelin) comparing to non-electroporated 
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cells. At postnatal day 2, electroporated cells show simplified dendrites also less likely to contact 
the MZ. This shows that Reelin-Dab1 signaling has an important function in the establishment or 
elaboration of neurites in the stage between neuronal precursor and postmigratory neuron [174]. 
Interestingly, the APP role in the regulation of neural precursor cells entry in the cortical plate 
appears to depend on binding to Dab1 (and downstream Dab1, on DISC) [175, 176]. 
The X11α (or Mint1, or APBA1 in the network) presents brain specific expression and also comes 
up as an APP protein interactor with potential function in neuronal development and synapse 
function. Although not mapped in the Figure  A.9 network, X11α interacts with the synaptic fusion 
protein, and APP interactor, Munc 18-1 (or STXBP1) [177]. In addition, X11α is described to be 
part of a tricomplex, formed by pre-synaptic protein CASK (which binds β-neurexin) and Veli 
proteins, proposed to couple membrane traffic and synaptic vesicle exocytosis to neuronal cell 
adhesion [178, 179]. X11 KO mice confirm the role of this protein in presynaptic function and 
neurotransmitter release, what might be dependent on a functional interaction with Munc 18-1 
[180]. The X11 family of adaptor proteins also interacts with ApoEr2 (a Reelin receptor), and 
might contribute, together with Reelin, to the regulation of ApoEr2-mediated cell motility (in this 
study, neither X11 nor Reelin had an effect in APP-mediated cell motility) [181]. X11α is also 
described to interact with Kalirin-7, a Rho-GEF that regulates dendritic morphogenesis [177]. In 
aged X11α/App double transgenic mice that produce high levels of brain Aβ and develop age-
related memory defects, X11α is able to decrease brain Aβ levels and to rescue the memory defects 
[182]. Munc 18-1 (or STXBP1; an isolated protein in the protein-protein interaction network in 
Figure  A.9) is a neuronal protein required for synaptic vesicle exocytosis that interacts with 
syntaxin 1 and X11α, as mentioned. Stxbp1 KO mice develop neurodegeneration and present 
abnormal synaptic transmission and complete loss of neurotransmitter secretion from synaptic 
vesicles during development [183]. Mutations in the human STXBP1 gene cause epileptic 
encephalopathies associated with intellectual disability, and neuronal cultures from human iPSCs 
of STXBP1 haploinsufficiency show impaired neurite outgrowth [184]. 
JIP2 (or MAPK8IP2, or islet brain-2 protein) is a brain enriched protein that seems to be an 
attractive APP protein interactor (high-confidence APP interactor) concerning its implication in 
nervous system development, synaptic transmission, and learning and memory. Within the network 
it binds to EGFR and Cofilin-1, an actin-severing protein (Figure  A.9). JIP-2 is an integral 
constituent of postsynaptic densities in cerebellar and cerebral cortices, and JIP-2 null-mice display 
motor and cognitive (social interaction, exploratory, and learning) deficits [185]. Such defects 
might be due to the described alterations in Purkinje cell morphology associated with abnormal 
glutamatergic transmission in the cerebellum [185, 186], or might reflect synaptic transmission 
deficits throughout the brain, an aspect still not evaluated. This protein has also been linked to 
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human neurodevelopment syndromes [187]. The proline-rich domain in the cytoplasmic tail of 
ApoER2 interacts with JIP-2 and JIP-1 proteins. The expression of proline-rich domain-containing 
splice variants of ApoER2 and the expression of JIP-2 coincide with murine brain stem cells 
differentiation into neurons. Binding of ApoER2 to JIPs links the Reelin signal to the JNK 
pathway, a parallel signal event to the well described Dab1 [188].  
One fascinating aspect, at this point, is that not only does Reelin interacts with APP, and APP is 
able to interact and signal via Dab1, but also the Reelin receptor ApoER2 seems to share several 
interactors with APP (JIP proteins, X11α, and even Fe65 [189]). Furthermore, APP seems to be 
tightly involved in lipoprotein metabolism, and vice-versa, via interactions with LDL receptor 
related proteins (LPR; APP is described to bind LRP1, LRP1b, ApoeR2 and LRP2/megalin, and 
the related family member SorLA). This is an important aspect since neurons in the adult brain 
depend on cholesterol derived from internalized lipoproteins via lipoprotein receptors. Cholesterol 
is, for example, required for membrane reorganization during synaptogenesis [190]. For instance, 
selective deletion of LRP1 (here highlighted as an APP protein interactor functioning  in ‘Nervous 
system development’ and ‘Neuron death’, see Table A.2 and Figure  A.9), in mice forebrain 
neurons, leads to decreased brain levels of cholesterol and results in age-dependent dendritic spine 
degeneration, synapse loss and memory decline [191]. LRP1 was also involved in a signaling 
pathway with major implications in neuronal function, through the activation of Src family kinases 
and transactivaton of Trk receptors. By this way, different LRP1 ligands were shown to be able to 
activate Akt and ERK1/2 and promote neurite outgrowth in PC12 cells and rat cerebellar granular 
neurons [192]. 
In Figure  A.9, we can also notice another brain-enriched APP interactor, the ubiquitin C-terminal 
hydrolase (UCH)-L1, also binding to EGFR, RanBP9, and polyubiquitin-B (UBB). Although 
mainly described for its role in the recycling of ubiquitin, deletion of the Uchl1 gene (and Uchl1 
mutant mice) causes a specific type of axonal degeneration, suggesting that this protein has a 
crucial role in the maintenance of axonal integrity [193]. During embryonic brain development, 
UCH-L1 expression changes showing increased levels in the cortical plate at the time of 
neuritogenesis and neuronal maturation. UCH-L1 is expressed in neural precursor cells and seems 
to regulate their morphology [194]. In addition, this enzyme is downregulated in sporadic AD 
brains, and impaired activity has been reported in many neurodegenerative diseases. UCH-L1 
inactivation leads to the inhibition of hippocampal LTP and impairs contextual learning. In 
APP/PS1 mice, transduction of UCH-L1 protein restores Aβ-induced synaptic dysfunction and also 
re-establishes synaptic plasticity and improves associative memory [195]. Such effect depends on 
the ability of UCHL1 to interact with APP and to mediate APP ubiquitination followed by 
trafficking to lysosome for degradation [196]. 
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Within the constructed protein-protein interaction network, UCH-L1 binds RanBP9. This APP 
protein interactor is also of interest when referring to neuronal development. RanBP9 (or RanBPM) 
is an evolutionarily conserved small GTPase located in cytoplasm and nucleus. Functionally, it was 
first described as having a role in nuclear import and export and spindle formation [197]. It has also 
been described to function as an adapter protein coupling membrane receptors to intracellular 
signalling pathways; namely, it was proposed to stimulate Ras-Erk-SRE pathway activation by 
recruiting Sos [198]. However, recently, RanBP9 was reported to function as an inhibitor of the 
ERK pathway by binding the c-Raf complex and regulating c-Raf stability. In this way, RanBP9 
loss of expression results in constitutive activation of the ERK pathway and promotes cell 
proliferation and cell migration [199]. Concordantly, RanBP9 is shown to physically interact with 
Plexin-A1, and when overexpressed cooperates with PlexinA1 to reduce cell spreading and to 
strongly inhibit axonal outgrowth and branching in vitro and in vivo [200]. Noteworthy, Sema3A is 
reported to promote dendritogenesis (in contrast to inhibition of axonal outgrowth), and RanBP9 
could also contribute (positively) to such process. Interestingly, it has been shown that RanBP9 
colocalizes with APP and Fe65 at lamellipodia, and in Ranbp9-transgenic mice, reduced levels of 
surface β1-integrin, LRP, and APP correlated with inhibition of neurite arborization in primary 
hippocampal neurons. In this way, the RanBP9 modulatory effects on the endocytosis and cell 
surface levels of β1-integrin, LRP, and APP appear to be correlated with its roles in cell 
attachment, spreading, focal adhesion signalling and assembly, and neurite arborisation [201]. A 
recent report showed that the endogenous levels of RanBP9 are required for Aβ-induced collapse 
of growth cones in immature neurons and depletion of synaptic proteins in mature neurons. 
RanBP9 reductions protected against cofilin–actin pathology, synaptic damage, gliosis, and Aβ 
accumulation associated with AD mice models [202]. 
As already mentioned, residues 657–676 of APP cytoplasmic domain possess affinity for Gαo (one 
of the isolated proteins in the Figure  A.9). Although, the interaction between APP and Gαo is 
confirmed, it remains to be clarified whether it promotes Gαo activation [87] or inhibition [203]. 
Analysis of this interaction in human brain samples from AD patients revealed that the interaction 
is decreased with disease progression, which further correlates with increases in the levels of 
membrane Aβ and Gαo activity [204]. In Manduca sexta nervous system, endogenously expressed 
full-length APPL (which retains the Gαo binding site) interacts with Gαo and both proteins 
colocalize in regions of active motility, including the leading processes of migrating neurons and 
the growth cones of elongating neurites. Furthermore, either interference with APPL expression or 
inhibition of Gαo leads to a similar phenotype characterized by inappropriate migration and 
outgrowth [205]. 
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The significance of APP and its protein-protein interactions can be further supported by their 
involvement in human diseases. The DisGeNET database (consulted on June 26, 2016) integrates 
human gene-disease associations from various expert curated databases and text-mining derived 
associations [206].  By exporting all the genes sharing diseases with APP, and filtering the 
exported list by MeSH Disease Class including Nervous System Diseases and/or Mental Disorders, 
we can see with which genes APP is commonly associated in these classes of diseases. By crossing 
the resulting list with the APP protein-interactors involved in nervous system development, 
synaptic function, and neuron death presented on Table A.2, we can see that APP and these specific 
protein interactors are annotated to 45 different nervous system or mental disorders (see Figure  
A.10).  
 
Figure  A.10 - Nervous system diseases network shared by APP and its binding partners. The complete list of 
diseases shared by APP and other human genes was retrieved from the DisGeNET database. This list was filtered for 
Nervous system diseases and mental disorders only. The APP protein interactors previously implicated in Nervous 
system development, Synapse function, and neuron death were searched in the obtained list, to create a network of 
diseases shared between all these human genes. Of note, SNCB, CLSTN1, NAE1, UBE2M, SHC1, YWHAG, RAB3A, 
NF1, ITM2A, TNFRSF21, RNF2, GSK3A, GNAO1, SPTAN1, SHC3, MAPK8IP2, CUL7, APBA2, TMEM30A, and 
APLP1 were not attributed to any APP associated Nervous System Diseases or Mental Disorders. Diseases are 
represented in diamond shape nodes and names are in blue. Gene name are represented by their symbol in circular nodes 
and dark color letters. Network nodes are configured by size accordingly to node degree (low values to small sizes) and 
by color accordingly to betweenness centrality (low values to bright colors). Network edges are configured by size 
accordingly to edge betweenness (low values to small sizes). 
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The diseases associated with the highest number of APP protein-interactors included Alzheimer's 
Disease (linked to 45 APP interactors), Schizophrenia (30), Parkinson Disease (20), Down 
Syndrome (16), Amyotrophic Lateral Sclerosis (16), and Bipolar Disorder (15). On the other hand, 
APP protein-interactors sharing more diseases associations with APP include APOE (31), MAPT 
(27), PSEN1 (21), GFAP (16), SNCA (16), CLU (14), and CHRNA7 (14). 
Concerning the above highlighted APP interactors all their coding genes seem to be associated, 
together with APP, with Alzheimer's Disease. In addition,  UCHL1 seems to be involved with APP 
in other specific diseases like Parkinson Disease, Lewy Body Disease, and Presenile dementia; 
SORL1 is involved in Bipolar Disorder, Mild cognitive disorder, Schizophrenia, Presenile 
dementia, and Down Syndrome; LRP1 is involved in Schizophrenia, Unipolar Depression, Major 
Depressive Disorder, and Presenile dementia; EGFR is involved in Major Depressive Disorder, 
Unipolar Depression, and Amyotrophic Lateral Sclerosis; DAB1 in Autistic Disorder, 
Schizophrenia, and Prion Diseases; STXBP1 is involved in Autistic Disorder, and Schizophrenia; 
NUMB is involved in Bipolar Disorder;  RANBP9 is involved in Schizophrenia. APBB1 (or Fe65) 
and APBA1 (X11) are only annotated for Alzheimer's disease. Again, Schizophrenia is the second 
most common disease associated with APP and these specific APP protein interactors. This is a 
very interesting aspect, since alterations in neuritogenesis have been recognized as an etiological 
factor for this development disease, and Schizophrenia’s neuroanatomical findings include reduced 
intraneural space (the space occupied by dendrites and axons), decreased dendritic markers and 
reduced dendritic length [207]. Furthermore, a study of abnormally expressed genes in postmortem 
prefrontal cortex samples of schizophrenia, bipolar disorder, and major depression patients 
highlighted APP as an essential gene. Namely, APP was defined as a tissue-specific gene, highly 
abundant in all disease and control samples, with the highest ranks in the centrality analysis of the 
constructed protein-protein interaction networks, where it emerged as a critical node interacting 
with marker genes of the specific diseases [208]. 
The simple analysis presented here demonstrates how APP, through its numerous bind partners, 
can be related to nervous system development and function, and disease. 
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4.!APP physiological role in brain development and maturation – specific 
role in neurite outgrowth 
In the previous sections, details about the complexity of APP biology were shown, namely the 
intricate relationships between its intercellular trafficking, proteolytic processing, phosphorylation 
events, and protein-protein interactions. It was also demonstrated how the APP interactome could 
relate with APP function in nervous system development and disease. 
Early in brain development, APP mRNA is expressed by all neuroepithelial cells in the ventricular 
zone, with the APP protein specifically localized within the apical cellular compartment. APP 
mRNA is also found in the cortical plate [70, 209]. During development, APP is present in growing 
neurites of neonatal rat brain [210], and developing neurons undergo increased APP expression, 
with this protein being preferentially localized in the neuritic growth cones [156, 211]. APP levels 
peak in the second postnatal week, the time of brain maturation and completion of synaptic 
connections, and the APP expression pattern correlates well with this protein having a role in brain 
development [212]. 
Although App knock-out (KO) mice do not show severe brain phenotypes, analysis of App KO 
phenotypes further implicated APP in brain development and brain function processes like 
neuritogenesis, axon guidance, dendritic organization and integrity, axonal transport, 
synaptogenesis and (pre- and post-) synaptic function, synaptic plasticity and adaptive spine 
remodeling associated events, and experience-dependent axonal pruning (See Table A.3).  
Table A.3 - APP knock-out (KO) mice studies. Ref, study reference. 
APP suggested 
function  KO mice described Phenotypes (vs control wild-type mice) Ref 
Neuritogenesis and 
axon guidance 
Retarded somatic growth; 
Severely impaired spatial learning and exploratory behavior; 
Reduced locomotor activity and grip strength; 
Alterations in sensorimotor development; 
Agenesis of the corpus callosum. 
[213] 
Neuro-muscular 
function 
Reduced body weight (decreased food and water intake); 
Decreased locomotor activity and forelimb grip strength; 
Age-dependent reactive gliosis in the hippocampus and various parts of the 
neocortex; 
Histopathological evaluation showed no signs of abnormal brain structures; 
No compensatory up-regulation of Aplp1 and Aplp2 mRNA. 
[214] 
 
Neuronal 
excitation/inhibition 
balance 
Hypersensitivity to kainate-induced seizures (Seizures started earlier, were more 
severe, and led to enhanced mortality); 
Enhanced expression of c-fos in the cortex and cingulate gyrus (but not in 
hippocampus); 
No differences in the amount of morphological damage, synaptodendritic 
damage and extent of TUNEL labeling. 
[215] 
(Postnatal) brain 
development 
(maturation); 
Neuritogenesis and 
axon guidance 
Retarded gain of body weight during postnatal development (no consistent 
reduction of body weight as adults); 
~10% reduction of adult brain weight (no difference when littermates); 
Size reduction of the anterior commissure; 
Increased frequency of callosal dysgenesis and agenesis in specific strains 
sometimes associated with smaller ventral hippocampal commissure. 
 
[216] 
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APP suggested 
function  KO mice described Phenotypes (vs control wild-type mice) Ref 
Modulation of 
copper homeostasis 
Increased copper levels in cerebral cortex (no difference in the levels of iron or 
zinc; no difference in the levels of metals in cerebella); 
Increased copper levels in the liver (no difference in the spleen); 
Tendency to decrease copper levels in sera. 
[217] 
Maintenance of 
neuronal 
homeostasis and 
synaptic function 
during ageing – 
potential role in 
spatial learning 
Decrease in the efficiency of LTP within the CA1 region of the hippocampus 
(impaired LTP after high-frequency stimuli, reduction in the EPSP slope 
immediately after the burst stimulus); 
Reactive gliosis; 
Younger mice show decreased body weight, are less active, and have lower 
forelimp grip strength; 
No differences in the levels of presynaptic markers, synapsin and synaptophysin, 
and MAP-2 either in younger or older mice; but a subgroup of mice showing 
weight loss and hypolocomotor activity revealed severe morphological 
abnormalities in the cortex and hippocampus (namely decreased levels of 
presynaptic and dendritic markers, and reduced branching of dendrites); 
No motor or sensory deficit; 
Older mice show impaired performance in the conditioned avoidance test; 
Inferior performance in the water maze test of spatial learning (for both younger 
and older mice). 
[218] 
Pre-synaptic and 
post-synaptic 
function within the 
hippocampus of 
mature animals 
Reactive gliosis throughout the hippocampus of 8–12-month-old mice; 
Morphological alterations: disrupted immunostaining for MAP-2 and 
synaptophysin within the stratum radiatum of the CA1 region of the 
hippocampus; 
Greater proportion of atypical neurons with smaller mean overall length; 
Reduction in the projections of CA1 neurons into the stratum radiatum; 
Reductions in overall dendritic length and loss of smaller branching fibers; 
Similar biophysical properties of post-synaptic neurons; 
Intrinsically lower capacity for LTP: impaired amplitude of action potentials; 
reduced paired-pulse depression of GABA-mediated synaptic currents (no 
difference in facilitation of glutamate-mediated EPSPs and no change in paired-
pulse facilitation). 
[219] 
Lipid homeostasis  Increased brain levels of cholesterol and sphingomyelin. Particular involvement of Aβ. [220] 
Control of cell cycle 
progression during 
cortical 
development 
Increased proportion of cells in G2/mitosis and in the duration of G2 (no 
alteration in the proportion of neurons and cell death; no gross morphological 
differences; no alteration in the expression of APLP1 or APLP2) in the 
developing cortex of the E15 mouse embryo. 
[209] 
Synapse formation 
and transmission  
(early development 
changes)  
No differences in the resting membrane potential in autaptic hippocampal 
neurons at 18–20 days in culture; 
Enhanced strength of excitatory synaptic transmission (AMPA-mediated EPSCs 
and NMDA-receptor-mediated EPSCs); 
Higher frequency of spontaneous mEPSCs (but mean amplitude unaffected); 
Enhanced readily releasable vesicle pool size per cell; 
Increased evoked EPSCs amplitude; 
Increased dendritic length and synapse number; 
Higher staining intensity of synaptophysin-positive presynaptic terminals in the 
stratum radiatum. 
[221] 
Spatial learning 
Decreased body weight and a strong reduction of wet brain (age: 10–12 months 
of age); 
No apparent abnormalities shown by histopathological analysis; 
Grip strength deficit; 
Altered circadian locomotor activity 
Reduced exploratory activity under aversive conditions; 
Spatial navigation deficit and delayed learning (increased thigmotaxis, less 
efficient orientation toward the platform, and increased swim path length in the 
water maze place navigation task) associated with motor impairment (reduced 
swim speed); 
Defect in the rate of induction and maintenance of LTP in the CA3/CA1 pathway 
on acute hippocampal slices (but unaltered basal synaptic transmission and 
presynapse functionality). 
 
 
[222] 
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APP suggested 
function  KO mice described Phenotypes (vs control wild-type mice) Ref 
Modulation of 
dendritic spine 
density 
Two fold increase in the number of dendritic spines in apical dendrites of layer 
III/V cortical neurons of 4-6 months age mice  (by in vivo transcranial two 
photon); 
Increased level of thin-, stubby-, and mushroom-shaped spines (especially of 
stubby- and mushroom-shaped persistent and functional spines). 
[223] 
Modulation of 
synaptic properties 
of GABAergic 
neurons by 
regulation of 
Cav1.2. subunit of 
L-type calcium 
channels 
Increased levels of Cav1.2 in GABAergic inhibitory neurons in striatum and 
hippocampus; 
Increased peak calcium current density and selective increase in Ca2+ influx; 
Normal GABA-mediated inhibition under baseline conditions; 
Reduced paired-pulse inhibition of GABAergic inhibitory postsynaptic currents; 
Increased GABAergic post-tetanic potentiation; 
Increases in GABAergic calcium currents. 
[224] 
Spine formation and 
development 
Fewer and shorter dendritic spines in cortical layers II/III and hippocampal CA1 
pyramidal neurons of 1 year-old mice (by Golgi staining); 
Decreased in apical oblique and basal dendrites of cortical pyramidal neuron; 
Decreased glutamate levels and increased GABA levels (by NMR analysis of 
brain extracts). 
[225] 
Axonal transport Reduced (in vivo) axonal transport at 2–4 months of age and 12-17 months of age mice (by Manganese Enhanced MRI). [226] 
Dendritic integrity 
and synaptic 
structure and 
function in the 
hippocampus 
Decreased spine density and dendritic complexity in cultured hippocampal 
neurons from P0-P1 neonatal pups; 
Decreased apical arbors complexity of CA1 neurons (brain slices of 13 months 
old mice), shorter apical dendritic length, no alteration in basal dendritic length; 
Reduction of spine numbers confirmed in vivo with no difference in mean spine 
volume for all spines and subtypes (younger mice showed a non-significant trend 
in reduction in spine density); 
Reduction in long-term potentiation after tetanic stimulation, but no changes in 
basal synaptic transmission. 
[227] 
Axonal transport 
Reduced transport from the hippocampus to the septal nuclei and amygdala after 
7 hours of Mn2+ administration, and 
reduced transport to the contralateral hippocampus after 25 hours (by MEMRI); 
Reduced Mn2+ transport in the visual pathway from eye to midbrain and 
superior colliculus. 
[228] 
Axon guidance of 
commissural 
neurons 
No major defect in the number of bundles or in the overall pathway of 
commissural extension in E11.5 spinal cord sections;  
Change in the distribution of axon bundles with significantly thicker bundles. 
[229] 
Dendritic 
architecture and 
spine density 
Reduced dendritic complexity in mid-apical dendrites and an increased number 
of primary and secondary basal dendrites, without overall differences in total 
dendritic length in organotypic hippocampal cultures (prepared at postnatal day 0 
and analysed at day in vitro 17); 
Decreased spine density and reduced number of mushroom spines (but increased 
number of stubby spines) in both apical and basal dendrites; 
No difference in basal synaptic transmission and no significant differences in 
paired-pulse facilitation. 
[230] 
Glial cell activation 
and innate immune 
cell response to 
inflammatory injury 
Reduced Iba-1-positive microglia cell number, with smaller cell body size, 
shorter microglia processes and less ramifications in both 3 and 9 months old 
mice (in response to intracranial LPS injection); 
Reduced astrocyte cell number, which were smaller and presented shorter 
processes only in 3 months old mice; 
Reduced expression of glia markers Iba1, CX3CR1, P2ry12 and Hexb mRNA, 
and increased expression of CD11b and Trem2 in 3 months old mice; Reduced 
expression of glia markers P2ry12 and Hexb, and increased expression of DAP12 
in 9 months old mice; 
Reduced expression of innate immune cytokine TNF-α, IL-1β, Il-10 and TGFβ 
mRNA in the hippocampus in 3 months old mice; more drastically reductions in 
the levels of TNFα, IL-1β and IL-10; 
Altered expression of Synaptophysin, PSD-95, and BNDF mRNA levels in 
response to injury. 
 
 
 
[231] 
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APP suggested 
function  KO mice described Phenotypes (vs control wild-type mice) Ref 
Dendritic spine 
dynamics and 
adaptive spine 
remodeling in the 
adult brain 
associated with 
maintenance of D-
serine homeostasis 
No difference in spine densities in apical tufts of layer V pyramidal neurons in 
the somatosensory cortex of 4-5-month-old mice (by long-term in vivo two-
photon microscopy); 
Reduced turnover rate (elimination and formation) of dendritic spines; 
Failed increase in spine density after: environmental enrichment due to abnormal 
rate of spine elimination; 
Reduced fraction of thin spines (more dynamic and responsive to external 
stimulation) and enhancement in relative number of mushroom spines; 
Decreased extracellular concentration of endogenous D-serine (increase of total 
D-serine and L-serine);  
Memory deficits showed in the novel objective recognition test (similar time to 
explore novel and already familiar objects). 
[232] 
Axonal pruning (in 
the adult 
somatosensory 
cortex after sensory 
loss) 
Block of axonal pruning 1, 2, and 7 days after whisker plucking; 
Increased length of axon collaterals 2 days after (no difference 7 days after); 
Impaired axonal pruning confirmed in the APPflox/flox conditional KO mice; 
Alteration on gross overall structure (e.g.: more branch points at baseline); 
Increased bouton density on stable axons 1 day after whisker plucking, pruned 
back by day 2; 
More bouton elimination 2 days after whisker plucking. 
[233] 
 
App KO mice are viable and fertile, but present reduced body weight and brain weight. Reactive 
gliosis, loss of grip strength and reduced locomotor activity appear to be consistent phenotypes, 
together with spatial learning and exploratory behavior deficits, sometimes correlated with long-
term potentiation (LTP) alterations. In general, it appears to exist a positive correlation between 
APP expression levels and spine density, but there are some contradictory results (see Table A.3), 
further complicated by results of transgenic mouse models of AD [234]. The APP role on dendritic 
spine formation and synaptic transmission is, therefore, very complex and most probably 
dependent on age, neuron type, and cognitive process. 
The mild phenotypes observed in App KO mice, and the phenotypes of combined KO of APP 
family members suggest the existence of functional complementation within the APP gene family, 
but also reveal key physiological roles for APLP2 and APP (see Table A.4).  
 
Table A.4 - APP family members combined knock-out (KO) mice and APP knock-ins. Ref, study reference. 
Type of KO or KI Main phenotypes described Ref 
App-/-Aplp1-/- 
Viable and fertile; 
body weight deficit similar to single KO; 
No apparent abnormalities, and no upregulation of APLP2 protein in brain 
homogenates. 
[235] 
Aplp1-/-Aplp2-/- Lethality (24h after birth) [235] 
App-/-Aplp2-/- 
Lethality (during development or 24h after birth) 
Reduced vesicle density in the presynaptic active zone, excessive nerve 
terminal sprouting and reduced apposition of presynaptic and postsynaptic 
markers at NMJ, and impaired synaptic transmission; 
No obvious histopathological abnormalities in the brain. 
[235], 
[236], 
[230]. 
Conditional App-/-
Aplp2-/- in excitatory 
forebrain neurons 
(results vs 
APLP2KO) 
Normal grip strength, basal locomotor activity, and locomotor activity and 
exploratory behavior in a novel environment; 
Water maze place navigation task: reduced learning, goal orientation, and 
spatial reference memory; 
Impaired spatial working memory, and impaired nested behavior; 
No gross brain abnormalities, no necrotic or apoptotic cell death, no overt 
disruptions of the cortical laminar cytoarchitecture or ectopias, absence of 
[237] 
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Type of KO or KI Main phenotypes described Ref 
gliosis; but small reduction in hippocampal volume; 
Reductions in dendritic length and complexity in proximal and distal apical 
dendrites, and reductions in basal dendritic length and branching in CA1 
hippocampal neurons brain slices from adult mice; 
Reduced spine density in both apical and basal dendrites, fewer mushroom-
type spines and increased stubby spines, and smaller spine head diameters 
(adult brain in vivo); 
Deficit in early LTP and late LTP, impaired paired pulse facilitation, reduction 
of PSD95 expression in both cortical and hippocampal brain extracts (no 
differences in patch clamp recordings of CA1 pyramidal cells in acute slices). 
Triple KO 
Perinatal lethality; 
Ectopic clusters of neuroblasts within the marginal zone and pial membrane 
(fronto-parietal cortex) originated ~E12-14 (incomplete penetrance); 
Disruption of the cortical architecture underneath the clusters (normal inside-
out generation of cortical layers); 
Reduced survival of Cajal Retzius cells; 
Disruption of the basal membrane, defective interactions of basal lamina and 
radial glia, and defects in neuronal markers in the region of the clusters. 
[238] 
 
App-/-APPsαki 
(constitutively 
production of 
sAPPα) 
Rescues the decreases in body weight; 
Completely corrects the reduction of brain mass; 
Partial rescues the deficit of grip strength; 
Rescues alterations in circadian locomotor activity; 
Rescues reduced exploratory activity under aversive conditions, spatial 
navigation deficit, delayed learning, and the LTP deficits. 
[222] 
 
App-/-APPΔCT15ki 
(lacks the last 15 CT 
residues) 
Rescues the decreases in body weight; 
Attenuated the reduction of brain mass; 
Rescues the deficit of grip strength; 
Rescues alterations in circadian locomotor activity; 
Reduced exploratory activity under aversive conditions, spatial navigation 
deficit, and delayed learning; 
Rescues the LTP deficits. 
[222] 
 
App-/-Aplp2-/- 
sAPPβki/ki 
The secreted APPsβ protein is stable in vivo (and no further proteolytic 
cleavage in vitro); 
No rescue of the lethality of the App/Aplp2 dKO mice; 
APPsβ is inactive in APP-mediated survival and neuromuscular synapse 
function. 
[239] 
App-/-Aplp2-/- 
sAPPαki/ki 
Partial rescue of the lethality of the App/Aplp2 dKO (still presented widened 
end plate, excessive nerve growth, impaired neuromuscular transmitter release, 
and structural abnormalities at the neuromuscular synapses); 
Rescues the defects in spine density and in dendritic branching of distal apical 
segments (but shows impaired LTP and impaired spatial memory). 
[230] 
App-/-Aplp2-/- 
APPΔCT15ki 
Partially viable (partially rescues the lethality of dKO mutants); 
Reduced Aβ40, Aβ42, and βCTF in cortical brain lysates, and reduced sAPPβ 
(no difference in sAPPα); 
NMJ morphology is aberrant (similar to dKO mice), nerve terminal sprouting, 
reduced pre- and post-synaptic contacts, and fragmented endplates; 
NMJ defective transmitter release and muscular weakness: reduction in the 
number of presynaptic release sites and grip strength deficit (but normal 
spontaneous transmitter release, normal paired-pulse facilitation, and normal 
basal locomotion); 
Impairments of synaptic plasticity in the CNS: postsynaptic, (but no 
presynaptic) defect, with defects in LTP induction and maintenance; 
Reduced performance in spatial working memory tests (different dry mazes) 
and hippocampus-dependent behavior tests (nesting behavior and burrowing 
behavior). 
[240] 
APPY682G/Y682G 
mice in Aplp2 KO 
Ssimilar to App/Aplp2 dko mice;  
Increase in sAPPα production and decrease in sAPPβ. 
[241], 
[242] 
APPT668A/T668A 
mice in Aplp2 KO 
Viable;  
No neuromuscular defects. [242] 
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Aplp1 KO and Aplp2 KO revealed somatic growth deficit, but presented normal locomotor activity 
and unchanged forelimb strength [230, 235]. Only the triple (all App family members) KO mice or 
the mice haploinsufficient for Aplp2 are lethal, and die 24h after birth. These mice have no gross 
abnormality in the brain, and the likely cause of dead relates to impaired neuromuscular 
transmission [238]. The main phenotypes described include ectopic clusters of neuroblasts within 
the marginal zone and pial membrane, similarly to type 2 lissencephaly, and decreased number of 
Cajal Retzius cells. Interestingly, as mentioned before, Fe65 and Fe65L1 double KO mice showed 
a strikingly similar phenotype to APP family triple KO [165], and the interaction between APP and 
Fe65 has been implicated in cell migration and axonal branching. Intriguingly, there is a report that 
embryonic stem cells derived from APP triple KO mice still form neuronal precursors, and 
apparently behave normally either in vitro or in vivo (normal neuronal migration, are able to extend 
long neurites, without differences in neuronal polarity, and can form active synapses) [243]. 
Since the Aplp2 KO is viable without any significant abnormal phenotype, APP and APLP1 must 
be compensating for the apparent indispensable function(s) of APLP2. For instance, in the 
peripheral nervous system, APP and APLP2 play a redundant and essential role for the correct 
organization and function of neuromuscular synapse formation. However, contrarily to App KO, 
analysis of dendritic spines of Aplp2 null mutant neurons did not reveal alterations in spine density 
of apical and basal hippocampal dendrites or LTP defects [230]. The App-/-Aplp2-/- double (d)KO 
also did not induced further alterations (only an additional branching defect in proximal apical 
dendrites). Organotypic hippocampal slices of App-/-Aplp2-/- dKO revealed defects in basal 
glutamatergic synaptic transmission in comparison to Aplp2-/- mice, probably due to reduced levels 
of vesicular glutamate transporter 2 expression [244]. Recently, conditional App and Aplp2 dKO in 
excitatory forebrain neurons, which overcomes the dKO lethality, indicates that both proteins 
might be required for normal neuronal morphology and complexity in vivo. Conditional dKO 
presented reduced total neurite length, dendritic branching, spine density and spine head volume in 
adult hippocampal CA1 neurons, and pronounced deficits in the induction and maintenance of 
hippocampal LTP and impairments in paired pulse facilitation, together with impairments in 
nesting behavior and hippocampus-dependent learning and memory tasks [237]. A transcriptional 
profile of prefrontal cortex of adult App and Aplp2 single KO mice showed different sets of genes 
for the two conditions. From the 1242 genes that are up or down regulated after deletion of Aplp2, 
only 181 are also found altered in App mutant mice. Genes only significantly down regulated in 
App mutant mice (359 genes were differentially regulated: 274 up-regulated, and 85 down-
regulated) strength the evidence for APP function in synaptic plasticity. Interestingly, the 
expression of genes involved in neurogenesis is altered in Aplp2 KO brains [245]. Despite their 
redundant role, APP and APLPs may regulate distinct processes in different regions of the 
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developing cortex. Accordingly, while App mRNA is found in all neuroepithelial cells in the 
ventricular zone and in the cortical plate, Aplp2 exists in the ventricular zone and subventricular 
zone, and Aplp1 in the cortical plate only. In addition, some authors propose that while APP is 
functional in both progenitors and post-mitotic migrating neurons, APLP2 is playing a specific role 
in regulating progenitor proliferation and differentiation [70]. 
Besides the increasing evidences for a role in synaptic formation and function, other results point to 
the involvement of APP in axonal outgrowth and dendritogenesis. Concordantly, several analyses 
of App KO revealed dendritic and axonal defects either in young and/or older mice (Table A.3). 
Such processes will have implications not only during brain development and maturation, but will 
also be indispensable for neuronal regeneration after brain injury or disease. In fact, alterations in 
APP levels, trafficking and proteolytic processing might contribute to the altered synaptic plasticity 
and pathology of several neurological disorders in addition to Alzheimer’s disease, namely to 
fragile X syndrome, Down’s syndrome, autism, epilepsy and Parkinson’s disease, and brain injury 
(see Figure 10; and for a review see reference [246]).  
The first evidences that APP was involved in neurite outgrowth came from the findings that 
antibodies against APP specifically diminished the effects of the nerve growth factor on neurite 
length and branching in pheochromocytoma PC12 cells, indicating that APP mediates neurite 
outgrowth promotion by NGF [247]. The expression of APP695, the major APP neuronal isoform, 
is developmentally regulated during the differentiation of hippocampal neurons and neuronal-like 
cell lines in vitro. Interestingly, despite fetal neuronal cells express high levels of APP, they show 
little secretory processing into its soluble derivative, suggesting that the principal functional role in 
central nervous system development is responsibility of APP membrane-bound full-length protein 
[248]. In the same line of evidence, by the use of a system in which developing neurons were 
grown on transfected non-neuronal cells expressing various isoforms of APP, Qui et al (1995) 
showed that neurite outgrowth from hippocampal neurons was promoted by increased surface-
expressed APP but not by increased sAPP or other secreted derivatives in the medium [249]. In 
addition, they showed that surface-expressed, KPI-positive APP770 and APP751 isoforms promote 
neurite outgrowth more vigorously than APP695, most probably due to their higher roles in cell 
adhesion [249]. In this same year, Allinquant et al. reported that a 6, 18, and 24h block of APP 
expression using antisense oligonucleotides was sufficient to produce significant inhibitory effects 
on neurite growth (both axon and dendrite) of primary cortical neurons, without changes in the size 
or pattern of cell bodies spreading on the substratum [250]. A previous study had demonstrated that 
the binding of APP to specific proteoglycan species of heparan sulfate proteoglycans (HSPGs), a 
component of the extracellular matrix, is an important step in the regulation of neurite outgrowth. 
Moreover, the study established that APP must be substrate-bound in vitro to exert its physiological 
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effects, since when added to the cultures in its soluble form, APP did no stimulate neurite 
outgrowth as efficiently [251]. Recent studies also showed that although APP is highly enriched in 
growth cones, where it forms complexes with integrin α3β1 and the tetraspanin CD81 to mediate 
growth cones adhesion, APP-mediated adhesion does not require integrin β1 (Itgβ1) participation 
and, by itself, can sustain neurite outgrowth [252]. 
A couple years later, an experience was performed exploiting the differences in neuron survival 
and development between hippocampal neurons deriving from wild-type (Wt) or App KO mice, co-
cultured with astrocytes from Wt or App KO mice. The App KO neurons showed markedly shorter 
axons at 1 day in vitro (DIV), but the App KO neurons grown with Wt astrocytes would end up to 
developed axons equal in length to those of Wt neurons. Moreover, Wt neurons had more branched 
neurites and ultimately had more minor processes than did App KO hippocampal neurons. At 3 
DIV, Wt and App KO neurons co-cultured with Wt astrocytes had significantly shorter axons than 
neurons co-cultured with App KO astrocytes, while the number of minor processes and the number 
of branch points were significantly greater. Data indicated that both cell-associated APP and 
secreted APP products appear to be important for normal neuronal development, but might affect 
specific events: cell-associated APP enhanced neuron survival, and contributed to the onset of axon 
formation and axon arborisation, whereas APP secreted products from astrocytes appeared to 
modulate neuronal polarization limiting the growth of axons and enhancing dendritic growth [253]. 
So the first hypothesis pointed out that full-length APP could act in a cell autonomous manner to 
promote neurite outgrowth, both in vitro and in vivo. But, apparently sAPP addition to neurons also 
stimulated neurite outgrowth. Later, a study showed that sAPPα competes with full-length APP for 
binding to Itgβ1. On one hand, sAPPα is able to inhibit the ability of APP to regulate Itgβ1-induced 
neurite outgrowth, and on the other hand sAPPα is not able to stimulate neurite outgrowth in the 
absence of cell surface APP. Noteworthy, in this study APP-deficient neurons, either from App KO 
hippocampal primary cultures or from in utero electroporation of APP shRNA, are reported to 
present longer longest neurites (axon) [254]. It is also important to mention that inhibition of sAPP 
generation, specifically sAPPα, can promote APP mediated trans-cellular adhesion via the protein 
E1 domain. Thus, shedding of APP can significantly impact the cell adhesion-dependent functions, 
like the demonstrated synaptogenic actitivity of APP [255]. 
In Drosophila mutants displaying an age-dependent degeneration of the central nervous system, 
either expression of APPL (the Drosophila orthologue of APP) or expression of human APP695 
protect against progressive neurodegeneration. Importantly, the study presents evidence that this 
protection is mediated by the extracellular ectodomain, more specifically by the α-cleaved form, 
and only in the presence of full-length APP protein [256]. Previous studies had already shown that 
flies lacking APPL exhibited neurological phenotypes (especially in the peripheral nervous system) 
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that could be partially rescued by expression of human APP695 [257]. APPL is approximately 30% 
identical to human APP695, with significantly higher homology in specific extracellular domains 
and in the AICD, and can be processed by secretases resembling α-, β-, and γ-secretases. APPL is 
expressed in all neurons, and during embryogenesis it is, like mammalian APP, especially abundant 
in growing axons and in areas of synaptogenesis [70].  
In Drosophila models, both APPL and the human homologue APP can promote post-
developmental neurite arborization. APP or APPL expression resulted in increased axonal 
extension and more extensive arborization in postmitotic Drosophila brain neurons (small lateral 
neurons ventral), in a dose-dependent manner. Such effect seems to depend on the presence of the 
C-terminal, specifically, on the presence of the YENPTY motif harboring intact tyrosines 682 or 
687 (susceptible to phosphorylation). APP downstream signal is transduced through the Abelson 
tyrosine kinase (Abl) pathway to profillin-induced actin cytoskeleton modifications, and in parallel 
through JNK pathway [258]. Furthermore, the study links APPL signals to brain injury and 
mortality after trauma [258], concordantly with previous results showing APP upregulation after 
brain injury in humans and mammalian models [259]. Loss of APPL was also shown to induce a 
developmental defect in axonal outgrowth in mushroom bodies (the D. melanogaster center for 
learning and memory). The molecular mechanism involved the interaction of APP with core 
components of the PCP-Wnt signaling, namely with Frizzled receptor and Van Gogh protein, and 
stabilization of the interaction between Abl with Disheveled, the cytoplasmic transducer 
component that is activated upon phosphorylation by Abl [260]. In flies and mice, JNK is the final 
effector of PCP in axon outgrowth and JNK was shown to be required for the effect of APP 
overexpression in the fly by the same group, as explained above [258]. In this way, APP could 
function, in a cell-autonomous manner, as neuronal-specific modulator of the PCP signaling 
efficiency at the developing growth cone to promote axonal outgrowth [260]. Interestingly, the 
authors also report a physiological role of the APPL soluble form in a different group of neurons of 
the Drosophila mushroom bodies (αlobe neurons) [260]. 
Differentiation of human induced pluripotent stem cells into fully mature neurons show a distinct, 
cell-stage dependent, pattern of APP expression and proteolytic processing. APP mRNA and 
protein expression are detected since day 0 until the end, and the first stage (stem cells) is 
characterized by expression of APP but no proteolytic processing. Around day 10 of 
differentiation, when cells start to express the marker Pax-6, sAPPα starts to be detected together 
with short Aβ peptides (1-16 and 1-19). This indicates a preference for non-amyloidogenic 
processing of APP and low rate of γ-secretase in this second-stage, when neuronal progenitors are 
being developed. Around day 45-50, while post-mitotic neurons form, sAPPβ is detected and 
longer Aβ peptides are favored. This last and third phase is, thus, characterized by an increase in 
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the activity of β- and γ-secretase coinciding with neuronal maturation [261]. However, the 
proteolytic biology of APP appears far more complex, with APP cleavage depending on additional 
cell state specifications. In other words, there will be groups of cells secreting high levels of sAPPα 
and distinct groups of cells (of the same type) secreting high levels of Aβ. Moreover, apparently 
different types of brain cells, including not only glutamatergic neurons but also GABAergic 
neurons and astrocytes, are capable of secreting high levels of sAPPα and Aβ [262]. 
Several studies strengthen that the APP proteolytic processing is highly regulated during brain 
development and neuronal maturation, and that most probable, each of resulting APP fragments 
will have specific roles. Furthermore, it has been proposed that not only the accumulation of Aβ 
but also reductions in the level or activity of the different APP fragments play a critical role in the 
cognitive dysfunction characteristics of AD, and potentially of other neurodegenerative and 
neurodevelopment disorders. Three APP products have received particular attention in regard to the 
here discussed APP role in neuronal development and function, namely the Aβ, the sAPPα, and the 
AICD.  
Aβ is uniquely present in APP, and is mainly referred as a cytotoxic fragment exerting opposite 
effects to sAPPα [263]. Soluble Aβ oligomers (overexpressed in e.g. transgenic AD model mice) 
are associated with severe disruption of the dendritic cytoskeleton as well as the axonal 
cytoskeleton (reviewed in reference [264]) and are reported to reduce spine density and impair 
synaptic plasticity in the cortex and hippocampus (see reference [265]). However, low 
concentration of Aβ (pM to nM) have been shown to have protective effects on neurons and 
synapses (reviewed in reference [266]). 
Secreted APPα is described to be neuroprotective and neurotrophic, and to regulate cell 
excitability, calcium homeostasis, and synaptic plasticity, therefore potentially regulating learning 
and memory [263]. The APP N-terminal domain display structural similarities with cysteine-rich 
growth factors, and most of the growth-promoting properties of sAPP in vivo are related to this 
attribute [267]. Importantly, this secreted fragment of APP is reported to function as a proliferation 
factor for adult neural progenitor cells [268, 269]. In adult mouse brain, total sAPP is produced in 
high levels and appear to have a superior half-life comparing to full-length APP [270]. Several 
lines of work report the rescue effects of sAPPα on the anatomical, behavioural and 
electrophysiological abnormalities of App KO mice and dKO (see Table A.4), and above we 
already discuss some of the reported sAPPα functions in neurite outgrowth in “coordination” with 
APP full-length. Infusion of sAPPα into the ventricle or an indirect increase in sAPPα levels due to 
α-secretase overexpression have been shown to increase synaptic density [271], but the opposite 
effects were also reported [255]. Nevertheless, reduced CSF levels of sAPPα, ADAM10 protein 
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level, and activity are prominent features of sporadic AD cases, and sAPPα is reported to decrease 
sAPPβ and Aβ production [272]. 
The neuroprotective and neurotrophic roles are mainly attributed to sAPPα, and the introduction of 
sAPPβ knock-in alleles does not rescue the lethality of App/Aplp2 double KO. Nevertheless, both 
sAPPα and sAPPβ can interact with the p75 neurotrophin receptor to stimulate neurite outgrowth 
[273]. Additionally, both fragments are reported to stimulate axon outgrowth via Egr1 signaling 
pathway [274]. Interestingly, N-APP, derived from sAPPβ, may act as a ligand for DR6 to induce 
axon pruning of peripheral sensory neurons and apoptosis during growth-factor dependent axonal 
outgrowth [275]. 
Intracellular CTFs of APP also deserve attention due to their ability to bind several proteins, as 
already mentioned. Particularly, AICD has been described to possess transcriptional regulatory 
activity when in complexes with other proteins, such as the ternary complex composed by AICD, 
Fe65 and TIP60. However, there is little consensus and several conflicting findings regarding the 
AICD-dependent regulated genes, with candidate target genes being: APP itself, KAI1, a tumor 
suppressor and antimetastasis gene; neprilysin, a neutral endopeptidase with Aβ-degrading activity; 
LRP1; the EGFR; GSK-3β, a kinase involved in tau phosphorylation; Transgelin, an actin cross-
linking protein; and α2-actin [276]. Furthermore, AICD has been shown to contribute to apoptosis, 
development, synaptic plasticity and cytoskeletal dynamics [110]. Independently of its 
transcriptional activity, AICD has also been related to neuronal differentiation with reports of both 
negative and positive effects. One study correlated increased AICD levels with suppression of 
NGF-induced PC12 differentiation [277]. It appears that AICD interferes with the TrkA signalling, 
and that elevated AICDs signalling to the nucleus downregulates p53 and cyclinD and suppresses 
STAT3 phosphorylation (an activator of transcription), potentially enhancing cell proliferation and 
inhibiting neuronal differentiation [277]. Such results corroborate previous studies in an in vivo 
mouse model using TAG1, as a functional ligand of APP that increases AICD production and 
simultaneously leads to low neurogenesis [151]. Mouse knock-ins lacking the last 15 aminoacids of 
APP C-terminal (APPΔCT15ki; see Table A.4) fail to completely rescue the App or App/Aplp2 KO 
phenotypes, indicating (especially in the App/Aplp2 dKO rescue experiments) that this domain has 
essential functions for PNS and CNS physiology.  
Recently, by the modulation of γ-secretase-dependent processing of APP-CTF (through 
pharmacological inhibition or loss-of-function PS1 mutations) and by the use of a membrane-
tethered APP intracellular domain construct, it was shown that the accumulation of membrane 
APP-CTF stimulates neurite outgrowth in mouse N2a neuroblastoma cells, rat H19-7 immortalized 
hippocampal cells, and mouse cortical primary neurons. The molecular mechanism involves the 
interaction between APP intracellular domain and the heterotrimeric G-protein subunit Gαs, which 
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stimulates adenylate cyclase and leads to steady-state increase of phosphorylated protein kinase A 
(PKA) substrates such as CREB and GSK3β (which is inhibited) [278]. A following up study 
confirmed that alterations of γ-secretase activity, including via expression of FAD-linked PS1 
variants, result in APP-CTF accumulation and that the subsequent signaling enhances neurite 
outgrowth. Importantly, the authors confirmed that APP is the major contributing substrate in 
FAD-linked PS1 mutation induced neurite outgrowth [279]. 
APP is thus a very complex molecule that suffers alternative splicing and posttranslational 
modifications, undergoes tightly regulated trafficking and processing, and participates in protein 
interactions with multiple partners. Various studies currently address the physiological roles of 
APP, but there are many contradictory results and missing pieces that deserve further attention and 
work. This means that the detailed dynamics of APP biology underlying each APP physiological 
function is still unknown. For example, regarding its role in neurite outgrowth, it is still unclear if 
APP (or one of its processing products) affects axon and dendritic outgrowth differentially, or if 
APP is particularly involved in the arising of new processes, in processes’ elongation or branching. 
In addition, although it is already described that APP phosphorylation at S655 can alter APP 
trafficking and processing (e.g.: promoting the generation of neurotrophic sAPPα), the effect of this 
phosphorylation on neuronal differentiation events is yet to be addressed. 
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Supplementary Data 
Supplementary Table A.1 – APP protein interactors. Known APP protein interactors were extracted from the HIPPIE 
database (http://cbdm-01.zdv.uni-mainz.de/~mschaefer/hippie/index.php, downloaded on June 27, 2016). The protein 
interactors list is ordered accordingly to the given score, and only the protein interactors with a minimum score of 0.59 
were considered here. Scores ≥ 0.73 can be considered high-confidence interactors. Gene, indicates the gene symbol; 
Uniprot nr, indicates the uniprot accession number; Score, refers to the HIPPIE confidence score that ranges from 0 to 1; 
experimental evidence, identifies the experimental techniques used in the detection of the interaction; # pub, the number 
of scientific publications describing the existence of the interaction. Together with the reproducibility in model 
organisms, the experimental evidence (number and quality) and the number of publication, define subscores used to 
compute the final confidence score. NMR, nuclear magnetic resonance; coIP, coimmunoprecipitation; ELISA, enzyme 
linked immunosorbent assay; Reconstituted complex, Rcomplex; AC, affinity chromatography; PCA, protein 
complementation assay; FRET, fluorescent resonance energy transfer; TAP, tandem affinity purification. 
Gene Uniprot nr Score Experimental evidence 
# 
pub 
APBB1 O00213 0.99 Rcomplex; NMR; anti tag coIP; AC technology; PCA; Two-hybrid; anti-bait coIP; Affinity Capture-Western; pull down; in vitro; in vivo. 21 
APBB3 O95704 0.99 Rcomplex; PCA; two-hybrid; pull down; in vitro; in vivo 5 
APBA2 Q99767 0.99 Rcomplex; AC technology; Affinity Capture-Western; two-hybrid; pull down; in vitro; in vivo 3 
SHC1 P29353 0.97 Rcomplex; AC technology; Affinity Capture-Western; two-hybrid; coIP. pull down; in vitro; in vivo 4 
MAPK8IP1 Q9UQF2 0.97 
FRET; anti tag coIP; coIP; AC technology; Two-hybrid; pull down; 
colocalization/visualisation technologies; in vitro; enzymatic study; imaging 
technique; in vivo. 
6 
APBA1 Q02410 0.96 Rcomplex; anti bait coIP; Affinity Capture-Western; anti tag coIP; AC technology; pull down; in vitro; fluorescence microscopy; in vivo 3 
APBB2 Q92870 0.96 AC technology; Affinity Capture-Western; two-hybrid; anti-tag coIP; in vitro; in vivo 4 
KLC1 Q07866 0.95 Rcomplex; AC technology; pull down; in vitro; in vivo 3 
APBA3 O96018 0.95 Rcomplex; AC technology; Affinity Capture-Western; two-hybrid; pull down; in vitro; in vivo 2 
DAB1 O75553 0.93 Rcomplex; pull down; in vitro 3 
HSD17B10 Q99714 0.90 Rcomplex; ELISA; AC technology; Affinity Capture-Western; cross-linking study; two-hybrid; pull down; in vivo 4 
KAT5 Q92993 0.89 FRET; Two-hybrid; AC technology; pull down; in vivo 6 
FBLN1 P23142 0.89 Rcomplex; AC technology; Affinity Capture-Western; two-hybrid; pull down; in vitro 2 
SNCA P37840 0.89 Rcomplex; AC technology; pull down; in vitro; imaging technique 5 
BLMH Q13867 0.89 Rcomplex; two-hybrid; pull down; in vitro; co-fractionation 3 
APPBP2 Q92624 0.89 Rcomplex; AC technology; two-hybrid; pull down; in vitro 3 
PRNP P04156 0.89 surface plasmon resonance; ELISA; anti bait coIP; pull down 4 
PSEN1 P49768 0.88 AC technology; anti bait coIP; Two-hybrid; in vitro 6 
NAE1 Q13564 0.88 Rcomplex; AC technology; Affinity Capture-Western; pull down; in vitro; in vivo 2 
APOA1 P02647 0.88 Two-hybrid; far western blotting; anti tag coIP; ELISA; pull down 2 
ACHE P22303 0.87 Rcomplex; electron microscopy; pull down; in vitro; 2 
BACE1 P56817 0.87 protease assay; AC technology; in vitro; fluorescence microscopy 3 
TGFB2 P61812 0.87 anti bait coIP; competition binding; protein cross-linking with a bifunctional reagent; imaging technique; in vivo; chromatography technology 2 
CALR P27797 0.87 Affinity Capture-Western; AC technology; comigration in non denaturing gel electrophoresis; in vivo; imaging technique 4 
COL25A1 Q9BXS0 0.87 Rcomplex; pull down; in vitro; imaging technique; in vivo; Co-localization 2 
UBQLN1 Q9UMX0 0.86 FRET; AC technology; Two-hybrid 2 
TGFB1 P01137 0.86 protein cross-linking with a bifunctional reagent; competition binding; in vitro; imaging technique; in vivo 4 
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EGFR P00533 0.86 Two-hybrd; PCA; ubiquitin reconstruction 2 
BGN P21810 0.85 Rcomplex; pull down; in vitro 2 
PSEN2 P49810 0.84 Two-hybrid; anti bait coIP; in vivo 3 
HGS O14964 0.84 Rcomplex; pull down 3 
HOMER3 Q9NSC5 0.84 anti bait coIP; anti tag coIP; pull down 2 
NGFR P08138 0.84 ELISA; anti bait coIP; pull down 2 
MAPK8IP2 Q13387 0.82 Two-hybrid; AC technology 2 
CTSD P07339 0.82 protease assay; in vitro; in vivo 6 
GSK3B P49841 0.82 AC technology; pull down; in vivo; in vitro 5 
CLSTN1 O94985 0.82 AC technology; Affinity Capture-Western 2 
HSP90AA1 P07900 0.82 AC technology; anti bait coIP 2 
HSPA8 P11142 0.82 AC technology; anti bait coIP 2 
A2M P01023 0.82 coIP; Two-hybrid 2 
SLC40A1 Q9NP59 0.82 anti tag coIP; anti bait coIP 2 
NUMB P49757 0.82 pull down; in vivo; imaging technique; in vitro 4 
UCHL1 P09936 0.82 AC technology; anti bait coIP 2 
CRYAB P02511 0.81 anti bait coIP; pull down; in vitro 4 
LRP1 Q07954 0.81 AC technology; pull down; in vivo 4 
GSN P06396 0.79 Rcomplex; Affinity Capture-Western; AC technology; pull down; in vivo; in vitro 1 
MAPT P10636 0.79 surface plasmon resonance; protein kinase assay; peptide array; ELISA; pull down; confocal microscopy 1 
RNF32 Q9H0A6 0.79 Two-hybrid; pull down 3 
STXBP1 P61764 0.78 anti bait coIP; pull down 2 
TUBB P07437 0.78 anti bait coIP; pull down 2 
GFAP P14136 0.78 anti bait coIP; pull down 2 
PPIA P62937 0.78 anti bait coIP; pull down 2 
YWHAZ P63104 0.78 anti bait coIP; pull down 2 
HOMER2 Q9NSB8 0.78 anti tag coIP; pull down 2 
CAT P04040 0.78 ELISA; pull down 2 
AKT2 P31751 0.78 Two-hybrid; pull down 2 
TMCC2 O75069 0.78 anti bait coIP; pull down 2 
HSPD1 P10809 0.78 AC technology; pull down 2 
MAPRE1 Q15691 0.78 Two-hybrid; pull down 2 
COPS5 Q92905 0.78 AC technology; pull down 2 
APOE P02649 0.78 anti tag coIP; experimental interaction detection; in vitro 4 
BCAP31 P51572 0.77 Two-hybrid; PCA; AC technology; imaging technique; in vivo; Co-fractionation 1 
TNFRSF21 O75509 0.76 saturation binding; ELISA; pull down 1 
IFIT3 O14879 0.76 AC technology; anti bait coIP; Two-hybrid 1 
FLOT1 O75955 0.75 Two-hybrid; anti bait coIP; pull down; in vitro 1 
HMOX2 P30519 0.75 Two-hybrid; in vivo 2 
SNCB Q16143 0.75 Rcomplex; pull down; in vitro 1 
TP53BP2 Q13625 0.75 Two-hybrid; ELISA; pull down; pull down 1 
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DAB2 P98082 0.75 Rcomplex; pull down 1 
PCBD1 P61457 0.75 AC technology; TAP; pull down 1 
FOS P01100 0.75 AC technology; TAP; pull down 1 
PARK2 O60260 0.75 AC technology; imaging technique 2 
NEFL P07196 0.75 anti bait coIP; imaging technique 2 
MAP3K5 Q99683 0.75 anti bait coIP; imaging technique 2 
PDIA3 P30101 0.74 comigration in non-denaturing gel electrophoresis; pull down 2 
CLU P10909 0.73 pull down; in vivo; in vitro 3 
NF1 P21359 0.73 anti bait coIP; Two-hybrid; in vivo 1 
CDK5 Q00535 0.73 pull down; in vivo; in vitro 4 
NCSTN Q92542 0.73 Affinity Capture-Western; AC technology; in vivo 1 
TM2D1 Q9BX74 0.73 Two-hybrid; AC technology; in vitro 1 
ND3 P03897 0.73 phage display; ELISA 1 
SET Q01105 0.73 AC technology 1 
ITM2A O43736 0.72 anti tag coIP; anti bait coIP 1 
YWHAG P61981 0.72 Two-hybrid; AC technology 1 
NOS3 P29474 0.72 AC technology; Two-hybrid 1 
GPR3 P46089 0.72 anti tag coIP; anti bait coIP 1 
PCOLCE Q15113 0.72 surface plasmon resonance 1 
QRICH1 Q2TAL8 0.72 Two-hybrid; AC technology 1 
GAPDH P04406 0.70 pull down; in vitro 5 
COL4A6 Q14031 0.70 pull down; in vitro 3 
GNAO1 P09471 0.70 anti bait coIP 1 
NECAB3 Q96P71 0.69 pull down; in vitro 2 
PPID Q08752 0.69 pull down; in vitro 2 
CHRNA7 P36544 0.69 anti bait coIP; in vitro; in vivo; imaging technique 1 
CASP4 P49662 0.69 pull down; in vitro 2 
UBE2M P61081 0.69 pull down; enzymatic study 2 
MAPK8 P45983 0.69 pull down; enzymatic study 2 
CASP3 P42574 0.69 in vivo; in vitro; imaging technique 3 
SHC3 Q92529 0.68 pull down; in vivo; in vitro 1 
GSK3A P49840 0.68 protein kinase assay 1 
ADAM17 P78536 0.68 protease assay 1 
KLK6 Q92876 0.68 protease assay 1 
PITRM1 Q5JRX3 0.68 protease assay 1 
GGA1 Q9UJY5 0.68 AC technology; pull down 1 
LDLRAP1 Q5SW96 0.67 Two-hybrid; in vivo; in vitro 1 
DLG4 P78352 0.67 anti bait coIP; cosedimentation in solution 1 
ABL1 P00519 0.66 pull down; in vivo 1 
BACE2 Q9Y5Z0 0.66 in vivo; in vitro 5 
TGM2 P21980 0.66 pull down 2 
GRB2 P62993 0.65 anti bait coIP; in vivo 1 
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CAV1 Q03135 0.65 Co-fractionation; in vitro; Protein-RNA 2 
SYVN1 Q86TM6 0.65 AC technology; enzymatic study 1 
NEDD8 Q15843 0.65 AC technology; enzymatic study 1 
FBXL2 Q9UKC9 0.65 AC technology; enzymatic study 1 
PION A4D1B5 0.65 AC technology; enzymatic study 1 
CASP6 P55212 0.65 imaging technique; in vitro 2 
EPB41 P11171 0.63 Two-hybrid 1 
SERPINA3 P01011 0.63 in vivo 3 
DNM1 Q05193 0.63 anti bait coIP 1 
NSF P46459 0.63 anti bait coIP 1 
SPTAN1 Q13813 0.63 anti bait coIP 1 
ACTB P60709 0.63 anti bait coIP 1 
MBP P02686 0.63 anti bait coIP 1 
MYH9 P35579 0.63 anti bait coIP 1 
DNAH1 Q9P2D7 0.63 anti bait coIP 1 
PGAM1 P18669 0.63 anti bait coIP 1 
APLP1 P51693 0.63 anti tag coIP 1 
APLP2 Q06481 0.63 anti tag coIP 1 
TTR P02766 0.63 coIP 1 
UGP2 Q16851 0.63 Two-hybrid 1 
PHLPP1 O60346 0.63 Two-hybrid 1 
PRAM1 Q96QH2 0.63 Two-hybrid 1 
MAST1 Q9Y2H9 0.63 Two-hybrid 1 
CDC37 Q16543 0.63 Two-hybrid 1 
AP1M2 Q9Y6Q5 0.63 Two-hybrid 1 
EXOC6 Q8TAG9 0.63 Two-hybrid 1 
MED4 Q9NPJ6 0.63 anti bait coIP 1 
TIRAP P58753 0.63 Two-hybrid 1 
TPD52L2 O43399 0.63 Two-hybrid 1 
HSPA4 P34932 0.63 AC technology 1 
NOTCH1 P46531 0.63 AC technology 1 
STUB1 Q9UNE7 0.63 AC technology 1 
NAPG Q99747 0.63 PCA 1 
UBB P0CG47 0.63 PCA 1 
YWHAB P31946 0.63 pull down 1 
ECSIT Q9BQ95 0.63 Two-hybrid 1 
KIF1B O60333 0.63 AC technology 1 
CFL1 P23528 0.63 Two-hybrid 1 
PAXIP1 Q6ZW49 0.63 Two-hybrid 1 
PI4K2A Q9BTU6 0.63 Two-hybrid 1 
RAB3A P20336 0.63 Two-hybrid 1 
PTGER2 P43116 0.63 anti tag coIP 1 
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ARRB1 P49407 0.63 anti tag coIP 1 
RANBP9 Q96S59 0.63 AC technology 1 
RNF2 Q99496 0.63 AC technology 1 
TMEM30A Q9NV96 0.63 AC technology 1 
USP25 Q9UHP3 0.63 AC technology 1 
SORL1 Q92673 0.63 AC technology 1 
CUL7 Q14999 0.63 AC technology 1 
PIN1 Q13526 0.62 pull down; light microscopy; in vivo 1 
HSPG2 P98160 0.62 in vitro 2 
HADHB P55084 0.62 in vitro 2 
F12 P00748 0.62 in vivo 2 
SPON1 Q9HCB6 0.59 pull down; in vitro 2 
 
Supplementary Table A.2 - Complete list of biological process gene ontology terms related to nervous system 
function and development and significantly enriched in the APP interactome.  F. Enrichment, the fold enrichment of 
the genes observed in the APP protein interactors list over the expected based on the reference list (the human genome). 
A number greater than 1, indicates that the category is overrepresented. pvalue, calculated pvalue with Bonferroni 
correction. Only pvalues higher than 0.05 were considered. 
 
 GO Biological process 
# 
proteins 
F. 
enrichment pvalue 
N
er
vo
us
 sy
st
em
 d
ev
el
op
m
en
t 
cerebral cortex development 10 11.64 1.76E-04 
pallium development 13 10.38 5.08E-06 
telencephalon development 16 8.68 6.69E-07 
forebrain development 21 7.30 1.60E-08 
brain development 28 5.21 8.18E-09 
central nervous system development 38 5.42 9.28E-14 
nervous system development 71 4.28 3.66E-24 
glial cell differentiation 10 9.07 1.74E-03 
gliogenesis 12 8.51 2.06E-04 
neurogenesis 55 4.91 5.96E-20 
limbic system development 8 9.76 1.71E-02 
negative regulation of neuron projection development 9 8.99 7.62E-03 
regulation of neuron projection development 19 5.82 8.10E-06 
regulation of neuron differentiation 25 5.66 2.71E-08 
regulation of neurogenesis 31 5.84 2.07E-11 
regulation of nervous system development 32 5.34 7.77E-11 
generation of neurons 53 5.03 1.61E-19 
negative regulation of neuron differentiation 14 9.11 5.72E-06 
negative regulation of neurogenesis 17 8.77 1.42E-07 
negative regulation of nervous system development 18 8.56 5.23E-08 
regulation of axonogenesis 11 8.36 9.50E-04 
axonogenesis 19 7.56 1.08E-07 
axon development 21 7.66 6.58E-09 
neuron projection development 32 7.49 6.16E-15 
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neuron development 33 6.03 8.84E-13 
neuron differentiation 37 5.32 5.05E-13 
neuron projection morphogenesis 25 7.99 1.39E-11 
cell morphogenesis involved in neuron differentiation 22 7.65 1.85E-09 
positive regulation of neuron projection development 11 5.89 2.79E-02 
positive regulation of neurogenesis 16 5.27 6.98E-04 
positive regulation of nervous system development 17 4.87 8.33E-04 
Sy
na
ps
e 
fu
nc
tio
n 
regulation of synaptic vesicle transport 6 24.56 1.77E-03 
regulation of neuronal synaptic plasticity 7 18.13 1.30E-03 
regulation of synaptic plasticity 12 10.80 1.52E-05 
regulation of synapse structure or activity 15 8.21 5.67E-06 
modulation of synaptic transmission 19 7.98 4.27E-08 
neuron-neuron synaptic transmission 7 15.86 3.15E-03 
synaptic transmission 25 7.89 1.84E-11 
anterograde trans-synaptic signaling 25 7.89 1.84E-11 
trans-synaptic signaling 25 7.89 1.84E-11 
synaptic signaling 25 7.70 3.19E-11 
chemical synaptic transmission, postsynaptic 7 13.88 7.62E-03 
presynaptic process involved in synaptic transmission 9 10.88 1.59E-03 
synapse organization 12 10.43 2.23E-05 
positive regulation of synaptic transmission 9 10.38 2.34E-03 
regulation of neurotransmitter levels 12 8.41 2.32E-04 
N
eu
ro
n 
D
ea
th
 
neuron apoptotic process 7 24.68 1.63E-04 
neuron death 8 21.15 5.10E-05 
positive regulation of neuron apoptotic process 9 24.30 1.69E-06 
positive regulation of neuron death 15 28.41 1.40E-13 
regulation of neuron death 26 12.99 3.29E-17 
regulation of neuron apoptotic process 20 13.15 1.21E-12 
negative regulation of neuron apoptotic process 12 11.20 1.02E-05 
negative regulation of neuron death 14 10.27 1.24E-06 
C
el
l m
ig
ra
tio
n 
negative regulation of cell migration 11 6.81 7.01E-03 
negative regulation of cell motility 13 7.64 1.86E-04 
regulation of cell motility 28 4.96 2.56E-08 
regulation of cell migration 26 4.94 1.85E-07 
positive regulation of cell migration 15 4.88 4.73E-03 
positive regulation of cell motility 15 4.74 6.87E-03 
cell migration 25 4.18 1.41E-05 
cell motility 26 3.95 2.10E-05 
ECM 
regulation of extracellular matrix organization 6 26.26 1.20E-03 
extracellular matrix organization 20 8.27 6.09E-09 
Cell adhesion 
negative regulation of cell adhesion 12 6.86 2.04E-03 
regulation of cell adhesion 22 4.38 6.54E-05 
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 GO Biological process 
# 
proteins 
F. 
enrichment pvalue 
- cytoskeleton organization 27 4.09 4.56E-06 
- Learning or memory 14 8.04 2.77E-05 
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Aims 
The major goal of the work here presented was to characterize the physiological role of APP in the 
morphological alterations underlying neuronal differentiation, especially in neurite outgrowth and 
elongation. 
We were particularly dedicated in unravelling signaling mechanisms mediated by APP and its 
proteolytic fragment sAPP relevant for neuronal differentiation, and how APP phosphorylation at 
serine 655 modulates such mechanisms. 
To this end we delineated the following specific aims: 
1.! Establishment and characterization of a cell model system to study neuronal-like 
differentiation, which allowed to evaluate time-dependent protein profiles of APP and its 
cleavage to sAPP with differentiation (Chapter 5). 
2.! To unravel the functional interplay between APP and the Epidermal Growth Factor and 
downstream neurotrophic/neuritogenic signaling pathways, and their dependence on APP 
S655 phosphorylation (Chapter 6). 
3.! Identification of specific protein binding partners of S655 phosphoAPP involved in 
neurotrophic functions, to better characterize the molecular mechanisms triggered by this 
phosphorylation, and to find novel APP protein effectors and regulators (Chapter 7). 
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5.1.!Abstract 
The existence of an intrinsic program controlling neuritogenesis and activated during early 
neuronal differentiation and regeneration stages, is well established. However, the identity and role 
of each molecular player and event, as well as how such a program is modified by environmental 
signals, remain a focus of research. The Amyloid Precursor Protein (APP) is a neuromodulator of 
the developing and mature nervous system, although in a highly complex manner, far from clear. 
To study APP-induced neuritogenesis, the Retinoic Acid (RA)-induced SH-SY5Y cell 
differentiation model was first detailed characterized in terms of RA dose, morphological outputs 
and relevant biochemical markers. The findings here reported unveiled two differentiation phases 
for the 10 µM RA dose: 1-4 (4 days excluded) and 4-8 days, clearly defined by the ratio between 
APP and acetylated Tubulin fold increases. Moreover, we describe for the first time a unique peak 
of secreted APP (sAPP)/APP ratio at the first phase. Subsequent APP and sAPP modulations 
confirmed that a high sAPP/APP ratio potentiates the elongation of smaller processes at the earlier 
neuritogenic phase. This ratio drops in the second phase, as holoAPP levels increases to assist the 
maintenance of the longer neurites, potentially via their stabilization.!  
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5.2.!Introduction 
The Amyloid Precursor Protein (APP) is an ubiquitously expressed type I transmembrane 
glycoprotein, dynamically sorted through the membranes of intracellular organelles and the plasma 
membrane. Intracellularly, it undergoes two mutually exclusive post-translational cleavage 
pathways. Briefly, proteolytic cleavage by an α-secretase enables the production and secretion of 
sAPPα into the extracellular medium or the lumen of the vesicles, and leaves the remaining C83 
fragment in the membrane. C83 can be cleaved by the γ-secretase complex to release two peptides, 
p3 and the APP intracellular C-terminal domain (AICD). Alternatively, cleavage by β-secretase 
results in the secretion of the slightly truncated sAPPβ molecule, and the retention of the C99 
fragment. This appears to be the major substrate of γ-secretase cleavage, leading to the production 
of AICD and Aβ, a potentially toxic peptide [1-3]. 
While mainly studied for its association with the Alzheimer’s disease (AD), this complex APP 
molecule is determinant for neuronal function, including neurite outgrowth and neuronal 
differentiation. In fact, APP is upregulated in the developing nervous system, where it is 
preferentially enriched in growing neurites and neuritic growth cones [4-6]. Furthermore, APP was 
observed to mediate the in vitro neuritic outgrowth promoted by neurotrophic molecules such as 
the Nerve Growth Factor (NGF) [7], and an association of Retinoic Acid (RA) plus Brain Derived 
Neurotrophic Factor (BDNF) [8, 9]. 
Although the neuritogenic activity was formerly attributed solely to the membrane-bound APP 
holoprotein (holoAPP) [10-13] and further on to its sAPPα product [14, 15], there is now evidence 
that both sAPPα and cell-associated holoAPP intervene in neuritogenesis, since sAPP is not able to 
stimulate neurite outgrowth in the absence of cell surface holoAPP [16, 17]. Several studies 
focusing the APP role in neuronal differentiation have been performed in RA-differentiated SH-
SY5Y cells, a well-documented neuronal-like model [18, 19]. The treatment of SH-SY5Y cells 
with RA induces a shift towards the α-secretase pathway, leading to increased sAPPα [8]. 
Additionally, different RA concentrations (mainly 1 and 10 µM) were shown to increase total APP 
gene expression. However, the time period indicated for this up regulation onset is contradictory [8, 
9, 20, 21]. On the other hand, it was suggested that it is the specific increase in the levels of the 
APP695 mRNA transcript, and not of total APP mRNA, that supports a neuronal phenotype in RA-
treated SH-SY5Y cells [22]. Besides this non-uniformity in APP-related data, the literature lacked 
a more detailed characterization of the RA-induced SH-SY5Y differentiation process. Thus, the 
first goal of the work here described was to establish a comprehensive and reproducible cellular 
differentiation model, by characterizing in detail the neuritogenic-related alterations of RA-
mediated SH-SY5Y neuronal-like differentiation. The time-dependent APP expression, sAPP/APP 
ratio, and a correlation between APP and acetylated tubulin were monitored using this model. 
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Based on the findings here presented, we propose a biphasic temporal response induced by 10 µM 
RA SH-SY5Y differentiation, where a sAPP/APP peak assists the initial phase marked by neuritic 
elongation, and increased holoAPP protein levels portrays the second phase, when it is necessary to 
sustain neuritic elongation and circumvent neuritic retraction.  
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5.3.!Material and Methods 
5.3.1.!SH-SY5Y cell culture and differentiation 
The SH-SY5Y human neuroblastoma cell line was maintained in MEM/F12 medium [23] and was 
previously enriched in the neuroblastic N-type of cells (immature nerve cells that are RA-
differentiated into neuronal-like cells), on the basis of their lower substrate adherence than S-type 
cells [24]. N-type enriched 1.0x104 cells/cm2 SH-SY5Y cells were plated onto six-wells plates and 
differentiated with 1 or 10 µM all-trans RA in 10% FBS medium for 2, 4, 6 and 8 days (D2-D8). 
Optimal cell densities to be plated and FBS % were previously optimized by us. RA was added 
every other day, and cell medium replaced at that time. 
5.3.2.!Microscopy and morphological analyses 
Cell counts and morphometric analysis of SH-SY5Y differentiated cells were performed on phase 
contrast (PhC) images of live cells (Olympus IX-81 inverted microscope; 350 cells/condition), 
analyzed using the AnalySIS (Olympus) and ImageJ software.  
Cell counts were expressed as a percentage relative to the number of cells initially plated. Cellular 
projections (‘processes’) were categorized as indicated. “Total”: all processes arising from a cell. 
“≥20 µm”: processes longer than 20 µm; “20-35 µm”: processes longer than 20 µm but shorter than 
35 µm (pre-neurites); “≥35 µm”: processes longer than 35 µm (neurites). When specified, neurites 
were further divided into shorter (<50 µm) and longer neurites (≥50 µm). Data was expressed as 
the number of processes per cell, or their percentage out of the ‘Total’ number of processes. 
For immunocytochemistry analysis, cells grown on coverslips were fixed with 4% 
paraformaldehyde and permeabilized with 0,2% TRITON [25]. Primary and secondary antibodies 
used (1-2h incubation): anti-APP C-terminal (CT695 antibody, Invitrogen), monoclonal anti-
acetylated α-tubulin (Sigma-Aldrich); Alexa 488- and 405-conjugated IgGs (Molecular Probes). To 
stain F-actin, AlexaFluor Phalloidin in 1% BSA PBS was added for 30 min in the dark. 
Preparations were mounted with Vectashield® media (Vector Labs) and visualized either by 
epifluorescence microscopy [Olympus IX-81 microscope; 20x/0.40 objective [25]], or by confocal 
microscopy [LSM 510 META confocal microscope (Zeiss); 63x oil objective [26]]. 
5.3.3.!Modulation of APP/sAPP levels  
SH-SY5Y cells were co-incubated for 48h with 10 µM of RA and 10 µM TAPI-1 (Santa Cruz 
Biotechnology) either at the onset of RA exposure (from D0 to D2) or at the 2nd day (D2 to D4). 
TAPI-1 is a metalloproteases' inhibitor that hinders APP cleavage into sAPPα by the α-secretase 
TACE. For sAPP overexposure, cells were incubated from D0 to D2 with 10 nM recombinant 
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human sAPPα (Sigma-Aldrich; [27, 28]). Cells were fixed and morphometric analyses performed 
on PhC microphotographs; differentiated cells at D4 were further subjected to 
immunocytochemistry analyses (as above described). The role of holoAPP was assayed by 
transfecting 10 µM RA differentiated cells at D6 with an APP695-GFP cDNA or the respective N1-
eGFP vector [29]. Cells were fixed at D8, and about 100 fluorescing cells/experiment were 
monitored for their neuritic number and length (n=3).  
5.3.4.!Western blot assays 
Cells and media were collected into 1% boiling SDS, cell lysates sonicated for 30 sec, and the total 
protein content measured (Pierce’s BCA kit; Thermo Scientific). Mass-normalized aliquots were 
resolved on 5-20% gradient SDS-PAGE and electrotransferred onto nitrocellulose membranes. 
These were initially processed for Ponceau S staining to assess gel loading [30], since beta-actin 
and other cytoskeleton markers are not suitable loading controls in cell differentiation assays [31-
33]. Primary antibodies used (2h-O/N incubation): anti-APP N-terminus (22C11, Chemicon), anti-
actin N-terminal (Sigma-Aldrich), anti-acetylated tubulin, and anti-MAP-2 clone HM2 (Sigma-
Aldrich). Horseradish peroxidase-linked secondary antibodies were from GE Healthcare. 
Membranes were washed (1X TBS-T or PBS-T) and submitted to ECL detection (see [34].  
5.3.5.!Data analysis and Statistics 
Ponceau-S stained membranes and autoradiograms were scanned (GS-800 imaging densitometer, 
Bio-Rad) and protein bands quantified (Quantity One densitometry software, Bio-Rad). All data 
was corrected to the relative loading control (Ponceau-S) and expressed as mean±SEM (standard 
error) of at least three independent experiments. When appropriated, data were analysed using two-
way ANOVA followed by the Bonferroni test (GraphPad Prism5 software); the RA dose and the 
differentiation day were the independent variables as follows: 0, 1 and 10 µM RA at days 2 and 8; 
1 and 10 µM RA at days 2-to-8. Step-down one-way ANOVAs were additionally performed within 
each RA dose, followed by the Dunnett's test (for comparison of data with control values) or the 
Tukey-Kramer multicomparisons test (to compare between indicated conditions). For clarification 
purposes, not all these statistical differences are shown (e.g. some differences to control NDf were 
left out of the graphs). Otherwise, the statistical analysis was conducted by one-way ANOVA or by 
the unpaired Student’s t-test.  
! !
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5.4.!Results 
5.4.1.!A biphasic differentiation model emerges for 10 µM RA-treated SH-SY5Y cells  
The differentiation output of neuronal-like cells is time- and morphogen dose-dependent. To 
characterize SH-SY5Y differentiation in respect to these factors, two concentrations (1 and 10 µM) 
of the RA morphogen were used, and differentiation was characterized at various time points: 2 
(D2), 4 (D4), 6 (D6) and 8 (D8) days. Non-differentiated (ND) cells, cultured for 2 (NDi, initial) 
and 8 days (NDf, final) in the absence of RA (0 µM RA), were used as controls.  
Morphological differences are readily evident from the PhC microphotographs representative of 
each differentiation day (Figure B.1). While ND cells maintain a more cuboid/polygonal shape, 
RA-differentiated cells are more plastic or elongated, and present elongated cellular projections 
(‘processes’) (Figure B.1 A versus B). Relatively to cell growth (Figure B.1 C), the number of non-
differentiated cells increases by 30% after two days in culture, and further duplicates from days 2 
to 8. This duplication in cell number already occurs at day 2 for 1 µM RA (p<0.05 against control 0 
µM RA), and the cell number remains unaltered thereafter. Contrarily, a dose of 10 µM RA 
decreases the cell number at D2 (p=0.053 against control 0 µM RA). This number only marginally 
increases thereafter, and cell number at day 8 is 130% lower than control values (p<0.001). Indeed, 
the higher 10 µM RA dose always decreases the cell number when compared to 1 µM RA 
(p<0.001 and p<0.05, by two-way ANOVA). Retinoic acid also modifies the cellular morphology, 
shifting the usual cuboid morphology of non-differentiated cells to a more plastic or elongated one 
(Supplementary Figure B.1). The majority (~70%) of SH-SY5Y non-differentiated cells (NDi and 
NDf) are cuboid in shape, and both 1 and 10 µM RA doses significantly lower this percentage to 
30-40% already at D2 (Supplementary Figure B.1, ‘cuboids’). The percentage of elongated cells is 
RA dose-dependent, and 10 µM RA treatment immediately significantly increases its number at D2 
(to ~50%), while for 1 µM RA this only occurs later on and at lower percentages (D8, ~40%) 
(Supplementary Figure B.1 B, ‘elongated’). Interestingly, 1 µM RA is the dose that significantly 
increases the percentage of plastic cells when compared to non-differentiated controls 
(Supplementary Figure B.1 A vs B, ‘plastic’). The plastic phenotype appears thus to be an 
intermediate phenotype, before the acquisition of an elongated morphology by cells when fully 
committed to differentiate.  
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Figure B.1 - SH-SY5Y cells differentiated for 8 days with 1 and 10 µM RA. PhC microphotographs of SH-SY5Y 
undifferentiated (A.) and RA-differentiated (B.) cells. NDi: initial non-differentiated cells (day 2); NDf: final non-
differentiated cells (day 8). Bar, 30 µm. C. Effects of RA concentration on cell number, expressed as percentages of the 
initial number of plated cells (100%). n=4. Statistic symbols: (*)(§), for comparison of 1 and 10 µM data with 0 µM RA 
controls (NDi and NDf, respectively), using one-way ANOVA followed by the Dunnett's test. (#), for differences between 
1 µM and 10 µM RA data, using two-way ANOVA. This analysis revealed extremely significant effects of the RA dose 
and differentiation time on cells number, but no significant interaction between these two variables. */#p<0.05; 
§§§/###p<0.001. 
 
Neuritogenesis was also evaluated, by scoring the number and length of the cellular processes 
(Figure B.2). RA significantly increases the number of processes per cell at D2 (Figure B.2 A, D2 
vs NDi), but in a RA dose-independent manner (no significant differences between doses were 
detected with two-way ANOVA). Nevertheless, while the 10 µM dose does not increase the final 
number of total processes (Figure B.2 A, NDf vs D8 10 µM), 1 µM RA is capable to induce the 
emergence of new processes. Indeed, 8 days of 1 µM RA exposure increases the number of 
processes above NDf (Figure B.2 A) and above the 10 µM dose (p<0.05 by the unpaired Student’s 
t-test). 
When the longer processes were divided by length (20-35 µm and >35 µm), another RA 
neuritogenic effect was revealed (Figure B.2 B). Incubation with 10 µM RA for only 2 days 
significantly decreases the 20-35 µm processes (also here termed as ‘pre-neurites’) to half of their 
percentage (Figure B.2 B, D2 10 µM vs NDi), while it simultaneously increases the percentage of 
>35 µm ones (neurites, as longer than two body lengths [35]. A second phase of increase in the 
number of these neurites is visible between D2 and D4, from which it stabilizes (no differences 
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being found in-between D4, D6 and D8). The lower 1 µM RA dose also significantly increases the 
number of neurites, but only at D6. Further, the 10 µM RA-induced increases in neurites and 
decreases in pre-neurites at D2 and D4 are significantly different from the 1 µM RA effects (D2 
p<0.05; D4 p<0.01 and p<0.05, by two-way ANOVA). 
 
Figure B.2 - Morphometric analysis of the cellular processes in 1 and 10 µM RA differentiated SH-SY5Y cells. A. 
Total number of processes per cell (all processes protruding from a cell, of all sizes, were scored). B. Percentage of each 
type of process. Processes were categorized according to their lengths, and the percentages of pre-neurites (20-35 µm) 
and neurites (≥35 µm) calculated out of the total number of processes (‘Total’). C. The mean lengths of pre-neurites (20-
35 µm), and neurites (35-50 and ≥50 µm processes) were determined; noticeably, control cells do not present >50 µm 
neurites. NDi: initial non-differentiated cells (day 2); NDf: final non-differentiated cells (day 8). D2-D8: days 2, 4, 6 and 
8 of differentiation. n=4. */§/+/#//p<0.05, **/§§/##/++p<0.01, ***/§§§/+++p<0.001. Statistic symbols: (*) (§), for 
comparisons to control NDi and NDf data, respectively; (+), for comparisons between indicated conditions, by using one-
way ANOVA followed by the Dunnett's or the Tukey-Kramer tests. () for comparisons to NDi data; (#) for differences 
between 1 µM and 10 µM RA data, by two-way ANOVA. Two-way ANOVA further revealed: significant RA dose 
effect and interaction between RA dose and differentiation time on the % of type of processes; a very significant RA dose 
effect on the 20-35 µm processes length; extremely significant RA dose effect and interaction between RA dose and 
differentiation time on the length of >50 µm neurites.   
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The mean length of the processes was also evaluated, with neurites being further divided into 
shorter (35-50 µm) and longer (>50 µm) neurites in this assessment (Figure B.2 C). 10 µM RA 
significantly increases the pre-neurites mean length (20-35 µm) from D4 on, when compared to 
both ND controls. For both RA doses, the shorter neurites length (35-50 µm) generally remains 
unchanged throughout time (exception for the 10 µM RA D6 and D8 increases). Differences in the 
length of the longer neurites (>50 µm) are however very notorious given their absence in both non-
differentiated controls. Moreover, this length is affected by the RA dose, the day of differentiation, 
and by the interaction of these two factors (p<0.0001, by two-way ANOVA). From D4 on, the 10 
µM RA dose tends to be more able to elongate and maintain neurites than 1 µM RA, inducing 
significantly lengthier >50 µm neurites at D8. In summary, again the 10 µM RA induced two 
specific neuritogenic phases, this time related to the elongation of longer neurites: a first increase at 
D2, and a second period from D4 on (where D4, D6 and D8 are equal in-between and all 
significantly different from D2). 
5.4.2.!APP and sAPP/APP time-dependent profiles follow the 10 µM RA biphasic model  
The time-dependent protein expression profiles of APP and its sAPP cleavage product were further 
monitored (Figure B.3) and related to the differentiation outputs. 
Interestingly, neither 1 nor 10 µM RA are able to immediately (D2) increase holoAPP expression. 
At D4 however, 10 µM RA-treated cells significantly express more APP than control NDi and 1 
µM RA cells, and these levels are maintained thereafter. 1 µM RA also up-regulates APP 
expression, but later in time (at D6) and less efficiently (Figure B.3 A vs B, ‘holoAPP’: 2.4-fold 
increase against 3.2 for 10 µM RA, p<0.05 by the Student’s t-test). Consistently, the 10 µM RA 
data again significantly separates D2 from the following time points (D4 to D8).  
Significantly, 1 µM RA induces similar time-dependent variation profiles in both holoAPP 
expression (Figure B.3 A) and in the percentage of neurites (Figure B.2 B ‘1 µM RA’). Likewise, 
10 µM RA also induces similar time-dependent behaviours of the following parameters: holoAPP 
expression, percentage of neurites (>35 µm), and mean length of longer neurites (>50 µm) (Figure 
B.3 A, Figure B.2 B and C ’10 µM’).  
APP shedding to sAPP is also affected by RA, and shows a major difference in-between RA doses 
at D2. The 10 µM RA dose induces a 2-fold increase in sAPP levels already at D2, from which it 
stabilizes (Figure B.3 B ‘sAPP’; compare to non-differentiated controls), while 1 µM RA only 
produces significant differences at D6 (Figure B.3 A ‘sAPP’). Both doses reach equal final sAPP 
fold increases. 
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Since sAPP was reported to support neuritogenesis by competing with membranar APP [17], the 
time-dependent profiles of sAPP/APP ratio were calculated. The sAPP/APP ratio has a downward 
trend with time in culture: from NDi vs NDf, and from D2 to D6 (Figure B.3 C for 10 µM; data not 
shown for 1 µM). For 1 µM RA, the increase in holoAPP is accompanied by a similar increase in 
sAPP secretion (Figure B.3 A), and thus no significant alterations in the sAPP/APP ratio occur 
(data not shown). The 10 µM RA dose, however, induces a significant increase in this ratio at D2 
(compared to both NDi and 1 µM RA), reflecting an increased APP cleavage into sAPP. At D4 the 
sAPP/APP ratio decreases to control NDi values, and tends to further decrease unto NDf values 
(D4 vs D6 only significantly different when using the Student’s t-test), revealing a tendency for 
APP to be less cleaved with the differentiation time. Two-way ANOVA did not identify significant 
differences in-between D4, D6 and D8, and again two groups emerge: D2 and D4-D8. 
Chapter 5 Results 
104 University of Aveiro!
 
Figure B.3 - Time-dependent holoAPP and sAPP protein profiles in SH-SY5Y cells differentiated with 1 (A.) or 10 µM 
RA (B.). Cellular APP and medium sAPP were probed with the 22C11 antibody. C. The sAPP/APP ratios in 10 µM RA-
differentiated cells were directly calculated from the optical densities values. NDi: initial non-differentiated cells (day 2); 
NDf: final non-differentiated cells (day 8); D2-D8: day 2, 4, 6 and 8 of differentiation. n=3-5. */§/+/#p<0.05, 
**/§§/++/##p<0.01, ***/§§§/+++p<0.001 for data against control NDi (*), NDf (§), or D2 values (+), using one-way 
ANOVA followed by the Dunnett's or the Tukey-Kramer tests. Two-way ANOVA (#, for differences between 1 µM and 
10 µM RA data) further revealed extremely significant effects of RA dose and time of differentiation on holoAPP protein 
levels, but no significant interaction in-between these variables. 
 
Given the morphological alterations associated with differentiation, cytoskeleton alterations were 
also essayed (Figure B.4). Acetylated α-tubulin levels are an indirect measure of microtubules 
(MT) stabilization and neuronal differentiation [36], and morphogenic alterations in neuritogenesis 
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also rely on actin remodelling [37]. This type of cytoskeleton response, with time of SH-SY5Y 
cellular differentiation, is surprisingly not well documented in the literature.  
Levels of acetylated tubulin are markedly affected by the RA dose applied (p<0.0001, by two-way 
ANOVA). While 1 µM RA treatment only significantly alters tubulin acetylation at D6 (Figure B.4 
A 1 µM RA graph), 10 µM RA induces an extremely significant decrease in tubulin acetylation at 
D2, potentially reflecting its higher need for MTs instability. Two distinct periods emerge again for 
this dose: until D2 acetylated tubulin levels decrease; from D2 to D4 these levels significantly 
increase, remaining overall stable from D4 on (D4-D8). Noteworthy, at D8 α-tubulin acetylation 
levels are equal in-between RA doses and significantly lower than NDf (Figure B.4 A, D8 vs NDf). 
This is most relevant to any future study using tubulin acetylation as a differentiation biochemical 
marker, as one could expect the opposite to occur. Actin levels also tend to increase with RA but 
also with time in culture; the highest increase appears to occur from D2 to D4 for both RA doses, 
and no decrease is visible from NDi to D2 (Figure B.4, actin immunoblots). 
Interestingly, when plotting the ratio between APP and acetylated tubulin fold increases for the 10 
µM RA (Figure B.4 B ‘APP/ATub ratio’), one can observe that APP induction correlates with 
tubulin acetylation in a very clear biphasic manner (Figure B.4 B). Again the differentiation 
process presents two distinct phases: from D0 until D4 (D4 excluded), and from D4 onward (D4 
included). In the first phase, APP/ATub ratio linearly increases with a slope of 1.5; in the second 
phase this ratio is maintained at its highest values (~4). Therefore, during the first period APP is 
much more induced than tubulin is acetylated; in the second period, the rate of APP increase equals 
the rate of increase in tubulin acetylation. 
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Figure B.4 - Differentiation time-dependent profiles of acetylated α-tubulin levels and APP/acetylated α-tubulin 
ratio. A. Immunoblot analyses of acetylated α-tubulin (Atub) and actin in 1 and 10 µM RA-exposed SH-SY5Y cells. 
MAP-2 was probed as a differentiation marker. Acetylated tubulin levels were plotted as fold increases of NDi values. Of 
note, all the lanes are from the same blot, being rearranged into the presented order. B. The ratio between APP and Atub 
fold increases was plotted against days of differentiation with 10 µM RA. NDi: initial non-differentiated cells (day 2); 
NDf: final non-differentiated cells (day 8); D2-D8: day 2, 4, 6 and 8 of differentiation. n=3-5. */+p<0.05, 
**/§§/++/##p<0.01, ***/§§§/###p<0.001 for data against control NDi (*), NDf (§) values, or D2 values (+), determined 
by one-way ANOVA followed by the Dunnett's or the Tukey-Kramer tests; or for 1 µM versus 10 µM RA data (#) using 
two-way ANOVA. This later revealed extremely significant RA dose and differentiation time effects on acetylated α-
tubulin levels, and a very significant interaction in-between these variables. 
 
The subcellular distribution of APP and acetylated α-tubulin were further analysed by 
immunostaining (Figure B.5). Non-differentiated and 10 µM RA differentiated cells were probed 
for APP (green), acetylated α-tubulin (blue) and F-actin (red) at D2 and D8. In NDi and NDf non-
differentiated cells, APP and acetylated tubulin are more abundant in a Golgi-like region [26], and 
are uniformly distributed throughout the fewer cellular processes. As expected from the 
immunoblots data, 2 days of RA incubation do not alter the holoAPP intensity but decrease α-
tubulin acetylation staining (Figure B.5, D2 vs NDi). In D2 differentiated cells, APP and acetylated 
α-tubulin stain less the proximal and/or middle parts of the cellular processes, and part of the APP 
pool is enriched in their tips (as F-actin positive growth cones, Figure B.5 arrowheads). Completion 
of differentiation (D8) is accompanied by an increase in APP and acetylated α-tubulin signals. At 
D8, the cellular processes have elongated and APP and acetylated α-tubulin stain these processes 
along all their length. Comparatively, the 8 days control NDf cells are characterized by cellular 
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overconfluence, a cuboid cellular shape with fewer and smaller processes, decreased APP and 
increased acetylated α-tubulin staining (Figure B.5 NDf). 
 
Figure B.5 - Cellular localization of APP and acetylated α-tubulin in non-differentiated and 10 µM RA-
differentiated SH-SY5Y cells. APP (green) and acetylated α-tubulin (blue) were monitored by immunocytochemistry 
means using the anti-APP c-terminus and the anti-acetylated α-tubulin antibodies. F-actin was probed with red 
fluorescent-labelled phalloidin. Arrowheads indicate APP-enriched growth cones. ROIs of neurites are shown (2x zoom). 
NDi: initial non-differentiated cells (day 2); D2 and D8: day 2 and 8 of differentiation; NDf: final non-differentiated cells 
(day 8). Bar, 20 µm.  
5.4.3.!APP and sAPP neuritogenic functions in the biphasic model  
Since a unique peak of sAPP/APP ratio was observed at D2 (Figure B.3) for 10 µM RA, the RA 
dose with higher differentiation triggering abilities, further evidence for the involvement of sAPP 
in early neurite elongation was sought.  
The effects of sAPP were first assessed in the absence of RA. Non-differentiated SH-SY5Y cells 
expressing GFP were incubated with sAPP-enriched medium for 24h, and while sAPP enrichment 
does not significantly alter the number of processes (Supplementary Figure B.3 A), it tends to 
elongate pre-existing ones. Indeed, cells exposed to sAPP-enriched medium tend towards higher 
percentages of >20 µm and >35 µm processes, and exhibited significantly longer >35 µm processes 
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(neurites) (Figure B.3 B and Supplementary Figure B.3 C, respectively). sAPP medium-enrichment 
also led to an elongation of the cell body (Supplementary Figure B.3 D).    
Subsequently, sAPPα levels were modulated in 10 µM RA-treated cells by co-exposure to specific 
drugs for 48h, from D0 to D2 and from D2 to D4 (Figure B.6). sAPPα was increased by addition of 
10 nM recombinant sAPPα, or decreased by inhibiting APP α-cleavage with 10 µM TAPI; both 
types of sAPP modulations increased holoAPP levels (Figure B.6 A). Morphometric analyses of 
the D0-D2 modulations revealed that these tend to primarily affect >20 µm processes and >35 µm 
ones (neurites) (Figure B.6 B, D0-D2 TAPI and D0-D2 sAPP). Decreasing sAPP levels from D0 to 
D2 resulted in a general reduction of neuritogenesis (Figure B.6 B, ‘D0-D2 TAPI’), whilst the 
opposite occurred in cells exposed to recombinant sAPPα (Figure B.6 B, ‘D0-D2 sAPP’). Although 
both treatments are not statistically different from D2, they are significantly different from each 
other, particularly for the >20 and >35 µm processes. 
Regarding the second time interval, TAPI exposure from D2 to D4 mainly affected 35 and >50 µm 
processes (shorter and longer neurites) (Figure B.6 B ‘D2-D4 TAPI’). The decrease in the neuritic 
network mainly resulted from a significant retraction of the >50 µm neurites (Figure B.6 B and C). 
The number of these longer neurites also decreased to half, with the smaller 20-35 µm pre-neurites 
proportionally doubling in number (data not shown). Neuritic retraction induced by D2-D4 TAPI is 
accompanied by a considerable increase in acetylated tubulin (1.66±0.32 versus 0.69±0.06 for 
control D4; data not shown) resulting in a decrease in the APP/ATub ratio to c.a. D2 levels (Figure 
B.6 D). This reversion on processes’ elongation is also visible in Figure B.6 E microphotographs, 
accompanied by a reversion of the cellular body elongation, rendering more plastic and cuboid 
cells. TAPI also induces visible APP and acetylated tubulin increases at the Golgi-like region, 
distributions more similar to the ones of D4 non-differentiated cells (Figure B.6 E, ND4). 
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Figure B.6 - Modulation of sAPPα levels during the first phase of 10 µM RA-induced SH-SY5Y differentiation. A. 
Immunoblot determination of APP and sAPP levels (22C11 antibody) upon modulation of sAPP production. D2-D4: 
days 2 and 4 of RA differentiation; D2 TAPI: 2 days of incubation with RA and 10 µM TAPI; D2 sAPP: 2 days of 
incubation with RA and 10 nM recombinant human sAPP; D4 TAPI: day 4 of RA differentiation with addition of 10 µM 
TAPI at D2. Of note, all the lanes are from the same blot, being rearranged into the presented order. B. The mean lengths 
of >20, >35 or >50 µm processes were summed up and expressed as µm per mm2 of occupied area (‘Total area occupied 
by processes’). C. The average lengths of the >20, >35 and >50 µm processes were determined for the D4 and D4 TAPI 
conditions. n=3. D. The APP/Acetylated α-Tubulin ratio (dashed line in graph) was determined for the D4 TAPI 
condition (based on immunoblots). E. Representative confocal microphotographs of D4 and D4 TAPI differentiating 
cells; ND4, control non-differentiated cells at D4. Staining: APP in green (C-terminal antibody), acetylated α-tubulin in 
blue, and F-actin in red (phalloidin). Bar, 10 µm. */+p<0.05, **/++p<0.01, **p<0.001, for data against control conditions 
(*), and for comparisons between indicated conditions (+), by unpaired two-tailed Student’s t-test. 
 
Finally, as significant APP fold increases are concomitant with the second differentiation period, 
the relevance of holoAPP at this phase was also investigated. SH-SY5Y differentiated cells were 
transfected with an APP-GFP cDNA from D6 until D8, and their neuritogenic output compared to 
the one of vector GFP transfected cells (Figure B.7). Microphotographs and morphometric analyses 
of Figure B.7 show that APP overexpression from D6 to D8 did not produce significant alterations 
in the final average length of 20-35 µm pre-neurites, and 35-50 µm neurites, but resulted in a 
tendency for lengthier >50 µm neurites (Figure B.7 B, ‘x>50’). More significantly, the number of 
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these longer neurites per cell significantly doubled in APP-GFP fluorescing cells, from 0.17±0.03 
to 0.34±0.02 (Figure B.7 C; p<0.01), at the apparent expense of the smaller pre-neurites (longer 
than 20 µm but shorter than 35 µm), as denoted in the ‘type of processes’ Figure B.7 D graph. 
These results indicate that APP potentiates neuritic elongation in this later differentiation phase, 
potentially via increasing neuritic stabilization. 
 
Figure B.7 - Full-length APP potentiates neuritic elongation in the second 10 µM RA SH-SY5Y differentiation 
phase. SH-SY5Y cells differentiated for 6 days with 10 µM RA were transfected for 48h (from D6 to D8) with APP-GFP 
or the GFP vector alone. A. Representative confocal microphotographs of D8 GFP and APP-GFP differentiating cells; 
the DAPI nuclear marker was used as a counterstaining. Bar, 20 µm. The average lengths of processes (B.), the number 
of processes per cell (C.), and the percentage of processes (D.)  with 20-35, 35-50 µm, and >50 µm of length were 
determined in GFP and APP-GFP expressing cells. n=3. **p<0.01, by unpaired two-tailed Student’s t-test. A statistical 
trend for an increase % of the >50 µm processes occurs in APP-GFP cells (p=0.08 when compared to GFP cells). 
! !
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5.5.!Discussion 
APP is reported to be neuritogenic, but the underlying mechanisms are still focus of ongoing 
research. RA-induced SH-SY5Y differentiation, a widely used neuronal differentiation model, was 
adopted to address the APP neuritogenic role. A search on the time-dependent characterization of 
this model revealed that morphologic and some biochemical parameters have not been 
characterized in full detail. We thus first addressed neuritogenic-related morphologic alterations 
and specific protein shifts occurring at key differentiation periods. 
Concerning cell number, SH-SY5Y cells are reported to synchronously arrest in the G1-phase of 
the cycle as soon as 2 days after RA treatment [18]. In our model, while 1 µM RA increased cell 
proliferation at an early time point, 10 µM RA arrested it, as expected (Figure B.1). The later 
observed slight increase in cell number for 10 µM RA (from D6 to D8) may reflect a higher degree 
of transdifferentiation from N- to S-type cells, the two main cellular phenotypes in neuroblastomas-
derived cell lines. Although our SH-SY5Y population was previously enriched in N-type cells, a 
percentage of S-type cells is expected to still coexist and to increase due to transdifferentiation 
events [24]. A way to surpass this and to have fully differentiated cells for longer periods may rely 
in the concomitant administration of BDNF from D6 onward [38]. Regarding the 1 µM RA dose, 
contrary to the strong decrease observed at D4 by [9] (the only data found in the literature), our 
results suggest that SH-SY5Y cellular division is allowed during the first 48h, and cell number 
maintained from this point on (Figure B.1 C).  
Regarding cellular morphology, RA appears to first induce cell plasticity (Figure B.1 A/B and 
Supplementary Figure B.1) that progresses to cellular elongation with time and at higher RA doses 
(as 10 µM). RA-induced neuronal like phenotypes (plastic and elongated) were not acquired 
homogeneously by the population, but only by about two thirds of it (Supplementary Figure B.1), 
possibly reflecting the presence of S-type cells. Unfortunately, the reported literature normally 
solely addresses the elongated phenotype [20-22, 38].  
Acquisition of a neuronal-like phenotype also involves the generation and elongation of cellular 
processes into neurites. Exposure of SH-SY5Y cells to RA readily increased the number and length 
of processes in a time- and morphogen dose-dependent manner. As expected, the longest neurites 
(>50 µm) were inexistent in non-differentiated cells, described as possessing ‘truncated’ processes 
[19]. Both RA doses significantly and equally increased the total number of processes per cell at 
D2 Figure B.2 A), an early time point greatly characterized by the emergence of new processes. 
The following D4-D8 time points are more related to the elongation of pre-neurites and neurites, 
especially efficient when using 10 µM RA. This dose highly increased the percentage of neurites 
(Figure B.2 B, ‘>35µm’), and significantly increased the length of pre-neurites (at D4) and longer 
neurites (at D8) (Figure B.2 C, ’20-35 µm’’ and ‘>50 µm’).  
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Neuronal differentiation depends on cytoskeleton-based cell body and neuritic remodelling, and is 
linked to increased tubulin acetylation, a dynamic process generally restricted to stable MTs [36, 
39]. However, our results stress that although tubulin acetylation may increase during the time of 
differentiation, it is never increased over control non-differentiated cells. Indeed, cells exposed to 
10 µM RA had significantly less acetylated tubulin than control NDi and 1 µM RA cells (Figure 
B.4 A graph), and both RA doses reduced tubulin acetylation at D8 (Figure B.4 A, D8 vs NDf). 
These decreases may reflect a need for higher initial MT instability in cells suffering more dramatic 
differentiation-related alterations. Indeed, the higher decreases in tubulin acetylation occur in 10 
µM RA treated cells, consistent with their higher number of neurites and their increased length. In 
agreement, sAPP D2-D4 inhibition highly induced tubulin acetylation, resulting in an abnormally 
low APP/ATub ratio (Figure B.6 D) and in inhibited neuritogenesis (Figure B.6 B/C/E). Solinger et 
al.reported that in the neurons of C. elegans mutant for α-tubulin acetyltransferase, the α-tubulin is 
hyperacetylated and the MTs are too short or prone to depolymerize, resulting in shorter neurites 
[40]. However, α-tubulin acetyltransferase silencing also results in impaired differentiation and 
branching defects in mouse cortical neurons [41]. This is in agreement with our data, which 
indicate that α-tubulin acetylation has to be tightly controlled during neuronal differentiation. 
The 10 µM RA-induced SH-SY5Y differentiation was, at this point, established as a more 
comprehensive model. Data collected already outlined frontiers of two specific time phases: a first 
early phase (D0-D4, D4 excluded) more associated with the emergence of new and the elongation 
of smaller processes and pre-neurites into neurites, and a second phase (D4-D8), more involved in 
neuritic elongation and stabilization. The first phase presents the lowest level (and highest fold 
increase) of the cytoskeleton-related acetylated tubulin, whilst in the second phase its levels are the 
highest and tend to stabilize. Distinct expression patterns of other cytoskeleton-related transcripts 
occur between early time points (as D3) and later time points (D5 and D8) of RA incubation, as 
unravelled by unsupervised hierarchical cluster analysis. These molecules have important role in 
neuronal-like differentiation, and include integrin α1, integrin β1 and RAC1 [42].  
The effects of RA in APP cell fate [9] were further addressed taking these key differentiation 
periods into account. Comparison of our RA time-dependent APP expression with previous reports 
revealed several matches and reinforces our data. The 10 µM RA dose greatly increased holoAPP 
protein levels at D4, almost up to its highest final level, in agreement with the D4 APP mRNA 
peak observed by König et al [20]. At D6, a 3-fold increase in holoAPP was observed by us, 
similar to the 3-fold increase reported by Holback et al [8]. The high levels of holoAPP expression 
during the D4-D8 period (10 µM RA) are concomitant with the second phase, supporting its 
particular involvement in the neuritic elongation mechanism. Also, APP values are higher for 10 
µM RA, the dose that induces more efficient neuritic elongation. Regarding 1 µM RA, our results 
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agree with increases in APP mRNA and sAPP levels reported for this RA dose to occur between 
D4 and D6 [9].  
A significant increase in sAPP levels in response to both RA doses was also observed (Figure B.3 
A D6, and B D2), most probably via α-secretase modulation [8, 9]. Distinct α-secretases can 
mediate APP α-cleavage into sAPPα in a cell-specific fashion, with TACE more related to 
regulated sAPPα release, and ADAM 10 to its constitutive production [43]. RA treatment of SH-
SY5Y cells increases both α-secretase activities, by inducing ADAM10 mRNA and protein levels 
[44, 45], TACE protein levels, and the activities of both α-secretases [46]. However, sAPPα levels 
do not only depend on α-secretase activity but also on APP availability, a balance reflected in the 
sAPP/APP ratio. Our findings showed, for the first time, that 10 µM RA induces an early and 
unique peak in the sAPP/APP ratio at D2. From this time point on the ratio progressively decreases 
to non-differentiation control values. This sAPP/APP D2 peak suggested a strong involvement of 
sAPP in the first differentiation phase, potentially on the onset of elongation. sAPPα medium 
enrichment potentiates the elongation of pre-neurites and smaller neurites (20-35 and 35-50 µm, 
respectively) in early differentiated cells (Figure B.6 B, D0-D2 sAPP), and even in cells non-
exposed to RA (Supplementary Figure B.3 C, ‘>35 µm’). Contrastingly, the lengths of these 
processes are tendentiously shorter in TAPI-exposed cells (Figure B.6 B, D0-D2 TAPI), which 
have decreased sAPP levels and sAPP/APP ratio (0,44±0,05 at ‘D2’; 0,33±0,04 at ‘D0-D2 TAPI’). 
If we decrease the sAPP/APP ratio later on (from 0,16±0,03 at ‘D4’ to 0,12±0,01 in ‘D2-D4 
TAPI’) a significant neuritic retraction is again observed (Figure B.6 B, C). Noteworthy, neither 
TAPI treatment nor recombinant sAPP addition produced significant alterations in the number of 
processes (data not shown).  
In essence, the data strengthens a role for the singular D2 sAPP/APP peak in the elongation of all 
processes at the first differentiation phase. The sAPP/APP ratio is not only important to the early 
elongation of processes, but also to the maintenance of an elongated bipolar differentiated 
phenotype of the cell body, highly reverted by TAPI at D4 (Figure B.6 E). Noteworthy, by 
inhibiting TACE we only slightly decreased APP shedding to sAPPα, and the consequences of 
more robust sAPPα modulations (such as complete abolition) to processes’ elongation would 
probably be more dramatic.  
Finally, the high and stable holoAPP levels observed at the second phase (D4-D8) suggested a key 
role for membranar holoAPP during this period. This phase is characterized by neuritic elongation 
and concomitant neuritic stabilization, related to increased tubulin acetylation. Through APP 
overexpression means we have confirmed that APP has a positive effect on neurites at this second 
differentiation phase (Figure B.7). The increased number of longer neurites with no real alteration 
in their average length strengthens our working hypothesis where holoAPP is not an inducer but a 
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positive modulator of neuritogenic mechanisms, such as the stabilization of longer neurites. 
Overall, our data agrees with the  Young-Pearse et al.view, in which the sAPP/holoAPP balance is 
of most importance in establishing regional stability or motility in a cellular process, thus 
modulating neuritic elongation [17]. 
Importantly, the data here presented reveal specific phases of SH-SY5Y neuronal-like 
differentiation, well defined for the 10 µM RA dose. A first phase, from D0 to D4 (D4 excluded) is 
characterized by a 2 fold-increase in the number of processes, and by consecutive increases (D0-
D2, and D2-D4) in the percentage of neurites and in the length of  > 50 µm  neurites. A linear 
increase in the APP/ATub fold increases ratio also characterizes this phase, to which sAPP is 
crucial. In this phase, APP is cleaved to sAPP and only later it is transcriptionally activated at the 
same rate, resulting in an early unique sAPP/APP peak that correlates with processes’ elongation. 
Of note, we did not find a direct correlation between APP and tubulin acetylation levels in APP-
GFP transfected versus non-transfected RA-differentiated SH-SY5Y cells [47] or in assays of 
increased transfected APP doses (data not shown). 
In the second phase, from D4 to D8 (D4 included), 10 µM RA-differentiated SH-SY5Y cells 
display more neurites. These become stable with time, in accordance with the concomitant higher 
levels of acetylated α-tubulin. The steady holoAPP (and APP/ATub ratio) values also indicate that 
APP has a role in this stabilization, securing that retraction will not occur, a hypothesis 
strengthened by our findings that APP does not increase the mean length but mainly the number of 
longer neurites.  
In conclusion, profiling neuritogenesis permits the establishment of new neurochemical marker(s) 
reflecting the status of neuronal differentiation, and allows studying how specific molecules such 
as APP affect that status, with clear benefits to neuroscientists.   
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5.7.! Supplementary Data 
 
Supplementary Figure B.1 - Effects of RA concentration on cell morphology. SH-SY5Y cells, differentiated with 1 or 
10 µM RA, were grouped into three different phenotypic categories, namely: “Cuboids” - polygonal cells with practically 
no cell processes; “Elongated” - longer cells with a slender cell body and normally with one or two extended processes; 
and “Plastic” - cells presenting an irregular morphology (normally derived from the other two morphologies), with 
numerous emerging processes, lamellipodia and/or fillopodia. Data are expressed as percentages of the total number of 
cells. Ndi: initial non-differentiated cells (day 2); NDf: final non-differentiated cells (day 8); D2-D8: day 2, 4, 6 and 8 of 
differentiation. n=4. */#p<0.05, **/§§/##p<0.01, ***/§§§p<0.001 for data against NDi (*) or NDf (§) controls, using one-
way ANOVA followed by the Dunnett's or the Tukey-Kramer tests. Two-way ANOVA analysis revealed an extremely 
significant RA dose effect for the % of cuboid cells (only between RA absence and presence, but not between 1 and 10 
µM RA) and elongated cells, and a very significant RA dose effect for the percentage of plastic cells (§ symbol for 
differences between 1 and 10 µM RA). 
!
!
Supplementary Figure B.2 - Identification of APP and sAPP bands in SH-SY5Y cellular and media lysates. SH-
SY5Y cells and media were collected into 1% SDS lysates and resolved in 5-20% homemade gradient SDS-PAGE gels. 
Immunoblot analysis was conducted using either the anti-APP N-terminus antibody, which detects all APP (and APLP) 
isoforms and their derived sAPP fragments, or the anti-APP KPI antibody, which detects the KPI-containing APP (and 
APLP) isoforms such as the highly abundant 751 and 770, and their derived sAPP fragments. I and II. represent different 
resolutions of equivalent samples, where the immature 751 APP isoform either co-migrates with the 770 isoform (I.) or 
with the 695 APP isoform (II.). 'Immt' - immature isoforms (arrowheads); 'mt'- mature isoforms (arrows). '**'KPI-
negative sAPP. 
 
!
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Supplementary Figure B.3 - Effects of sAPP medium enrichment on non-differentiated SH-SY5Y cells. Non-
differentiated SH-SY5Y GFP-transfected cells were incubated for 24h with sAPP-enriched conditioned medium, 
previously obtained by transfecting SH-SY5Y cells for 24h with an APP695-GFP cDNA. Fluorescence microphotographs 
were obtained, and an average of 60 GFP-expressing cells per condition analysed. Morphometric analyses of sAPP 
effects included: A. Number of processes per cell [all processes protruding from a cell (‘Total’), processes >20 and 35 
µm were scored, and the scores divided by the total cell number]; B. Percentage of Types of processes (the percentage of 
processes < and >20 µm, and >35 µm, were calculated out of the total number of processes); C. Mean neuritic length (the 
mean neuritic lengths of all processes >20 and 35 µm were calculated); n=4. **p<0.01, between control and plus sAPP 
conditions, as determined by unpaired two-tailed Student’s t-test; of note, the number of >20 and >35 processes per cell 
and their % of type of processes, showed a statistical tendency (not quite significant, p<0.1, for C vs sAPP values). D. 
Representative epifluorescence microphotographs are shown. Immunocytochemistry of acetylated α-tubulin (blue) is 
shown, exhibiting no major differences between control and sAPP conditions. Bar, 10 µm. 
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6.!PhosphoS655 APP promotes neuritogenesis via modulation of EGFR 
trafficking and enhanced ERK activation 
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6.1.!Abstract 
The amyloid precursor protein (APP) and the epidermal growth factor/receptor (EGF/EGFR) are 
implicated in common neurological diseases and aging. Both are widely expressed in the central 
nervous system and have a role in brain development. 
In the present work we show the existence of a functional interplay between APP and EGF-EGFR 
signaling in neuronal differentiation. APP is able to interact with both proEGF and EGFR, and 
combined APP overexpression and EGF stimulation have a synergistic effect on neuronal-like 
differentiation. Such effect seems to relate well with promotion of ERK1/2 activation, and APP 
ability to modulate both EGFR expression levels and trafficking. In addition, we show that APP 
S655 phosphorylation is able to positively modulate EGFR and ERK1/2 activation, while the 
constitutively dephosphorylated mutant seems to target EGFR to LAMP2-positive lysosomes and 
is associated with lower levels of ERK1/2 phosphorylation. Finally, we show that APP S655 seems 
to play a role in dendritogenesis in mice cortical neurons. 
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6.2.!Introduction 
The amyloid precursor protein (APP) is a type 1 integral membrane glycoprotein with a large 
extracellular domain and a short cytoplasmic region. During its dynamic intracellular trafficking, 
APP undergoes proteolytic cleavages to release biologically active peptides [1]. Close to the 
membrane domain APP can be cleaved by β-secretase or α-secretase, releasing soluble N-terminal 
fragments. The resulting membrane tethered C-terminal fragments are subsequently cleavage by 
the γ-secretase complex to release two peptides: Abeta and the APP intracellular domain, AICD 
(after β-secretase), or p3 and AICD (after α-secretase) [2]. In addition, direct phosphorylation of 
the APP has important roles in the regulation of APP traffic and sorting [3-6], processing [5-8], and 
binding to protein interactors [9].  
APP is a central protein in the most prevalent neurodegenerative disorder, the Alzheimer’s disease 
(AD) [10], and has been further implicated in several other neurological disorders and brain injury 
[11]. Highly enriched in neurons, APP appears to be critical for normal brain development and 
adult brain plasticity [12]. Specific roles in neurogenesis [13], neuronal migration [14], neurite 
outgrowth [15] and guidance [16], synaptogenesis [17], and synaptic plasticity [18] have been 
described. 
Similar to APP, the epidermal growth factor precursor (proEGF) is a type I transmembrane 
glycoprotein cleaved by cell surface proteases to release the mature epidermal growth factor 
(EGF). The human precursor has a large extracellular domain with 9 EGF-like domains, a helical 
transmembrane domain, and a shorter cytoplasmic domain [19, 20]. Solubilized forms of the 
precursor have been described as biological active, competing with EGF for EGF Receptor (EGFR) 
binding [21]. 
EGF is a well described mitogen for multiple cell lines, ranging from epithelial cells and fibroblasts 
to neural stem and progenitor cells of different origins in the central nervous system (CNS) [22]. 
Moreover, it is also a neurotrophic and neuromodulator actor in postmitotic neurons, promoting 
differentiation, maturation, survival and synaptic plasticity [23-25]. Both EGF and EGFR (also 
known as ErbB1) are expressed in various regions of the CNS, and their expression pattern is 
suggestive of a role in neurodevelopment, i.e., in the telencephalon EGFR expression is precisely 
increased from early embryonic stages to mid-late embryonic stages, where higher levels of EGFR 
mRNA and protein are expressed by different cell populations, namely astrocytes, neurons and 
multipotent stem cells [26]. Additionally, both EGF and EGFR have been implicated in 
neurological disorders like Schizophrenia, Parkinson's and Alzheimer’s diseases, and in 
neurometabolic aging [27]. 
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EGF binding to EGFR induces receptor dimerization and auto-phosphorylation of receptor tyrosine 
residues, which in turn recruits phosphotyrosine binding proteins and initiates different signaling 
events. The major pathways activated by EGFR include Ras stimulation of RAF-MEK-ERK1/2 
cascade, PI3K stimulation of Akt and PLCgamma, and JAK stimulation of STAT pathway [28]. 
Activated receptors are internalized (potential via CBL recruitment) in early endosomes, where it is 
now known that tyrosine kinase receptors’ signal continues [29]. After activation, the receptor 
follows two possible fates: 1) recycling to the cell surface; or 2) sorting onto intraluminal vesicles 
of maturating endosomes and targeting to lysosomal degradation. Modulation of this EGFR 
trafficking has major consequences for signaling outcomes [30, 31]. 
EGF stimulation has been implicated in the regulation of APP expression and processing [32, 33]. 
On the other hand, the AD-related APP Swedish mutation has been shown to alter EGFR 
degradation after EGF stimulation [34], and AICD seems to regulate EGFR gene expression [35].  
The aim of the present work was to investigate the interplay between APP and EGF-EGFR 
signaling in neuronal differentiation. We here show that combined APP and EGF have a synergistic 
effect on neuronal-like differentiation that relates to ERK1/2 activation. This might be in part due 
to the APP ability to modulate both EGFR expression levels and trafficking. Furthermore, we show 
that APP phosphorylation at S655 positively modulates such events. 
 
  
Results  Chapter 6 
University of Aveiro   123 
6.3.!Material and Methods!
6.3.1.!Antibodies and Reagents 
The following primary antibodies were used: rabbit anti-EGF (antibodies-online), rabbit anti-
proEGF (against aa 700-800; Novus Biologicals), rabbit anti-EGFR (Abcam), rabbit anti-APP C-
Terminal (clone CT695; Invitrogen), mouse anti-APP N-terminal (clone 22C11; Chemicon), mouse 
anti-APP residues 1-16 of Abeta (clone 6E10), rabbit anti-phosphorylated ERK1/2 (Thr202/Tyr204 
and Thr185/Tyr187 for Erk1 and Erk2, respectively; Millipore), rabbit anti-ERK1/2 (Millipore), 
mouse anti-Grb2 (BD Bioscience), rabbit anti-Shc (BD Bioscience), mouse anti-BIII Tubulin 
(Sigma-Aldrich), mouse anti-MAP2 (Sigma-Aldrich), mouse anti-Rab5, and mouse anti-Rab4 
(Sicgen), mouse anti-LAMP2 (Abcam ab25631). HRP-conjugated secondary antibodies, anti-
mouse and anti-rabbit, were from GE-Healthcare. Secondary antibodies Alexa Fluor 405 goat anti-
mouse or goat anti-rabbit, and Alexa Fluor 594 goat anti-rabbit or goat anti-mouse were from Life 
Technologies. Donkey anti-mouse Cy3 was also used.  
Human recombinant EGF was from Cell Signaling and was diluted to a final concentration of 
100ng/mL. Human recombinant sAPPalpha (diluted to 5 nM) and the EGFR inhibitor drug PD 
168393 (diluted to 10 µM) were from Sigma-Aldrich. Texas Red-conjugated Transferrin was from 
Molecular Probes. 
6.3.2.!Cell culture 
Cell cultures cells were kept in a humidified, 37oC, 5% CO2 incubator. The HeLa cell line was 
maintained in 10% FBS DMEM, and cells were plated onto 60 mm plates in order to reach 60-80% 
confluency next day. The SH-SY5Y human neuroblastoma cell line was maintained in 10% FBS 
MEM/F12 medium. For morphometric and immunocytochemistry studies initial cell density plated 
was 2.0x104 cells/cm2 onto six-wells plates containing sterile coverslips, and cells were allowed to 
grow for 24h. For biochemical studies cells were plated onto six or twelve-wells plates in order to 
reach 60-80% confluency next day.  
6.3.3.!Expression vectors and DNA constructs 
Human APP isoform 695 (APPWt) cDNA, and the respective S655 phosphomutants, Serine 655 to 
Alanine (S655A, APPSA) or to Glutamate (S655E, APPSE) are fused in frame with GFP in the 
pEGFP-N1 mammalian expression vector, and were previously produced and described by our lab 
[36]. These cDNAs were used as template to generate an additional Tyrosine 682 to Phenylalanine 
(Y682F, APPYF) point mutation using the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene). The following primers were used: FW-
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GATGCAGCAGAACGGCTTCGAAAATCCAACCTAC; RV-
GTAGGTTGGATTTTCGAAGCCGTTCTGCTGCATC (NZYTech). Resulting constructs and 
mutations were confirmed by DNA sequencing (ABI PRISM 310 Genetic Analyzer, Applied 
Biosystems). Empty pEGFP-N1 expression vector (here named ‘V) was used as control in 
experiments involving transfection. 
6.3.4.!Cellular Transfection and incubation with EGF 
Mammalian cell lines transfections were carried out with the TurboFectTM reagent according to the 
manufacturer’s instructions (Fermentas Life Sciences). Briefly, for each monolayer of cells grown 
in 6-well plates, 2 µg of cDNAs (GFP empty vector or APPs-GFP cDNA) were diluted in 100 µL 
of serum-free growth medium. After being briefly vortex, 4 µL of TurboFectTM were added to the 
diluted DNA. The mixture was vortexed and incubated for 15-20 min at room temperature (RT), 
after what the mixture was added dropwise, to each well, with gently rocking. Cells were further 
incubated for 6h at 37oC in a CO2 incubator, after which medium was changed. For cell 
morphology/morphometric assays, EGF treatment included a brief pulse of 3-5 minutes before 
transfection medium change; when indicated the PD 168393 inhibitor was added 1h before the 
EGF stimulation. For immunoblot analysis of protein levels, EGF was added to the cells 1h before 
cells’ harvesting. 
Mouse cortical primary neurons were transfected using Lipofectamine® 2000 (ThermoFisher 
Scientific). To sum up, for each well of a 24-well plate, 2 µL of Lipofectamine were diluted in 
50µL Neurobasal medium, and incubated for 5 min at RT. cDNAs were diluted in 50µL 
Neurobasal medium in a separate microtube. Both solutions were mixed, and the mixture incubated 
for 20 min, RT. During this time, neurons conditioned medium was collected and new pre-warmed 
Neurobasal medium (without supplements) was added to the neurons. Lipofectamine-cDNA 
precipitates were added to the neurons for 3h, after which medium was replaced by the previous 
conditioned medium. At this time, the PD 168393 inhibitor was included in the respective 
conditions, and after 3h EGF was added. Transfection was let to occur for 24h at 37oC in a CO2 
incubator. 
6.3.5.!GFP-Trap co-precipitation assay 
GFP tagged-APP protein overexpressed by HeLa cells, were precipitated by pulling-down the GFP 
moiety with GFP-Trap® (Chromotek), according to the manufacturer’s instructions. Briefly, after 
transfection, cells were washed in phosphate buffer saline (PBS), and collected with a scrapper in 1 
ml ice-cold PMSF-containing PBS, on ice. After a centrifugation step, cell pellet was lysed for 30 
min on ice with non-denaturant lysis buffer 1 (10 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 0.5% 
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Gepac-ca-630, 150 mM NaCl, 1 mM PMSF) supplemented with protease inhibitors cocktail 
(Sigma-Aldrich), 1 mM NaF, and 10 mM sodium orthovanadate. Following centrifugation (5 min 
at 20000 g, 4oC), the supernatant was collected, an aliquot of 25 µL was taken (‘cells lysates’ 
fraction), and total protein quantified (Pierce’s BCA kit; Thermo Scientific).  Mass normalized 
lysates were pull-downed with GFP-Trap for 3h with orbital shaking at 4oC. The beads were 
magnetically separated until supernatant was clear, and ressuspended in wash buffer (10 mM Tris-
HCl pH 7.5; 150 mM NaCl; 0.5 mM EDTA; 10 min incubation with agitation at 4oC). Magnetic 
separation and washing step were repeated 4 times, after what the proteins were eluted in Laemmli 
sample buffer. 
6.3.6.!Cortex dissection and Co-Immunoprecipitation 
Wistar Hannover rats (9–12 weeks) were obtained from Harlan Interfaune Ibérica, SL. Animal 
suffering and the number of animals were minimized, and all the experiments met the European 
legislation for animal experimentation (2010/63/EU; European Council Directive 86/609/EEC). 
The experiment was approved and supervised by our Institutional Animal Care and Use Committee 
(IACUC): Comissão Responsável pela Experimentação e Bem-Estar Animal (CREBEA). Briefly, 
animals were sacrificed by cervical stretching followed by decapitation and, cortex was dissected 
out on ice. Tissues were further weighed and homogenized on ice with a Potter-Elvehjem tissue 
homogenizer (10–15 pulses at 650–750 rpm) in non-denaturating lysis buffer 2 (50 mM Tris–HCl 
pH 8.0, 120 mM NaCL and 4% CHAPS) containing protease inhibitors [37]. The tissue extracts 
were used for immunoprecipitation analysis as described below. 
Mice cortex dissection was performed as described above for rat, but tissue was homogenized in 
non-denaturating lysis buffer 1, containing protease inhibitors.  
For immunoprecipitation of rodent cortices, dynabeads Protein G (Dynal, Invitrogen) were washed 
in 3% bovine serum albumin (BSA) in PBS, and primary antibodies (rabbit anti-proEGF or mouse 
anti-APP 22C11) were incubated with Dynabeads according to the manufacturer's instructions. 
Cortex lysates were precleared with 0.6 mg Dynabeads for 1 h at 4°C with agitation and incubated 
with antibody-Dynabeads overnight (O/N) at 4°C with agitation. The immunoprecipitates were 
washed in PBS and proteins denatured by boiling in Laemmli loading buffer followed by SDS-
PAGE and immunoblotting. 
6.3.7.!Neuronal primary cultures 
Pregnant mouse (E14-15; in-house breed) was anaesthetized with Isoflurane (Piramal Healthcare 
India, 99.9% purity) followed by cervical stretching and decapitation. The mouse embryos were 
then decapitated and used for the isolation of cortex to prepare cortical primary cultures. Briefly, 
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after dissociation with TrypLETM Express Enzyme (Thermo Scientific), cells were plated onto 
poly-D-lysine-coated dishes at a density of 100000 cells/cm2 in 10% horse serum DMEM 
(Invitrogen). After 12h DMEM medium was removed and replaced by serum-free, B27-
supplemented Neurobasal A (Thermo Scientific), plus Glutamax (Invitrogen) and sodium pyruvate 
(Sigma-Aldrich). Cultures were maintained in an atmosphere of 5% CO2 at 37°C, and every 2 days 
half of medium was replaced by fresh medium. 
6.3.8.!SH-SY5Y cells proliferation assay 
Immediately before changing the medium of cell transfection, 100 ng/mL of EGF were added to 
the culture medium in the defined conditions for 3-5 min [38]. Transfection medium was changed 
to cell medium without FBS. Immediately after changing the medium, the 10 µM of 5-ethynyl-2’-
deoxyuridine (EdU) was added to the cell medium to perform the proliferation assay. Cells were 
maintained for further 12h, in a total of 18h of transfection. 
Cell proliferation was determined using the Click-iT® EdU Alexa Fluor® imaging kit (Invitrogen) 
according to the manufacturer’s protocol. This kit uses the EdU as a nucleoside analogue of 
thymidine to directly measure DNA synthesis. Coverslips containing the cells monolayer were 
fixed with 4 % paraformaldehyde in PBS (PFA) for 15 min. After washing twice with 3% bovine 
serum albumin (BSA) in PBS the cells were permeabilized with 0.5% Triton X-100 in PBS for 20 
min, and again twice washed with 3% BSA in PBS. EdU detection is performed by incubating the 
coverslips with a Click-iT® reaction cocktail (Click-iT® reaction buffer, CuSO4, Alexa Fluor® 
594 Azide, and reaction buffer additive) for 30 min while protected from light, followed by a wash 
with 3% BSA in PBS. For subsequent DNA staining, coverslips were first washed 1x with PBS, 
and incubated with 5 µg/mL Hoechst 33342 in PBS for 30 min. Finally, coverslips were directly 
mounted on microscope slides with Vectashield® mounting media (Vector Labs).  
EdU and Hoechst double labelled SH-SY5Y cells were imaged with the Olympus IX81 inverted 
epifluorescence microscope. For each condition random images of 20 fields were taken in 
triplicate, in which EdU positive and Hoechst positive nuclei were manually scored using the Fiji 
software. The total number of positive cells in the well was estimated based on the area covered by 
the objective, and the percentage of cell proliferation was determined by calculating the number of 
EdU positive cells against the number of Hoechst positive cells. 
6.3.9.!Endocytic trafficking assays 
Endocytosis of Texas Red-conjugated Transferrin (Molecular Probes) was monitored in SH-SY5Y 
24h transfected with the GFP vector (‘V’), and APPWt. In order to eliminate endogenous 
transferrin, cells were further incubated for 30 min at 37oC with DMEM medium supplemented 
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with 20 mM HEPES. Medium was exchanged for 500 µL fresh medium of equal composition but 
containing 1mg/ml BSA and 100 nM Texas Red-conjugated transferrin, and cells incubated for a 
further 15 min at 37oC. In the last 5 min, EGF was include in a subset of cells [4]. The plates were 
immediately cooled to 4oC, washed twice with ice-cold PBS, and cells fixed and processed for 
immunocytochemistry. 
To compare the ability of the different APP-GFP proteins (Wt, SA, SE) to regulate EGFR 
endocytic trafficking, SH-SY5Y cells were plated and transfected for 24h with the GFP vector 
(‘V’), APPWt, APPS655A and APPS655E as described above. Cells were washed with ice-cold 
PBS and fixed with 4% PFA. Immunocytochemistry with rabbit anti-EGFR and mouse anti-Rab5, 
mouse anti-Rab4, or mouse-LAMP2 were subsequently performed [31]. 
6.3.10.!Immunocytochemistry assays  
SH-SY5Y cells grown on coverslips were fixed with a 4% PFA for 20 min and, upon three washes 
with PBS, permeabilized with a 0.2% TRITON PBS solution for subsequent immunocytochemistry 
analysis. Briefly, cells were first blocked for 30 min-1h with 5% BSA in PBS, then incubated with 
specific primary antibodies, and finally incubated with fluorophore conjugated-secondary 
antibodies. Preparations were washed with PBS, mounted with Vectashield® mounting media, 
with or without DAPI (Vector Labs).  
Mouse cortical primary neurons, grown on coverslips, were pre-fixed for 10 min by adding equal 
amounts of warm 4% PFA to the culture medium, followed by a fixation step as described above. 
Permeabilization was performed by washing coverslips 3 times, 10 min each, with 1X TBS with 
0.05% Triton, and unspecific sites were blocked by 1h incubation at RT with fresh 1X TBT with 
0.2% Triton, 5% goat serum and 5% horse serum. Primary antibodies were incubated O/N at 4oC, 
and after washing cells were blocked again for 30 min, and secondary antibodies were incubated 
for 2h. Before mounting with Mowiol, coverslips were washed 3 times with 1X TBS with 0.05% 
Triton. 
Cells visualization was performed by epifluorescence microscopy under an Olympus IX-81 
motorized inverted microscope equipped with a LCPlanFl 20x/0.40 objective lens [5], or by 
confocal microscopy using a LSM 510 META confocal microscope (Zeiss) and a 63x oil objective 
[4]. 
For colocalization studies related to EGFR trafficking, stack images of delimited single cells (APP-
GFP or control GFP vector transfected cells) were analysed using the Fiji plugin JaCoP [39]. The 
percentage of colocalization of one protein with another (for example of EGFR with the endosomal 
protein markers Rab5 or Rab4; specified in each graph) was obtained by applying the Manders’ 
method. 
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6.3.11.!Morphometric analyses of cell neuritogenesis 
For the experiments including cells treatment with EGFR inhibitor PD 168393, morphometric 
analysis of cells was performed on ~30 random digitized images per sample, with an average of 
140 transfected cells per biological replica of each condition being analyzed. Transfected cells 
were identified by GFP expression, measurements were performed on matching acetylated-tubulin 
fluorescent microphotographs (similar to using PhC microphotographs). All the measurements 
were performed as previously described [40], using Fiji. Process scoring was divided as follows: 1) 
“Total”, all processes arising from a cell; 2) “>20 µm”, processes longer than 20 µm; and 3) “35 
µm”, processes longer than two times the cell body length (≥ 35 µm). Data was expressed as a 
quotient of the total number of processes per cell. 
For quantitative morphometric analysis of cortical primary neurons, GFP-positive and MAP2/BIII-
Tubulin-positive neurons were randomly imaged. Neurons extensively entangled, or the 
exceptional cases when neurites extended outside the visualization field were excluded. Neurites 
were quantified using NeuronJ [41], a Fiji Plug-in. Several parameters were analyzed for each cell, 
chosen accordingly to previous reports [42, 43] (see Supplementary Table 1), with a total of ~50 
cells being analyzed for each condition. 
6.3.12.!Western blot assays 
For western blot (WB) purposes, cells were washed and harvested with either 1% boiling SDS, or 
RIPA buffer (Sigma-Aldrich-Aldrich) containing 1% protease inhibitors cocktail ( Sigma-Aldrich-
Aldrich), 1 mM NaF, and 10 mM sodium orthovanadate. SDS harvested cell lysates were further 
boiled for 10 min, cells with RIPA buffer are incubated for 5 min at 4oC. Cell lysates were 
sonicated for 30 sec, and total protein content was measured as above described. When required, 
conditioned medium was collected, cleared by centrifugation, and harvested into final 1% SDS 
samples. Aliquots for WB were mass-normalized to the respective lysates total protein content. 
Mass-normalized aliquots were subjected to electrophoresis on 5-20% gradient SDS-PAGE, being 
subsequently electrotransferred into nitrocellulose membranes. These were initially processed for 
Ponceau-S staining in order to assess gel loading (according to [44]), since in cell differentiation 
studies beta-actin and other cytoskeleton markers are not suitable loading controls [40, 45-47]. 
Following, primary antibodies were incubated as specified by the manufacturer’s instructions (from 
2h to O/N) and secondary antibodies for 2h. Membranes were further washed 3x with TBS-T or 
PBS-T for 10 min, and submitted to the ECLTM (enhanced chemiluminescence; GE Healthcare) 
detection method, using x-ray films (GE Healthcare), or directed imaged by ChemiDocTM touch 
Imaging System (BioRad).  
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Ponceau-S stained membranes and ECL x-ray films were scanned (GS-800 imaging densitometer, 
BioRad) and protein immunoreactive bands quantified (Quantity One densitometry software or 
Image Lab software from BioRad). All data is presented as fold-increase of a control condition 
(stated in figure caption), corrected to Ponceau-S used as loading control, and expressed as mean ± 
SEM (standard error of the mean). The number of independent experiments is specified in the 
figure caption. 
6.3.13.!Protein phosphorylation analysis by Phos-tag SDS-PAGE 
SH-SY5Y cells 24h transfected with the APP-GFPs proteins and stimulated or not with EGF for 5 
min, were directly harvested in Laemmli buffer. Samples were then subjected to phos-tag SDS-
PAGE performed with 5% polyacrylamide gels containing 25 µM phos-tagTM (AAL-107, Wako 
Pure Chemicals Industries, Ltd) and 100 µM MnCl2. After electrophoresis, phos-tag acrylamide 
gels were washed with transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol) 
containing 10 mM EDTA, for 10 min with agitation and then with transfer buffer without EDTA 
for 10 min according to the manufacturer´s protocol. Proteins were transferred onto nitrocellulose 
membranes followed by immunoblotting detection as indicated above. 
6.3.14.!Statistical analysis 
All statistical analysis was performed using the GraphPad Prism5 software. The test applied to 
infer statistical significance is stated in each figure caption. In general, to compare 3 or more 
groups one-way ANOVA followed by the Dunnett’s post-test or the Tukey-Kramer 
multicomparision post-test were performed; to compare two groups the unpaired Student’s t-test 
was applied. Cortical neurons morphometric data and the specified colocalization data included 
non-normally distributed samples were analyzed by the Kruskal-Wallis test with Dunn´s multiple 
comparison post-test (comparison of 3 or more groups) or by the by the Mann Whitney test 
(comparison of two groups). Colocalization data following normal distribution were analyzed by 
the unpaired t-test or by the one-way ANOVA followed by the Tukey-Kramer multicomparision 
post-test. 
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6.4.!Results 
6.4.1.!APP interacts with precursor form of the epidermal growth factor 
APP and proEGF are both type 1 transmembrane glycoproteins. Due to the display of overlapping 
cell and tissue expression and functions, we tested the hypothesis of a physical interaction between 
both proteins. Human HeLa cells transiently overexpressing APPWt were used to pull down the 
APP-GFP protein and its interactors, using the GFP-trap technique (Figure B.8 A, upper panel). 
The anti-EGF antibody detects 3 protein forms of proEGF in HeLa cells’ lysates (between ~95 and 
120 kDa, possibly indicating different glycosylated forms), with the band of lowest molecular 
weight (~95 kDa) co-immunoprecipitating with APP-GFP (Figure B.8 A, lower panel).  
 
Figure B.8 - APP interacts with the precursor form of EGF. A. HeLa cell lysates from cells transiently overexpressing 
the GFP empty vector (V) or the wild-type APP695-GFP cDNA (APP) were immunoprecipitated using GFP-Trap® 
magnetic beads. No APP is pull down in the control condition. The anti-EGF antibody reveals that a precursor form of 
EGF is precipitated bound to APP-GFP. n=3. B. Rat cortices were lysated with CHAPS buffer and immunoprecipitated 
by anti-APP antibody (22C11, against APP N-terminal) bound to Protein G Dynabeads. Immunobloting with anti-
proEGF (specific antibody for the precursor form of the EGF protein) revels several immunoreactive bands in cortex 
lysates and confirms that pro-EGF is co-precipitated with APP. Negative control: absence of the 22C11 primary 
antibody. n=2.  C. Rat cortices were lysated with NP-40 based buffer and immunoprecipitated by anti-proEGF antibody. 
Immunobloting with anti-APP 22C11 proved that APP is co-precipitated with pro-EGF. Negative control (‘Ctr neg’ - 
cortex extracts incubated with protein G Dynabeads but no primary antibody). Cortex lysate from APP knock-out 
animals (APPKO) was included to show the specificity of the APP antibody. n=1. 
 
Next, we tested the physical interaction between APP and proEGF in rat and mouse cortex lysates. 
Rat cortex lysates homogenised and lysed with non-denaturant CHAPS buffer were 
immunoprecipitated with anti-APP N-terminal antibody 22C11. Figure B.8 B shows that the 
majority of the proEGF immunoreactive bands found in rat cortex lysates co-precipitate with APP. 
Mouse cortex lysed with non-denaturant NP-40 based lysis buffer was immunoprecipitated with 
the anti-proEGF antibody. In mouse cortex lysates, proEGF appears mainly as 3 immunoreactive 
bands (Figure B.8 C, upper blot): one around 98 kDa, and other two below this marker. An 
additional higher molecular weight band (above 198 kDa) can also be detected with longer 
exposure time. Concordantly with these results from HeLa cells and rat cortex, proEGF also co-
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immunoprecipitates full-length APP. The APP form of higher molecular weight, most probably 
corresponding to its mature glycosylated form, is particularly more efficiently co-precipitated with 
proEGF (Figure B.8 C, * in lower panel). In mouse cortex proEGF could also be co-precipitated 
with an anti-APP antibody (data not shown). 
6.4.2.!APP potentiates EGF-mediated neuritogenesis in SH-SY5Y cells 
Following the evidence on the physical interaction between APP and proEGF, the role of such 
interaction was pursued. Since EGF is a known strong mitogen, we combined APP overexpression 
and EGF stimulation to study a potential functional interaction in cellular proliferation 
(Supplementary Figure B.4). An Edu incorporation assay was performed in SH-SY5Y cells 
transiently transfected with the GFP empty vector (‘V’) or with APPWt for 18h, and exposed or not 
to a 3 min EGF pulse right before transfection medium exchange (Supplementary Figure B.4 A). 
After the EGF pulse, the DNA of SH-SY5Y cells undergoing mitosis was labelled by incubation 
with the fluorescing nucleotide Alexa594-Edu for 12h (Supplementary Figure B.4 B). In these 
conditions, no differences in the percentage of proliferating cells (Edu-positive/Hoescht-positive 
nuclei ratio) are observed in all the conditions (Supplementary Figure B.4 C). Although EGF does 
potentiate proliferation over basal values, at the assay’s end point there is a higher number of EGF-
stimulated cells than non-stimulated cells, indicating a pro-survival effect. APP has no influence in 
this EGF pro-survival effect, as no differences are observed between APP transfected cells and 
vector transfected cells (Supplementary Figure B.4 D).  
A closer look on the morphology of the SH-SY5Y cells of the proliferation assay suggested that an 
APP-proEGF functional interaction may reside on neuronal-like differentiation (Figure B.9). 
Morphometric analyses included scoring the total number of neurite-like processes arising from 
each cell (‘Total’, all processes of all sizes), and measuring and categorizing these processes by 
length: processes higher than 20 µm, and processes higher than 35 µm (pre-neurites and neurites, 
respectively) [40]. Relatively to the number of processes longer than 20 µm, EGF alone-stimulated 
cells tend to increase this number (Figure B.9 B, 2C, ‘V+EGF’) while APP overexpression alone 
significantly increases it (Figure B.9 C, ‘APP’). The concomitant overexpression of APP with EGF 
stimulation (‘APP+EGF’) further increases the number of longer processes. Particularly, combined 
APP overexpression and EGF treatment increases the number of processes longer than 35 µm per 
cell when compared to any of the other conditions (Figure B.9 C), and is the only condition able to 
significantly increase neuritic length (Figure B.9 D). 
Since EGFR activation mediates EGF neuritogenic effects, its involvement in the APP+EGF co-
induced neuronal-like differentiation was pursued. SH-SY5Y cells were transfected with APPWt 
and, in addition to EGF stimulation, cells were also exposed to the EGFR inhibitor PD168393 
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(Figure B.9 B scheme).  Cells concomitantly treated with EGF and the EGFR inhibitor (‘INIB’) 
show significantly lower number of processes per cell than EGF only treated cells (Figure B.9 B 
and C, Total and >20 µm processes). The number of total processes per cell is only slightly 
decreased in APP+EGF cells tretated with the EGFR inhibitor, and the number is very similar to 
APP alone (Figure B.9 B, ‘APP+INIB+EGF’ vs ‘APP’). However, EGFR inhibition has a more 
drastic effect on neurite elongation, significantly decreasing the number of >20 µm processes and 
the number of processes > 35 µm when compared to both ‘APP’ and ‘APP+EGF’ conditions 
(Figure B.9 C; p=0.0399 for > 35 µm processes in ‘APP’ vs ‘APP+INIB+EGF’ conditions by the 
two-tailed unpaired t test). These results suggest that the EGFR receptor has a role in APP-induced 
processes elongation, besides mediating EGF-induced elongation. Further confirmation was 
obtained from the significant decrease in the mean processes’ length when APP overexpressing 
cells are exposed to EGF in the presence of the EGFR inhibitor (Figure B.9 D, ‘APP+INIB+EGF’ 
vs ‘APP+EGF’). This also resulted in a decrease in the neuronal BIII-tubulin protein levels 
comparing to the EGF+APP condition (data not shown).  
ERK1/2 activation is a well-known signalling event downstream EGF-EGFR that has been 
implicated in neuronal differentiation events. To confirm that ERK was also a mediator of this 
APP/EGF neuritogenic effect, ERK1/2 activation was monitored via western blot analysis of 
phosphorylated ERK1/2 levels (pERK1/2, Figure B.9 E and F). The immunoblots clearly show that 
EGF-stimulated cells presented high levels of pERK and, more interestingly, that APP 
overexpression appears to promote this ERK activation state. The presence of the EGFR inhibitor 
hindered this EGF- and APP+EGF-induced pERK1/2 activation bellow control (‘V ctr’) levels. 
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Figure B.9 - APP increases EGF-mediated neuronal-like differentiation. SH-SY5Y cells were either transfected with 
the GFP empty vector (‘V’) or wild-type APP-GFP cDNA (‘APP’) and exposed or not for 3 min to 100 ng/mL human 
recombinant EGF (‘V+EGF’ and ‘APP+EGF’). When indicated, EGF stimulation was performed under EGFR inhibition 
by PD168393 (‘INIB’). A. Representative epifluorescence microphotographs of vector GFP or APP-GFP expressing cells 
labeled for acetylated α-tubulin (‘Acetyl Tub’, in red) and nuclear stained with DAPI (blue). Bar, 10 µm. B. Total number 
of processes per cell (all processes protruding from a cell, independently of the size, were scored). C. Number of 
processes longer than 20 µm (‘>20 µm’) and longer than 35 µm (‘>35 µm’) per cell were scored. D. Processes mean 
length, determined based on all processes longer than 20 µm. n=4-6 independent assays. On average, 30 
microphotographs (>100 cells) were analyzed per independent assay. */#/§ p < 0.05, **/##/§§ p < 0.01, ***/###/§§§ p < 
0.001 by one-way ANOVA followed by the Tukey’s post-test against control empty vector (‘V’), between indicated 
conditions or against condition ‘APP+INIB+EGF’, respectively. Statistical differences not fundamental for result 
interpretation are omitted. E. Immunoblots of cell lysates probed with the 22C11 antibody for the APP N-terminal, 
phospho-ERK1/2 (‘pERK’), and total ERK 1/2 (‘ERK’), suggested a synergy of APP and EGF on ERK1/2 activation. F. 
pERK/ERK ratio was calculated based on immunoblots of cell lysates probed with the antibody for phospho-ERK1/2 and 
total ERK 1/2, and plotted as fold increases of control (“ctr”) empty vector (“V”). 
 
6.4.3.!APP binds to and modulates EGFR protein levels 
The mechanisms by which APP could influence EGFR and ERK activation were subsequently 
studied. EGF stimulation has been observed to regulate APP expression and processing. This was 
confirmed to occur under our experimental conditions (Figure B.10 A). Immunoblots of cell lysates 
exposed to the previous conditions of Figure B.9 B show that EGF stimulation significantly 
increases APP protein levels (both endogenous APP and exogenous APP-GFP upper bands); 
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concomitant EGFR inhibition blocks this effect (Figure B.10 A, upper blot and left graph). 
Furthermore, EGF also significantly stimulates total sAPP secretion, either in control cells (‘V 
sAPPtotal’) or APPWt expressing cells (‘APP sAPPtotal’) (Figure B.10 A middle blot, and right 
graph). In APP overexpressing cells we were able to confirm that EGF stimulates sAPPalpha 
release by using the anti-APP 6E10 antibody (Figure B.10 A lower blot, and ‘APP sAPPalpha’ in 
right graph). As seen for cellular APP protein levels, EGFR inhibition blocks this EGF-induced 
sAPP production/medium secretion. Noteworthy, EGFR treatment in APP overexpressing cells 
significantly decreases all sAPP levels below control cells (untreated APPWt overexpressing cells, 
established as 1.0).  
These results indicate that neuritogenesis mediated by APP+EGF might involve EGF-induced APP 
cleavage into sAPPalpha, the most neuritogenic sAPP fragment [48], in a EGFR activation-
dependent manner. Further analyses indicate that it may also involve APP-induced EGFR protein 
levels. As shown in Figure B.10 B, APP overexpression increases EGFR protein levels, in a dose-
dependent manner (at least until 1.25µg of APPWt cDNA). Although APP overexpression is 
accompanied by increased production of medium sAPP, incubation with recombinant sAPPalpha 
does not increase EGFR protein levels per se (Figure B.10 C).  
This co-increased APP and EGFR half-life may occur via APP-proEGF-EGFR co-endocytosis. 
Indeed, we found evidence that endogenous APP and EGFR also physically interact, by efficient 
co-immunoprecipitation of EGFR after immunoprecipitation of APP using an anti-APP 22C11 
antibody in rat cortex (Figure B.10 D). Additionally, transfected APP-GFP and endogenous EGFR 
were observed to highly co-localize in cytoplasmic vesicles in APPWt transfected SH-SY5Y cells 
(Figure B.10 E). 
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Figure B.10 - EGF increases APP and sAPP levels via EGFR activation. SH-SY5Y cells either transfected for with 
the GFP empty vector (‘V’) or wild-type APP-GFP cDNA (‘APP’), stimulated or not for 3 min with 100 ng/mL human 
recombinant EGF (‘V+EGF’ and ‘APP+EGF’) in the presence (‘V+IN+EGF’ and ‘APP+IN+EGF’) or not of 10 µM 
EGFR inhibitor PD168393. A. Immunoblots of cell lysates and medium were probed with: anti-APP C-terminal antibody 
(‘APP CT’, to detect APP in cell lysates), and the anti-APP N-terminal antibodies 22C11 (detecting all sAPP forms in the 
medium, ‘sAPP’) and 6E10 (only recognizing ‘sAPPalpha’). The effects of EGF on endogenous and exogenous full-
length APP protein levels were plotted as fold increases of EGF treated conditions over their corresponding controls (left 
graph). n=8 independent assays. *p < 0.05, ***p < 0.001 against control condition (established as 1.0) by one-way 
ANOVA followed by the Dunnet’s post-test. ###p < 0.001 against EGF stimulated cells by unpaired two-tailed t-test. 
The effects of EGF on all sAPP forms (endogenous: ‘V sAPP total’; and after APPWt transfection: ‘APP sAPP total’) or 
specifically on sAPP alpha (‘APP sAPPalpha’, after APPWt transfection) were also plotted (right graph). n=4-6. *p < 
0.05, **p < 0.01, ***p < 0.001 against control condition (established as 1.0) by one-way ANOVA followed by the 
Dunnet’s post-test. #p < 0.05, ### p < 0.001 against EGF-stimulated cells by unpaired two-tailed t-test. B. SH-SY5Y 
cells transfected with increasing concentrations of APPWt cDNA (final concentration of transfected cDNA was 
normalized to 2.0 µg/µL of cDNA with empty vector cDNA). The immunoblots of cell lysates were probed with the anti-
APP C-terminal (‘APP CT’) and anti-EGFR antibodies. C. SH-SY5Y cells transfected with vector GFP plasmid and 
treated with 5 nM human recombinant sAPP for 18h. Immunoblots of cell lysates were probed with anti-APP C-terminal 
(‘APP CT’) and anti-EGFR antibodies. Cell medium was collected and the 22C11 immunoblot shows a sAPP enrichment 
in treated cells. EGFR protein fold increase was calculated relative to control (non-treated vector-transfected cells, ‘V’). 
n=4. D. Rat cortices were lysed with CHAPS buffer and immunoprecipitated with anti-APP 22C11 antibody. 
Immunobloting with anti-EGFR antibody shows that EGFR co-precipitates with APP. No reactive bands appear in the 
negative control (‘Ctr neg’): cortex extracts incubated with protein G Dynabeads in the absence of the 22C11 antibody. 
n=2. E. Representative microphotographs of APP-GFP (green) expressing cells immunolabeled for EGFR (in red), and 
nuclear stained with DAPI (blue). 
6.4.4.!APP S655 phosphorylation modulates EGFR trafficking 
One fundamental aspect of EGF signal is the availability and activation of its receptor, modulated 
in turn by receptor expression levels, endocytosis and degradation [49]. 
Based on the results from APP overexpression on EGFR protein levels, their binding, and their 
high cytoplasmic colocalization, we predicted that APP might be modulating EGFR endocytosis 
and degradation. We tested this possibility by first monitoring the co-localization of EGFR with 
three proteins that are associated with the endocytic route - endocytosed Texas red-conjugated 
transferrin molecules; the early/sorting endosomal marker Rab5 and Rab4 (both stained by 
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immunocytochemistry means). Besides colocalizing with EGFR (Figure B.10 D), APP-GFP is 
observed to colocalize with intracellular EGF/proEGF in basal conditions, although at lesser extent 
than with EGFR (Figure B.11 A microphotographs). Importantly, the percentages of colocalization 
between endocytosed fluorescent transferrin and EGF or EGFR increase in conditions of APPWt 
overexpression, when compared to vector GFP expressing cells (Figure B.11 A graph). An increase 
of the EGFR endocytic population in APPwt overexpressing cells was also observed when using 
the Rab5 marker for early endosomes (by the Unpaired t test p=0,0182) (Figure B.11 B 
microphotographs and 4D graph). Since APP S655 phosphorylation regulates APP endocytic route 
and fate [4, 5], the effect of mimicking APP S655 constitutive dephosphorylation (S655A, ‘SA’) 
and phosphorylation (S655E, ‘SE’) on endocytic EGFR was analyzed. From Fig. 4B and 4D we 
can observe that all APP-GFP species (Wt, SA, SE) increased the EGFR population in Rab5-
positive endosomes, although APPSE shown the highest increases (statistically different from 
control empty vector cells and from APPWt or APPSA cells). When at the Rab5 early/sorting 
endosome, EGFR is thought to follow three possible fates – fast recycle to the surface via Rab4-
positive vesicles; mature to late endosomes (also termed Multivesicular Bodies, MVB) and to 
LAMP2-lysosomes for degradation; and slowly recycle to the surface via Rab11-positive recycling 
endosomes. We investigated directly the first two, and observed that although all APP species tend 
to decrease the amount of EGFR rapidly recycled to the surface, assessed via EGFR/Rab4 
colocalization (Figure B.11 E graph), only APPSA significantly lowers the percentage of 
colocalization comparing to control empty vector. Relatively to EGFR degradation pathway, only 
APPSA increases the presence of EGFR in LAMP2-positive lysosomes (Figure B.11 C 
microphotographs and 4F graph).  
We have subsequently examined the percentage of EGFR colocalization with the different APP-
GFP species. Results show that APPSE presents significantly higher percentage of colocalization 
comparing to APPSA (Figure B.12 A). Following, we determined the effects of the APPS655 
phosphomutants on the endogenous EGFR protein levels, either in basal conditions or following 
EGF treatment (Figure B.12 B). All APP species increase EGFR protein levels in basal non-
stimulated conditions. As expected, EGF-stimulated control cells (V+EGF) show a high decrease 
in EGFR levels. This is a well described mechanism of signal regulation in which, following EGF 
stimulation, the levels of the EGFR protein are downregulated due to receptor increased 
degradation [30]. In cells transfected with any of the APP species, EGF stimulation is not able to 
induce EGFR downregulation as efficiently (Figure B.12 B, ‘+EGF’ conditions).  
In order to understand if the APPWt and the phosphomutants activated EGFR, we performed a 
phostag assay that allows to separate proteins accordingly to their level of phosphorylation (Figure 
B.12 C ‘+Phostag’). Results suggest that, under basal conditions, the EGFR receptor is slightly 
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more phosphorylated in cells expressing APPWt and APPSE (red asterisks) than in vector GFP 
expressing cells. This delayed migration of EGFR bands due to higher phosphorylation does not 
occur in cells expressing APPSA (blue asterisks) (Figure B.12 C, ‘-EGF’ ‘+Phostag’).  
 
Figure B.11 - APP modulates EGFR intracellular trafficking in a phosphoS655-APP dependent manner. SH-SY5Y 
cells were transfected for 24h with the GFP empty vector (‘V’), or different APP-GFP cDNAs: wild-type (‘APP-Wt’), 
S655A mutant (‘APP-SA’), S655E mutant (‘APP-SE’). A. Co-localization of EGFR or EGF with Texas-Red (TR)-
conjugated Transferrin following 15 min of TR-Transferrin incubation, when TR-Transferrin and its receptor are 
expected to be on the early endocytic route. n=30 and n=20 cells analyzed for each condition (‘V’ and ‘APP-Wt’) for the 
EGFR and the EGF groups, respectively. *p<0.05, ** p<0.01 by the Mann Whitney test (failed normality test). B. 
Representative microphotographs showing the co-localization of EGFR with the early endocytic marker Rab5 in APP-
GFP transfected cells. C. Representative microphotographs showing the co-localization of EGFR with the lysosome 
marker LAMP2 in APP-GFP transfected cells. Represented images are maximum projections of the stack images used to 
calculate the percentage of colocalization between proteins. Scale bar, 10 µm. D. Percentage of EGFR colocalization with 
Rab5. n=20 cells analyzed per condition. * p<0.05 by one-way ANOVA followed by the Tukey's Multiple Comparison 
Test (data followed normal distribution). E. Percentage of EGFR colocalization with Rab4. n=20-30 cells analyzed per 
condition. * p<0.05 by Kruskal-Wallis test followed by the Dunn's Multiple Comparison Test (data failed normality test). 
F. Percentage of EGFR colocalization with LAMP2. n=30 cells analyzed per condition. * p<0.05 by Kruskal-Wallis test 
followed by the Dunn's Multiple Comparison Test (data failed normality test). 
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Figure B.12 - APP overexpression reduces EGFR degradation induced by EGF stimulation. SH-SY5Y cells were 
either transfected with the GFP empty vector (‘V’), or the three APP-GFP cDNAs: wild-type (‘APP-Wt’), S655A mutant 
(‘APP-SA’), S655E mutant (‘APP-SE’), for 24h. A. Co-localization of EGFR with the different APP-GFP proteins. 
n=80-90 cells analyzed per condition, from 3 independent assays. ### p < 0.001 by Kruskal-Wallis test followed by the 
Dunn's Multiple Comparison Test. B. SH-SY5Y transfected cells were exposed to 100 ng/mL of hEGF for 1h in the 
indicated conditions, and immunoblots of cell lysates were probed with the anti-EGFR and the anti-APP C-terminal 
(‘APP CT’) antibodies. EGFR protein fold increase relative to control empty-vector (‘V’) was calculated. n=3-8. *p < 
0.05, **p < 0.01, ***p < 0.001 against control condition ‘V’ (established as 1.0) by one-way ANOVA followed by the 
Dunnet’s post-test. #p < 0.05, ## p < 0.01 against APP-Wt by one-way ANOVA followed by the Tukey’s post-test. C. 
Analysis of the phosphorylation state of EGFR by the phos-tag SDS-PAGE assay, in the SH-SY5Y cells transfected with 
the APP-GFP cDNAs. Cell samples were loaded onto a normal SDS-PAGE gel (‘- Phostag’) or onto a phos-tag SDS-
PAGE gel (‘+ Phostag’) gels. Phostag gels delay the migration of phosphorylated proteins, which appear in apparently 
higher molecular weight bands. In unstimulated cells, EGFR bands of APPWt and APPSE transfected cells (red asterisks) 
presented slightly delayed migrations, while in APPSA cells the EGFR bands did not (blue asterisks). n=3. 
 
Together these data suggest that 1) All the APP-GFP species are able to retain EGFR molecules in 
Rab5-positive endosomes, retarding EGFR degradation, and thus increasing their levels; 2) APPSA 
increases EGFR targeting to LAMP2 vesicles destined to the degradation route, while APPWt and 
APPSE do not; 3) thus APPWt and APPSE might perpetuate more EGFR signalling in the sorting 
endosomes. 
6.4.5.!APP activates ERK1/2 in a S655 phosphorylation-dependent manner 
Based on the previous trafficking results, and as APPWt overexpression enhanced EGF-induced 
ERK1/2 activation (Figure B.9), the levels of phosphorylated ERK (pERK) were quantified in SH-
SY5Y cells overexpressing APPWt or its S655 phosphorylation mutants. The assay was performed 
in the presence (EGF stimulation) or absence (basal conditions) of EGF (Figure B.13).  
In basal conditions, and as shown in Figure B.13 A and B, APPWt again increased pERK levels 
above vector transfected cells. Comparing to APPWt, the APP S655 dephosphomimimetic mutant 
(‘APPSA’) presents a significantly decreased pERK/total ERK ratio (Figure B.13 B right graph, 
APPSA vs APPWt). The phosphomimetic mutant (‘APPSE’), however, is able to significantly 
increase pERK levels above the Wt species (Figure B.13 B, APPSE vs APPWt right graph). 
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Upon cells stimulation with EGF (Figure B.13 C, ‘EGF stimulation’ condition), APPWt 
overexpressing cells (‘APPWt+EGF’) significantly increases pERK activation when compared to 
vector transfected cells (‘V+EGF’), confirming the previous Figure B.9F observations. This 
increased pERK stimulation above control V cells is not observed in cells overexpressing the APP 
S655A mutant (‘APPSA+EGF’), while the phosphomimetic mutant (‘APPSE+EGF’) is able to 
further increase pERK levels. The same pattern is seen for the ratio between pERK and total ERK 
1/2 protein levels (Figure B.13 C, ‘pERK/ERK ratio’).  
 
Figure B.13 - APP increases ERK 1/2 activation in basal and EGF-stimulated conditions in a S655 
phosphorylation- dependent manner. A. SH-SY5Y cells were either transfected either with the GFP empty vector 
(‘V’), the Wt or the S655 mutants APP-GFP cDNAs (‘APP-Wt’, ‘APP-SA’, ‘APP-SE’). Before cell harvesting 
stimulated cells were exposed to 100 ng/mL of hEGF for 1 hr. Immunoblots of cell lysates were probed with the antibody 
for the APP C-terminal (‘APP CTerm’), phospho-ERK1/2 (‘pERK’), and total ERK 1/2 (‘ERK’). Dashed square at the 
right: a blot corresponding to a different biological replicate of the blot in the left but with more similar levels of APP-SA 
and APP-SE transfection confirms an increased ERK1/2 activation for APP-SE. B. pERK and total ERK were plotted as 
fold increases of APP-Wt samples for the basal condition, since in some biological replicates their band could not be 
detected in empty-vector transfected cells. pERK/ERK ratio is shown on the right. n=9 independent assays. * p<0.05, ** 
p<0.01 against control condition ‘APP-Wt’ (established as 1.0) by one-way ANOVA followed by the Dunnet’s post-test. 
+ p<0.05 unpaired t-test (with Welch correction) to compare indicated conditions. C. pERK and total ERK were plotted 
as fold increases of empty vector samples for EGF-stimulated cells. pERK/ERK ratio is shown on the right. n=3 
independent assays. * p<0.05, ** p<0.01, *** p<0.001 against control condition ‘V+EGF’ (established as 1.0) by one-
way ANOVA followed by the Dunnet’s post-test. # p<0.05, ## p<0.01 against APP-Wt by one-way ANOVA followed 
by the Tukey’s post-test. Note that APP-SA is also significantly different from APP-SE (p<0.001). 
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Noteworthy, the induction of pERK1/2 signalling by APP overexpression was found to be equally 
sensitive to the EGFR inhibitor as vector transfected cells (~40% less pERK in the presence of the 
EGFR inhibitor) in this experimental design. The S655 phosphomimetic mutants were also 
sensitive to cells treatment with the EGFR inhibitor as the APPWt (Supplementary Figure B.5). 
6.4.6.!pS655 APP-induced ERK1/2 activation does not depend on pY682 APP 
APP has been reported to interact with the adaptor proteins Grb2 and Shc, involved in linking 
tyrosine kinases receptors as EGFR to downstream Ras-MEK-ERK1/2 signalling [9]. The APP 
binding to Grb2 and Shc is dependent on APP Y682 phosphorylation. In order to understand the 
involvement of Grb2 and Shc binding in the APP-induced ERK activation, an (additional) point 
mutation - Tyrosine 682 to Phenylalanine (Y682F) - was introduced in the APP-GFP Wt, SA and 
SE cDNAs. In the case of the APPWt protein, the Y682F mutation indeed significantly reduces 
pERK levels (Figure B.14, ‘YF’ vs ‘Wt’ left graph), although it does not significantly change the 
pERK/ERK ratio (right graph). The combination of S655A and Y682F showed the lowest levels of 
both pERK and pERK/ERK ratio (Figure B.14, ‘SAYF’), indicating this to be the APP species 
more dependent on pY682 phosphorylation. Surprisingly, the combination of S655E and Y682F 
does not decrease the levels of pERK, and also shows a tendency to slightly increase the 
pERK/ERK ratio (Figure B.14 right graph, ‘SEYF’ vs ‘SE’ and other conditions). These results 
suggest that APP phosphorylated at S655 (mimicked by the SE mutant) can bind by itself to the 
adaptor protein(s) or is using an alternative mechanism to induce ERK1/2 activation, other than via 
direct binding to Grb2 and Shc. We have also attempted to directly access the interaction of S655 
phosphomutants with Grb2 and Shc, via pull-down of the GFP-moiety, but unfortunately we were 
not successful.  However, we could observe in the immunoblots of the lysates that Grb2 and Shc 
levels are differently altered by the different APP S655 mutants (Supplementary Figure B.6). 
Further quantification showed that APPSA overexpression is associated with increased protein 
levels of Grb2 and Shc, while the APPSE does not affect the levels of both adaptor proteins 
(Supplementary Figure B.6). 
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Figure B.14 - APP S655E-induced ERK activation is not decreased by APP tyrosine 682 dephosphorylation. SH-
SY5Y cells were either 24h transfected with the GFP empty vector (‘V’), or the APP-GFP cDNAs: wild-type (‘Wt’), 
S655A mutant (‘SA’), S655E mutant (‘SE’), Y682F mutant (‘YF’), or S655A and S655E double mutants additionally 
mutated in the APP tyrosine 682 to phenylalanine (‘SAYF’ and ‘SEYF’, respectively), to mimic Y682 constitutive 
dephosphorylation. Immunoblots of cell lysates were probed with the antibody for the APP C-terminal (‘APP CTerm’), 
phospho-ERK1/2 (‘pERK’), and total ERK 1/2 (‘ERK’). pERK and total ERK were plotted as fold increases of APP-Wt 
samples. pERK/ERK ratio is shown on the right side. n=4 independent assays. * p<0.05 against control condition ‘APP-
Wt’, established as 1.0, by one-way ANOVA followed by the Dunnet’s post-test. Note that for the pERK/ERK ratio, 
APP-SA and APP-SAYF exhibited p-values =0.0542 and =0.053, respectively. # p<0.05, ## p<0.01, ### p<0.001 by 
one-way ANOVA followed by the Tukey’s post-test. Note that for the phosphoERK levels in APP-SE and SEYF 
transfected cells were also significantly different from the empty vector ‘V’ cells (p<0.01); APP-SA from SEYF 
(p<0.01); APP-SE from YF (p<0.05) and from SAYF (p<0.001). Additionally, for the pERK/ERK ratio, APP-SEYF is 
also significantly different from the empty vector ‘V’ (p<0.01); APP-SA from SEYF (p<0.01); and APP-SE from SAYF 
(p<0.001). 
 
6.4.7.!APP and EGF-EGFR interplay in cortical neurons differentiation 
Based on our results in the neuronal-like cell model, we pursued the interplay between APP and 
EGF-EGFR signaling in neuronal differentiation. Dissociated mouse cortical embryonic neurons 
were transfected at 5 days in vitro (DIV) with either the GFP empty vector or the APP-GFP cDNAs 
(APPWt, APPSA or APPSE), and incubated with EGF in the presence or absence of the EGFR 
inhibition up to 6 DIV.  
In vector GFP control neurons, EGF stimulation (‘GFP+EGF’) or the inhibition of EGFR results in 
a slightly, not significant, increase in the number of primary neurites per neuron comparing to GFP 
alone, and the presence of the EGFR inhibitor blocks this increase (Figure B.15 A, and see 
Supplementary Figure B.7 A for representative tracings). Such tendency was translated by an 
increase in the number of dendrites (both primary dendrites and dendrite branches, Figure B.15 C 
and D), while the presence of the EGFR inhibitor abolishes this increase. Simultaneously, EGF 
tends to decrease the length of primary neurites (Figure B.15 B). The total length of the dendritic 
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tree does not change with EGF treatment, while it tends to decrease in the EGFR inhibitor 
condition (Figure B.15 E). Of note, EGF treatment of GFP-expressing neurons reduces axon length 
without affecting the number of axonal branches (Supplementary Figure B.7 B). 
Looking now to the APP overexpressing neurons, in the absence of any other treatment APP 
overexpression tends to increase the number of primary neurites (Figure B.15 A), and the number 
of neurites branches (data not shown), while slightly decreasing their length (Figure B.15 B). The 
increase in the number of neurites appears to be dependent on the status of APP S655 
phosphorylation since the APPSA dephosphomutant has similar values as the GFP expressing 
neurons, while APPSE is similar to APPWt (Figure B.15 A). Such behavior is translated to the 
number of dendrites, either primary dendrites or of its branches: APPWt and the SE 
phosphomimetic mutant tend to increase dendrites’ number (when compared to GFP control 
neurons), while APPSA levels are similar to the GFP control (Figure B.15 C and D). These 
differences are maintained in the dendritic tree’s total length (Figure B.15 E). Of note, all APPs 
similarly decrease the axon length (when compared to GFP), but APPWt and S655E do not induce 
alterations in axonal branching, while APPSA decreases all parameters related to axonal branching 
(Supplementary Figure B.7 B and C). 
Intriguingly, APP overexpression in combination with the EGF treatment leads to a significant 
reduction in the number of neurites - primary neurites and neurites branches (Figure B.15 A and 
D). This decrease is translated to the number of dendrites– primary dendrites and dendritic 
branches (Figure B.15 C and D) – and axonal branches (Supplementary Figure B.7 B). In general, 
APPSA shows the highest decreases and APPSE was similar or less affected (for instance in 
primary neurites and primary dendrites) than APPWt. No major effects of APP overexpression 
combined with EGF was seen on the neurites’ mean length (not shown), but in the presence of 
EGF, all APPs reduce even more the dendritic tree’s total length (Figure B.15 E) and the axon’s 
mean length (Supplementary Figure B.15 C), particularly APPSA. Such behavior was also seen for 
total axon length (data not shown).  
The number of neurites - primary neurites and their branches - is reverted to APP “basal” levels by 
the presence of the EGFR inhibitor (Figure B.15 A, and data not shown). However, the mean 
length of primary neurites is significantly decreased when compared to non-EGF treated conditions 
(data not shown). Noteworthy, the sum length of neurite branches also shows some signs of 
“recovery” when compared to single treatment with EGF, with APPSE reverting to non-treated 
levels (Figure B.15 B). The number of dendrites (primary and branches) returns back to APP basal 
levels when the neurons were treated with both EGF and the EGFR inhibitor (Figure B.15 C and 
D); however, the dendritic tree total length does not recover (Figure B.15 E) since, in general, the 
dendrites’ mean length tends to be smaller (data not shown). Of note, the axon length does not 
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seem to change, but the number of axonal branches increases in comparison to APPs combined 
with EGF (Supplementary Figure B.7 B and C). 
 
 
Figure B.15 - APP and EGF-EGFR signaling in mouse cortical neuronal differentiation. Embryonic primary cortical 
neurons at 5 DIV were transfected with the GFP empty vector (GFP), or the APP-GFP cDNAs: wild-type (‘APP-Wt’), 
S655A mutant (‘APP-SA’), S655E mutant (‘APP-SE’). A subset of cells was incubated with 100 ng/mL EGF after 
transfection medium change (21h of incubation before fixation), and a third group of cells was treated with the 
PD168393 EGFR inhibitor 3h before the same EGF stimulation treatment. Morphometric analyses of cortical primary 
neurons were performed: A. Number of primary neurites (neurites arising directly from the cell soma) per neuron. B. 
Primary neurites sum length per neuron. C. Number of primary dendrites (arising directly from the cell soma) per neuron. 
D. The number of dendrite branches (any branch arising from a primary dendrite) per neuron. E. Dendritic tree total 
length was calculated as the sum length of the primary dendrites and dendrite branches per neuron. n=50 neurons 
analyzed for each condition. * p<0.05, ** p<0.01, *** p<0.001 by the Kruskal-Wallis test followed by the Dunn’s 
multicomparison post-test, as indicated in the table below each graph. 
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6.5.!Discussion 
APP and proEGF are both type 1 transmembrane glycoproteins, co-expressed in several tissues and 
cells, and display some functional overlap. Here we proved that APP and proEGF can form 
complexes, including in brain cortex (Figure B.8). Pull down of APP, either of the GFP moiety of 
exogenous APP-GFP or of endogenous APP, using anti-APP N-terminal antibody, co-
immunoprecipitated different proEGF forms. This proEGF forms may derive from glycosylation 
on at least 10 glycosilation sites, and from alternative splicing, as 3 isoforms have already been 
described for proEGF. Furthermore, different molecular weight immunoreactive bands of proEGF 
in cell lysates, have been shown to result not only from different glycosylated forms but also from 
proEGF cleavage in the N-terminal distal part of the prodomain [50]. We believe that APP might 
interact with different forms of proEGF, that result in different immunoreactive bands after co-
immunoprecitation depending on the cell type used, lysis buffer, loading buffer and gel conditions.  
The existence of an APP-proEGF complex can meet existing models on the regulation of APP 
processing and signaling [51]. By one hand, we and others have shown that EGF stimulation 
induce the release of sAPP through activation of EGFR (Figure B.10 A), a mechanism that might 
be dependent on PKC activity and/or ERK1/2 activation [33, 52]. On the other hand, APP could be 
further modulated through direct interaction with a membrane-bound ligand, as proEGF, affecting 
e.g. the conformation of the intracellular domain of APP and APP affinity for interacting proteins, 
which in turn could alter APP localization and/or promote specific cleavage events of APP. Within 
the same rationale, APP interaction with proEGF could influence the cleavage of the membrane-
bound ligand into EGF mature growth factor and modulate EGFR signaling events. We tested this 
hypothesis indirectly, by studying the proEGF protein levels on cell lysates and conditioning 
medium after 24h of APP overexpression. Although we could not detect significant changes on 
proEGF or soluble proEGF after APP overexpression, this hypothesis should not be excluded for 
different time scales, cell models, or in vivo systems. It would be very interesting to explore this 
situation and to test APP binding to other EGF-family growth factors.  
Using the neuronal-like SH-SY5Y cell model, we proceed to test the existence of a functional 
interaction between APP and the growth factor EGF. No alteration in cell proliferation was found 
between EGF stimulated versus non-stimulated cells, either in APP transfected cells or control 
cells. It seems that in SH-SY5Y cells, the general described mitogenic effect of EGF does not 
occur. This is concordant with previous results showing unaltered cell proliferation after EGF 
treatment, either in the presence or absence of serum, in the same cell line [53].  EGF-stimulated 
cells tended to have higher number of cells comparing to the non-stimulated ones, but since there 
was no alteration in cell proliferation, EGF is most probably promoting cell survival.  
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Morphometric analyses of SH-SY5Y cells 24h after APP overexpression showed that the 
combination with EGF treatment accelerates neurite outgrowth, the emergence and elongation of 
cellular processes (Figure B.9). Combined treatment significantly increases the number of 
processes per cell (including of longer processes), and processes’ mean length. Although APP 
alone is able to significantly increase the number of processes longer than 20 µm per cell 
comparing to control empty vector, APP combined with EGF increases the number of processes 
longer than 35 µm per cell above control, and above conditions of EGF treatment only and APP 
overexpression only. The neuronal-like differentiation induced by APP and EGF combined 
treatment was accompanied by an increase in ERK1/2 activation. Previous work has demonstrated 
that EGFR activation triggers neurite outgrowth of neuroblastoma cells potential via activation of 
the PI3K-Akt and MEK-ERK1/2 pathways [54, 55]. As expected, EGF treatment in the presence of 
EGFR inhibitor decreases all the parameters to similar or slightly below control empty vector 
levels. Interestingly, in APP overexpressing cells the presence of the EGFR inhibitor significantly 
decreases the number of >20 µm (and >35 µm) processes comparing to not only to the APP+EGF 
condition but also to the APP overexpression alone, suggesting that EGFR activation is implicated, 
at least partially, in the role played by APP in neurite outgrowth. Results on pERK/ERK ratio (and 
BIII-tubulin protein levels, data not shown) further support this conclusion.  
The observed morphologic and signaling alterations seem to be accompanied by alterations in APP 
protein levels and in its processing. EGF stimulation significantly increases APP full-length protein 
levels and sAPP release, whereas previous EGFR inhibition blocked this effect. In APP 
overexpressing cells the protein levels of both total sAPP and sAPPalpha significantly decrease 
bellow control levels (APP transfection only) in the presence of the EGFR inhibitor. Others have 
shown that APP cleavage into sAPP is necessary for APP-induced neurite outgrowth [40, 56], and 
might be in part regulated by EGFR and ERK1/2 activation [52]. APP overexpression, here shown 
to activate ERK1/2 and to modulate EGFR protein levels, is suggestive of a positive-feedback 
pathway culminating in sAPP release, ERK1/2 activation and neurite outgrowth in SH-SY5Y cells. 
Indeed, APP is able to increase the cellular levels of EGFR, potentially via a mechanism involving 
APP-EGFR binding and APP-induced altered EGFR trafficking. At steady state, when the majority 
of EGFR is expected to be unliganded, only a small percentage of EGFR are in transit in the 
endocytic pathway and, in general, are rapidly recycled back to the plasma membrane (PM). The 
constitutive internalization of the receptor establishes EGFR surface expression and its potential to 
signal when presented with ligand [57]. Upon EGF binding to EGFR, specific autophosphorylation 
sites recruit adaptor protein Grb2, which in turn brings SOS to interact with and activate Ras at the 
PM. Activates Ras initiates the RAF-MEK-ERK1/2 signaling cascade. Grb2 can additionally bind 
EGFR through Shc, also stimulating the Ras signaling pathway. Active EGFR can signal from the 
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PM and from endosomes, since endocytic trafficking might be required for optimal activity of 
some signal transducers and to propagate specific signals. Thus, the duration and intensity of the 
EGFR-ERK1/2 signaling can be modulated by receptor expression levels at the PM, by its 
endocytic trafficking, and by its subsequent fate: recycling or degradation [30, 49]. Here we show 
that APP overexpression increases the protein levels of EGFR in basal conditions, and partially 
impairs the usual downregulation of the EGFR protein after EGF-stimulation. This particular effect 
of APP seems independent of S655 phosphorylation and sAPP levels. Additionally, we have shown 
that APP interacts with EGFR, and that endogenous EGFR colocalizes with APP-GFP in 
cytoplasmic vesicles. APP interaction with a chimeric EGFR molecule was shown by Petschnigg et 
al., and the interaction seems to be stronger with phosphorylated EGFR, as demonstrated using a 
constitutive kinase active EGFR chimera mutant [58]. Importantly, we proved that APP impacts on 
EGFR trafficking, and subsequently in its levels, fate, active state, and signaling rate. At steady 
state most of the EGFR should be at the cell surface, but APP overexpression relocates EGFR 
molecules to early endosomes. This is demonstrated by the higher percentage of EGFR (and EGF) 
colocalization with Texas Red-Transferrin and with Rab5, in APP transfected cells. Accordingly, 
recent reports show that APP interacts with the Rab5 binding protein APP-BP1, and with the Rab5 
effector APPL1, and that APP up-regulation can induce Rab5 over-activation and thus accelerates 
endocytosis [59, 60].  
We have also demonstrated that particular events of the EGFR intracellular trafficking might be 
differentially affected by the APP S655 phosphorylation status. S655 phosphorylation, at the APP’s 
functional motif YTSI, has been previously shown to regulate APP’s endocytic route and fate. 
Specifically, the S655A dephosphomimetic mutant (‘SA’) is less endocytosed, while the S655E 
phosphomimetic mutant (‘SE’) presents slightly higher rate of membranar endocytosis and 
increased recycling (higher rate of traffic between the TGN and the PM). APPSA-containing 
vesicles are more targeted towards lysosomes, while APP phosphorylation at S655 partially rescues 
APP from degradation [4, 5]. This APP phosphorylation site also promotes sAPP release, and data 
from our group suggests it might be implicated in neuronal differentiation ([61], Dias R et al, 
submitted). Results here gathered indicate that, in general, all the three APP species used increased 
EGFR colocalization with the early endocytic marker Rab5, and all increased total EGFR protein 
levels over vector-transfected cells, even in EGF stimulation conditions. However, the fate of the 
increased half-lived EGFR protein may be different. While APPSE showed the highest 
colocalization with EGFR and the highest increase of EGFR colocalization with Rab5, APPSA 
increased the presence of EGFR in LAMP2-positive vesicles and fail to increase the total level of 
EGFR phosphorylation above vector-transfected cells as APPWt and APPSE appear to do 
(PhosTag gel at basal conditions, see Figure B.11 and Figure B.12).  
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Mechanisms that increase the duration of pEGFR and/or slow EGFR degradation might shift 
ERK1/2 signal from transient to sustained activation and promote neuronal differentiation in 
response to EGF [62-64]. Such behaviour might thus be favoured by APP phosphorylation at S655, 
while APP S655 dephosphorylation seems to promote EGFR inactivation and late 
endosomes/lysosomal targeting. Indeed, when at the sorting early endosome, EGFR can be targeted 
to recycling to the PM via Rab11-positive vesicles, or be targeted to intraluminal vesicles (ILV) of 
multivesicular bodies (MVB). This later occurs upon ubiquitinated EGFR recognition by the 
‘endosomal sorting complexes required for transport’ (ESCRT) machinery, but requires prior 
receptor deubiquitination. Sorting onto ILVs already physically removes the tyrosine kinase 
domain from cytosolic substrates, and is followed by fusion with lysosomes, for cargo degradation 
[49, 65]. In the face of similar percentage of EGFR colocalization with LAMP2 and Rab4 for 
APPSE as for APPWt, but higher percentage of EGFR colocalization with Rab5 and increased 
ERK signal promotion (discussed below) for APPSE, the hypothesis that APPSE increases EGFR 
residence in the endosomal outer membrane and diverts EGFR from being sorted into ILV during 
MVB formation, gains some evidence.  
APPSA, by its turn, would increase EGFR sorting into MVB and ILV, for subsequent lysosome 
targeting and degradation. Accordingly, MVB/late endosomes can already present the LAMP2 
marker and APPSA showed increased EGFR colocalization with the late endosome/lysosome 
LAMP2. The fact that our immunoblot results showed impaired EGFR degradation for all APP 
species might indicate decreased EGFR de/ubiquitination, impaired sorting into ILVs, and/or 
delayed MVB maturation into/fusion with lysosome. The impairment of lysosome function and 
accumulation of endocytic cargos within enlarged late endosomes is consistently described to 
follow the APP-induced Rab5 over-activation and accelerated endocytosis [59, 60]. We also 
hypothesize that APP interaction with APPL1, a downstream effector of EGF-EGFR signaling that 
impairs EGF-induced EGFR lysosomal degradation when overexpressed, stabilizes both APPL1 
and EGFR proteins in early and late endosomes [66]. Alternatively, APP might regulate EGFR 
ubiquitination and targeting to degradation via Grb2 interaction, since Grb2 mediates EGFR 
binding to the ubiquitin-protein ligase CBL [30]. APP might also influence receptor ubiquitination 
by binding to the described CBL inhibitors lipoprotein receptor-related protein LRP1 and/or the 
tyrosine kinase c-Src [9, 67, 68]. 
The deubiquitination of EGFR, necessary to occur prior translocation into the ILVs, might also be 
modulated by APP interaction with the deubiquitinating enzyme UCH-L1 [69]. Of note, in neurons 
from the Swedish mutant APP transgenic mice, increased intracellular abeta was linked to 
decreased UCH-L1 and proteasome activity, and consequently impaired degradation of EGFR 
following EGF stimulation [34]. 
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Consistent with increased level of total EGFR phosphorylation, APPSE was observed to 
particularly increase signalling downstream EGFR. ERK1/2 signalling, resulting from EGFR and 
other growth factors signalling, is crucial for cortical development. Specific ERK1/2 functions 
seem to include the control of cortical neural progenitor proliferation, fate determination, and 
differentiation [70]. Abnormally diminished ERK activity, early in cortical development, 
significantly impact cortical cytoarchitecture due to alterations in the cellular composition of the 
postnatal cortex, and abnormal axon length and dendritic arborisation [71]. Here we show that 
combined APP overexpression and EGF treatment results in amplified ERK1/2 activation in an 
APP S655 phosphorylation- dependent manner. APP phosphomimicking mutant, S655E, is 
associated with increased ERK activation either in basal or EGF-stimulated conditions, while the 
dephosphomimicking mutant, S655A, has similar levels of ERK activation to control cells (Figure 
B.13). Since, phosphorylation of Y682, located at the YENPTY motif of APP cytodomain, 
mediates APP binding to adaptor proteins Shc and Grb2, linking APP to theERK1/2 signalling 
pathway [9], we further analysed its role in S655E-mediated ERK1/2 activation.  Opposing this 
hypothesis, an APP double mutant, constitutively dephosphorylated at Y682 in association with the 
S655E mutation, failed to decrease ERK activation (Figure B.14). Results suggest that APP 
phosphorylated at S655 could be using a different mechanism for ERK1/2 activation, other than via 
direct recruitment of Grb2 and Shc. Curiously, APPSE overexpression leads to decreased protein 
levels of endogenous Grb2 and Shc, while APPSA show increased levels of these proteins. 
Under different cellular contexts, specific APP phosphorylation events could modulate 
compartmentalization and duration of phosphoERK1/2 signalling to achieve specific outcomes [72, 
73]. For instance, Y682 phosphorylation of full-length APP molecules might promote direct 
binding to Grb2 and link ERK activation to cell proliferation. On the other hand, upon apoptotic 
stimulus, ERK activation seems to result from Y682 phosphorylated APP-CTFs that complex with 
both Shc and Grb2, a situation that might occur in AD [74-76]. In the case of S655 
phosphorylation, APP could be channelling ERK1/2 activation to neuronal differentiation events. 
This might involve binding to different ERK scaffolds or the modulation of receptor tyrosine 
kinases, like the here proposed EGFR. 
In order to analyze a role for APP phosphorylation and EGF in neuronal differentiation, cultured 
cortical neurons were used. These are described to express EGFR, and it has been shown that EGF 
stimulates survival and neurite outgrowth of rat cerebral cortical neurons [77]. More recently, EFG 
was shown to stimulate axon extension of mouse spinal cord neurons during development [78]. Our 
results show that, in general, EGF treatment increases the number of dendrites (primary and 
branches) without changing the total dendritic tree length. The EGFR inhibitor blocks the effect of 
EGF on dendrites number. Furthermore, in apparently EGF stimulation-independent effects, EGFR 
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inhibition 1) tends to decrease the total length of the dendritic tree, potentially via diminished 
dendrites’ mean length; and 2) tended to increase the number of axonal branches. Similar results 
were presented by others and related to impaired axonal pruning [79], and might implicate other 
EGFR family member(s) since the inhibitor used can also suppress the kinase activity of erbB2 and 
erbB4 [80]. 
Both EGF and EGFR inhibitor slightly decreased the axon length, suggesting that promotion of the 
number of dendrites and of axonal branches are events that impair axon elongation.  
APPs overexpression, particularly of APPWt and APPSE, mainly increases the number of primary 
neurites and neurite branches. These mainly translate to increases in the number of primary 
dendrites and dendritic branches, in a S655 phosphorylation-dependent manner, with no apparent 
alteration in the number of axonal branches. Of note, APP overexpression, independently of S655 
phosphorylation, also tended to decrease the mean length of primary neurites (including the axon), 
although with no alteration in the mean length of the neurites’ branches. 
Intriguingly, APP overexpression in combination with EGF treatment led to a significant reduction 
in the number of primary neurites and neurite branches, although with a notorious dependency on 
the APP S655 phosphorylation state. The number of primary neurites and neurite branches per 
neuron is reverted to APP “basal” levels in the presence of the EGFR inhibitor. In general, there 
were no major effects of APP combined with EGF on neurites’ mean length, but combined 
treatment reduced markedly the axon’s mean length. 
In summary, APPWt and APPSE contribute to dendritogenesis, while APPSA does not. The 
surprisingly decreased number of neurites for APP overexpression in combination with EGF, 
brought to our attention that in cortical primary cultures both effects might involve mutually 
exclusive signaling pathways, or the resulting increase in signaling might reach a limit from which 
it is detrimental for neurite outgrowth, an idea explored in other reports [26, 81]. Furthermore, the 
quality and duration of the signaling generated by the combination of APP and EGF might be 
promoting a different output, i.e. neural progenitor’s proliferation and/or cell survival [82]. This is 
consistent with our observations that EGF treatment always led to more GFP expressing neurons 
per visual field, while the presence of the EGFR inhibitor was more associated with GFP 
expressing neurons showing signs of degeneration.  
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6.7.!Supplementary Data 
 
Supplementary Figure B.4 - Effect of EGF and APP on SH-SY5Y cell proliferation and survival. SH-SY5Y cells 
were either transfected with the GFP empty vector (‘V’) or wild-type APP-GFP cDNA (‘APP’), exposed or not for 3 min 
to 100 ng/mL human recombinant EGF (‘V+EGF’ and ‘APP+EGF’). n=3 independent assays. A. Experimental approach 
schematics. B. Representative epifluorescence microphotographs of cells tested with the Click-iT® EdU Alexa Fluor® 
imaging kit. C. Percentage of cell proliferation was calculated by scoring the number of EdU Alexa Fluor® 594 positive 
cells versus the total number of Hoechst 33342 positive cells. D. Total cell number - the number of cells (Hoechst 
positive) was scored. 
 
 
 
Supplementary Figure B.5 - EGFR inhibition reduces ERK activation independently of the transfected APP species. 
SH-SY5Y cells were either 24h transfected with the GFP empty vector (‘V’), or the APP-GFP cDNAs: wild-type (‘APP-
Wt’), S655A mutant (‘APP-SA’), S655E mutant (‘APP-SE’). Before cell harvesting the treatment group was exposed for 
10 µM EGFR inhibitor PD168393 for 1 hour. Immunoblots of cell lysates were probed with the antibody for the APP C-
terminal, phospho-ERK1/2 (‘pERK’), and total ERK 1/2 (‘ERK’). Of note, all the lanes are from the same blot but were 
rearranged into the present order. The percentage of decrease in the pERK protein levels and pERK/ERK ratio was 
calculated in relation to the corresponding cDNA in non-EGFR Inhibitor treated conditions. 
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Supplementary Figure B.6 - S655 APP phosphorylation and the levels of the adaptor proteins Grb2 and Shc. SH-
SY5Y cells were transiently overexpressing the empty GFP vector (V) or the APP-GFP cDNAs: wild-type (‘Wt’), S655A 
mutant (‘SA’), S655E mutant (‘SE’). Immunoblots of cell lysates were probed with the antibodies for the adaptor 
proteins GRB2 and SHC, and their protein levels plotted as fold increases of empty vector lysates (‘V’). n=6. ** p<0.01 
against control condition ‘V’, established as 1.0, by one-way ANOVA followed by the Dunnet’s post-test. # p<0.05 for 
indicated conditions by one-way ANOVA followed by the Tukey’s post-test. Of note, all the lanes are from the same blot 
but were rearranged into the present order. 
 
 
Supplementary Figure B.7 - Representative images of the neurite tracings and cortical neurons axonal parameters. 
Embryonic primary cortical neurons at 5 DIV were transfected with the GFP empty vector (GFP), or the APP-GFP 
cDNAs: wild-type (‘APP-Wt’), S655A mutant (‘APP-SA’), S655E mutant (‘APP-SE’). A subset of cells was incubated 
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Supplementary Figure B.7 (continuation) - with 100 ng/mL EGF after transfection medium change (21h of incubation 
before fixation), and a third group of cells was treated with the PD168393 EGFR inhibitor 3h before the same EGF 
stimulation treatment. A. MAP2- or BIII Tubulin-positive, GFP expressing mouse cortical primary neurons were traced 
using the NeuronJ. Tracings are color coded: the primary neurites that arise directly from the cell soma are in red; the 
secondary neurites that emanate from a primary neurite are in blue; the tertiary neurites that arise from a secondary 
neurite and in yellow. Secondary and tertiary neurites were grouped as neurite branches for the morphometric 
quantifications. Scale bar = 50 µm. B. The number of axonal branches per neuron. C. The mean axon length calculated 
based on the length of the longest neurite considered here as the axon. * p<0.05, ** p<0.01, *** p<0.001 by the Kruskal-
Wallis test followed by the Dunn’s multicomparison post-test, as indicated in the table below each graph. 
 
Supplementary Table B.1 – Neuronal morphometric parameters analyzed. 
Parameters directly obtained by the NeuronJ pluggin analyses 
# neurites Total count of neurites traced per neuron 
Neurites total length The sum of the length of all the neurites traced per neuron 
Neurites mean length The mean length of all the neurites traced per neuron 
Parameters obtained by the NeuronJ pluggin but dependent on the user assessment 
# primary neurites Number of neurites arising directly from the cell soma per neuron 
Primary neurites total length The sum of the length of all primary neurites traced per neuron 
Primary neurites mean length The mean length of all primary neurites traced per neuron 
# neurite branches 
Sum of the number of secondary (branches from a primary 
neurite), tertiary (branches from a secondary neurite), and 
quaternary (branches from a tertiary neurites) neurites per neuron 
Neurite branches total length The sum of the length of all neurite branches per neuron 
Neurite branches mean length The mean length of all neurite branches traced per neuron 
Parameters inferred or estimated  
“Theoretical” axon mean 
length 
The longest neurite – maximum tracing length value – of a neuron 
was consider the axon. 
# axonal branches Number of neurites (secondary and/or tertiary neurites) branching from the longest neurite per neuron. 
Total axon length The sum of the length of the axon and all its branches. 
# Primary dendrites Number of dendrites per neuron. Obtained by subtracting an axon and the number of neurite branches to the total neurite count. 
# dendritic branches Obtained by subtracting the number of axon branches to the neurite branches total count, per neuron. 
Dendritic tree total length Obtained by subtracting the “total axon length” to “Neurites total length”. 
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7.1.!Abstract 
APP has been described to be determinant for neuronal development and function, not only in its 
full-length conformation but also after proteolytic cleavage events in the form of several biological 
peptides. Furthermore, APP phosphorylation tightly regulates its trafficking, proteolysis, protein-
protein binding, and consequently its several functions. One possible APP phosphorylation site is 
the S655 residue located in the basolateral sorting motif YTSI. Some lines of evidence indicate that 
phosphoS655 potentially modulates APP-mediated neuronal differentiation. In the present work, 
we used RA-differentiated SH-SY5Y cells overexpressing Wt or S655 phosphomutants APP-GFP 
cDNAs, and immunoprecipitate the specific APP species and their respective interacting partners. 
After protein identification by mass spectrometry we were able to characterize APP-
phosphoS655/dephosphoS655 interactomes potentially involved in neuronal differentiation events. 
The APP-dephosphoS655 interactome was particularly enriched in actin binding proteins what 
correlated with a cortical actin phenotype, while the APP-phophoS655 interactome presented 
specific binding partners that correlate well with neurite outgrowth output. 
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7.2.!Introduction 
The Amyloid Precursor Protein (APP) is mainly studied for its association with the Alzheimer’s 
disease (AD). This transmembrane protein is dynamically sorted through the membranes of 
intracellular organelles and the plasma membrane. During its trafficking the full-length APP 
protein suffers proteolytic cleavages by proteases into some functional peptides. Briefly, alpha-
secretases generate the sAPPalpha and a membrane tethered C-terminal fragment (CTF), whereas 
cleavage by beta-secretase releases the sAPPbeta. The resulting CTFs of both pathways are 
subsequently processed by the gamma-secretase complex to produce the p3 or Abeta peptides, 
respectively, and the intracellular AICD fragment [1]. 
Several crucial physiological roles have been attributed to the complex APP molecule. Particularly, 
APP has been described to be determinant for neuronal development and function, with attributed 
functions in cell migration [2], neuritogenesis [3, 4] and synaptic plasticity [5, 6]. Several of these 
functions have been attributed not only to the full-length protein but also to its proteolytic 
fragments [7-10]. However, contradictory results have been reported regarding the benefits of 
knocking-down or overexpressing APP, and its role in neuronal development is far from being 
clarified [11, 12] and most possible involves its regulation through post-translational modifications.  
As a phosphoprotein, APP phosphorylation tightly regulates its trafficking [13], proteolysis [14], 
and protein-protein binding [15]. One possible APP phosphorylation site is the S655 residue 
located in the basolateral sorting motif 653YTSI656. Phosphorylation at S655 has been observed to 
occur in mature APP molecules in cultured cell lines and rat cortex [16]. In human hippocampus of 
AD patients it was reported the existence of phosphoS655 APP-CTFs [14]. Additionally, this 
phosphorylation site is the only APP Ser/Thr residue described to be phosphorylated by PKC [16, 
17]. NMR analyses showed that APP phosphorylation at S655 induces significant local 
conformational changes in the APP C-terminus at and downstream the 653YTSI656 motif, potentially 
regulating protein-protein interactions at those regions [18]. 
We have collected several data indicating that phosphoS655 potentially modulates APP-mediated 
neuronal differentiation. Mechanisms underlying this modulation may involve altered APP 
trafficking to and from the plasma membrane and subsequent increased APP cleavage to its 
neuritogenic fragment sAPP [13, 19], altered APP-mediated cytoskeleton rearrangements [20], 
promotion of intracellular signaling events (i.e. amplified ERK1/2 activation), and differential 
binding to neurotrophic effectors (Dias R., et al, 2016 and da Rocha J.F., et al, 2016 unpublished 
data) .  
The work here reported aimed to identify specific protein binding partners of phosphoS655 and 
dephosphoS655 APP, particularly those potentially involved in neuronal differentiation events. To 
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this end, we used the neuritogenic cellular model retinoic acid (RA)-differentiated SH-SY5Y cells 
transiently overexpressing APP-GFP S655 phosphomutants (S655A and S655E). The 
differentiation days 3 and 7 were chosen as they represent two distinct periods of RA-induced SH-
SY5Y neuronal differentiation. In the first one, more related to an increase in the number of pre-
neuritic projections, APP levels rise but holo APP is cleaved at a higher rate into sAPP. Neurites 
appear more abundantly during the second period, related to neuritic elongation and to the 
stabilization of longer neurites in a holo APP-assisted manner [21]. 
The GFPTrap assay was used to immunoprecipitate APP-GFP proteins and their respective 
interacting partners, which were identified by mass spectrometry (MS). In general, we found a 
special enrichment in RNA-binding proteins linking APP neuronal differentiation role with 
regulation of mRNA processing (splicing, decay and translation). This RNA regulatory proteins 
were found for both the phosphoS655 and dephosphoS655 categories, but particularly enriched in 
the later. The dephosphoS655 APP interactome was also enriched in energy metabolism related 
proteins, and in actin-binding proteins, what correlated with a cortical actin phenotype. The 
phophoS655 APP interactome presented a reduced number of protein interactors, when compared 
to the other categories, denoting a higher degree of functional specificity. The phosphoS655 APP 
interactome included proteins involved in the regulation of proliferation, survival and 
differentiation, and in various signaling pathways that appear to promote cell fate, neurite 
outgrowth and neuronal maturation.  
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7.3.!Material and Methods 
7.3.1.!SH-SY5Y cell culture and differentiation 
The SH-SY5Y human neuroblastoma cell line was maintained in minimum essential media/F12 
medium supplemented with 10% fetal bovine serum. Before differentiation, cell culture was 
enriched in the neuroblastic N-type of cells (immature nerve cells that are RA-differentiated into 
neuronal-like cells), on the basis of their lower substrate adherence comparing to the S-type cells 
[21]. For the experiments N-type enriched 30000 cells/cm2 were plated onto 100 mm culture plates.  
The day after, cells were incubated with 10 µM RA complete medium to start neuronal-like 
differentiation. New cell medium supplemented with 10 µM RA was added every other day. Cells 
were kept under humidified, 37ºC, 5% CO2 incubator. 
7.3.2.!Cell Transfection 
Previously produced human APP isoform 695 (“APPWt”) cDNA, and the respective S655 
phosphomutants, Serine 655 to Alanine (S655A, “APPSA”) or to Glutamate (S655E, “APPSE”) 
fused in frame with GFP in the pEGFP-N1 mammalian expression vector, were used [22]. The 
“empty” pEGFP-N1 expression vector was used as control. Cells were transfected at day 3 or day 6 
of differentiation, and collected 24h after transfection. These time points were chosen as key 
regulatory differentiation periods, based on previous data obtained by us on time-dependent APP-
induced neuritogenic alterations [21]. Cell transfections were carried out with the TurboFectTM 
reagent according to the manufacter’s instructions (Fermentas Life Sciences). Briefly, for each 
monolayer of cells grown in 100 mm plates, 9 µg of DNA, either eGFP-N1 empty vector or APPs-
GFP cDNA, were diluted in 900 µL of serum-free growth medium. After a brief vortex, 18 µL of 
TurboFectTM were added to the diluted DNA. The mixture was vortexed and incubated for 15-20 
min at room temperature (RT), after what this mixture was added dropwise with gently rocking. 
Cells were further incubated for 6h at 37ºC in a CO2 incubator, after which medium was changed. 
After 24h, the efficiency of cell transfections was confirmed by visualization of GFP expressing 
cells with the Olympus IX81 inverted epifluorescence microscope. The experiments were 
performed in duplicate. 
7.3.3.!GFP Trap IP assays 
Pull down of the GFP moiety was performed by GFP-trap® (Chromotek) according to the 
manufacturer. After transfection, SH-SY5Y cells were washed in PBS, and 1 mL of ice-cold PBS 
with 1x PMSF (dilute stock 1:100). Cells were collected with a scrapper to a microtube and 
immediately placed on ice. Subsequent steps were always performed at 4ºC. The samples were 
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centrifuged for 5 min at 3000 g, and the supernatant removed. Cell pellet was lysed with 500 µL 
non-denaturant Lysis buffer (10 mM Tris HCl pH 7.5, 0.5 mM EDTA, 0.5% Gepac-ca-630, 150 
mM NaCl, 1 mM PMSF) supplemented with protease inhibitors cocktail (Sigma-Aldrich), 1 mM 
NaF, and 10 mM Sodium Orthovanadate, for 30 min. During this time, GFP-TRAP beads 
(Chromotek) were resuspended in wash buffer, centrifuged at 13000 g for 1 min. Samples were 
then centrifuged for 5 min at 20000 g, and an aliquot of 25 µL of supernatant transferred to a new 
microtube (‘cells lysates’) for transfection assessment via immunoblot procedures. The remaining 
supernatant was incubated with the GFP-TRAP beads (25 µL for sample) and incubated for 3h with 
orbital shaking. The beads were magnetically separated until supernatant was clear, and 
ressuspended in wash buffer. Magnetic separation and washing step were repeated 4 times. Beads 
were finally ressuspended in 100 µL 2x SDS-sample buffer and boiled for 10 min at 95ºC to 
dissociate immunocomplexes from GFPTrap beads. After vortexed, beads were magnetically 
separated, and the supernatant transferred to a new microtube. Samples were immediately stored at 
-20ºC for later mass spectrometry.  
7.3.4.!Mass spectrometry (MS) 
The MS experiments were performed under the PRIME-XS consortium in collaboration with the 
Biomolecular Mass Spectrometry and Proteomics group at Utrecht University.  
The samples were defrosted, 45 µL of each sample were loaded on a 12% SDS-PAGE gel (Bio-
Rad 345-0117) and run for 2h under a constant amperage of 20 mA. Afterwards the gel was fixed 
for 30 min in 40% MeOH, 10% HAc solution. Subsequently the gel was stained with coomassie 
(Gelcode blue stain, Pierce). Each lane was divided in 3 equal gel bands. These gel bands were 
excised and cut into small (approximately 1 mm3) pieces. The gel pieces were washed, in-gel 
reduced with 6.5 mM dithiothreitol (RT, 60 min), alkylated with 54 mM iodoacetamide (dark, RT, 
30 min), and digested by adding trypsin at a concentration of 3 ng/µL (overnight at 37 °C) as 
described in [23]. 
After the incubation, peptides were extracted with 100% acetonitrile (Biosolve) and dried by 
vacuum centrifugation. The peptides were dissolved in 45 µl 10% Formic acid and spun for 10 min 
at 20000 rpm prior to analysis. 20 µl of each sample was analyzed on a Q exactive plus (Thermo 
Fisher Scientific, Bremen) connected to Thermo Scientific EASYnLC 1000 (Thermo Fisher 
Scientific, Bremen). All columns were packed in-house. The trap column was a double fritted 100 
µm inner diameter capillary with a length of 20 mm (Dr Maisch Reprosil C18, 3 µm). The 
analytical column (Agilent Poroshell EC-C18, 2.7 µm) had an id of 75 µm and a length of 50 cm, 
and was heated to 40°C. 
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Trapping of the sample was performed at a flow rate of 100 nl/min for 10 min in solvent A (0.1 % 
Formic acid in water) and elution was achieved with a gradient of 7–38% B (0.1% Formic acid 
100% acetonitrile) in 75 min, 38–100% B in 3min, 100% B for 2min at a maximum pressure of 
800 bar. Nano spray was achieved using a distally coated fused silica emitter (made in-house, o.d. 
375 µm; i.d. 20 µm) biased to 1.7kV. The mass spectrometer was operated in the data dependent 
mode to automatically switch between MS and MS/MS. MS full scan spectra were acquired from 
m/z 375–1600 after accumulation to a target value of 3x106. Up to ten most intense precursor ions 
were selected for fragmentation. HCD fragmentation was performed at normalised collision energy 
of 25% after the accumulation to a target value of 5x104. MS/MS was acquired at a resolution of 
17500.   
7.3.5.!Data analysis and bioinformatics 
IP samples of N1-eGFP transfected cells were used as negative controls. A list of 180 proteins were 
identified in N1-eGFP samples (including replicates of both differentiation days) and established as 
false positives – proteins that bind nonspecifically to the GFPTrap beads and/or to the GFP fusion 
tag – being excluded from the APP interactomes. Exceptions were considered when the ratio 
between the number of peptide spectrum matches (PSM) for a given protein in an APP sample and 
the PSM in the N1-eGFP sample of the same differentiation day, was equal or higher than 2.0. 
Additionally, we directly excluded well described common MS contaminants [24], and proteins 
characteristic of hair, skin/epidermis, tongue and gums that are highly probable contaminants 
(KRT33A, KRT78, KRT85, KRT14, KRT5, KRT3, KRT31, KRT32, KRT33B, KRT35, KRT36, 
KRT4, KRT77, KRT8, FLG2, HRNR, SPRR1A, SPRR3, KRT17). In this manner, for each APP 
species (Wt, S655A, S655E) in a specific differentiation day (days 3 and 7) we generated a 
“cleaned list” of potential interactors.  
Following, based on the condition in which the potential interactor was pull-downed and detected 
by MS, we divided the APP potential interactors in the following categories: 1) Total APP 
interactors – all interactors experimentally identified, independent of the experimental condition; 2) 
Interactors that bind APP independently of its S655 phosphorylation status. This category includes 
interactors that are common to all APP backgrounds (APPWt, APPSA, and APPSE) or common to 
both S655 phosphorylation mutants (APPSA and APPSE). 3) Interactors that bind APP in a S655 
phosphorylation status dependent manner; this is further divided in the subcategories: 3a) APP 
S655 dephospho interactome (interactors present uniquely in APPSA, or common to APPWt and 
APPSA conditions); and 3b) APP S655 phospho interactome (interactors present uniquely in 
APPSE or common to APPWt and APPSE conditions).  
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Protein lists’ comparison was performed using a Venn diagram tool available online – jvenn 
(http://bioinfo.genotoul.fr/jvenn) [25].  
Construction of protein-protein interactions (PPI) networks was performed using the Cytoscape 
software (version 3.4.0). Protein-protein data was retrieved from the International Molecular 
Exchange (IMEx) consortium partners only [26]. The HIPPIE database was used for retrieving 
additional human APP PPI data (downloaded on June 27, 2016).  This database is regularly 
updated by incorporating interaction data from major expert-curated experimental PPI databases 
(such as BioGRID, HPRD, IntAct, and MINT). To the 1111 APP protein interactors retrieved from 
HIPPIE, we added interacting proteins from a published APP interactome [27], and imported the 
final curated APP PPI list into Cytoscape to add information on APP interactors to the constructed 
networks. In the PPI networks proteins are represented by their gene names as retrieved by the 
databases. 
Functional enrichment analysis of Gene Ontology categories (Biological Processes and Molecular 
Function), and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed using the 
Cytoscape app ClueGO, version 2.2.6 [28]. Complementarily, the Panther overrepresentation test 
was performed [29]. For both analysis, the overall set of human protein-coding genes was used as 
reference set, and only enriched functions with a P value < 0.05 (including Bonferroni-correction) 
were considered. 
Functional classification of single proteins lists was performed by Panther functional classification 
analysis [29]. Proteins annotated with GO terms related to brain development, neuron function, 
neurogenesis, neuronal differentiation and/or related events (cytoskeleton organization, cell 
adhesion, and cell migration), and related signaling pathways, were selected as interactors of 
interest. The Uniprot [30] and PubMed databases were manually searched for each of the 
interactors of interest to verify involvement in neuronal differentiation. The association of selected 
proteins with brain alterations and disorders, especially brain development and neurodegenerative 
diseases, was verified using the Mouse Genome Informatics database 
(http://www.informatics.jax.org/) [31] and, in the human context, the OMIM (http://omim.org/) and 
the Uniprot databases. Identification of the brain specific or brain enriched proteins was performed 
using The Human Protein Atlas database [32]. Figure 1, gives an overview of the methodological 
approach used, from cells differentiation to bioinformatics analysis. 
7.3.6.!Cell morphology studies: immunocytochemistry, microscopy and image analysis 
Cells grown on coverslips were fixed with a 4% paraformaldehyde PBS solution (PFA) for 20 min 
and, upon three washes with PBS, coverslips were permeabilized with a 0,2% TRITON PBS 
solution (10 min), for subsequent immunocytochemistry analysis. Briefly, cells were first blocked 
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for 30 min-1h with 5% bovine serum albumin in PBS, then incubated with specific primary 
antibodies, and finally incubated with the fluorophore conjugated-secondary antibodies. 
Preparations were washed with PBS, mounted with Vectashield® mounting media with or without 
DAPI (Vector Labs). Alexa Fluor 568 Phalloidin was diluted in the secondary antibody solution for 
the specified conditions. 
Cells visualization was performed either by epifluorescence and phase contrast (PhC) illumination 
microscopy under an Olympus IX-81 motorized inverted microscope equipped with a LCPlanFl 
20x/0.40 objective lens, or by confocal microscopy using a LSM 510 META confocal microscope 
(Zeiss) and a 63x oil objective 
Morphometric analysis of cells was performed on ~30 random digitized images per sample, with an 
average of 40 transfected cells per biological replica of each condition being analyzed. Transfected 
cells were identified by GFP expression, measurements were performed on matching PhC 
microphotographs. 
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7.4.!Results 
The main aim of this study was the identification of APP protein interactors dependent on its S655 
phosphorylation state. RA-differentiated SH-SY5Y cells overexpressing Wt or S655 
phosphomutants APP-GFP cDNAs were used as the protein pool. The GFPTrap assay was used to 
immunoprecipitate the specific APP proteins (Wt, SA, and SE) and their respective interacting 
partners, which were subsequently identified by mass spectrometry (Figure B.16 and 
Supplementary Table B.2).  
 
Figure B.16 - Methodological approach schematic representation. SH-SY5Y cells, differentiated for 3 and 7 days with 
10 µM RA, and overexpressing Wt or S655 phosphomutants APP-GFP cDNAs by 24h transient transfection, were used 
as the protein pools to identify APP S655 interactors. The GFPTrap assay was used to immunoprecipitate the specific 
APP (Wt, SA, and SE) proteins and their respective interacting partners, which were subsequently identified by mass 
spectrometry. The list of identified proteins was pre-processed (‘cleaned’) to exclude unspecific protein interactors and 
potential contaminants. Before bioinformatics analysis, the interacting proteins were grouped based on their appearance 
or not in specific APP S655 phosphorylation groups (Wt, SA, SE).   
 
Some proteins were identified only in the APP-GFP pull-down samples and never in the controls 
(cells expressing the N1-eGFP empty vector on day 3 and day 7), and other proteins were enriched 
in the APP-GFP conditions and were also considered potential APP interactors (PSM ratio between 
APP samples and N1-eGFP ≥ 2.0). In this manner, after a processing step to clean unspecific and 
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contaminant proteins, we obtained a list of 456 potential APP protein interactors (including APP), 
of which 105 were already described as APP interactors.  
As shown in Figure B.17, APPWt show a decrease in the number of interactors (almost half) from 
day 3 to day 7. On differentiation day 3 (D3), APPWt and APPSA have a similar number of 
interactors, and most are shared between these two conditions. From day 3 to day 7, APPSA shows 
a small increase in the number of protein interactors. Very interestingly, on differentiation day 7 
(D7), APPSA more than triplicates the number of unique interactors (and decreases the number of 
interactors shared with APPWt). APPSE is the condition with the lowest number of interactors. 
This APP species roughly maintains the number of interactors from D3 to D7 (a minor decrease 
from 90 to 74 was noted), including similar numbers of unique interactors between days. 
Based on the condition where the putative APP interactor was detected, we divided the APP 
protein interactors in 3 categories: 1) Total APP interactors (D3 = 289, D7 = 345), which includes 
all APP interactors identified in this work; 2) APP interactors whose interaction seems independent 
of the S655 phosphorylation status; and 3) APP interactors dependent of the APP S655 
phosphorylation status, this subdivided in the dephosphoS655 APP interactome, and the 
phosphoS655 APP interactome. Of note, some proteins are included in an APPS655 
phosphorylation-dependent category at the first differentiation day, and in a different category at 
the last differentiation day (Supplementary Table B.3). 
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Figure B.17 - Total APP protein interactors detected by MS. Venn’s diagrams presenting the numbers of interactors 
experimentally detected in the three pull-downs (of APPWt and the S655 phosphomimetic mutants, APPSA and APPSE), 
and the intersections between these conditions, at both differentiation days (3 and 7).   
 
7.4.1.!Total APP interactors with differentiation time 
We considered as “Total” APP interactors all the proteins detected, independently of the APP 
nature (Wt, SA, or SE). This category was created to allow a general view of the dynamics of the 
APP interactome with the differentiation time (Figure B.18). The list of proteins identified on D3 
included APP itself and 289 different APP protein interactors, 63 of which already described as 
APP interactors. Almost half of these interactors are nucleic-acid binding proteins (mainly RNA 
binding proteins, RBP). Other represented protein classes include cytoskeletal proteins (7.6% of the 
D3 protein list, with similar numbers of actins, microtubules (MTs), and intermediate filaments 
(IFs)), enzyme modulators (6.0% of proteins; mainly G-proteins and G-protein modulators), 
hydrolases (4.6%), and transcription factors (TFs; 5.0%).  Differentiation D7 included 345 different 
APP protein interactors and APP itself, 86 of which were known APP interactors. Like in D3, the 
majority of proteins belong to the nucleic-acid binding protein class (mainly RBP), followed by 
cytoskeletal proteins (9.6% of D7 proteins; half of which belong to the actin family), enzyme 
modulators (5.9%; mainly G-proteins and G-protein modulators), chaperons (5.9%; comprising 
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Hsp90 family and chaperonin family members), oxidoreductases (4.5%), transferases (3.7%), 
hydrolases (3.7%), TFs (3.7%), calcium-binding proteins (3.1%), and signaling molecules (2.8%).  
The APP interactor network is dynamic with time of differentiation. 180 APP interactors (including 
APP) are shared between differentiation days 3 and 7 (Figure B.18 A). The remaining (~40% at D3 
and ~50% at D7) are protein interactors specific of each differentiation day. In order to test if the 
APP interactome could be assigned to specific functions depending on the differentiation day we 
performed cluster comparison functional enrichment analysis using the Cytoscape app ClueGO 
(Figure B.18 B). For both differentiation days, a large number of proteins are associated with RNA 
and mRNA binding, leading to enrichment in these functions. Common enriched functions include 
RNA biosynthetic and metabolic processes, gene expression, RNA splicing, ribonucleoprotein 
complex biogenesis and organization, and protein target to endoplasmic reticulum (ER).  
Very interestingly, while D3 is assigned to negative regulation of mRNA metabolic processing and 
RNA splicing, and to negative regulation of telomere maintenance via telomere lengthening, D7 is 
associated with positive regulation of the same functions (Table B.1 and Figure B.18 B).  
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Figure B.18 - Comparison of Total APP interactors at differentiation days 3 (D3) and 7 (D7). A. The number of 
Total APP interactors identified for each differentiation day (APP included). B. Biological processes gene ontology (GO) 
terms specifically enriched at D3 (red color) or D7 (green color). Grey color indicates non-specific GO terms, meaning 
the two differentiation days display similar % of genes attributed to the functional term. The enrichment analysis was 
performed using the Cytoscape app ClueGO cluster analysis. Only terms with pvalue < 0.05 are represented. 
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Table B.1 - Examples of enriched biological processes differentially attributed to APP ‘Total’ interactors 
depending on the differentiation day (D3 versus D7). The enrichment analysis was performed using the Cytoscape app 
ClueGO. Pvalue, calculated p value that includes Bonferroni step down correction. 
Biological Process 
(GO term) 
Enriched at 
(Pvalue) 
%Genes 
D3 
%Genes 
D7 Genes Cluster at D3 Genes Cluster at D7 
stress granule assembly D3 (230.0E-6) 77.40 46.44 
ATXN2, ATXN2L, 
CIRBP, DDX3X, PUM2 ATXN2L, CIRBP, DDX3X 
negative regulation of 
mRNA processing 
D3 
(49.0E-3) 73.25 58.60 
HNRNPA2B1, 
HNRNPK, RBMX, 
SFSWAP, U2AF2 
HNRNPA2B1, HNRNPK, 
RBMX, U2AF2 
negative regulation of 
mRNA splicing, via 
spliceosome 
D3 
(9.5E-3) 73.25 58.60 
HNRNPA2B1, 
HNRNPK, RBMX, 
SFSWAP, U2AF2 
HNRNPA2B1, HNRNPK, 
RBMX, U2AF2 
negative regulation of 
telomere maintenance via 
telomere lengthening 
D3 
(36.0E-3) 71.24 53.43 
HNRNPA1, HNRNPC, 
HNRNPU, PARP1 
HNRNPA1, HNRNPC, 
HNRNPU 
cerebellar Purkinje cell 
layer development 
D3 
(49.0E-3) 66.17 49.63 
ATXN2, HSPA5, 
LDB2, MYH10 AARS, HSPA5, MYH10 
canonical glycolysis D7 (2.8E-6) 0.00 100.00 - 
ALDOA, ENO1, ENO3, 
GAPDH, GPI, PFKM, 
PGAM2, PGK1, PKM, 
TPI1 
protein localization to 
nuclear body/Cajal 
body/telomere 
D7 
(3.7E-3) 0.00 100.00 - CCT2, CCT4, CCT5, CCT8 
ATP generation from ADP D7 (140.0E-6) 8.33 91.67 OGT 
ALDOA, ENO1, ENO3, 
GAPDH, GPI, LDHA, 
PFKM, PGAM2, PGK1, 
PKM, TPI1 
gluconeogenesis D7 (18.0E-6) 20.88 83.53 KHSRP, OGT, SOGA1 
ALDOA, ENO1, ENO3, 
GAPDH, GPI, KHSRP, 
MDH2, PC, PGAM2, 
PGK1, SLC25A1, TPI1 
substantia nigra 
development 
D7 
(1.7E-6) 43.85 80.40 
ACTB, ATP5F1, 
CALM1, HSPA5, INA, 
YWHAQ 
ACTB, BASP1, CALM1, 
CKB, ENO3, G6PD, 
HSPA5, INA, LDHA, 
YWHAE, YWHAQ 
positive regulation of 
mRNA processing 
D7 
(13.0E-3) 51.88 77.82 
HSPA8, PABPC1, 
RBMX, SNW1 
HSPA8, PABPC1, RBMX, 
SNRNP70, SNW1, TRA2B 
positive regulation of 
mRNA splicing, via 
spliceosome 
D7 
(2.8E-3) 46.44 77.40 HSPA8, RBMX, SNW1 
HSPA8, RBMX, 
SNRNP70, SNW1, TRA2B 
positive regulation of 
telomere maintenance via 
telomere lengthening 
D7 
(15.0E-3) 30.69 76.73 AURKB, HNRNPA1 
CCT2, CCT4, CCT5, 
CCT8, HNRNPA1 
positive regulation of 
mitochondrial membrane 
permeability involved in 
apoptotic process 
D7 
(29.0E-3) 57.96 69.56 
SFN, SLC25A5, 
YWHAB, YWHAG, 
YWHAQ 
SFN, YWHAB, YWHAE, 
YWHAG, YWHAQ, 
YWHAZ 
 
Other functions particularly enriched at D3 include stress granule assembly and cerebellar Purkinje 
cell layer development, although D7 also presented interactors involved in these functions. 
Differentiation D7 presented enriched biological processes to which there are no or few associated 
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proteins present in D3, like protein localization to nuclear body, to Cajal body, and to telomere; 
glycolysis; and ATP generation from ADP. Other highly enriched at D7 include gluconeogenesis; 
substantia nigra development; and positive regulation of mitochondrial membrane permeability 
involved in apoptotic process, besides the above mentioned positive regulation of mRNA 
processing and telomere maintenance (Table B.1 and Figure B.18 B). Table B.2 presents Molecular 
Function terms with particular interest for neuronal differentiation specifically enriched on D7. The 
higher number of proteins associated with the cytoskeleton, particularly actin and actin filaments 
binding proteins, is notorious. 
Table B.2 - ‘Total’ APP interactors: examples of enriched Molecular Function gene ontology terms attributed to 
differentiation day 7 (D7). The enrichment analysis was performed using the Cytoscape app ClueGO. Pvalue, p value 
that includes Bonferroni step down correction. 
Molecular 
Function 
(GO term) 
Pvalue %Genes D3 
%Genes 
D7 Genes Cluster at D3 Genes Cluster at D7 
protein kinase C 
inhibitor activity 
 
2.9E-3 45.51 68.26 SFN, YWHAG HSPB1, SFN, YWHAG 
cytoskeletal 
protein binding 
 
64.0E-6 44.38 72.63 
ACTB, CALM1, CAMSAP2, 
CAMSAP3, DLG1, EEF2, EMD, 
EPB41, FUS, HNRNPK, KTN1, 
MAGI1, MAP4, MYH10, MYH9, 
MYO1B, PLEC, RPS3, RTCB, 
S100A8, SHROOM3, SYNPO2 
ACTB, ACTN1, ACTN4, 
ALDOA, ANXA2, CALD1, 
CALM1, CAPZB, CCT5, CFL1, 
EEF2, EMD, FKBP4, FLNA, 
FLNB, FMR1, FUS, GAPDH, 
HNRNPK, KIF26A, LASP1, 
MAP1B, MSN, MYH10, MYH9, 
PFN1, PLEC, RPS3, S100A4, 
S100A6, SHROOM3, STMN1, 
TLN1, TMSB4X, TPM4, VCL 
actin filament 
binding 
 
4.1E-3 37.34 82.16 
EEF2, MYH10, MYH9, MYO1B, 
SHROOM3 
ACTN1, ACTN4, CAPZB, EEF2, 
FLNA, LASP1, MYH10, MYH9, 
SHROOM3, TLN1, VCL 
actin binding  4.1E-3 33.74 82.49 
EEF2, EMD, EPB41, MYH10, 
MYH9, MYO1B, PLEC, 
SHROOM3, SYNPO2 
ACTN1, ACTN4, ALDOA, 
CALD1, CAPZB, CFL1, EEF2, 
EMD, FLNA, FLNB, LASP1, 
MSN, MYH10, MYH9, PFN1, 
PLEC, S100A4, SHROOM3, 
TLN1, TMSB4X, TPM4, VCL 
 
Additionally, KEGG enrichment analysis attributed as main pathways for D3: mRNA surveillance 
(Pvalue, p = 200.0E-9) and spliceosome (p = 8.0E-42); for D7 it attributed as main pathways: 
spliceosome (p = 8.0E-42), ribosome (p = 2.2E-21), RNA degradation (p = 550.0E-6), glycolysis 
and gluconeogenesis (p = 890.0E-9), and pentose phosphate pathway (p = 600.0E-6). The Panther 
overrepresentation test was also performed (Supplementary Table B.4). In most cases this analysis 
confirmed the results obtained by ClueGo, but also highlighted functions in cell adhesion 
(including via cadherin) and in Parkinson disease pathway for both differentiation days. Further, 
D3 interactors might be more associated with MTs-based processes, while D7 interactors are 
enriched in the cytoskeleton regulation by Rho GTPases pathway. 
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To evaluate how the APP interactors identified by our system were interconnected, we constructed 
PPI networks using Cytoscape software, and by importing data on the relation between these 
proteins from public databases, as explained in the Methods section. For differentiation D3, we 
were able to map 284 of the interactors with 760 edges (connections between nodes). 56 (~20%) 
nodes were found to be isolated, and the network had a mean clustering coefficient (a measure of 
how nodes are interconnected, that ranges from 0 to 1) of 0.198. APP was connected to 62 protein 
interactors, representing known APP interactors. Based on node degree (k, the number of proteins 
that interact with a specific protein within the network) [33], the following proteins are highlighted: 
SNW1 (k = 91), HNRNPU (k = 38), SF1 (k = 38), YWHAG (k = 33), and SF3A2 (k = 47). For 
differentiation D7, we were able to map 342 of the interactors with 1059 edges. 47 (~14%) nodes 
were isolated, and the network had a mean clustering coefficient of 0.256. APP was connected to 
96 reported protein interactors. Node degree analysis highlighted the same proteins as in day 3: 
SNW1 (k = 106), HNRNPU (k =46), SF1 (k = 30), YWHAG (k = 31), and SF3A2 (k = 45), and 
additionally highlighted the following proteins: YWHAZ (k = 93), NPM1 (k = 38), RPL10 (k = 
30). The generated PPI networks are not shown due to space restrictions. 
7.4.2.!APP interactors independent of the S655 phosphorylation state 
This category included interactors common to the three APP backgrounds (APPWt, APPSA, and 
APPSE) plus interactors common to both S655 phosphorylation mutants (APPSA and APPSE), at a 
specific differentiation day. Since these proteins interact with both dephosphomimetic and 
phosphomimetic mutants of S655, they most probably interact with APP independently of its S655 
phosphorylation status. For differentiation D3 we retrieved 75 potential interactors (68 common to 
the three conditions +7 common to both S655 mutants), and for differentiation D7, 51 (44+7) 
proteins, indicating a decrease in the number of interactors independent of S655 phosphorylation 
state with differentiation time. The two differentiation time periods shared 22 APP protein 
interactors. For both differentiation days, the majority of proteins are nucleic-acid binding proteins 
(~60.0% of proteins), mainly RBP. At D3, the other most represented protein classes are TFs (8.1% 
of proteins) and cytoskeletal proteins (6.8%; mainly IFs, but also MTs). In Day 7, enzyme 
modulators (9.6%), cytoskeletal proteins (5.8%; with IFs and MTs), and signaling molecules 
(5.8%) are the main protein classes represented.  
The protein-protein interaction sub-network of differentiation D3 presented 75 nodes (APP 
included) with 68 edges (Figure B.19 A). Of note, one entry was not mapped by Cytoscape and we 
found that the uniprot accession number has been deleted. This D3 sub-network had 22 isolated 
nodes (29%), and a mean clustering coefficient of 0.14. Within this sub-network, APP presented 19 
known protein interactors; the other two major clusters have as central nodes SF1 (with k = 10), 
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EWSR1 (with k = 7), and SNRPB (with k = 6). For differentiation D7, the PPI sub-network 
included 52 nodes (considering APP, and excluding one deleted entry as above; Figure B.19 B). 
This sub-network had 19 isolated nodes (~36%). APP presented 8 known protein interactors, and 
again SF1 was highlighted by the number of direct known interactors (k = 10), followed by PUF60 
with k = 7. 
Functional enrichment analysis, either using ClueGO or Panther, did not attributed gene ontology 
terms with interest for neuronal differentiation. Even if we increase the input list to include the 
protein interactors only identified in the APPWt condition, the majority of the attributed functions 
are related to ribonucleoprotein and spliceosomal complex assembly, regulation of RNA splicing, 
translation and translation regulation, with some specificities depending on the differentiation day ( 
Supplementary Table B.5). 
Nevertheless, we performed functional annotation of individual proteins. Based on the assigned 
gene ontology, followed by literature search on PubMed and study of the association with brain 
anomalies, we were able to select a list of a few APP protein interactors with special interest for 
neuronal differentiation, which included e.g. ELAV-like protein 4 (ELAVL4) and Caprin-1 
(CAPRIN1) (Table B.3). 
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Figure B.19 - APP S655 phosphorylation state independent protein-protein interaction sub-network for 
differentiation days 3 (A.) and 7 (B.). Black marked nodes indicate APP interactors with a potential high level of 
interest for neuronal differentiation studies. APP is presented in red, bound to already reported APP interactors (by red 
edges). Light blue nodes indicate protein interactors shared by both differentiation days. 
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Table B.3 - APP interactors independent of the S655 phosphorylation state with potential interest for neuronal differentiation. From the interactors’ list specific of each 
differentiation day, proteins were selected based on functional annotations directly related to brain development, neuron function, neurogenesis, and/or neuronal differentiation related 
events (cytoskeleton organization, cell adhesion, and cell migration) and signaling pathways. In bold are the UniProt accession number of newly identified APP interactors. The gene 
ontology (GO) terms determinant for the selection are described in the biological process column. Node degree (‘k’), is the number of APP interactors that the protein presents and refers 
to the position of the protein inside the protein-protein interaction network that includes all the interactors identified for each differentiation day. ‘Ref’, indicates references retrieved from 
the PubMed supporting the role of the indicated interactor in neuronal differentiation. ‘Mammalian phenotype/human diseases’, KO mouse phenotypes were searched on Jackson 
Laboratories mouse knockout database, and human diseases retrieved from UniProt and other indicated references. ‘Expression’, brain enrichment or altered expression in RA-
differentiated SH-SY5Y cells are indicated. ‘Dif.’ – differentiation; ‘Reg.’ – regulation; ‘PM’ – plasma membrane.  
Uniprot 
nr 
Gene name and 
symbol k Biological Process Ref. Mammalian phenotype/ human diseases Expression 
D3 
P26378 
ELAV-like 
protein 4; 
ELAVL4 
1 Learning (GO:0007612); dendrite morphogenesis (GO:0048813). [34] 
increased neuron apoptosis; abnormal nervous system 
development, and neuron dif. [35]. 
Tissue enhanced (cerebral 
cortex); 
RA dif. SH-SY5Y regulated 
gene [36]. 
Q14444 Caprin-1; CAPRIN1 1 
positive reg. of dendrite morphogenesis 
(GO:0050775) and of dendritic spine 
morphogenesis (GO:0061003); cell 
dif.(GO:0030154). 
[37] 
increased neuron apoptosis; abnormal neuron 
physiology; abnormal dendrite and synapse 
morphology; abnormal miniature excitatory 
postsynaptic currents [38]. 
 
P08670 Vimentin; VIM 12 
negative reg. of neuron projection development 
(GO:0010977); Bergmann glial cell dif. 
(GO:0060020); movement of cell or subcellular 
component (GO:0006928); intermediate filament 
organization (GO:0045109). 
[39] abnormal Purkinje cell dendrite morphology [40]. 
RA dif. SH-SY5Y regulated 
gene [36, 41]. 
Neuronal precursors 
(replaced by Nfs in post-
mitotic neurons)[42]. 
P02545 Prelamin-A/C; LMNA 4 
reg. of cell migration (GO:0030334); 
establishment or maintenance of microtubule 
cytoskeleton polarity (GO:0030951). 
[43] 
abnormal cholinergic neuron morphology [44]; 
axonal neuropathy Charcot-Marie-Tooth disorder type 
2 in humans. 
 
 
P14923 
Junction 
plakoglobin; 
JUP 
2 
cell adhesion (GO:0007155); desmosome 
assembly (GO:0002159); adherens junction 
assembly (GO:0034333) and organization 
(GO:0034332); cytoskeletal anchoring at 
PM(GO:0007016); cell migration (GO:0016477); 
reg. of cell proliferation (GO:0042127); positive 
reg. of canonical Wnt signaling. 
[45] 
 
 
 
 
 
 
RA dif. SH-SY5Y regulated 
gene [41]. 
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D7 
Q6Y7W6 
PERQ amino 
acid-rich with 
GYF domain-
containing 
protein 2; 
GIGYF2 
6 
post-embryonic development (GO:0009791); 
spinal cord motor neuron dif. (GO:0021522); 
homeostasis of number of cells within a tissue 
(GO:0048873); cell-cell adhesion (GO:0098609) 
[46] 
motor neuron degeneration; abnormal neuron number ; 
postnatal lethality, incomplete penetrance; neonatal 
lethality, incomplete penetrance [47]; 
Involvement in Parkinson disease 11. 
 
Q8NC56 
LEM domain-
containing 
protein 2; 
LEMD2 
3 
Neurogenesis (GO:0022008); negative reg. of 
MAPK cascade (GO:0043409); negative reg. of 
BMP signaling pathway (GO:0030514). 
- 
abnormal embryonic neuroepithelium morphology, 
increased apoptosis and decreased proliferation; 
impaired neuron dif.; absent embryonic telencephalon; 
abnormal dorsal root ganglion, and retinal neuronal 
layer morphology; embryonic lethality during 
organogenesis, complete penetrance [48]. 
 
P51116 
Fragile X mental 
retardation 
syndrome-
related protein 2; 
FXR2 
7 
positive translation reg. of PSD95 mRNA (mouse 
hippocampus); role in neuronal dendritic 
development (binds, stabilizes, and enhances  
GluA1 mRNA expression); FXR2 deficiency in 
dendate gyrus neural stem cells enhances cell 
proliferation and dif. (by reg. Noggin 
expression). 
[49-
51] 
hyperactivity; abnormal locomotor activity, sensimotor 
gating, and cognitive function; altered hippocampal 
synaptic plasticity [52-54]. 
High expression in the brain 
[55]. 
 
Q9UNN5 FAS-associated factor 1; FAF1 3 
cytoplasmic sequestering of NF-kB 
(GO:0007253); reg. of cell adhesion 
(GO:0030155); positive reg. of extrinsic 
apoptotic signaling pathway via death domain 
receptors (GO:1902043) 
[56] 
embryonic lethality before implantation, complete 
penetrance; decreased susceptibility to dopaminergic 
neuron neurotoxicity; embryonic lethality, complete 
penetrance [57, 58]. 
 
P68363 
Tubulin alpha-
1B chain; 
TUBA1B 
1 
microtubule cytoskeleton organization 
(GO:0000226); cytoskeleton organization 
(GO:0007010) 
- 
abnormal cerebral cortex (including visual, auditory, 
and somatosensory), hippocampus, and dentate gyrus 
morphology; abnormal hippocampal mossy fiber 
morphology; abnormal neuronal migration, neuron 
morphology, and dendrite morphology; decreased 
number and abnormal hippocampus pyramidal cell 
layer; abnormal cortex pyramidal cell morphology; 
several altered behaviors and cognitive functions [59, 
60]; gene mutations cause Lissencephaly. 
 
Q16352 Alpha-internexin; INA 0 
nervous system development (GO:0007399); 
substantia nigra development (GO:0021762); cell 
dif. (GO:0030154); NF cytoskeleton organization 
(GO:0060052); intermediate filament 
cytoskeleton organization (GO:0045104) 
[61]  Group enriched (adrenal gland, cerebral cortex) 
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7.4.3.!The dephosphoS655 APP interactome 
This category included protein interactors uniquely identified in APPSA, and the interactors 
present in both APPWt and APPSA conditions. Since APPWt can be either phosphorylated or 
dephosphorylated at S655, the detection of the same protein interaction in APPWt and in the 
dephosphomimetic S655A mutant most probably indicates that this interaction happens when APP 
is S655 dephosphorylated. On differentiation D3, this category comprised 147 APP protein 
interactors (39 + 106). Again, most identified proteins are nucleic-acid binding proteins (40.7%; 
mainly RBP). The second most represented protein class is cytoskeletal proteins (8.3%; similar 
numbers of actin, MTs, and IFs), and enzyme modulators (8.3%), followed by hydrolases (6.9%), 
and TFs (5.5%). On differentiation D7, the total number of APP protein interactors detected 
increased to 222 (178 +43). 34.5% of these proteins are nucleic-acid binding proteins, 11.6% are 
cytoskeletal proteins (mainly from the actin family), 8.6% are chaperones, 6.9% are 
oxidoreductases, 5.2% are enzyme modulators (mainly small GTPases), and 4.7% are transferases. 
The two differentiation days share 49 APP protein interactors. 
The differentiation D3 PPI sub-network presented 144 nodes (3 identified protein interactors were 
not mapped by the software) and 312 edges. This network had 35 isolated nodes (~24%), and an 
overall cluster coefficient of 0.172. APP gathered 28 already known interactions. Other important 
proteins based on node degree were: SNW1 (k = 52), SF3A2 (k = 27), HNRNPU (k = 23), 
HNRNPA1 (k = 18), and YWHAG (k = 16). The differentiation D7 sub-network had 218 nodes, of 
which 28 were isolated nodes (~13%), and 576 edges with an average clustering coefficient of 
0.292. Within this sub-network APP presented 74 known protein interactors. Also, highlighted by 
their node degree are: YWHAZ (k = 77), SNW1 (k = 61), ACTB (k = 34), HRNPN4 (k = 33), 
NPM (k = 29), and RPL10 (k = 28). These D3 and D7 PPI networks are not presented as figures 
due to space restrictions. 
Figure B.20 A and B show the results obtained for differentiation D3 functional enrichment 
analysis of the dephosphoS655 APP interactome. Enriched biological process gene ontology terms 
are mainly related to regulation of mRNA processing and translation (Figure B.20 A). KEGG 
enrichment analysis (Figure B.20 B) showed that, in addition to a role in ribosome, spliceosome, 
and mRNA surveillance, this group might have an involvement in tight-junction and in the Hippo 
signaling pathway. Molecular functions not included in Figure B.20 but also found enriched are: 
neural nucleus development (p = 510.0E-6) and substantia nigra development (p = 99.0E-6) with 
the following associated gene names: ACTB, CALM1/2/3, HSPA5, INA, YWHAQ. Additionally, 
the Panther overrepresentation analysis (Supplementary Table B.6) assigned a function as 
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structural constituent of cytoskeleton, cytoskeleton regulation by RhoGTPases, cell-cell adhesion 
via cadherin binding, and a relation to Parkinson disease. 
The results obtained for differentiation D7 functional enrichment analysis (Figure B.20 C and D) 
also assigned a role in substantia nigra development (p = 170E-9) and in negative regulation of MT 
polymerization (p = 11E-3). Functional enrichment in regulation of protein localization to Cajal 
body, and in energy metabolism, indicates that these functions (above observed when analyzing the 
total APP interactome, can be mainly attributed to the dephosphoS655 APP interactome. In Figure 
B.20 D we can see the enriched KEGG functions attributed to this D7 S655A group, highlighting 
transcription and translation-related regulatory pathways, and energy metabolism. The Panther 
overrepresentation analysis (Supplementary Table B.6), attributed similar functions as the ones of 
day 3, and reinforced the results obtained by ClueGo. This analysis further highlighted functions in 
actin filament binding and actin binding. Of note, both analyses attributed PKC inhibitor activity 
(ClueGO Pvalue = 100E-6) due to the presence of HSPB1, SFN, and YWHAG. Functional 
annotation of individual proteins allowed to select dephosphoS655 APP protein interactors that 
might be of special interest for neuronal differentiation. The selection criteria applied indicated 11 
protein interactors shared by D3 and D7 (Table B.4), 10 unique for differentiation D3 (Table B.5), 
and 25 unique for differentiation D7 (Table B.6 and Supplementary Table B.7). 
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Figure B.20 - Functional annotation analysis of the dephosphoS655 APP interactome. A. Pie chart representation of the biological process functional groups attributed to 
differentiation day 3 (D3). B. Enriched pathways (KEGG) gene ontology terms attributed to differentiation day 3 (D3). C. Pie chart representation of the biological process functional 
groups attributed to differentiation day 7 (D7). D. Enriched pathways (KEGG) gene ontology terms attributed to D7. The enrichment analysis was performed using the Cytoscape app 
ClueGO, and only terms with pvalue < 0.05 are represented; each group was named accordingly to the most significant GO term. Gene’s names were added using the CluePedia app. 
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Table B.4 - APP interactors associated with dephosphoS655 present in both differentiation days 3 and 7, and with potential interest for neuronal differentiation. Proteins were 
selected based on functional annotations directly related to brain development, neuron function, neurogenesis, and/or neuronal differentiation related events (cytoskeleton organization, 
cell adhesion, and cell migration) and signaling pathways. In bold are the UniProt accession number of newly identified APP interactors. The gene ontology (GO) terms determinant for 
the selection are described in the biological process column. Node degree (‘k’), is the number of APP interactors that the protein presents and refers to the position of the protein inside 
the protein-protein interaction network that includes all the interactors identified in the S655A conditions at differentiation days 3 and 7, respectively. ‘Ref’, indicates references retrieved 
from the PubMed supporting the role of the indicated interactor in neuronal differentiation. ‘Mammalian phenotype/human diseases’, KO mouse phenotypes were searched on Jackson 
Laboratories mouse knockout database, and human diseases retrieved from UniProt and other indicated references. ‘Expression’, brain enrichment or altered expression in RA-
differentiated SH-SY5Y cells are indicated. ‘Dif.’ – differentiation; ‘Reg.’ – regulation; ‘PM’ – plasma membrane; ‘AD’ - Alzheimer’s disease; ‘PD’ – Parkinson’s disease. 
Uniprot 
nr 
Gene name and 
symbol 
k at 
D3 / 
D7 
Biological Process Ref Mammalian phenotype/ human diseases Expression 
Q9H0D6 
5'-3' 
exoribonuclease 2; 
XRN2 
4 / 5 hippocampus development (GO:0021766); neuron dif. (GO:0030182); cell growth (GO:0016049) 
[62, 
63]   
P15884 Transcription factor 4; TCF4 5 / 3 
positive regulation of neuron dif. (GO:0045666); nervous system 
development (GO:0007399); cell dif. (GO:0030154) 
[64, 
65] 
abnormal brain development [66]; 
Pitt-Hopkins mental retardation 
Syndrome; schizophrenia 
susceptibility gene 
 
Q13573 
SNW domain-
containing protein 
1; SNW1 
89 / 
106 
positive regulation of neurogenesis (GO:0050769); Notch signaling 
pathway (GO:0007219); positive regulation of TGFBR signaling 
(GO:0030511); regulation of RAR signaling (GO:0048385); 
[67, 
68]   
P11021 
78 kDa glucose-
regulated protein; 
HSPA5 
11 / 
20 
cerebellum structural organization (GO:0021589); cerebellar Purkinje cell 
layer (GO:0021680), and substantia nigra development (GO:0021762); 
positive regulation of cell migration (GO:0030335); negative regulation 
of TGFBR signaling (GO:0030512); negative regulation of apoptotic 
process (GO:0043066); cell-cell adhesion (GO:0098609) 
[69-
71] 
abnormal cerebral cortex morphology 
and stratification; abnormal 
hippocampus and cerebellum 
morphology; abnormal brain white 
matter and internal capsule 
morphology; abnormal neuron dif. 
and  proliferation [69] 
APP-KO 
(prefrontal 
cortex) down-
regulated gene 
[72]; 
RA dif SH-
SY5Y regulated 
gene [36]. 
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Uniprot 
nr 
Gene name and 
symbol 
k at 
D3 / 
D7 
Biological Process Ref Mammalian phenotype/ human diseases Expression 
P35580 Myosin-10; MYH10 3 / 3 
brain development (GO:0007420); cerebellar Purkinje cell layer 
development (GO:0021680); neuron migration (GO:0001764); neuron 
projection development (GO:0031175); axonogenesis (GO:0007409); 
axon guidance (GO:0007411); substrate-dependent cell migration, cell 
extension (GO:0006930); cell adhesion (GO:0007155); cell proliferation 
(GO:0008283); regulation of cell shape (GO:0008360); actin filament-
based movement (GO:0030048); actomyosin structure organization 
(GO:0031032);  actin cytoskeleton organization (GO:0030036) 
[73, 
74] 
abnormal neuronal migration; 
abnormal Purkinje cell dendrite 
morphology [75, 76] 
 
Id as APP 
interactor in 
mouse brain 
[77]. 
P07196 
Neurofilament 
light polypeptide; 
NEFL 
3 / 4 
neuron projection morphogenesis (GO:0048812); positive regulation of 
axonogenesis (GO:0050772); axon development (GO:0061564); 
regulation of axon diameter (GO:0031133); PNS axon regeneration 
(GO:0014012); spinal cord (GO:0021510), hippocampus (GO:0021766), 
and cerebral cortex development (GO:0021987); negative regulation of 
neuron apoptotic process (GO:0043524); anterograde (GO:0008089) and 
retrograde (GO:0008090) axonal transport; NF bundle assembly 
(GO:0033693); NF cytoskeleton organization (GO:0060052); MAPK 
cascade (GO:0000165); MT cytoskeleton organization(GO:0000226); 
intermediate filament polymerization or depolymerization (GO:0045105) 
[78] 
Demyelinating neuropathy Charcot-
Marie-Tooth disease 1F, and axonal 
neuropathy Charcot-Marie-Tooth 
disease 2E 
Tissue enriched 
(cerebral cortex) 
P61981 14-3-3 protein gamma; YWHAG 
28 / 
31 
regulation of neuron dif. (GO:0045664); regulation of synaptic plasticity 
(GO:0048167); cellular response to insulin (GO:0032869); membrane 
organization (GO:0061024); positive regulation of protein insertion into 
mitochondrial membrane involved in apoptotic signaling pathway 
(GO:1900740) 
[79, 
80]  
Increased 
expression in 
AD, decreased 
in Down 
Syndrome, 
present in Lewy 
bodies in PD 
[79]. 
Id as APP 
interactor in 
mouse brain 
[77]. 
P62158 Calmodulin; CALM1/2/3 2 / 5 
NT release; regulates expression of synaptic proteins; mediates calcium 
signal involved in growth cone guidance and dendrite growth 
[81, 
82] 
Downregulated in AD substantia 
nigra samples [83].  
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Uniprot 
nr 
Gene name and 
symbol 
k at 
D3 / 
D7 
Biological Process Ref Mammalian phenotype/ human diseases Expression 
P11142 
Heat shock 
cognate 71 kDa 
protein; HSPA8 
7 / 
10 
neurotransmitter secretion (GO:0007269); regulation of cell cycle 
(GO:0051726); cell-cell adhesion (GO:0098609) 
[71, 
84]   
P35579 Myosin-9; MYH9 
11 / 
23 
cell morphogenesis involved in dif. (GO:0000904); regulation of cell 
shape (GO:0008360); cell adhesion(GO:0007155); integrin-mediated 
signaling (GO:0007229); actin filament-based movement (GO:0030048); 
actomyosin structure organization (GO:0031032); actin cytoskeleton 
reorganization (GO:0031532); negative regulation of actin filament 
severing (GO:1903919) 
[73]  
Id as APP 
interactor in 
mouse brain 
[77]. 
Q15149 Plectin; PLEC 7 / 7 
hemidesmosome assembly (GO:0031581); cell-cell adhesion 
(GO:0098609) 
[85, 
86]   
 
Table B.5 - DephosphoS655 APP associated protein interactors present only in differentiation day 3, and with potential interest for neuronal differentiation. Proteins were 
selected based on functional annotations directly related to brain development, neuron function, neurogenesis, and/or neuronal differentiation related events (cytoskeleton organization, 
cell adhesion, and cell migration) and signaling pathways. In bold are the UniProt accession number of newly identified APP interactors. The gene ontology terms determinant for the 
selection are described in the biological process column. Node degree (‘k’), is the number of interactors the protein presents and refers to the position of the protein inside the protein-
protein interaction network that includes all the interactors identified for differentiation day 3. ‘Ref’, indicates references retrieved from the PubMed supporting the role of the indicated 
interactor in neuronal differentiation. ‘Mammalian phenotype/human diseases’, KO mouse phenotypes were searched on Jackson Laboratories mouse knockout database, and human 
diseases retrieved from UniProt and other indicated references. ‘Expression’, brain enrichment or altered expression in RA-differentiated SH-SY5Y cells are indicated. ‘Dif.’ – 
differentiation; ‘Reg.’ – regulation; ‘PM’ – plasma membrane; ‘PD’ – Parkinson’s disease. 
Uniprot 
nr 
Gene name and 
symbol 
K 
D3 Biological Process Ref Mammalian Phenotype Expression 
Q6Y7W6 
PERQ amino acid-rich 
with GYF domain-
containing protein 2; 
GIGYF2 
7 
post-embryonic development (GO:0009791); spinal cord motor 
neuron dif. (GO:0021522); insulin-like growth factor receptor 
signaling (GO:0048009); homeostasis of number of cells within a 
tissue (GO:0048873); cell-cell adhesion (GO:0098609) 
[46] 
motor neuron degeneration; impaired 
coordination; abnormal movement; 
neurodegeneration; abnormal neuron 
number; postnatal lethality, incomplete 
penetrance; neonatal lethality, incomplete 
penetrance [47]; Involvement in PD 11. 
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Uniprot 
nr 
Gene name and 
symbol 
K 
D3 Biological Process Ref Mammalian Phenotype Expression 
Q8NC56 
LEM domain-
containing protein 2; 
LEMD2 
2 neurogenesis(GO:0022008); negative reg. of MAPK cascade (GO:0043409); negative reg. of BMP signaling (GO:0030514) - 
increased apoptosis, decreased cell 
proliferation and abnormal morphology of 
embryonic neuroepithelium; absent 
embryonic telencephalon; abnormal retinal 
neuronal layer, and dorsal root ganglion 
morphology; impaired neuron dif.; 
embryonic lethality during organogenesis, 
complete penetrance [48]. 
 
P51116 
Fragile X mental 
retardation syndrome-
related protein 2; 
FXR2 
11 
positive translation reg. of PSD95 mRNA (mouse hippocampus); 
role in neuronal dendritic development (binds, stabilizes, and 
expression enhancement of GluA1 mRNA); FXR2 deficiency in 
dendate gyrus neural stem cells enhances cell proliferation and 
dif. (by reg. Of Noggin expression) 
[49-
51] 
hyperactivity; abnormal locomotor activity, 
sensimotor gating, and cognitive function; 
altered hippocampal synaptic plasticity [52-
54]. 
High 
expression in 
the brain [55]. 
P61978 
Heterogeneous nuclear 
ribonucleoprotein K; 
HNRNPK 
20 
CNS (GO:0007417) and PNS (GO:0007422) development; 
cerebellum (GO:0021549), hippocampus (GO:0021766), and 
cerebral cortex development (GO:0021987); positive reg. of 
neuron projection development (GO:0010976); positive reg. of 
dendrite extension (GO:1903861), dendritic spine development 
(GO:0060999), synapse maturation (GO:0090129), synaptic 
transmission (GO:0050806), and long-term synaptic potentiation 
(GO:1900273); negative reg. of branching morphogenesis of a 
nerve (GO:2000173); aging (GO:0007568); cellular response to 
insulin (GO:0032869); negative reg. of apoptotic process 
(GO:0043066). 
[87, 
88] Au-Kline syndrome (intellectual disability).  
Q8TF72 Protein Shroom3; SHROOM3 4 
cell morphogenesis (GO:0000902); neural tube closure 
(GO:0001843); reg. of cell shape (GO:0008360). 
[89-
91] 
open neural tube in 100% of mice, which 
leads to exposure of the forebrain 
neuroepithelium (exencephaly) [92].  
Results  Chapter 7 
University of Aveiro   185 
Uniprot 
nr 
Gene name and 
symbol 
K 
D3 Biological Process Ref Mammalian Phenotype Expression 
Q12959 Disks large homolog 1; DLG1 0 
nervous system development (GO:0007399); chemical synaptic 
transmission (GO:0007268); reg. of myelination (GO:0031641); 
receptor localization to synapse (GO:0097120); APP metabolic 
process (GO:0042982); establishment or maintenance of cell 
polarity (GO:0007163); positive reg. of cell proliferation 
(GO:0008284); reg. of cell shape (GO:0008360); positive reg. of 
actin filament polymerization (GO:0030838); cortical actin 
cytoskeleton organization (GO:0030866); cortical MT 
organization (GO:0043622); negative reg. of ERK1 and ERK2 
(GO:0070373); bicellular tight junction assembly (GO:0070830); 
reg. of NIK/NF-kB signaling (GO:1901222). 
[93] abnormal dendrite morphology [94].  
P21741 Midkine; MDK 0 
cerebral cortex (GO:0021987), hippocampus (GO:0021766), 
dentate gyrus (GO:0021542), and cerebellar granular layer 
development (GO:0021681); short-term memory (GO:0007614); 
Notch signaling pathway (GO:0007219); cell migration 
(GO:0016477); cell dif. (GO:0030154); negative reg. of neuron 
apoptotic process (GO:0043524). 
[95, 
96] abnormal hippocampus development [97].  
Q8NFD5 
AT-rich interactive 
domain-containing 
protein 1B; ARID1B 
0 nervous system development (GO:0007399) [98] 
Coffin-Siris syndrome (malformations of the 
CNS, intellectual disability and speech 
impairment).  
Q16352 Alpha-internexin; INA 0 
nervous system development (GO:0007399); substantia nigra 
development (GO:0021762); cell dif. (GO:0030154); NF 
cytoskeleton organization (GO:0060052); intermediate filament 
cytoskeleton organization (GO:0045104) 
[61]  
Group 
enriched 
(adrenal gland, 
cerebral 
cortex) 
Q6DN90 
IQ motif and SEC7 
domain-containing 
protein 1; IQSEC1 
0 
reg. of ARF protein signal transduction (GO:0032012); positive 
reg. of GTPase activity (GO:0043547); actin cytoskeleton 
organization (GO:0030036) 
[99]   
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Table B.6 - DephosphoS655 APP associated protein interactors present only in differentiation day 7, and with potential interest for neuronal differentiation. Proteins were 
selected based on functional annotations directly related to brain development, neuron function, neurogenesis, and/or neuronal differentiation related events (cytoskeleton organization, 
cell adhesion, and cell migration) and signaling pathways. In bold are the UniProt accession number of newly identified APP interactors. The gene ontology (GO) terms determinant for 
the selection are described the biological process column. Node degree (‘k’), is the number of interactors the protein presents and refers to the position of the protein inside the protein-
protein interaction network that includes all the interactors identified for differentiation day 7. ‘Ref’, indicates references retrieved from the PubMed supporting the role of the indicated 
interactor in neuronal differentiation. ‘Mammalian phenotype/human diseases’, KO mouse phenotypes were searched on Jackson Laboratories mouse knockout database, and human 
diseases retrieved from UniProt and other indicated references. ‘Expression’, brain enrichment or altered expression in RA-differentiated SH-SY5Y cells are indicated. ‘Dif.’ – 
differentiation; ‘Reg.’ – regulation; ‘PM’ – plasma membrane; ‘AD’ - Alzheimer’s disease; ‘PD’ – Parkinson’s disease. 
Uniprot 
nr 
Gene name and 
symbol k Biological Process Ref Mammalian Phenotype Expression 
P16949 Stathmin; STMN1 2 
cell dif. (GO:0030154); nervous system development 
(GO:0007399); neuron projection development 
(GO:0031175); axonogenesis (GO:0007409); brain 
development (GO:0007420); reg. of cytoskeleton 
organization (GO:0051493); reg. of MT 
polymerization or depolymerization (GO:0031110); 
MT depolymerization (GO:0007019); negative reg. of 
MT polymerization (GO:0031115). 
[100] abnormal nervous system morphology; abnormal brain morphology; axon degeneration; demyelination [101].  
P09382 Galectin-1; LGALS1 2 
negative reg. of neuron projection development 
(GO:0010977); response to axon injury 
(GO:0048678); negative reg. of cell-substrate 
adhesion (GO:0010812); reg. of apoptotic process 
(GO:0042981); positive reg. of I-kB kinase/NF-kB 
signaling (GO:0043123) 
[102] 
abnormal dorsal root ganglion, sensory neuron, nociceptor, 
mechanoreceptor, and  olfactory sensory neuron 
morphology [103, 104]; 
increased number of neural precursor cells; impaired 
memory formation [105]. 
 
P62826 
GTP-binding 
nuclear protein 
Ran; RAN 
4 
hippocampus development (GO:0021766); actin 
cytoskeleton organization (GO:0030036); cell division 
(GO:0051301); cell-cell adhesion (GO:0098609) 
[106]   
Results  Chapter 7 
University of Aveiro   187 
Uniprot 
nr 
Gene name and 
symbol k Biological Process Ref Mammalian Phenotype Expression 
Q06787 
Fragile X mental 
retardation protein 
1; FMR1 
1 
positive reg. of dendritic spine development 
(GO:0060999); negative reg. of long term synaptic 
depression (GO:1900453); negative reg. of synaptic 
vesicle exocytosis (GO:2000301); positive reg. of 
receptor internalization (GO:0002092); glutamate 
receptor signaling (GO:0007215); positive reg. of 
filopodium assembly(GO:0051491) 
[37, 
49, 
82] 
decreased Purkinje cell number, and abnormal 
morphology; abnormal brain morphology; abnormal CNS 
synaptic transmission; abnormal hippocampal mossy fiber 
and  pyramidal cells morphology; abnormal nerve fiber 
response; abnormal neuronal precursor proliferation; 
abnormal neuron dif., and dendritic spine morphology; 
abnormal learning/memory/conditioning [53, 54, 107-109] 
; gene mutations cause fragile X syndrome; Fragile X 
tremor/ataxia syndrome. 
High expression 
in the brain 
[55]. 
P62258 14-3-3 protein epsilon; YWHAE 8 
neuron migration (GO:0001764); substantia nigra 
(GO:0021762), hippocampus (GO:0021766), and 
cerebral cortex development (GO:0021987); hippo 
signaling (GO:0035329); membrane organization 
(GO:0061024); cell-cell adhesion (GO:0098609) 
[79, 
110] 
abnormal neuronal migration; abnormal hippocampus 
pyramidal cell layer; perinatal lethality, complete 
penetrance; perinatal lethality, incomplete penetrance 
[111]; gene deletion in Miller-Dieker syndrome; 
Increased 
expression in 
AD, present in 
Lewy bodies in 
Parkinson 
disease PD [79]. 
Id as APP 
interactor in 
mouse brain 
[77]. 
P63104 
14-3-3 protein 
zeta/delta; 
YWHAZ 
93 
negative reg. of apoptotic process (GO:0043066); 
membrane organization (GO:0061024); positive reg. 
of protein insertion into mitochondrial membrane 
involved in apoptotic signaling pathway 
(GO:1900740); cell-cell adhesion(GO:0098609) 
[79, 
110] 
abnormal neuronal migration; abnormal dendrite 
morphology; abnormal hippocampus pyramidal cell layer; 
abnormal hippocampus granule cell morphology; ectopic 
hippocampus pyramidal cells; 
postnatal lethality, incomplete penetrance [112]; 
Present in AD 
tangles, and 
Lewy bodies in 
PD [79]. 
Id as APP 
interactor in 
mouse brain 
[77]. 
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Uniprot 
nr 
Gene name and 
symbol k Biological Process Ref Mammalian Phenotype Expression 
P27797 Calreticulin; CALR 4 
negative reg. of neuron dif. (GO:0045665); cell cycle 
arrest (GO:0007050); positive reg. of cell proliferation 
(GO:0008284), and of substrate adhesion-dependent 
cell spreading (GO:1900026); cortical actin 
cytoskeleton organization (GO:0030866); reg. of 
apoptotic process (GO:0042981); negative reg. of 
RAR signaling pathway (GO:0048387); positive reg. 
of NIK/NF-kB signaling(GO:1901224) 
[113] Brain defects: defects in neural tube closure and exencephaly [114].  
P46821 
MT-associated 
protein 1B; 
MAP1B 
1 
nervous system development (GO:0007399); positive 
reg. of axon extension (GO:0045773); axonogenesis 
(GO:0007409); dendrite development (GO:0016358); 
MT cytoskeleton organization(GO:0000226); MT 
bundle formation(GO:0001578); 
[82, 
115]  
Tissue enhanced 
(cerebral cortex) 
P80723 Brain acid soluble protein 1; BASP1 3 substantia nigra development (GO:0021762) [116] 
abnormal cerebral cortex and hippocampus morphology; 
abnormal Schwann cell morphology; abnormal neuron 
morphology and axon extension; abnormal motor nerve 
collateral sprouting; postnatal lethality, incomplete 
penetrance [117]. 
Tissue enhanced 
(cerebral cortex) 
P23528 Cofilin-1; CFL1 6 
reg. of dendritic spine morphogenesis (GO:0061001); 
actin filament depolymerization (GO:0030042);  Rho 
protein signal transduction (GO:0007266); reg. of cell 
morphogenesis (GO:0022604); actin cytoskeleton 
organization (GO:0030036); negative reg. of apoptotic 
process (GO:0043066) 
- 
abnormal neural tube morphology; premature neuronal 
precursor dif. and abnormal proliferation; abnormal neuron 
dif., axon extension, and neurite morphology; postnatal 
lethality, incomplete penetrance; prenatal lethality, 
complete penetrance; enlarged brain ventricles; decreased 
embryonic neuroepithelium thickness [118, 119]. 
 
O43175 
D-3-
phosphoglycerate 
dehydrogenase; 
PHGDH 
1 
brain (GO:0007420) and spinal cord development 
(GO:0021510); glial cell development (GO:0021782); 
neural tube development (GO:0021915); neuron 
projection development (GO:0031175); 
neurogenesis(GO:0022008); GABA metabolic process 
(GO:0009448) 
[120] 
decreased brain size; abnormal embryonic neuroepithelial 
layer dif.; absent cerebellum; abnormal brain development; 
exencephaly; decreased brain weight; abnormal neuron 
dif.; embryonic lethality during organogenesis, complete 
penetrance [121]; Neu-Laxova syndrome 1 (CNS 
anomalies: lissencephaly, cerebellar hypoplasia and/or 
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Uniprot 
nr 
Gene name and 
symbol k Biological Process Ref Mammalian Phenotype Expression 
abnormal/ agenesis of the corpus callosum), 
Phosphoglycerate dehydrogenase deficiency 
(microcephaly, psychomotor retardation). 
P08670 Vimentin; VIM 16 
negative reg. of neuron projection development 
(GO:0010977); movement of cell or subcellular 
component (GO:0006928); intermediate filament 
organization (GO:0045109); Bergmann glial cell dif. 
(GO:0060020); SMAD protein signal transduction 
(GO:0060395) 
[39] abnormal Purkinje cell dendrite morphology [40]. 
RA dif SH-
SY5Y regulated 
gene [36, 41]. 
P62995 
Transformer-2 
protein homolog 
beta; TRA2B 
8 cerebral cortex regionalization (GO:0021796); embryonic brain development (GO:1990403) - 
conditional KO mouse: extensive apoptosis of NPC, 
defects in dif. of cortical layers and development of 
projection neuron axons, massive apoptosis in the 
ventricular layers of the cortex, die immediately after birth 
[122, 123]. 
 
P06748 Nucleophosmin; NPM1 38 
reg. of neuron apoptotic process (GO:0043523); cell 
aging (GO:0007569); positive(GO:0008284) and 
negative (GO:0008285) reg. of cell proliferation; 
negative reg. of apoptotic process (GO:0043066); 
positive reg. of NF-kB transcription factor activity 
(GO:0051092) 
[124] abnormal brain morphology [125].  
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7.4.4.!The phosphoS655 APP interactome 
This category included interactors present uniquely in the APPSE condition, and the interactors 
common to both APPWt and APPSE conditions. On differentiation D3 we were able to identify 15 
APP protein interactors specific of phosphorylated APP655 at this time point, and at differentiation 
D7 we identified 23 APP S655E protein interactors. Comparing with the other aforementioned 
groups, this category had considerably less protein interactors. The sub-networks were mainly 
composed of isolated nodes, and functional enriched analysis did not retrieve any significant 
results. For these reasons, specifically for the phosphoS655 APP interactome, we performed 
network augmentation by increasing our protein-protein interaction network with known protein 
partners (in blue) of our protein interactors input list (in pink). To control the network complexity, 
we only add blue nodes with a minimum node degree of 2 (i.e., proteins that bind to at least two of 
our experimentally identified interactors). Differentiation day 3 “augmented” network had 46 
nodes with 96 edges (Figure B.21 A; note that the interactor UPS17L3, Uniprot accession number 
A6NCW0, a described APP interactor also detected by us, was not mapped by the cystoscape). 
APP connected to 15 known protein interactors, 4 of which now identified by us as S655-
phosphorylation dependent: CNBP, COL14A1, FAM184A, and PRDX2. Other protein interactors 
identified by us which stand out based on their node degree included: histone H4 (k = 18) and 
histone H1.2 (k = 16), and PRDX2 (k = 17). The differentiation D7 “augmented” network had 126 
nodes with 278 edges (Figure B.22 A; note that the interactors DNAH12 and IGHV3, Uniprot 
accession number Q6ZR08 and P01765, were not mapped by the cystoscape). APP connected to 15 
already described protein interactors, 5 of which here identified by us as S655 phosphorylation 
dependent: CAPRIN1, CLP1, FUBP3, HNRNPA1, RPS14. Within this network, detected protein 
interactors highlighted due to their high node degree include: HNRNPA1 (k = 49), PPPICB (k = 
35), and the ribosomal proteins RPS14 (k = 33), RPS27 (k = 19), RPL12 (k = 21), and RBM14 (k = 
18). Curiously, some proteins attributed by network augmentation have been also identified in this 
work, although allocated to a different S655 phosphorylation category. Interestingly, functional 
enrichment analysis of the phosphoS655 APP interactome after network augmentation assigned 
modulatory roles in various relevant signaling pathways (as neurotrophic and apoptotic signaling) 
to the D3 and D7 interactors (Figure B.21 B; Figure B.22 B; Table B.7). These include roles in the 
FoxO signaling pathway, in the regulation of EGFR signaling, response to NGF signaling, and 
beta-tubulin binding/GABA receptor binding (these last functions relate to the presence of 
GABARAP, GABARAPL1, and GABARAPL2). Interestingly, D7 had a high number of proteins 
associated with: cell response to TGFbeta, signal transduction by p53 class mediator and negative 
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regulation of cell death (Table B.7); TNF signaling pathway (p = 9.4E-3), tight junction (p = 700E-
6) and focal adhesion (p = 8.5E-3) (Figure B.22 B).  
 
Figure B.21 - PhosphoS655 APP interactome at differentiation day 3. A. Expanded phosphoS655 APP protein-protein 
interaction network. APP interacting proteins experimentally identified in this work are presented in pink. The protein-
protein interaction network was augmented to include known interactors of the identified proteins (nodes in blue); to 
reduce complexity, only blue nodes with a minimum node degree of 2 were maintained and here presented. Black marked 
nodes indicate APP interactors that might have special interest for neuronal differentiation studies. B. Enriched molecular 
functions and KEGG pathways gene ontology terms. The enrichment analysis was performed using the Cytoscape app 
ClueGO; only terms with pvalue < 0.05 are represented. The genes associated with each term were added using the 
CluePedia app. 
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Figure B.22 - PhosphoS655 APP interactome at differentiation day 7. A. Expanded phosphoS655 APP protein-protein 
interaction network. APP interacting proteins experimentally identified in this work are presented in pink. The protein-
protein interaction network was augmented to include known interactors of the identified proteins (nodes in blue), which 
bind to at least two of the here identified APP interactors (blue nodes with a minimum node degree of 2). Black marked 
nodes indicate the APP interactors that might have special interest for neuronal differentiation studies. B. Enriched 
KEGG pathways gene ontology terms. The enrichment analysis was performed using the Cytoscape app ClueGO, only 
terms with pvalue < 0.05 are represented. The genes associated with each term were added using the CluePedia app. 
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Table B.7 - Enriched biological processes (BP) and molecular functions (MF) attributed to the phospho655 APP 
interactome and with interest for neuronal differentiation. The enrichment analysis was performed using the 
Cytoscape app ClueGO. D3 and D7, differentiation days 3 and 7, respectively. GO term, the enriched term attributed. GO 
source, the gene ontology sources, namely molecular function (MF), biological processes (BP), and KEGG pathways. 
Pvalue, calculated pvalue with Bonferroni correction; % genes, percentage of proteins (here by the gene name) associated 
to the attributed enriched term; ID, the gene names of the proteins associated with the attributed enriched terms. EGFR, 
Epidermal growth factor receptor; NGF, Nerve growth factor; TGF, Transforming growth factor. 
Dif. 
day GO term 
GO 
source PValue % Genes ID 
D3 
regulation of EGFR signaling 
pathway BP 1.4E-3 4.94 APP, EGFR, ESR2, GRB2 
cellular response to NGF stimulus BP 2.6E-3 7.89 APP, EIF4A3, NFKB1 
receptor internalization BP 12.0E-3 3.45 ARRB1, CD81, GRB2 
D7 
regulation of EGFR signaling 
pathway BP 27.0E-3 6.17 APP, ESR1, ESR2, GRB2, NCK2 
positive regulation of actin filament 
polymerization BP 32.0E-3 3.00 GRB2, MAP3K1, NCK2 
cellular response to TGFbeta 
stimulus BP 49.0E-3 3.01 
ARRB2, FN1, JUN, MAP3K1, NEDD8, 
PPP1CB, SNW1, WWOX 
intracellular estrogen receptor 
signaling pathway BP 41.0E-3 7.84 ESR1, ESR2, RBM14, SAFB 
cellular response to estrogen 
stimulus BP 24.0E-3 9.30 ESR1, ESR2, HNRNPD, MDM2 
signal transduction by p53 class 
mediator BP 41.0E-3 3.59 
CDK2, MDM2, SNW1, TAF9, TP53BP2, 
USP10, WWOX 
intrinsic apoptotic signaling pathway BP 10.0E-3 3.12 
IKBKE, LRRK2, NCK2, RIPK3, SNW1, 
TAF9, TNFRSF1B, TP53BP2, WWOX, 
YWHAZ 
negative regulation of neuron death BP 38.0E-3 3.65 ESR1, ESR2, FOXB1, IKBKG, ILK, JUN, LRRK2 
posttranscriptional gene silencing by 
RNA BP 3.6E-3 9.80 
AGO1, AGO2, CLP1, HNRNPA2B1, 
RBM3 
production of miRNAs involved in 
gene silencing by miRNA BP 3.3E-3 16.00 AGO1, AGO2, HNRNPA2B1, RBM3 
GABA receptor binding MF 4.2E-3 20.00 GABARAP, GABARAPL1, GABARAPL2 
beta-tubulin binding MF 30.0E-3 8.11 GABARAP, GABARAPL1, GABARAPL2 
cell adhesion molecule binding MF 30.0E-3 3.00 ACTN1, ACTN4, FN1, ILK, RPL10, VCAM1 
integrin binding MF 4.5E-3 5,17 ACTN1, ACTN4, FN1, ILK, RPL10, VCAM1 
p53 binding MF 4.2E-3 6,94 MDM2, TAF9, TP53BP2, USP10, YBX1 
receptor signaling protein 
serine/threonine kinase activity MF 22.0E-3 5,80 IKBKE, MAP3K1, MAPK13, RIPK3 
 
Functional annotation of individual protein interactors here detected, allowed to discriminate 
phosphoS655 APP protein interactors that might be of special interest for neuronal differentiation 
studies (Table B.8). Since some of the interactors belong to another category at a different 
differentiation day (Supplementary Table B.3), the interactors were divided into ‘exclusive’ or 
‘enriched at a given time point of differentiation. In general, functional annotation of individual 
proteins revealed that from the 11 exclusive phosphoS655 APP interactors identified at D3, 8 
(GINS3, DSP, USP17L3, GSDMA, OPTN, CRNN, COL14A1, SPRR3) (73%) can be associated 
to the regulation of epithelial cell division, apoptosis and differentiation. Other 2 are involved in 
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mRNA processing: PPIH, a chaperone involved in RNA splicing, and CNBP, a zinc finger protein 
that binds translation-related mRNAs in response to growth factors and heat shock. The four D3-
enriched phospho655 interactors include 2 histones that are associated with negative regulation of 
cell growth (HIST1H4A, and HIST1H1C), and 2 interactors involved in redox regulation, cellular 
response to drug and regulation of cell growth: MT2A, and Peroxiredoxin-2. From the 23 proteins 
that only interact with S655E APP at D7, 9 are exclusive phosphoS655 APP interactors, and 14 are 
enriched at this time point. From the 9 exclusive phosphoS655 APP interactors identified at D7, 3 
are involved in mRNA maturation and translation: 2 polyadenylation complex members/factors 
that may also regulate mRNA decay (SYMPK, CLP1), and a 60S ribossomal protein (RPL12). 
DNAH12 is a dynein, and the remaining 4 exclusive interactors appear to regulate (directly or 
indirectly) cell signaling: FAM20B catalyzes proteoglycans; PLPP6 is a phospholipid phosphatase 
that decreases the rate of phosphatidylinositol synthesis; ApoD is involved in lipid metabolism; 
FUBP3 binds to the 3'-UTR of FGF9 mRNA and promotes the expression of FGF9 [126]. Nine of 
the 14 (64.3%) D7-enriched phospho655 interactors are RNA binding and RNA 
processing/translation regulators: RPS14, RPS27, CPSF7, CLP1, FUBP3, KHDRBS3, RPL12, 
CAPRIN1, and ELAVL4. We considered three phosphoS655 APP protein interactors to be of 
particular interest for neuronal differentiation events at D3, and five (2 exclusive and 3 enriched) at 
D7 (Table B.8). Of note, on D3 all the three assigned proteins are one node away from PRDX2, a 
protein with high node degree, within the “augmented” network (see Figure B.21 A). On D7, 
SHROOM3 and CAPRIN1 are connected by integrin-linked protein kinase (ILK). 
7.4.5.!APP S655 phosphomimetic mutants are associated with specific cell phenotypes 
To complement our APP interactome results, we analyzed cell morphology parameters related with 
neuronal-like differentiation. From the F-actin analysis, we distinguished three different 
phenotypes accordingly to the organization of the actin filaments: a fibrous phenotype with cells 
that shown mainly long actin stress fibers that cross all cell (‘Fibers’, Figure B.23 A); a cortical 
phenotype, where it is visible disorganization of actin fibers within the cell body and clumping of 
F-actin at the periphery, beneath the plasma membrane (‘Cortical’, Figure B.23 A); and an 
intermediate phenotype, showing less stress fibers and some spots of F-actin polymerization within 
the cell body (‘Intermediate’, Figure B.23 A). Very interestingly, the three phenotypes showed 
different patterns of F-actin distribution according with each APP cDNA. Thus, for S655A APP-
GFP transfected cells differentiated for 4 days, stabilization of stress fibers was more affected, as 
these cells showed higher number of cortical cells at the expense of intermediate and fibers 
phenotypes (Figure B.23 A). S655E APP-GFP presented was the APP cDNA less affected 
comparing to control N1 –EGFP expressing cells, for this differentiation time period. We further 
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proceed to characterize the neuronal-like differentiation, and measure the number of processes per 
cell by category, namely: all processes of all sizes (‘Total’), processes higher than 20 µm, and 
processes higher than 35 µm (Figure B.23 B). In general, S655E APP-GFP expression favors the 
elongation of processes and shows higher percentage of differentiated cells (Figure B.23). 
 
Figure B.23 - Effects of overexpressing the APP S655 phosphomimetic mutants S655A and S655E in SH-SY5Y 
differentiation. A. Cells were differentiated with 10 µM RA for 2 days and transfected for the last 48h with the different 
APP cDNAs to analyse their effect on filamentous actin (F-actin) distribution. Scale bar, 10 µm. Arrows indicate 
transfected cells presenting actin depolymerization. B. Cells were scored based on their F-actin organization: Fibers, 
presence of F-actin stress fibers throughout the cell; Cortical, F-actin fibers accumulated at the cell periphery and short 
disorganized fibers within the cell body; Intermediate, not entirely cortical, and exhibiting reduced number of stress 
fibers together with F-actin spots within the cell body. Results are show as a percentage of the total number of cells (75-
100 cells analysed per replica, at least 3 independent replicas). *, p <0.05.  C. Cells were exposed to 10 µM RA for 6 
days and transfected for the last 48h with the different APP cDNAs to analyse their effect on neurite elongation. Scale 
bar, 20 µm. D. Processes ≥20 µm were measured and their mean length calculated. */#, p<0.05 by unpaired t-test (after 
Ln transformation of data) against control empty vector or APPSA, respectively. E. Processes were categorized 
accordingly to their length, and the percentage of the different types calculated in relation to the total number of 
processes per cell. Processes ≥35 µm are considered differentiated neurites. */#, p<0.05; **/##, p<0.01 by Mann Whitney 
test against control empty vector or APPSA, respectively. Note that for 20-35 µm processes, APPSA vs APPWt had 
p=0.0536; for 35-50 µm processes APPWt vs APPSE or APPSA had p=0.0513 and p=0.0556, respectively. F. The 
percentage of neurites per cell. **/##, p<0.01 by Mann Whitney test against control empty vector or APPSA, 
respectively. Note that APPWt against APPSE had p=0.0596. 
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Table B.8 - PhosphoS655 APP protein interactors with potential interest for neuronal differentiation. From the total phosphoAPP interactome, proteins were selected based on 
functional annotations directly related to brain development, neuron function, neurogenesis, and/or neuronal differentiation related events (cytoskeleton organization, cell adhesion, and 
cell migration) and signaling pathways. In bold are the UniProt accession number of newly identified APP interactors. The gene ontology (GO) terms determinant for the selection are 
described in the biological process column. Node degree (‘k’), is the number of interactors the protein presents and refers to the position of the protein inside the protein-protein 
interaction network that includes all the interactors identified for each differentiation day. ‘Ref’, indicates references retrieved from the PubMed supporting the role in neuronal 
differentiation. ‘Mammalian phenotype/human diseases’, KO mouse phenotypes were searched on Jackson Laboratories mouse knockout database, and human diseases retrieved from 
UniProt and other indicated references. ‘Expression’, brain enrichment or altered expression in RA-differentiated SH-SY5Y cells are indicated. ‘Dif.’ – differentiation; ‘Reg.’ – 
regulation; ‘PM’ – plasma membrane. 
Uniprot nr Gene name and symbol k Biological Process Ref Mammalian Phenotype Expression 
phosphoS655 exclusive interactors at D3 
Q96CV9 Optineurin; OPTN 4 
negative regulation of receptor recycling 
(GO:0001920); negative regulation of I-
kappaB kinase/NF-kappaB 
[127-
129] Amyotrophic lateral sclerosis type 12 
Found in disease-
specific bodies or 
inclusions in a variety 
of neurodegenerative 
conditions [130]. 
P15924 
Desmoplakin; 
DSP 
 
2 
desmosome (GO:0002934) and adherens 
junction organization (GO:0034332); protein 
localization to adherens junction 
(GO:0071896); intermediate filament 
cytoskeleton organization (GO:0045104) 
[86, 
131] 
Conditional KO in motoneurons (evaluation 7 
days after quadriceps femoris nerve crush): 
delayed axon extension; abnormal sciatic nerve 
morphology (worse sciatic functional index, 
slower recovery, worse toe spreading); impaired 
ability to fire action potentials  and decreased 
nerve conduction velocity; reduced number and 
delayed regeneration of motor fibers [131] 
 
P62633 
Cellular nucleic acid-
binding protein; 
CNBP 
9 
cholesterol biosynthetic process 
(GO:0006695); positive regulation of cell 
proliferation (GO:0008284); positive 
regulation of transcription, DNA-templated 
(GO:0045893) 
[132, 
133] 
abnormal cephalic neural fold, and embryonic 
neuroepithelium morphology; decreased 
embryonic neuroepithelial cell proliferation; 
decreased forebrain size, absent diencephalon and 
telencephalon [134]. 
 
phosphoS655 exclusive interactors at D7 
Q92989 
Polyribonucleotide 5'-
hydroxyl-kinase Clp1; 
CLP1 
 
1 cerebellar cortex development (GO:0021695) [135] 
motor neuron degeneration; 
decreased motor neuron number; decreased brain 
weight; increased neuron apoptosis; abnormal 
axon morphology; axon degeneration; thin 
cerebral cortex; decreased neuron number; 
neonatal lethality, complete penetrance; 
embryonic lethality, complete penetrance; 
lethality, complete penetrance [136]; 
Pontocerebellar hypoplasia 10 [137]. 
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Uniprot nr Gene name and symbol k Biological Process Ref Mammalian Phenotype Expression 
P05090 Apolipoprotein D; APOD 0 
brain development (GO:0007420); PNS axon 
regeneration (GO:0014012); tissue 
regeneration (GO:0042246); response to axon 
injury (GO:0048678); negative regulation of 
focal adhesion assembly (GO:0051895) 
[138, 
139] 
abnormal motor learning, abnormal spatial 
learning, abnormal spatial reference memory, 
decreased vertical activity, and hypoactivity; 
increase in levels of lipid peroxides in the brain 
(not in the lung) [140]. 
Up-regulated during 
brain aging and in 
many 
neurodegenerative 
diseases [141, 142]. 
phosphoS655-enriched interactors at D7 
P26378 ELAV-like protein 4; ELAVL4 0 
learning (GO:0007612); dendrite 
morphogenesis (GO:0048813) [34] 
increased neuron apoptosis; abnormal nervous 
system development; abnormal neuron 
differentiation [35]. 
Tissue enhanced 
(cerebral cortex); 
RA dif SH-SY5Y 
regulated gene [36]. 
Q8TF72 Protein Shroom3; SHROOM3 4 
cell morphogenesis (GO:0000902); neural tube 
closure (GO:0001843); regulation of cell shape 
(GO:0008360) 
[89-
91] 
open neural tube in 100% of mice, which leads to 
exposure of the forebrain neuroepithelium 
(exencephaly) [92].  
Q14444 Caprin-1; CAPRIN1 1 
positive regulation of dendrite morphogenesis 
(GO:0050775) and dendritic spine 
morphogenesis (GO:0061003); cell 
differentiation (GO:0030154) 
[37] 
increased neuron apoptosis; abnormal miniature 
excitatory postsynaptic currents; abnormal neuron 
physiology; abnormal dendrite morphology; 
abnormal synapse morphology [38]. 
 
Chapter 7 Results 
198 University of Aveiro!
7.5.!Discussion 
APP S655 phosphorylation is known to occur in healthy neurons and in AD patients. However, the 
molecular function(s) and mechanisms triggered by this phosphorylation remain elusive. Our group 
has been gathering experimental evidences on specific roles for this phosphorylation using S655 
phosphomimetic APP mutants. In order to begin to unravel the APP protein effectors and 
regulators involved in such roles, we start to characterize the S655 phosphorylation-dependent APP 
interactome. SH-SY5Y cells were differentiated with retinoic acid to a neuronal-like phenotype, 
and transfected at two different time periods with either APPWt or APPS655A/E phosphomimetic 
mutants. All these exogenously expressed APP proteins correspond to the neuron-enriched APP 
isoform 695. The APP proteins and their respective interaction partners were isolated by GFP-trap, 
and identified by MS. By comparing the interactomes of APPWt, APPS65A, and APPS655E we 
were able to obtain differential (sub)interactomes based on the dependency on the S655 
phosphorylation state with differentiation time: the APP S655 phosphorylation-independent 
interactome, the dephosphoS655 APP interactome, and the phosphoS655 APP interactome. The 
‘Total’ APP interactome resulted from the addition of all the interactors here experimentally 
identified. 
The methodology applied has some limitations that should be stated. The first one is related to the 
use of APP overexpression that might lead to incorrect subcellular localization and unspecific 
binding; nevertheless, the immunoprecipitation takes place in vitro, after cells lyses, what increases 
the probability of protein-protein interaction. Secondly, the GFP-fusion tag is located in the APP 
C-terminal. Since APP suffers proteolytic cleavages that originate different APP C-terminal 
fragments, when we perform the GFP pull-down we isolated not only full length APP-GFP and its 
interactors, but also the different APP C-terminal fragments, including AICD, and their interactors. 
Furthermore, we cannot exclude the possibility that the presence of the GFP-fusion tag could 
impair some interactions. A third limitation derives from the cell model applied. Although very 
attractive because of its human origin, ease of access, and the lack of ethical concerns, RA-
differentiated SH-SY5Y cells only mimic to a certain extent neuronal differentiation events and 
function. Specifically, RA-differentiated SH-SY5Y cells have been shown, by genome-wide 
transcriptional analysis, to share some characteristics with dopaminergic neurons [36]. We also 
have to consider that neuronal differentiation events will have many variants depending on the cell 
type. Other limitations to consider are related to the MS technique and the fact that the analysis was 
performed from extracts. For example, this technique does not distinguish a direct interaction from 
an indirect one, and might detect protein-protein interactions that do not occur in vivo just by 
bringing together proteins that exist in different subcellular compartments. MS is also described as 
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biased toward proteins of high expression, and thus might fail to identify interactors of lower 
expression. Additionally, the obtained interactomes most probably miss some interactions between 
APP and membrane proteins and nuclear proteins due to their typical poor solubilization under 
these conditions, and might lack weak or transient interactions. Because of the aforementioned 
reasons, the interactomes presented in this work are not complete, and all the detected protein 
interactors are “potential interactors” that will need further validation. 
In general, we detected more APP protein interactors at D7 than at D3 (‘Total’ APP interactors). 
Accordingly, the differentiation day 7 PPI network is more complex than day 3, showing more 
nodes (342 at D7 vs 284 at D3) and edges (1059 vs 760), smaller percentage of isolated nodes 
(14% vs 20%), and higher clustering coefficient (0.256 vs 0.198). This behavior is also visible for 
the dephosphoS655 APP and the phosphoS655 APP interactomes, separately. Contrarily, the APP 
interactome independent of S655 phosphorylation show a decrease in the number of interactors 
from D3 to D7. Noteworthy, if we look at the specific experimental conditions, while APPWt and 
APPSA shared a high number of protein interactors at D3, APPSA more than triplicates the 
number of unique interactors from D3 to D7. The change in the number of APP protein interactors 
attractively suggests that modulation of APP S655 phosphorylation is more tightly controlled at 
later differentiation periods. The smaller number of phosphoS655 interactors indicates that S655 
phosphorylation leads to a functional sub-specialization (and/or enrichment of sub-specializations), 
as expected.  
Functional enrichment analysis results showed that the most significant attributed functions to the 
APP protein interactors are related to ribonucleoprotein and spliceosomal complex assembly and 
organization, RNA biosynthesis, RNA metabolism, RNA splicing and regulation of RNA splicing, 
translation regulation, and gene expression. Consistent with a role in such functions is the fact that 
the majority of APP interactors detected by us are RBP (including mRNA processing/mRNA 
splicing factors, ribosomal proteins, ribonucleoproteins, translation factors, RNA helicases). 
Additionally, several APP protein interactors belong to the class of DNA-binding proteins and TFs. 
One study involving transcriptome profiling of HEK 293 cells stable overexpressing human APP 
shows that several of the differentially regulated genes are involved in DNA replication, 
transcription and translation regulation (including RNA splicing and ribosome biogenesis). 
Specifically, they show that upregulated genes were involved in regulation of transcription and 
negative regulation of translation, and downregulated genes were involved in DNA replication, 
DNA-dependent transcription, and translation [143]. Transcriptome profiling of pre-frontal cortex 
of adult APPKO mice also show that differentially expressed genes are involved in regulation of 
transcription (either negative or positive) [72]. 
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The AICD fragment of APP has been shown to be involved in the regulation of gene transcription, 
although this issue is still controversial. AICD is known to translocate to the nucleus to form a 
transcriptionally active complex in combination with Fe65 and the histone acetyltransferase Tip60 
[144-146]. Besides its implication in gene transcription regulation, it was already suggested by co-
localization studies that APP C-terminal fragments accumulate in the intranuclear splicing factor 
compartments [147].  
The human brain is the tissue with the highest level of alternatively spliced transcripts, and this 
process affect all aspects of neurodevelopment and function [148]. Also, defects in alternative 
splicing have been implicated in neurological and neurodegenerative diseases [149]. Alternative 
splicing is thus an important APP function that can affect various physiological processes and 
should be further studied. Different alternative splicing choices can alter the structure and activity 
of a protein, alter mRNA localization, translation or decay, and impact the overall expression of a 
newborn protein. Splicing of a given alternative exon can be affected by multiple RBP, and RBPs 
interact dynamically with mRNA, controlling all aspects of mRNA posttranscriptional fate, 
including translation, surveillance and decay [149]. Indeed, RBP actions occur not only in the 
nucleus but also in the cytoplasm. Cytoplasmic actions comprise translation control via transcript 
stabilization, regulation of microRNA binding, regulation of mRNA transport and differential 
localization. These aspects are very important in neurons, where the correct transport, target and 
local translation of mRNA are determinant for neuronal polarity and synaptic plasticity. The 
transcripts of splicing regulators or other RNA binding proteins often contain an alternative exon 
that is controlled by the protein itself or by other RBP. Splicing regulators extensively modulate 
each other’s activity, as well as control the activity of transcriptional regulators. APP might bind 
different RBPs to modulate their function and/or APP could be part of messenger ribonucleoprotein 
complexes, influencing the cellular fates of different mRNAs [150, 151]. 
On differentiation D3, the S655 phosphorylation-independent APP interactome included the 
ELAVL4 protein (Table B.3, D3), a splicing regulatory protein specific of neurons [150]. This 
protein regulates, via different post-transcriptional effects, several mRNAs whose protein products 
(like GAP-43, Tau, AchE, PSD95, Homer 1a, neuritin and CamKIIα) have key roles in neurons. 
ELAVL4 has been implicated in neurogenesis, neuronal survival, and synaptic plasticity during 
learning and memory [150]. Besides the brain phenotype demonstrated by an Elavl4 mouse KO 
(see Table B.3), this protein has been implicated in several human CNS disorders, namely 
Alzheimer’s and Parkinson’s diseases, schizophrenia, amyotrophic lateral sclerosis, and epilepsy 
[34]. Inside the D3 network, ELAVL4 binds the transcription repressor Ewing Sarcoma Protein 
Ewsr1, also allocated to the same category. Ewsr1 KO mouse display a very high post-natal 
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lethality, while in Zebrafish the gene knockdown led to p53-mediated apoptosis in the brain and the 
spinal cord [152].  
Additionally, in the same differentiation day and in the same APP interactome category, we 
identified the previously described APP interactors Caprin-1 and G3BP1, which also interact with 
each other. Both proteins are described to be part of ribonucleoprotein complexes like RNA 
granules and Stress granules [149, 153]. Caprin-1 has been implicated in the control of local 
translation required for synaptic plasticity [38], with part of its actions performed in collaboration 
with one of the best known RBP, the synaptic functional regulator FMR1 (FMRP) [37]. The 
interaction between the FMRP protein and APP was also detected by us, at differentiation D7 in the 
dephosphoS655 APP interactome. This protein binds to approximately 5% of all transcripts present 
in the mammalian brain, modulating several aspects of brain development and function [149]. 
Alterations in FMRP have been reported in several neurodevelopment and psychiatric disorders 
(Fragile X Syndrome, autism, schizophrenia, bipolar disorder, and major depression) [154]. 
Previous work has shown a link between APP and FMRP, with FMRP binding to and repressing 
the APP mRNA, and loss of FMRP (KO mouse) resulting in increased levels of APP [154]. 
Furthermore, RanBP9, a well described APP interactor [155], was described to interact with the c-
terminal of FMR1 in the microtubule organizing center [156]. 
On differentiation D7, the S655 phosphorylation-independent APP interactome included the PERQ 
amino acid-rich with GYF domain-containing protein 2 (GIGYF2) and the Fragile X mental 
retardation syndrome-related protein 2 (FXR2). Both proteins have been implicated in the 
regulation of mRNA translation. The FXR2 protein is a selective RBP, paralog of the FMRP, with 
which it cooperates to regulate the translation of different mRNA targets (for example in the 
positive translation control of PSD95), controlling several aspects of locomotor activity, 
sensorimotor gating, and cognitive processes [53]. FXR2 also functions independently of FMRP 
[49]. GIGYF2 is an mRNA translation silencing protein that competes with the eukaryotic 
initiation factor 4E (eIF4E) and binds to the Argonaute protein AGO2, being part of mRNA 
silencing and decay complexes. Besides its role in mRNA translation, GIGYF2 functions in the 
CNS; the neurodegeneration observed in Gigyf2 KO mice was related to the role of this protein in 
the regulation of endosome signaling, IGF-1 trafficking, and ERK1/2 activation [46, 47]. 
Curiously, at D3 the ELAVL4 and Caprin-1 proteins are allocated to the S655 phosphorylation 
independent category, while at D7 they are included in the phosphoS655 APP interactome 
(Supplementary Table B.3). The GIGYF2 and FXR2 proteins, above described as APP interactors’ 
independent of S655 phosphorylation at D7, are included in the dephosphoS655 APP interactome 
on D3. This phenomenon, although indicative that the interaction with APP itself must be 
independent of the S655 phosphorylation, may also indicate that the different APP backgrounds 
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and/or the differentiation time might affect these protein levels (or the levels of bridge proteins), 
subcellular localization, and post-translational modifications, making the protein more specific or 
enriched in a different APPS655 category at different differentiation times. For example, protein 
levels of neuronal ELAVL are significantly decreased in the hippocampi of AD brain, and 
negatively correlate with the amount of Abeta [157]. On the other hand, APP phosphorylation at 
S655 has been associated to diminished Abeta production [13, 158]. Since neurons have higher 
rates of Abeta production, these might justify the specificity of the presence of ELAVL4 in the 
phosphoS655 APP interactome on the more mature neuronal-like cells of D7. Related to this, it 
would be very interesting to explore how APP and its S655 phosphorylation state alters the protein 
levels of different RBP, and the presence of APP in the different messenger ribonucleoprotein 
complexes (RNA granule, stress granule, polysome, miRISC, etc).  
Functional enrichment analysis of the D7 dephosphoS655 APP interactome attributed as a 
significant biological process ‘protein localization to nuclear body and Cajal body’, due to the 
presence of different subunits of the chaperonin-containing TCP1 complex (CCT2, CCT4, CCT5, 
and CCT8). The main function of this complex appears to be in protein folding (including of actin 
and tubulin monomers), but recently it has been implicated in telomerase function and trafficking 
of telomerase and small Cajal body RNAs to Cajal bodies [159]. Although in our specific 
conditions the retrieval of the CCT proteins from a nuclear localization is less likely (due to poor 
nuclear solubilization), their detection as APP interactors is very interesting due to the previously 
reported APP association to Cajal bodies. Indeed, the well-established AICD-Fe65-TIP60 complex 
was described to be in close proximity with Cajal Bodies and PML bodies [146]. Other significant 
function specifically attributed to the dephosphoS655 APP interactome on differentiation D7 was 
glycolysis. Upon RA differentiation, SH-SY5Y cells increase their rate of glycolysis and there is an 
upregulation of genes involved in this pathway [160]. Neuronal differentiation events are very 
demanding in energetic terms, and a possible role for APP in the glycolysis pathway deserves 
future attention. For instance, it would be interesting to explore if APP and APP S655 
phosphorylation have a role in metabolic reprogramming, namely in the transition from aerobic 
glycolysis in neural progenitor cells to neuronal oxidative phosphorylation [161]. A very 
interesting aspect of the D7 dephosphoS655 APP interactome was the high number of cytoskeleton 
proteins, especially from the actin family, which translated in an overrepresentation of functions 
like cytoskeleton organization, actin and actin filament binding (see Supplementary Table B.6). 
There is no question that alterations in cytoskeleton dynamics are of central importance for 
neuronal differentiation. Rearrangements of actin and microtubules both establishes and maintains 
polarity in neurons, but are also fundamental for other steps like neural progenitor’s proliferation, 
neural migration, and vesicle trafficking [162, 163]. Concordantly, upon 4 days of RA exposure, 
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APPSA overexpression could be particularly associated with actin depolymerization and cortical 
actin distribution (Figure B.23 A). The APP interactors detected that belong to the family of actin 
binding and were already associated with neuronal differentiation events include: cofilin-1 (Table 
B.6), F-actin-capping protein subunit beta, profilin-1, filamin-A (and filamin-B), moesin, and 
thymosin beta-4 (Supplementary Table B.7). Interestingly, APP has been associated before with 
mobile membrane structures like actin-positive and cortactin-rich extending lamellipodia. The APP 
function in such structures seems to depend on the interaction of APP and Fe65 with the actin-
associated protein Mena. Additionally, Mena is known to bind profiling [164, 165]. 
An additionally dephosphoS655 APP protein interactor that we found particularly interesting was 
the MT-destabilizing protein Stathmin. Stathmin expression is regulated during neuronal 
development, and this protein has been implicated in neuronal polarization by destabilizing the MT 
in minor neurites [166]. Overexpression of Stathmin in neurons of the subgranular zone (SGZ) and 
in primary cultured hippocampal neurons induced aberrant arborization of axons [167]. Stathmin 
appears to be crucial in adult SGZ neurogenesis by modulation of several MT-associated events, 
since proliferation and migration to differentiation [100]. 
Regarding the phosphoS655 APP interactome, a simple comparison of the number of APP 
interactors detected for the APPSA and for the APPSE, suggests that S655 phosphorylation 
commits APP to a more specific role by endorsing in a smaller number but specific protein 
interactions. This behavior might be associated with the more dynamic TGN-to-PM trafficking of 
APPSE, and it’s increased processing by alpha-secretase [13, 19].  
In line with our preliminary data correlating the overexpression of the phosphomimicking mutant, 
APPSE, with neurite elongation in SH-SY5Y cells (Figure B.23), we identified potential APP- 
phosphoS655 specific interactors that are strongly associated with neurite outgrowth (Table B.8). 
On D3 we considered desmoplakin (DSP), optineurin (OPTN), and cellular nucleic acid-binding 
protein (CNBP) particularly interesting. The protein desmoplakin (DSP), together with plakoglobin 
and members of the cadherin family, form the desmosomes where DSP functions as the 
cytoskeleton adaptor that anchors IFs to the plasma membrane. Forebrain-specific Dsp mouse 
mutants show decreased stem-cell proliferation rate in the dentate gyrus, and defective 
differentiation [168]. In this study, the authors suggest that DSP mediated cell–cell adhesion is 
important to establish the signaling pathway from neighboring cells to allow neuronal 
differentiation [168]. Concordantly, in spinal cord motor neurons, the DSP complex with N-
cadherin, plakoglobin and vimentin appears to be a crucial process for axon regeneration and 
outgrowth in vitro and in vivo [131]. 
Within the constructed network, DSP is one node away from a known APP protein interactor and 
one of the proteins with the highest node degree, the Peroxiredoxin-2 protein (PRDX2; see Figure 
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B.21 A, DSP and PRDX2 share the MAP1A/1B light chain 3A as a protein interactor). This 
peroxidase, the most abundant neuronal peroxidedoxin, is involved in the response to oxidative 
stress, and its overexpression was described to be neuroprotective for dopaminergic neurons [169]. 
On the other hand, PRDX2 is one protein (MPP1) away from OPTN. OPTN seems to be involved 
in anterograde trafficking pathways, and can be found in recycling endosomes. In scratch wound 
assays, loss of OPTN results in the loss of EGFR from the plasma membrane facing the wound and 
reduces the number of cells extending lamellipodia into the scratch wound. In addition, the delivery 
of β1-integrin towards the front of the cell also seems affected [128]. In retinal ganglion cells, 
OPTN siRNAs increase the number of cells undergoing apoptotic cell death, and reduces the 
amount of secreted growth factors [170]. Transient knockdown of OPTN in zebrafish embryos 
resulted in abnormal morphology and defects in spinal motor axon guidance [129].  
CNBP is a nucleic-acid binding protein involved in regulation of transcription, and most of the 
described putative CNBP target genes are related to embryonic developmental processes [132]. 
Specifically, CNBP appears to downregulate the transcription of Wnt [132]. This protein is 
required for forebrain formation during mouse, chick, and zebrafish embryogenesis by its ability to 
control proliferation and cell survival [133, 134, 171]. 
Curiously, three APP protein interactors (ELAV4, Caprin-1, and Shroom3) highlighted in this work 
for their potential role in neuronal differentiation, shift from the APP interactome independent of 
the S655 phosphorylation status and the APP- dephosphoS655 interactome on day 3, to the APP- 
phosphoS655 interactome on differentiation day 7. The presence of these protein in late 
differentiation periods in the APP- phosphoS655 interactome may support such phenotype. We 
already mentioned that Caprin-1 and ELAV4 are positive modulators of dendritogenesis and 
synaptic plasticity. Shroom3 is an actin binding protein, reported to bind f-actin and to modulate f-
actin subcellular distribution, a function that is related to neural tube closure failure in Shroom3 
KO mice [92]. Furthermore, this protein directly binds Rho kinase (ROCK), and the Shroom3-
ROCK interaction has been shown to negatively regulate neurite outgrowth [89]. It will be 
interesting to test if pS655 APP binding to Shroom 3 prevents its interaction with ROCK, and 
promotes neurite outgrowth.  
Apolipoprotein D (APOD), is another specific APP- phosphoS655 protein interactor that could be 
assisting the APPSE induced neuritogenesis. APOD is reported to be neuroprotective and 
neurotrophic [138, 140, 172]. This extracellular glycosylated lipocalin, binds and transports a 
variety of ligands (for example, RA, arachidonic acid, and the endocannabinoid anandamide). 
APOD levels are increased during prefrontal cortex maturation, and APOD is a consistently 
upregulated gene during brain aging in mammals. Regarding its potential neurotrophic role, APOD 
was shown to exert differentiating and synaptogenic effects in dorsal root ganglion neurons, and to 
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be necessary for the transcription factor p73 mediated [173], and for RA mediated- neurite 
outgrowth in SH-SY5Y cells [139]. Thus, the APP- phosphoS655 interactome includes interesting 
potential protein partners that could be assisting APP in the promotion of neurite outgrowth. 
In line with the functional annotation of individual protein interactors, the functional enrichment 
analysis of the expanded phosphoS655 APP interactome linked APP interactors to several 
signaling pathways important for neuronal differentiation, namely FoxO [174], TGFbeta [175, 
176], TNF [177], NF-kB [160], and estrogen signaling pathways [178] (Figure B.22, Figure B.23 
and Table B.7), with some of these being functionally related [179].  
All these data indicate roles for APP S655 phosphorylation in controlling cell proliferation and 
survival, as well as in the modulation of signaling pathways crucial for cell commitment to 
neuronal differentiation. Accordingly, we have observed that APPSE overexpression correlates 
with enhanced neurite elongation in SH-SY5Y cells (Figure B.23 B). Further work exploring some 
of these fascinating interactions will help to increase our knowledge on APP physiology, in 
particular its role in neuronal differentiation.  
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7.7.!Supplementary Data 
Supplementary Table B.2 - MS data for the identified proteins. Each condition was performed in duplicate (b indicates the duplicate). 3D, differentiation day3. 7D, differentiation day 
7. #pep, indicates the number of unique peptides identified for each protein. # PSM, indicates the number of peptide-spectrum matches. 
  N1b N1 N1b APP-WT APP-WTb APP-WT APP-WTb APP-SA APP-SAb APP-SA APP-SAb APP-SE APP-SEb APP-SE APP-SEb 
  3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 
Uniprot ID Gene name # pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
Present in both differentiation days 
Q92841 DDX17   7 10 7 31 8 52 3 20 9 61 7 38 10 66 4 14 6 55 3 9 4 9 2 9 4 32 1 3 
Q15459 SF3A1   3 3 2 2 12 43 2 2 9 32 5 21 10 26 3 3 4 17 3 3 3 3 1 1 3 3   
Q13283 G3BP1   7 17 5 15 7 36 3 8 10 67 5 18 11 82 4 8 5 44 2 6 2 2 4 6 3 35 2 8 
P11940 PABPC1   5 7 4 11 7 25 1 1 10 30 6 26 10 29 1 1 3 14 3 5 1 1 3 3 2 7   
Q13310 PABPC4   3 3 2 4 4 14 1 1 5 16 3 13 5 14   4 10 2 3 1 1 2 2 2 2   
Q14444 CAPRIN1   4 8 2 14 5 14 2 6 3 10 2 7 5 15 2 3 4 11 2 1 3 7 2 6 3 21   
P0DMV8/P08107 HSPA1A   1 1 2 2 4 11 1 2 2 2 2 2 3 6 1 1 2 2 5 21   2 3 1 1   
Q15365 PCBP1   1 1 3 6 3 10 1 8 3 15 2 15 2 31   2 8 2 13 1 1   3 21 2 13 
Q15637 SF1   1 1 1 3 3 10 1 8 1 6 1 8 1 7 1 2 1 16 1 9 1 1 1 1 1 13 1 4 
P09012 SNRPA   4 9 3 4 5 8 1 3 7 27 2 6 4 10 1 1 4 15 3 5 1 1 1 1 4 17 3 17 
P08670 VIM   3 6 4 12 5 5 2 3 5 6 6 32 5 6 4 7 8 11 10 57 2 72 3 3 5 10 2 8 
Q9NXV6 CDKN2AIP   1 1 2 2 4 4 1 2 5 5 3 4 4 4 3 3 5 5 2 2 3 3 2 2 4 4   
Q9Y383 LUC7L2       3 4 1 1 1 1   2 2   1 1 2 2 1 1 1 1 1 1   
Q8WWM7 ATXN2L   1 1 1 1 4 4 1 1 3 3   4 4 2 2 3 3 2 2 2 2 1 1 1 1   
P08579 SNRPB2   2 2 1 2 3 3 1 3 3 4 1 5 3 5 1 1 2 3 2 4 2 2   2 3 2 4 
O75525 KHDRBS3   1 1 1 2 2 2 1 1 1 2 2 3 2 2   1 1 1 1 1 1 1 1 1 1 1 3 
P26378 ELAVL4     2 11 1 1 2 21 1 5 4 11 1 2 1 4 2 8 1 12   1 4 2 19 2 24 
Q96PK6 RBM14   1 1 4 11 1 1 3 5 2 3 1 1 2 2   1 1 1 1 1 1 1 1 3 11   
P50402 EMD   1 1 1 1 1 1 1 2 2 2 1 1 1 1   1 1 1 1 1 1 1 1 1 1 1 1 
O43933 PEX1   1 3 1 10 1 1 1 5 1 1 1 1 1 2 1 2 1 8 1 3 1 13 1 1 1 1 1 1 
P46782 RPS5   1 1 1 1 6 8   2 3   7 9   2 2 1 1 3 3 1 1 1 1 2 2 
Q8NC51 SERBP1   1 2   5 8   4 11 2 3 7 27 2 3 3 14 2 6 3 4     2 3 
P62316 SNRPD2     1 1 2 8   1 1 1 2 2 9 1 1 2 19 1 1   1 1 1 2 1 1 
Q96AG4 LRRC59       4 8   2 2   2 2   1 1 1 1 1 1       
O00571 DDX3X   2 2 3 7 6 7   9 10 4 14 6 6 3 3 4 4 3 3 3 3 2 2 3 4 1 1 
P52272 HNRNPM   4 4 4 4 5 5   9 9   11 11 2 2 5 5 2 2 1 1 1 1 4 7   
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O94906 PRPF6       4 5   5 5 1 1 2 2 2 2     1 1       
P02545 LMNA       4 4   2 2   3 3   1 1 9 14 1 1       
P23396 RPS3   1 1   3 3   5 8   3 3   2 2 2 3 2 2   2 2 3 3 
P60468 SEC61B       2 3   2 2   2 2       1 1       
O43143 DHX15   1 1 1 1 3 3   2 3   3 3   3 3 1 1 1 1   1 2   
Q9P2N5 RBM27   1 1 1 1 3 3   2 2 2 2 2 2 1 1 1 1 1 1   1 1 1 1   
P62269 RPS18   1 1 1 4 2 2   1 1 1 2 1 1   1 1 2 2 1 1       
P55081 MFAP1   1 1 1 1 2 2   1 2   1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
O00425 IGF2BP3   1 1 1 1 2 2   3 3 1 1 3 3   2 2 2 2   1 1 2 2   
Q5T8P6 RBM26   2 2 2 2 2 2   3 3   3 3 1 1 3 8 1 1 1 1 1 1 2 5   
Q06830 PRDX1   1 1   1 1       1 1     4 26 1 5       
P37108 SRP14       1 1       2 2   1 1 1 1 1 1   1 1   
P10809 HSPD1       1 1   1 1   1 1   1 1 7 37 1 1   1 1   
P62851 RPS25       1 1       1 1   1 1 1 2 1 1       
P62701 RPS4X       1 1       1 1   1 1 1 1 1 1       
P38646 HSPA9       1 1   2 2   2 2 1 1 1 1 4 5 1 1   1 1   
P42677 RPS27   1 1 1 2 1 1   1 1 1 2 1 1   1 1 1 1 1 1   1 4 1 1 
O95639 CPSF4   1 1   1 1   2 2   2 2   1 1   1 1   1 1   
Q9BZ01 FRG1B       1 1   1 1   1 1 1 1 1 1 1 1 1 1   1 1 1 1 
Q96CT7 CCDC124       1 1   1 1   1 1   1 1   1 1       
Q96LL9 DNAJC30       1 1       1 1   1 1   1 1       
Q5T749 KPRP   1 1 1 1 1 1   1 1   1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 3 
P48634 PRRC2A     1 1 1 1   2 2   2 2   1 1 1 1   1 1 1 1   
P23246 SFPQ 4 9 13 101 11 64 24 197 6 23 20 128 8 107 22 194 6 51 14 97 7 68 9 42 7 18 10 62 2 7 
Q15393 SF3B3 2 4 9 28 3 26 22 80 5 19 17 113 10 72 13 82 6 13 13 64 4 29 9 21 5 16 6 46   
Q16630 CPSF6 2 3 6 21 5 31 8 52   10 59 7 63 12 79 5 23 5 46 5 25 5 12 4 24 5 26 2 10 
Q7RTV0 PHF5A 1 1 2 2 2 7 5 13   3 12 1 12 4 15 3 6 4 33 1 1 4 10 1 1 3 20 3 14 
P62318 SNRPD3 1 3 3 7 1 15 2 17   2 2 2 15 2 16   2 16 1 6 2 8 1 1 1 4 1 1 
Q01081 U2AF1 1 1 1 1 1 2 2 4 1 1 2 4 1 1 2 4 1 1 2 3 2 2 2 2 1 1 2 13 2 7 
P35637 FUS 4 22 5 72 4 29 6 77 3 13 4 51 6 80 7 85 4 30 4 30 3 19 4 16 4 41 5 26 3 10 
Q92804 TAF15 1 9 2 18 1 14 3 18 3 11 2 22 3 42 3 20 1 12 3 27 1 14 1 2 1 19 4 17 3 17 
P04083 ANXA1       2 2   1 1                   
Q03252 LMNB2       2 2             1 1         
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O75323 GBAS       1 2   1 1                   
P07900 HSP90AA1       1 1             6 19         
P08238 HSP90AB1       1 1             5 21         
P13639 EEF2       1 1           1 1 7 9         
P20700 LMNB1       1 1             2 2         
Q00325 SLC25A3       1 1   1 1                   
P51114 FXR1     1 1 1 1   3 8 2 9     1 1           
Q96AE4 FUBP1       1 1   1 1                   
Q9BY77 POLDIP3       1 1           1 1       1 1   
Q9HBH1 PDF       1 1   1 1                   
Q14974 KPNB1       1 1             1 1         
Q15366 PCBP2     1 1 1 8 1 8 2 13 1 13 1 20   1 5 2 5     1 7 1 6 
P07910 HNRNPC       1 3 1 3 1 1 1 1 1 3   1 2 1 10     1 5 1 6 
Q6Y7W6 GIGYF2       2 2 1 1 1 1 1 1 5 7 1 1 2 2       1 1   
Q3MHD2 LSM12       1 1 1 2 1 1   1 1           1 1   
P49750 YLPM1   2 2 1 1 1 1 1 1 2 2 2 2 2 2   1 1 1 1     1 1   
O43719 HTATSF1       4 17   1 6   1 2               
Q9UN86 G3BP2   1 1 1 6 3 14   4 26 1 8 2 25   2 11 1 1     1 12   
Q9Y3B4 SF3B6       2 11       1 5   1 14           
P26368 U2AF2       6 9   3 4 1 1 3 3 1 1             
Q13435 SF3B2   2 2   6 9   5 17   4 14   3 6 1 1     2 2   
Q9Y2H5 PLEKHA6       3 8   1 8   3 8   1 9       1 1   
P63173 RPL38       4 6       3 13   1 4           
O60506 SYNCRIP     1 9 4 5   5 14 2 23 4 8 1 4 1 4 1 5         
O75533 SF3B1   1 1   4 4   6 12 2 2 5 6   6 19       3 5   
Q8IWX8 CHERP   1 1 1 1 2 4   3 4   4 4   2 2       2 2   
Q7L014 DDX46       4 4   2 2   3 3   2 2           
Q9NVI7 ATAD3A       2 3   2 2   2 3   2 2       2 2   
P15880 RPS2       3 3   1 1 2 12 2 2   3 5           
Q96GY0 ZC2HC1A       3 3   1 1   2 2               
P62263 RPS14   1 1 1 6 1 3   1 1 1 5 1 1   1 1       1 6 1 4 
P31943 HNRNPH1   1 1   1 3   1 2   2 2               
Q13573 SNW1       2 3   1 1   1 1 2 2 1 1           
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P05067 APP       2 3   2 2 1 1 2 3   1 1 1 1     1 1   
Q5T6F2 UBAP2       3 3   2 2   2 2 1 1 2 2           
P35268 RPL22       2 2       2 3   2 5 1 1         
P09661 SNRPA1       2 2   1 1   1 1   1 1           
Q16352 INA       2 2   1 1   1 1   1 1 1 8     2 2   
P02765 AHSG       2 2   1 1   2 2   2 2       1 1   
P42167 TMPO       2 2   1 1   1 1   1 1           
Q15428 SF3A2       2 2   2 2   1 1   1 1           
Q9Y2W2 WBP11       2 2   1 1   1 1 2 2             
Q5VT52 RPRD2       2 2   1 1   1 1   1 1       1 1   
P62987 UBA52       1 1     1 1 1 1   1 3       1 1   
P31946 YWHAB     1 1 1 1   1 1   1 1     3 5         
P31947 SFN     1 1 1 1   1 1   1 1     2 4         
P27348 YWHAQ     1 1 1 1   1 1   1 1     4 10         
P61981 YWHAG     1 1 1 1   1 1   1 1     2 4         
P11021 HSPA5       1 1     1 1 2 2     4 8         
P62158 CALM1       1 1       1 1   1 1 1 1         
Q07955 SRSF1       1 1   1 1 1 1 1 1   2 2 1 1         
Q9Y224 C14orf166   1 1 1 5 1 1   2 2   2 2   1 1 1 1         
P14866 HNRNPL       1 1   1 1   2 2     2 2         
P51116 FXR2       1 1   2 6 3 10 1 1   2 2       1 3   
Q15149 PLEC       1 1       1 1     8 8         
P61626 LYZ       1 1       1 1   1 1           
Q14498 RBM39       1 1       1 1     1 1         
P43243 MATR3       1 1   1 1   2 2               
Q8N954 GPATCH11       1 1   1 1   1 1   1 1       1 1   
P50416 CPT1A   1 1   1 1   2 2 1 1 1 1   1 1           
P62140 PPP1CB   1 1 1 2 1 1   1 1   1 1   1 1       1 11 1 1 
Q92945 KHSRP       1 1     1 2 1 1 1 1 1 3           
Q9HC52 CBX8       1 1   1 1   1 1   1 1           
Q08211 DHX9       1 1   3 3   1 1   1 1           
Q96DI7 SNRNP40       1 1   1 1   1 1   1 1           
Q8NC56 LEMD2       1 1   1 1   1 1   1 1       1 1   
Results  Chapter 7 
University of Aveiro   217 
  N1b N1 N1b APP-WT APP-WTb APP-WT APP-WTb APP-SA APP-SAb APP-SA APP-SAb APP-SE APP-SEb APP-SE APP-SEb 
  3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 
Uniprot ID Gene name # pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
Q5VW36 FOCAD   1 1 1 1 1 1   3 3   3 3   1 1       1 1   
Q75N03 CBLL1       1 1   1 1   1 1               
Q9H7E2 TDRD3       1 1   1 1   1 1               
Q9H0D6 XRN2       1 1   1 1   1 1   1 1           
Q14694 USP10       1 1   1 1   1 1 1 1         1 1   
O94973 AP2A2       1 1   1 1   1 1               
Q07065 CKAP4 1 1     10 20   2 2   9 20 1 1 1 1   1 1       
P17844 DDX5 3 7 6 9 9 30 19 85 3 19 15 74 11 70 16 84 7 22 10 55 4 15 5 10 4 11 3 25 2 4 
P11142 HSPA8 1 3 2 2 1 1 8 25 2 3 7 14 3 4 12 25 2 3 4 7 6 21 2 3 3 5     
Q9BWJ5 SF3B5 1 1   1 1 1 6   1 2 1 8 1 7   1 13       1 7   
Q12874 SF3A3 1 1 1 1   4 6   3 7 3 3 5 5 1 1 2 2     1 1     
Q00839 HNRNPU 1 3   1 1 6 16 1 1 3 12   5 14   4 12 2 2 1 1       
Q9UHX1 PUF60 3 6 2 2 3 7 14 31   9 17 4 10 11 29 2 2 5 11 3 4 2 2 2 2 5 8 1 1 
P68363 TUBA1B 3 7 3 4 3 11 11 33 2 6 3 8 2 16 5 10 1 1 3 16 3 33 3 3 2 2 3 21 2 2 
P68371 TUBB4B 2 8 1 6 1 1 4 31 1 1 5 15 2 10 5 13 2 15 2 2 4 26 1 5 2 13 2 2   
Q14011 CIRBP 2 2   1 2 4 7 1 2 3 10 1 3 2 2 1 1 1 2 1 1 2 3 1 1 1 1   
O15240 VGF 6 73 16 147 11 86 25 230 7 63 20 216 12 152 22 243 11 84 16 141 11 83 10 82 8 49 12 124 4 28 
P07437 TUBB 3 15 2 13   7 41 1 1 6 22 3 15 7 18 2 15 3 3 5 39 2 10 3 23 2 2   
Q13885 TUBB2A 2 14 2 13   6 38 1 1 5 21 3 15 5 16 2 15 3 3 4 26 2 10 3 23 2 2   
P84103 SRSF3 2 3   1 1 3 8   2 4   1 1 1 1 1 2 1 1 2 3   1 1 1 1 
P68104 EEF1A1 2 24 2 15 1 12 13 58 1 23 5 25 1 17 7 36 1 14 1 12 5 37 2 5 1 10 1 19 1 20 
P62304 SNRPE 2 5     3 12   2 4 1 3 2 7   2 4           
P60709 ACTB 5 43 5 27 4 25 12 96 3 20 8 30 4 40 13 108 3 42 4 36 9 153 2 4 2 13 6 35 4 16 
P38159 RBMX 2 3 1 1 3 4 3 4 1 1 7 7 4 8 6 6   4 4 1 1   1 1 2 2 3 15 
P62913 RPL11 1 1 1 1 2 2 1 1   1 1   2 3   2 4 2 3     1 1   
Q5VUA4 ZNF318           1 1   3 3   1 1           
A8MWD9 SNRPGP15 2 5 1 1   1 5   1 1   2 2   2 2   1 1   1 1   
Q6DN90 IQSEC1           2 2   2 2               
O60814 HIST1H2BK 1 2 1 10   2 2 1 1 2 2   1 1   3 24 3 41 2 3   1 1 1 1 
P22626 HNRNPA2B1           1 1   1 1   1 1 3 8         
P01764/ P01765 IGHV3-23 1 1             1 1             1 1 
P09651 HNRNPA1 1 1 2 2 1 1 1 1   2 4   1 1   1 1 1 1 1 1 1 1 1 1 1 2 
P35579 MYH9               1 1     5 5         
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P62820 RAB1A               1 1     2 2         
Q6UXN9 WDR82 1 1         1 1 1 1 1 1               
P07196 NEFL               1 1     1 8         
P35580 MYH10               1 1     1 1         
P15884 TCF4           1 1   1 1   1 1           
Q9H2U1 DHX36               1 1   1 1           
Q9BTC0 DIDO1           1 1   1 1               
O94913 PCF11           1 1   1 1               
P61978 HNRNPK 16 154 14 90 9 108 25 278 9 111 15 173 13 224 17 278 12 175 10 157 8 105 11 73 10 82 8 118 7 88 
Q8N684 CPSF7 3 37 6 41 3 29 8 50 4 16 9 50 5 76 9 65 7 59 6 55 5 52 3 3 6 42 6 64 5 54 
O43809 NUDT21 4 25 3 4 3 28 9 46 4 36 5 41 3 23 5 42 1 1 4 35 3 22 6 32 2 5 2 11 3 25 
Q8NFD5 ARID1B   1 1       2 2   1 1 1 1             
Q8TF72 SHROOM3             1 5   1 1           1 11 
P02768 ALB 3 11 3 11 1 3 5 14 1 4 5 17 3 5 6 76   5 10 3 7 4 5 8 53 4 9 2 2 
O75643 SNRNP200   1 1 1 1     6 6   5 5   2 2 1 1   1 1 1 1   
P62888 RPL30               1 1   1 1   1 1       
P14678 SNRPB 1 1     1 1   3 7   1 1   1 1   1 2       
P62306 SNRPF 2 7 1 2 3 58 1 5 1 1 1 3 2 16 1 13 1 1 2 65 1 1 2 16 2 2 2 18 1 14 
P02795 MT2A           1 1       1 1   1 1 1 1 1 1   
P62805 HIST1H4A                   2 4   2 5       
P32119 PRDX2                     3 17 1 5       
P16403 HIST1H1C                   1 2   1 1   1 6   
Present only in differentiation day 3 
Q96KK5 HIST1H2AH       1 2 1 1     1 3       1 6       
P81605 DCD       1 1 1 8     1 1 1 1     1 1 1 1     
Q8WXF1 PSPC1       1 1 1 1     2 2         1 1     
P62829 RPL23       2 2       2 2         1 1     
Q9UPT8 ZC3H4       2 2       3 3       1 1       
P39019 RPS19       1 1       2 2       1 1       
P05109 S100A8       1 1       1 1       2 4 2 2     
Q02413 DSG1       1 1       1 1 1 1     1 1 1 1     
P14923 JUP       1 1       1 1       1 1 1 1     
Q01844 EWSR1 1 1     3 27 1 14     4 47 2 12       3 10     
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Q14157 UBAP2L 2 13     18 89 3 15     18 126 4 37     4 22 4 38     
Q92499 DDX1       1 2 1 3                     
O94874 UFL1       2 2                       
O15294 OGT       2 2                       
Q9UMS6 SYNPO2       2 2                       
Q04837 SSBP1       1 1                       
P05388 RPLP0       1 1                       
P0CG12 CHTF8       1 1                       
Q9Y3D7 PAM16       1 1                       
P60866 RPS20       1 1                       
Q6P5R6 RPL22L1       1 1                       
P59780 AP3S2       1 1                       
Q9UKK6 NXT1       1 1                       
Q8ND56 LSM14A       1 1                       
Q9UEU0 VTI1B       1 1                       
Q96GD4 AURKB       1 1                       
P27816 MAP4       1 1                       
P19387 POLR2C       1 1                       
Q96I25 RBM17       1 1                       
Q9BUU2 METTL22       1 1                       
P24539 ATP5F1       1 1                       
O95400 CD2BP2       1 1                       
Q9Y265 RUVBL1       1 1                       
P05141 SLC25A5       1 1                       
O43679 LDB2       1 1                       
Q9Y5U2 TSSC4       1 1                       
Q9NZB2 FAM120A       1 1                       
Q15007 WTAP       1 1                       
Q99700 ATXN2       1 1                       
O60313 OPA1       1 1                       
Q9UPN4 CEP131       1 1                       
Q9NRA8 EIF4ENIF1       1 1                       
Q9UQE7 SMC3       1 1                       
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Q9P1Y5 CAMSAP3       1 1                       
Q12866 MERTK       1 1                       
O43795 MYO1B       1 1                       
Q9H6K5 PRR36       1 1                       
Q96QZ7 MAGI1       1 1                       
Q08AD1 CAMSAP2       1 1                       
Q5SW79 CEP170       1 1                       
P0DMR2 SCGB1C2         1 1                     
P39060 COL18A1         1 1                     
Q99623 PHB2       2 2       1 1               
Q15029 EFTUD2       2 2       2 2               
Q9Y520 PRRC2C       2 2       3 3 1 1             
P62273 RPS29       1 1       2 2               
Q9Y3C6 PPIL1       1 1       1 1               
P21741 MDK       1 1       1 1               
P30048 PRDX3       1 1       1 1               
Q9UI30 TRMT112       1 1       1 1               
Q96QR8 PURB       1 1       1 1               
O43174 CYP26A1       1 1       1 1               
Q86UP2 KTN1       1 1       1 1               
Q13263 TRIM28       1 1       1 1               
Q8WWY3 PRPF31       1 1       2 2               
O60884 DNAJA2       1 1       1 1               
Q8WYQ5 DGCR8       1 1       1 1               
Q10570 CPSF1       1 1       1 1               
O75420 GIGYF1       1 1       1 1               
P30153 PPP2R1A       1 1       1 1               
Q9BUJ2 HNRNPUL1       1 1       1 1               
Q12959 DLG1       1 1       1 1               
Q9BWU0 SLC4A1AP       1 1       1 1               
P56730 PRSS12       1 1       1 1               
O75400 PRPF40A       1 1       1 1               
Q8TB72 PUM2       1 1       1 1               
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# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
P09874 PARP1       1 1       1 1               
Q01804 OTUD4       1 1       1 1               
Q15233 NONO 6 14     17 111 2 7     22 160 4 18     5 12 5 20     
Q07666 KHDRBS1 4 12     7 92 3 26     7 89 4 38     4 8 4 13     
Q86V81 ALYREF 5 14     8 35 2 4     5 19 2 2     2 2 3 6     
Q9Y3I0 RTCB 1 2     2 2 1 1     2 2               
Q9BPW8 NIPSNAP1 1 7     1 3       2 2       1 4       
O43172 PRPF4               2 2               
Q9Y421 FAM32A               1 1               
P62244 RPS15A               1 1               
Q9Y4Z0 LSM4               1 1               
P31944 CASP14               1 1               
Q5JVS0 HABP4               1 1               
Q5JVF3 PCID2               1 1               
Q6PKG0 LARP1               1 1               
Q9BYJ9 YTHDF1               1 1               
P11171 EPB41               1 1               
Q12872 SFSWAP               1 1               
O94964 SOGA1               1 1               
P05783 KRT18 1 39     1 32 1 8     1 40 1 37     1 47 1 39     
Q9P2I0 CPSF2                 1 1             
P48668 KRT6C 4 28     12 51 4 17     6 52 7 47     5 106 13 100     
Q14D04 VEPH1                 1 1       1 1     
Q9UBC9 SPRR3                       1 1       
O43447 PPIH                       1 1       
Q9BRX5 GINS3                       1 1       
Q9UBG3 CRNN                       1 1       
Q96CV9 OPTN                       1 1       
A6NCW0 USP17L3                       1 1       
Q8NB25 FAM184A                       1 1       
Q96QA5 GSDMA                         1 1     
P62633 CNBP       1 1               1 1       
P15924 DSP       1 1               1 1 1 1     
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  N1b N1 N1b APP-WT APP-WTb APP-WT APP-WTb APP-SA APP-SAb APP-SA APP-SAb APP-SE APP-SEb APP-SE APP-SEb 
  3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 
Uniprot ID Gene name # pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
Q05707 COL14A1       1 1               1 1       
Present only in differentiation day 7 
Q9HCD5 NCOA5     1 1       1 12     2 2       3 5   
Q14966 ZNF638           1 1 1 1                 
Q9NVH0 EXD2           2 2                   
Q9BYR8 KRTAP3-1           1 1                   
Q99816 TSG101           1 1                   
Q9NYF8 BCLAF1           1 1                   
Q9NX05 FAM120C           1 1                   
Q99959 PKP2           1 1                   
O15042 U2SURP           1 1                   
Q07157 TJP1           1 1                   
Q9ULI4 KIF26A           1 1                   
Q5JSZ5 PRRC2B           1 1                   
Q06787 FMR1           2 5 1 7     1 1 1 1         
P07355 ANXA2           1 1         4 24         
P00338 LDHA           1 1       1 1 3 39         
P08237 PFKM           1 1         1 1         
P46779 RPL28                   1 1 1 1         
P06748 NPM1                   1 1 2 20         
P16949 STMN1                   1 1 1 1         
P84098 RPL19                   1 1 1 1         
P08621 SNRNP70             1 1     2 2           
Q6P2Q9 PRPF8             1 1     2 2           
P62081 RPS7                   1 1           
P53007 SLC25A1                   1 1           
O75955 FLOT1                   1 1           
Q08188 TGM3                   1 1           
Q7L2E3 DHX30                   1 1           
P07195 LDHB                     4 46         
P29401 TKT                     8 45         
P80723 BASP1                     7 35         
P21333 FLNA                     13 27         
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  N1b N1 N1b APP-WT APP-WTb APP-WT APP-WTb APP-SA APP-SAb APP-SA APP-SAb APP-SE APP-SEb APP-SE APP-SEb 
  3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 
Uniprot ID Gene name # pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
P60174 TPI1                     4 17         
P06454 PTMA                     1 17         
P61604 HSPE1                     2 16         
P63104 YWHAZ                     4 13         
P06703 S100A6                     2 12         
P07737 PFN1                     1 11         
P00558 PGK1                     3 8         
P62826 RAN                     2 7         
Q14103 HNRNPD                     1 6         
P31327 CPS1                     4 5         
P04075 ALDOA                     4 4         
O75369 FLNB                     4 4         
P62258 YWHAE                     3 3         
P31949 S100A11                     2 3         
P26038 MSN                     2 3         
P25705 ATP5A1                     2 3         
P13929 ENO3                     1 3         
P47914 RPL29                     1 3         
P62328 TMSB4X                     2 2         
P04792 HSPB1                     2 2         
P23284 PPIB                     2 2         
P37802 TAGLN2                     1 2         
P26639 TARS                     2 2         
P07237 P4HB                     2 2         
P29692 EEF1D                     1 2         
P67936 TPM4                     2 2         
P31948 STIP1                     2 2         
Q9Y266 NUDC                     2 2         
Q02790 FKBP4                     2 2         
Q01105 SET                     1 2         
P06744 GPI                     2 2         
P49588 AARS                     2 2         
P50990 CCT8                     2 2         
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  N1b N1 N1b APP-WT APP-WTb APP-WT APP-WTb APP-SA APP-SAb APP-SA APP-SAb APP-SE APP-SEb APP-SE APP-SEb 
  3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 
Uniprot ID Gene name # pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
P13010 XRCC5                     2 2         
P12268 IMPDH2                     2 2         
P53396 ACLY                     2 2         
P11586 MTHFD1                     2 2         
P58107 EPPK1                     2 2         
O43707 ACTN4                     2 2         
Q9Y490 TLN1                     2 2         
Q14978 NOLC1                     2 2         
P05387 RPLP2                     1 1         
P23528 CFL1                     1 1         
P62937 PPIA                     1 1         
P06576 ATP5B                     1 1         
P62241 RPS8                     1 1         
Q9UBI6 GNG12                     1 1         
P26641 EEF1G                     1 1         
Q14847 LASP1                     1 1         
P40926 MDH2                     1 1         
P63241 EIF5A                     1 1         
O43175 PHGDH                     1 1         
P78371 CCT2                     1 1         
P61247 RPS3A                     1 1         
P48047 ATP5O                     1 1         
P37837 TALDO1                     1 1         
P10599 TXN                     1 1         
P30086 PEBP1                     1 1         
P83881 RPL36A                     1 1         
P12004 PCNA                     1 1         
P26447 S100A4                     1 1         
P49207 RPL34                     1 1         
P09382 LGALS1                     1 1         
P30101 PDIA3                     1 1         
P62995 TRA2B                     1 1         
P13987 CD59                     1 1         
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  N1b N1 N1b APP-WT APP-WTb APP-WT APP-WTb APP-SA APP-SAb APP-SA APP-SAb APP-SE APP-SEb APP-SE APP-SEb 
  3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 
Uniprot ID Gene name # pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
P26373 RPL13                     1 1         
P14625 HSP90B1                     1 1         
Q99733 NAP1L4                     1 1         
P84085 ARF5                     1 1         
P62847 RPS24                     1 1         
P11413 G6PD                     1 1         
P48643 CCT5                     1 1         
Q16836 HADH                     1 1         
P31040 SDHA                     1 1         
P12277 CKB                     1 1         
P60842 EIF4A1                     1 1         
P27635 RPL10                     1 1         
P28072 PSMB6                     1 1         
P09622 DLD                     1 1         
Q12931 TRAP1                     1 1         
P27797 CALR                     1 1         
P15259 PGAM2                     1 1         
Q16186 ADRM1                     1 1         
P30040 ERP29                     1 1         
Q7L1Q6 BZW1                     1 1         
Q9H1E3 NUCKS1                     1 1         
Q05682 CALD1                     1 1         
Q7KZF4 SND1                     1 1         
P55809 OXCT1                     1 1         
Q6UVW9 CLEC2A                     1 1         
Q99436 PSMB7                     1 1         
P62753 RPS6                     1 1         
Q01130 SRSF2                     1 1         
P47756 CAPZB                     1 1         
P27695 APEX1                     1 1         
O75821 EIF3G                     1 1         
P13667 PDIA4             1 1       1 1         
Q09666 AHNAK                     1 1         
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  N1b N1 N1b APP-WT APP-WTb APP-WT APP-WTb APP-SA APP-SAb APP-SA APP-SAb APP-SE APP-SEb APP-SE APP-SEb 
  3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 
Uniprot ID Gene name # pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
P25786 PSMA1                     1 1         
Q16881 TXNRD1                     1 1         
P12814 ACTN1                     1 1         
P22234 PAICS                     1 1         
Q15645 TRIP13                     1 1         
Q92973 TNPO1                     1 1         
P14324 FDPS                     1 1         
Q6ZV70 LANCL3                     1 1         
P55072 VCP                     1 1         
P23526 AHCY                     1 1         
P08195 SLC3A2                     1 1         
Q9Y5B9 SUPT16H                     1 1         
Q15019 SEPT2                     1 1         
Q09028 RBBP4                     1 1         
P50991 CCT4                     1 1         
Q08J23 NSUN2                     1 1         
P16070 CD44                     1 1         
P11498 PC                     1 1         
P46821 MAP1B                     1 1         
P06733 ENO1   1 1               1 1 9 85         
P14618 PKM   1 1                 7 45         
P39023 RPL3   1 1                 3 4         
P18206 VCL   1 1                 2 2         
P19338 NCL   1 1                 2 2         
P04406 GAPDH     1 1             1 1 4 47         
Q9UNN5 FAF1                   1 1 1 1     1 1   
P62979 RPS27A             1 1     1 3       1 1   
Q92989 CLP1                           1 3   
Q8IY26 PLPP6                           1 1   
Q96I24 FUBP3                           1 1   
Q92797 SYMPK                           1 1   
A3KMH1 VWA8                           1 1   
P05090 APOD                             1 1 
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  N1b N1 N1b APP-WT APP-WTb APP-WT APP-WTb APP-SA APP-SAb APP-SA APP-SAb APP-SE APP-SEb APP-SE APP-SEb 
  3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 3D 3D 7D 7D 
Uniprot ID Gene name # pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
# 
pep 
# 
PSM 
Q6ZR08 DNAH12                             1 1 
P30050 RPL12     2 3     2 3 1 4     1 1 1 1     2 6   
O75063 FAM20B           1 1                 1 1 
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Supplementary Table B.3 - Proteins that were placed at different APPS655 phosphorylation categories in each 
differentiation day (D3 vs D7). Might indicate that such proteins during differentiation and/or in different APP 
backgrounds suffer alterations in protein expression and consequently are/are not detected by MS. In bold are proteins 
that were selected as potential interesting for neuronal differentiation studies. 
Condition UniProt nr Gene name Condition UniProt nr Gene name 
D3 dephospho and 
D7 independent 
P51116 FXR2 
D3 independent and 
D3 dephospho 
O43933 PEX1 
P07910 HNRNPC Q8NC51 SERBP1 
Q6Y7W6 GIGYF2 Q96AG4 LRRC59 
Q9NVI7 ATAD3A P02545 LMNA 
Q16352 INA P62269 RPS18 
P02765 AHSG Q06830 PRDX1 
Q9Y2H5 PLEKHA6 P62851 RPS25 
Q8N954 GPATCH11 P62701 RPS4X 
Q8NC56 LEMD2 Q96CT7 CCDC124 
Q5VT52 RPRD2 Q96LL9 DNAJC30 
Q9UN86 G3BP2 Q15393 SF3B3 
Q9UHX1 PUF60 Q16630 CPSF6 
P17844 DDX5 P62318 SNRPD3 
P68371 TUBB4B O75643 SNRNP200 
O75533 SF3B1 P62888 RPL30 
O43809 NUDT21 P14678 SNRPB 
P38159 RBMX D3 phospho and D7 
independent 
P02795 MT2A 
P68363 TUBA1B P16403 HIST1H1C 
Q15366 PCBP2 D3 phospho and D7 
dephospho 
P62805 HIST1H4A, … 
Q9BWJ5 SF3B5 P32119 PRDX2 
Q8IWX8 CHERP 
D3 dephospho and 
D7 phospho 
Q8TF72 SHROOM3 
P62987 UBA52 P01764 IGHV3-23 
D3 independent and 
D7 dephospho 
Q15459 SF3A1 P62140 PPP1CB 
P11940 PABPC1 Q3MHD2 LSM12 
Q13310 PABPC4 Q14694 USP10 
P0DMV8 HSPA1A P09651 HNRNPA1 
P08670 VIM P62263 RPS14 
Q8WWM7 ATXN2L Q8N684 CPSF7 
 
Supplementary Table B.4 - Additional cell differentiation related functions retrieved using Panther 
overrepresentation test for “Total” APP protein interactors. Dif. day, indicates the differentiation day. GO term, the 
enriched gene ontology term attributed. GO source, the gene ontology sources, namely molecular function (MF), 
biological processes (BP), and pathways. # proteins, number of proteins associated to the attributed enriched term. 
Pvalue, calculated pvalue with Bonferroni correction. 
Dif. day GO source GO term # proteins pvalue 
D3 
BP MT-based process 25 5.18E-03 
BP cell-cell adhesion 39 7.81E-06 
BP cell adhesion 44 1.22E-03 
MF cadherin binding involved in cell-cell adhesion 29 6.03E-13 
MF structural constituent of cytoskeleton 10 1.45E-02 
Pathways Parkinson disease 8 1.91E-02 
D7 
BP homotypic cell-cell adhesion 8 4.70E-02 
BP cell-cell adhesion 64 1.34E-18 
BP cell adhesion 67 3.20E-12 
MF cadherin binding involved in cell-cell adhesion 55 3.51E-37 
Pathways cytoskeleton regulation by Rho GTPases 9 2.41E-03 
Pathways Parkinson disease 13 4.06E-06 
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Supplementary Table B.5 - Examples of enriched functions attributed to the combined list of APP S655 
phosphorylation-independent interactors (Figure 4) plus the list of APPWt interactors. The enrichment analysis was 
performed using the Cytoscape app ClueGO, comparing differentiation day 3 and differentiation day 7. Pvalue, 
calculated p value with Bonferroni correction; GO term, the enriched term attributed. GO source, the gene ontology 
sources, namely biological processes (BP) and KEGG pathways. % genes, percentage of proteins (here by the gene 
name) associated to the attributed enriched term; ID, the gene names of the proteins associated with the attributed 
enriched terms. 
Go Term Go source 
Enriched at 
(Pvalue) Genes Cluster at D3 Genes Cluster at D7 
% 
Genes  
D3 
% 
Genes 
D7 
translation BP D3 (630.0E-15) 
[ATXN2, CAPRIN1, DDX1, 
DDX3X, EEF2, EIF4ENIF1, 
FXR1, IGF2BP3, LSM14A, 
PABPC1, PABPC4, PDF, 
POLDIP3, RPL22L1, RPL23, 
RPL30, RPLP0, RPS18, 
RPS19, RPS20, RPS25, 
RPS27, RPS3, RPS4X, RPS5, 
SEC61B, SLC25A3, 
SLC25A5, SRP14] 
[DDX3X, FXR1, FXR2, 
GIGYF2, IGF2BP3, PDF, 
POLDIP3, RPS27A, RPS3, 
RPS5, SEC61B, SLC25A3, 
SRP14, SYNCRIP, UBA52] 
79.48 41.11 
negative regulation of 
translation BP 
D7 
(390.0E-6) 
[CAPRIN1, DDX3X, 
EIF4ENIF1, FXR1, IGF2BP3, 
RPS3] 
[DDX3X, FXR1, FXR2, 
GIGYF2, IGF2BP3, RPS3, 
SYNCRIP] 
57.11 66.63 
positive regulation of 
translation BP 
D3 
(2.2E-3) 
[DDX3X, EEF2, IGF2BP3, 
PABPC1, POLDIP3, RPS4X] 
[DDX3X, IGF2BP3, 
POLDIP3, SYNCRIP] 72.44 48.29 
RNA splicing BP D7 (38.0E-33) 
[CD2BP2, DDX1, DHX15, 
HNRNPM, HSPA1A, 
LUC7L2, PABPC1, PCBP1, 
PHF5A, POLR2C, PRPF6, 
PSPC1, RBM17, SF1, SF3A1, 
SF3B3, SFPQ, SNRNP200, 
SNRPA, SNRPB, SNRPB2, 
SNRPD2, SNRPD3, SNRPF, 
U2AF1, WTAP] 
[C14orf166, DDX5, DHX15, 
FUS, HNRNPC, HNRNPH1, 
HNRNPK, HNRNPM, 
HTATSF1, LUC7L2, 
NUDT21, PCBP1, PCBP2, 
PCF11, PHF5A, PRPF6, 
PUF60, RBMX, SF1, SF3B1, 
SF3B5, SFPQ, SNRPA, 
SNRPB2, SNRPD2, SNRPF, 
SYNCRIP, U2AF1, U2AF2, 
WBP11, ZNF638] 
55.31 65.94 
ribonucleoprotein 
complex assembly BP 
D3 
(250.0E-15) 
[ATXN2, ATXN2L, CD2BP2, 
DDX1, DDX3X, LSM14A, 
LUC7L2, PRPF6, RPS19, 
RPS27, RPS5, SF1, SF3A1, 
SNRNP200, SNRPB, 
SNRPD2, SNRPD3, SNRPF] 
[DDX3X, HNRNPC, 
LUC7L2, PRPF6, RPS5, SF1, 
SF3B1, SNRPD2, SNRPF, 
U2AF2] 
78.31 43.51 
spliceosomal complex 
assembly BP 
D3 
(580.0E-12) 
[DDX1, LUC7L2, PRPF6, 
SF1, SF3A1, SNRNP200, 
SNRPD2, SNRPD3] 
[HNRNPC, LUC7L2, PRPF6, 
SF1, SF3B1, SNRPD2, 
U2AF2] 
64.40 56.35 
spliceosomal snRNP 
assembly BP 
D3 
(11.0E-6) 
[CD2BP2, PRPF6, SNRPB, 
SNRPD2, SNRPD3, SNRPF] 
[HNRNPC, PRPF6, SNRPD2, 
SNRPF] 72.44 48.29 
stress granule 
assembly BP 
D3 
(4.8E-3) [ATXN2, ATXN2L, DDX3X] [DDX3X] 79.25 26.42 
positive regulation of 
RNA splicing BP 
D7 
(5.7E-3) [HSPA1A] [HNRNPK, RBMX, U2AF2] 25.00 75.00 
alternative mRNA 
splicing, via 
spliceosome 
BP None specific (170.0E-6) 
[HNRNPM, RBM17, SFPQ, 
WTAP] 
[DDX5, HNRNPM, RBMX, 
SFPQ] 57.44 57.44 
negative regulation of 
mRNA metabolic 
process 
BP D7 (1.4E-3) [PABPC1] 
[HNRNPK, RBMX, 
SYNCRIP, U2AF2] 20.00 80.00 
negative regulation of 
mRNA splicing, via 
spliceosome 
BP D7 (32.0E-3) [] [HNRNPK, RBMX, U2AF2] 0.00 100.00 
Ribosome KEGG D3 (8.7E-9) 
[RPL22L1, RPL23, RPL30, 
RPLP0, RPS18, RPS19, 
RPS20, RPS25, RPS27, RPS3, 
RPS4X, RPS5] 
[RPS27A, RPS3, RPS5, 
UBA52] 81.59 27.20 
mRNA surveillance 
pathway KEGG 
None specific 
(69.0E-6) 
[CPSF4, CPSF6, NXT1, 
PABPC1, PABPC4] 
[CPSF4, NUDT21, PCF11, 
WDR82] 59.15 47.32 
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Go Term Go source 
Enriched at 
(Pvalue) Genes Cluster at D3 Genes Cluster at D7 
% 
Genes  
D3 
% 
Genes 
D7 
RNA degradation KEGG D3 (18.0E-3) 
[HSPA9, HSPD1, PABPC1, 
PABPC4] [HSPA9, HSPD1] 77.37 38.69 
Spliceosome KEGG D7 (26.0E-27) 
[DHX15, HNRNPM, 
HSPA1A, PCBP1, PHF5A, 
PRPF6, RBM17, SF3A1, 
SF3B3, SNRNP200, SNRPA, 
SNRPB, SNRPB2, SNRPD2, 
SNRPD3, SNRPF, U2AF1] 
[CHERP, DDX5, DHX15, 
HNRNPC, HNRNPK, 
HNRNPM, PCBP1, PHF5A, 
PRPF6, PUF60, RBMX, 
SF3B1, SF3B5, SNRPA, 
SNRPB2, SNRPD2, SNRPF, 
U2AF1, U2AF2, U2SURP, 
WBP11] 
55.62 68.70 
 
Supplementary Table B.6 - Additional cell differentiation-related functions retrieved using Panther 
overrepresentation test for the dephosphoS655 APP interactome. ‘Dif. day’, differentiation day. ‘GO term’, the 
enriched term attributed. ‘GO source’, the gene ontology sources, namely molecular function (MF), biological processes 
(BP), and pathways. ‘# proteins’, number of proteins associated to the attributed enriched term. ‘Pvalue’, calculated 
pvalue with Bonferroni correction; ‘ID’, the gene names of the proteins associated with the attributed enriched terms. 
Dif. day GO term GO source # proteins pvalue ID 
D3 
structural constituent of 
cytoskeleton MF 8 3.00E-03 
[TUBA1A, ACTB, TUBB, EPB41, TUBB4B, 
NEFL, TUBB2A, INA] 
cadherin binding involved in 
cell-cell adhesion MF 16 3.54E-07 
[GIGYF2, PLEC, RAB1A, HSPA5, KTN1, RPS2, 
YWHAB, LARP1, SFN, HSPA8, UBAP2, PUF60, 
HNRNPK, DLG1, MYH9, KRT18] 
cytoskeletal regulation by 
Rho GTPases pathways 6 4.41E-03 
[MYH10, ACTB, TUBB, TUBB4B, TUBB2A, 
MYH9] 
Parkinson disease pathways 6 1.23E-02 [HSPA5, YWHAB, SFN, HSPA8, YWHAG, YWHAQ] 
D7 
substantia nigra 
development BP 10 1.47E-06 
[ACTB, BASP1, CALM1, CKB, ENO3, G6PD, 
HSPA5, LDHA, YWHAE, YWHAQ] 
cytoskeleton organization BP 28 1.99E-02 
[EPPK1, PFN1, HSP90B1, KPNB1, MYH10, 
STMN1, RAN, MSN, FLNA, NPM1, ACTB, 
TUBB, CALR, FLNB, GAPDH, MAP1B, NEFL, 
TUBB2A, LMNA, CFL1, CAPZB, TLN1, ACTN1, 
ACTN4, ALDOA, TMSB4X, MYH9, VIM] 
PKC inhibitor activity MF 3 1.58E-02 [HSPB1, SFN, YWHAG] 
cadherin binding involved in 
cell-cell adhesion MF 45 1.90E-34 
[PSMB6, PFN1, SEPT2, CCT8, YWHAZ, PAICS, 
PLEC, RAB1A, HSPA5, BZW1, EEF1G, PKM, 
AHNAK, RAN, RPS2, FLNA, NUDC, YWHAB, 
S100A11, SFN, EEF2, YWHAE, FLNB, HSPA8, 
UBAP2, SND1, LDHA, SLC3A2, CAPZB, TLN1, 
RPL29, SERBP1, ANXA2, ALDOA, RPL34,  
CALD1, TAGLN2, MYH9, PRDX1, LASP1, 
ENO1, HSP90AB1, ATXN2, EEF1D, VCL] 
actin filament binding MF 11 9.87E-04 [MYH10, FLNA, EEF2, CFL1, CAPZB, TLN1, ACTN1, ACTN4, MYH9, LASP1, VCL] 
actin bindidng MF 20 1.25E-04 
[PFN1, PLEC, MYH10, MSN, FLNA, EEF2, 
FLNB, CFL1, CAPZB, TPM4, TLN1, S100A4, 
ACTN1, ACTN4, ALDOA, TMSB4X, CALD1, 
MYH9, LASP1, VCL] 
glycolysis Pathways 10 9.38E-10 [ALDOA, ENO1, ENO3, GAPDH, GPI, PFKM, PGAM2, PGK1, PKM, TPI1] 
cytoskeletal regulation by 
Rho GTPases Pathways 8 8.24E-04 
[PFN1, MYH10, STM1, ACTB, TUBB, TUBB2A, 
CFL1, MYH9] 
Parkinson disease Pathways 11 3.76E-06 [SEPT2, HSPA5, PSMB7, HSPA8, PSMA1, SFN, YWHAZ, YWHAB, YWHAE, YWHAQ, YWHAG] 
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Supplementary Table B.7 - Additional dephosphoS655 APP associated protein interactors present only in differentiation day 7 (D7). Proteins were selected based on functional 
annotations directly related to brain development, neuron function, neurogenesis, and/or neuronal differentiation related events (cytoskeleton organization, cell adhesion, and cell 
migration) and signaling pathways. In bold are the UniProt accession number representing newly identified APP interactors. The gene ontology (GO) terms determinant for the selection 
are described in the biological process column. Node degree (‘k’), is the number of interactors the protein presents and refers to the position of the protein inside the protein-protein 
interaction network that includes all the interactors identified for each differentiation day. ‘Ref’, indicates references retrieved from the PubMed supporting the role in neuronal 
differentiation. ‘Mammalian phenotype/human diseases’, KO mouse phenotypes were searched on Jackson Laboratories mouse knockout database, and human diseases retrieved from 
UniProt and other indicated references. ‘Expression’, brain enrichment or altered expression in RA-differentiated SH-SY5Y cells are indicated. ‘Dif.’ – differentiation; ‘Reg.’ – 
regulation; ‘PM’ – plasma membrane. 
Uniprot nr gene name and symbol k Biological Process REF Mammalian Phenotype Expression 
O75955 Flotillin-1; FLOT1 4 
axonogenesis (GO:0007409); positive reg. of synaptic transmission, 
dopaminergic (GO:0032226); ECM disassembly (GO:0022617); 
positive reg. of heterotypic cell-cell adhesion (GO:0034116), of cell-
cell adhesion mediated by cadherin (GO:2000049), and of cell 
adhesion molecule production (GO:0060355); reg. of receptor 
internalization (GO:0002090); reg. of Rho protein (GO:0035023), 
and PKC signaling (GO:0070528); positive reg. of cell junction 
assembly (GO:1901890) 
[1, 2]   
Q9Y490 Talin-1; TLN1 5 
movement of cell or subcellular component (GO:0006928); 
cytoskeletal anchoring at PM (GO:0007016); cell-cell 
(GO:0007043) and cell-substrate (GO:0007044) junction assembly; 
cortical actin cytoskeleton organization (GO:0030866); cell 
adhesion (GO:0007155) 
[3, 4]   
P18206 Vinculin; VCL 3 
axon extension (GO:0048675); movement of cell or subcellular 
component (GO:0006928); cell-matrix adhesion (GO:0007160); 
lamellipodium assembly (GO:0030032); negative reg. of cell 
migration(GO:0030336); adherens junction assembly (GO:0034333) 
[4] 
embryonic lethality during 
organogenesis, complete penetrance; 
incomplete rostral neuropore closure; 
exencephaly;  absent brain ventricles;  
increased embryonic neuroepithelium 
apoptosis [5]. 
 
P07737 Profilin-1; PFN1 2 
actin cytoskeleton organization (GO:0030036); neural tube closure 
(GO:0001843); negative (GO:0030837) and positive (GO:0030838) 
reg. of actin filament polymerization; negative (GO:0032232) and 
positive (GO:0032233) reg. of actin filament bundle assembly; 
positive (GO:0051496) and negative (GO:0051497) reg. of stress 
fiber assembly; Wnt signaling pathway, planar cell polarity pathway 
(GO:0060071); cell-cell adhesion(GO:0098609) 
[6, 7] Amyotrophic lateral sclerosis 18.  
P62328 Thymosin beta-4; TMSB4X 1 
actin filament organization (GO:0007015); reg. of cell migration 
(GO:0030334); actin cytoskeleton organization (GO:0030036); 
sequestering of actin monomers(GO:0042989) 
[8, 9]   
P47756 F-actin-capping protein subunit beta; CAPZB 0 
neuron projection development (GO:0031175); cell projection 
organization (GO:0030030); reg. of cell morphogenesis 
(GO:0022604); actin cytoskeleton organization (GO:0030036); 
barbed-end actin filament capping (GO:0051016); negative reg. of 
MT polymerization (GO:0031115); reg. of PKC signaling 
(GO:0090036); movement of cell or subcellular component 
[10, 11]   
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Uniprot nr gene name and symbol k Biological Process REF Mammalian Phenotype Expression 
(GO:0006928); negative reg. of filopodium assembly (GO:0051490); 
cell-cell adhesion (GO:0098609) 
Q09666 
Neuroblast 
differentiation-
associated protein 
AHNAK; AHNAK 
5 cell-cell adhesion (GO:0098609) - 
increased cell proliferation and 
neuronal differentiation 
in the hippocampal dentate gyrus [12]. 
RA dif SH-SY5Y regulated 
gene [13, 14]. 
P26038 Moesin; MSN 2 
movement of cell or subcellular component (GO:0006928); reg. of 
cell shape (GO:0008360); reg. of cell size (GO:0008361); positive 
reg. of protein localization to early endosome (GO:1902966), and of 
early endosome to late endosome transport (GO:2000643); 
cytoskeleton organization (GO:0007010) 
[15, 16]   
P21333 Filamin-A; FLNA 15 
cell projection organization (GO:0030030); adenylate cyclase-
inhibiting dopamine receptor signaling (GO:0007195); reg. of cell 
migration (GO:0030334); actin cytoskeleton reorganization 
(GO:0031532); cell junction assembly (GO:0034329); negative reg. 
of apoptotic process (GO:0043066); positive reg. of I-kB kinase/NF-
kB signaling(GO:0043123); actin crosslink formation 
(GO:0051764); semaphorin-plexin signaling (GO:0071526); 
positive reg. of substrate adhesion-dependent cell spreading 
(GO:1900026); positive reg. of integrin-mediated signaling 
(GO:2001046) 
[17, 18] 
abnormal brain size [19]; 
Frontometaphyseal dysplasia 1 
(intelectual disability); Periventricular 
nodular heterotopia 1 (abnomal 
neuronal migration). 
 
P16070 CD44 antigen; CD44 3 
cell-matrix adhesion (GO:0007160); ECM 
disassembly(GO:0022617), and organization(GO:0030198); 
positive reg. of heterotypic cell-cell adhesion (GO:0034116); 
negative reg. of apoptotic process (GO:0043066); cellular response 
to FGF (GO:0044344); positive reg. of ERK1 and ERK2 
(GO:0070374) 
[20] abnormal miniature excitatory postsynaptic currents [21]. 
RA dif SH-SY5Y regulated 
gene [13, 14]. 
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General Discussion and Future Perspectives 
The Amyloid precursor protein (APP) is a ubiquitously expressed type 1 transmembrane 
glycoprotein. For long APP was mainly studied for its association with Alzheimer’s disease (AD), 
since it is the precursor protein of the amyloid β-peptide (Aβ), the main component of the senile 
plaques, one of the histopathological hallmarks of this neurodegenerative disease. Nevertheless, 
APP is highly enriched in neurons and has been established as a neuromodulator of developing and 
mature nervous system. Attributed physiological roles include cell adherence, survival, migration, 
differentiation, axon guidance, dendritogenesis, synaptogenesis, and synaptic plasticity. However, 
this protein has proved to be very complex due to its elaborate intracellular trafficking, 
posttranslational modifications (for instance, several phosphorylation sites that modulate APP fate 
and function), proteolytic cleavage (with the production of several bioactive peptides), and the 
existence of multiple protein interactors. Importantly, several of the APP protein interactors are 
highly involved in nervous system related functions, namely neuronal development, synaptic 
signaling, synapse organization, and neuron death. In addition, the APP interactor’s share several 
nervous system diseases and mental disorders with APP. 
The main aim of this thesis was to contribute to the characterization of the APP physiological role 
in the cellular alterations underlying neuronal differentiation events. Particularly, we focused on 
mechanisms mediated by APP, its proteolytic fragment sAPP, and APP phosphorylation at serine 
655. Figure  C.1 schematizes the main findings of the present work. 
 
 
Figure  C.1 - APP S655 phosphorylation and neuronal differentiation mechanism. 
 
We started by establishing a comprehensive model of the neuritogenic-related alterations in RA-
mediated SH-SY5Y neuronal-like differentiation, namely cell morphology and neurite outgrowth, 
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and cytoskeleton related biochemical parameters (especially tubulin acetylation) and APP protein 
levels. The comprehensive analysis of this model pointed to a biphasic temporal differentiation 
response induced by 10 µM RA treatment on SH-SY5Y cells: a first early phase (D0-D4, D4 
excluded), where a sAPP/APP peak assists the emergence of new processes and their elongation 
into neurites; and a second phase (D4-D8) where increased holoAPP protein levels are necessary to 
sustain neuritic elongation and stabilization.  
In this first study, we focused on APP full-length protein levels and medium secreted APP. A more 
complete study could involve further characterization of the levels of additional APP fragments, 
namely C-terminal fragments (CTFs), intracellular domain (AICD), and Aβ with cell 
differentiation. More specifically, it would be very interesting to monitor the production of non-
amyloidogenic pathway-resulting fragments versus the ones resulting from the amyloidogenic 
pathway, potentially in association with expression studies and activity assays of the corresponding 
secretases. It would be also very important to fully address the changes in the different APP 
isoforms with differentiation time, potentially by combination of mRNA expression analysis with 
proteomic studies using specific antibodies.  
The SH-SY5Y cell line was chosen for our studies because it has some advantages when compared 
to other extensively used models, like primary neuronal cells and neural stem cells. Its usefulness 
as an in vitro model relates to its human origin, the cells ability to rapidly divide, to be cultured and 
subcultured for relatively long periods of time, and its comparative low resource requirements. SH-
SY5Y cells are easy to obtain, to grow and manipulate and, importantly, do not involve animal 
sacrifice. Moreover, once clonal-based, they are quite reproducible, exhibit relatively low genetic 
variability between seedings and can be scaled-up to perform a high number of multiple 
simultaneously analyses. The main limitation is that this model only mimics in some extent 
neuronal differentiation events [1, 2]. Nevertheless, it can constitute a useful starting point model to 
screen important players for brain development and disease. In our work this model has been useful 
to distinguish between neuritogenesis and neurite outgrowth/elongation events. 
We used the knowledge gathered during the characterization of the RA-mediated SH-SY5Y 
neuronal-like differentiation to delineate two specific differentiation time points for APP 
modulation. Subsequent work focused on the discovery of potential APP protein effectors and 
regulators involved in neuronal differentiation events, and the role played by a specific APP 
posttranslational modification in the establishment of protein-protein interactions – APP 
phosphorylation at its serine 655. To this end, we used RA-differentiated SH-SY5Y cells for 3 or 7 
days (comprising the two differentiation phases). Cells were transfected with Wt or S655 
phosphomutants APP-GFP cDNAs in the last 24h, and used as the protein pool. The GFPTrap 
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assay was used to immunoprecipitate the specific APP proteins (Wt, S655A, and S655E) and their 
respective interacting partners, which were subsequently identified by mass spectrometry (MS). 
In general, we found a special enrichment in RNA-binding proteins linking APP role in neuronal 
differentiation with regulation of mRNA processing (splicing, decay and translation). These RNA 
regulatory proteins were found for both the phosphoS655 and dephosphoS655 categories, but 
particularly enriched in the latter. The hypothesis that APP can bind different RBPs to modulate 
their function and/or that APP can be part of messenger ribonucleoprotein complexes, influencing 
the cellular fates of different mRNAs is very curious and should be further studied. These aspects 
are very important in neurons where alternative splicing events, and the correct transport, target, 
and local translation of mRNA are determinant for neuronal development (e.g. neuronal polarity) 
and function (e.g. synaptic plasticity) [3].  
The dephosphoS655 APP (S655A) interactome was also enriched in energy metabolism related 
proteins, and in cytoskeleton-related proteins, especially from the actin family, which translated in 
an overrepresentation of functions like cytoskeleton organization, actin and actin filament binding.  
Concordantly, upon 4 days of RA exposure, APP-S655A overexpression could be particularly 
associated with actin depolymerization and cortical actin distribution. The phophoS655 APP 
(S655E) interactome presented a reduced number of protein interactors, when compared to the 
other categories, possibly denoting a higher degree of functional specificity. The phosphoS655 
APP interactome included proteins involved in the regulation of proliferation, survival and 
differentiation, and in various signaling pathways that appear to promote cell fate, neurite 
outgrowth and neuronal maturation. Concordantly, we could demonstrate that overexpression of 
the APP phosphomimetic mutant from differentiation day 6 to day 7 promotes SH-SY5Y neurite 
outgrowth. Although we have detected several functional interesting new APP protein interactors, 
validity of the interactions is imperative. Each new interaction should be demonstrated using 
different assays, preferably including techniques that would allow to distinguish direct protein-
protein interactions. The interpretation of the protein-protein interactions, at this point, can only be 
speculative. Nevertheless, this study allowed to start to characterize the biological/molecular 
context of APP S655 phosphorylation during neuronal-like differentiation, and substantiates the 
hypothesis that this phosphorylation could be acting as a ‘‘biochemical switch’’ changing the 
molecular composition of APP complexes to perform specific functions. The APP-S655 
phosphorylation interactome follow-up studies could be further supplemented with the study of 
transcriptome alterations under the different APP backgrounds [2, 4], and/or with the study of 
overall cell proteome changes [5, 6].  
In line with our main aim, we pursed the APP physiological role in neuronal differentiation by 
characterizing APP relationship with a specific growth-factor signaling pathway – the EGF-EGFR-
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ERK signaling. We showed, for the first time, that APP interacts with the proEGF, and with 
endogenous EGFR in rat cortex lysates. We have also showed that combined APP and EGF have a 
synergistic effect on ERK1/2 activation and on neuronal-like differentiation. The APP ability to 
activate ERK1/2 was further associated with APP phosphorylation at S655, and we collected data 
supporting the involvement of APP and its S655 phosphorylation in the modulation of EGFR 
expression levels and trafficking. All the three APP species tested increased EGFR colocalization 
with the early endocytic marker Rab5, and all increased total EGFR protein levels. Nevertheless, 
we hypothesize that the fate of the increased half-lived EGFR protein may be different: on one 
hand, the APP-S655E phosphomutant presented the highest colocalization of EGFR and APP-GFP, 
the highest increase of EGFR colocalization with Rab5, and increased promotion of ERK 
signaling; on the other hand, the dephosphomimetic mutant APP-S655A increased the presence of 
EGFR in LAMP2-positive vesicles, failed to increase the total level of EGFR phosphorylation, and 
failed to induce ERK1/2 activation. Such results raise the hypothesis that APP-S655E increases 
EGFR residence in the endosomal outer membrane and diverts EGFR from being sorted into 
intraluminal vesicles (ILVs) during multivesicular body (MVB)’s formation, in this way 
contributing to ERK1/2 signaling promotion. Previous work from our lab showed that the APP-
S655E enhanced APP retrieval via retromer (and decreased its lysosomal targeting) [7], and recent 
evidences extended the functions of the retromer complex beyond regulating endosome-to-Golgi 
retrieval to include mediation of the endosome-to-plasma membrane recycling pathway [8]. In this 
direction, we soon plan to test if overexpression of the APP-S655E phosphomutant increases 
EGFR colocalization with the recycling endosome (RE; identified as Rab11 positive vesicles). The 
use of high-resolution imaging techniques (electronic microscopy, or super-resolution light 
microscopy techniques) would be helpful to define if there are specific sorting events occurring at 
the endosome favored by each of the APP S655 mutants. For example, it would help to distinguish 
between the tubular extensions emerging from the outer membranes of the sorting endosomes 
characteristic of recycling events, and the ILVs, from where cargo is generally targeted for 
lysosomal degradation [9]. 
The spatio-temporal distribution of tyrosine kinase receptors along the endosomal system seems to 
be tightly associated to signaling specificity, signaling amplitude and duration. Changing how the 
phosphorylated EGFR is distributed between endosomes can, thus, alter signal properties and lead 
to differential cell responses after exposure to receptor ligands [10]. Our findings that the different 
APP S655 phosphomimetic mutants alter the dynamic of EGFR endocytosis and are associated 
with differential ERK1/2 activation correlates well with such arguments.  
We are currently addressing how the different APP species influence EGFR trafficking after EGF 
stimulation, and we need to further consolidate the effects of APP phosphomutants on EGFR 
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activation. As shown, we tried to perform a first general evaluation of the EGFR phosphorylation 
status using the phos-tag assay. Although results appear to show a differential level of total EGFR 
phosphorylation depending on the APP S655 phosphorylation status, the assay has proven to be 
very difficult to perform and analyze, due to the high molecular weight of the receptor, and we 
recognize a need for validation by a different assay. A simple approach would be to 
immunoprecipitate EGFR and, after SDS-PAGE, probe the immunoblot with an antibody specific 
for tyrosine phosphorylation sites (an indirect measure of the activation of the EGFR tyrosine-
kinase domain). Such approach would further allow to use antibodies against other 
posttranslational modifications, like ubiquitination, that can as well provide important clues 
regarding EGFR fate. A complementary approach could involve flow cytometry studies using an 
EGFR phospho-specific antibody (a first possible residue of choice would be the T1068, previously 
implicated in Ras-ERK1/2 downstream signaling). Flow cytometry would offer the additional 
advantages of distinguish between transfected cells and non-transfected ones, and would allow to 
evaluate the expression levels of the APP-GFP exogenous protein. MS techniques would also allow 
to map phosphorylated residues and to study protein phosphorylation (and other relevant 
posttranslational modifications) patterns [11, 12]. Additionally, MS techniques would allow to 
characterize (at least in part) the “topology”, and possibly the dynamics, of the EGFR signaling 
network elicited by the two APP S655 phosphomutants [13].  
Another interesting point, based on the different percentages of colocalization that we have 
obtained between EGFR and the different APP-GFP species, would be to evaluate if the strength 
(and subcellular location) of the interaction between APP and the EGFR changes with the state of 
APP phosphorylation at S655. EGFR is activated by the formation of ligand-dependent dimers. The 
receptors dimerization, through contacts between the two receptor molecules, allows trans- and 
auto-phosphorylation of tyrosine residues within the cytoplasmic (C-terminal) domain of both 
receptors. The process of dimerization has proven to be very complex, with the formation of homo-
dimers, heterodimers with other EGFR family members, and even heterodimers with other more 
distantly related tyrosine kinase receptors (TKRs). The type of dimers formed has important effects 
on the downstream signaling events due to the distinct adaptor binding profile of each receptor. 
The main mechanisms of receptor dimerization seem to depend on a conformational change that 
exposes the "dimerization arm" located in the extracellular domain of the receptors. Additionally, 
the transmembrane alpha helices of EGFR family receptors which include GxxxG motifs, have 
been implicated in both ligand-dependent and-independent interactions, and it has been proposed 
that such motifs may also facilitate the formation of heterodimers between TKRs [14]. APP 
transmembrane domains can also form homodimers and the interaction is primarily mediated by 
the three consecutive GxxxG motifs, similar to the transmembrane domains of ErbB!receptors (the 
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EGFR protein family) [15]. These transmembrane motifs might also be mediating the APP 
interaction with EGFR, assuming it is a direct interaction. Since APP contains a conserved 
682YENPTY687 cytoplasmic motif similar to nonreceptor tyrosine kinases which may be involved in 
propagating signaling responses, the formation of a functional EGFR:APP dimer, as mentioned 
above for EGFR and other TKRs, is a very attractive hypothesis. The formation of heterodimers 
between TKRs could be also mediated through interactions at the intracellular region [14]. In the 
particular case of the interaction between APP and EGFR, this would also be an attractive 
possibility as it would intuitively explain how the APP phosphorylation at S655 could be 
modulating the strength of such interaction, since this phosphorylation is described to induce 
structural alterations to the APP C-terminus [16]. 
APP shares several protein interactors with the EGFR (as indirectly demonstrated in the previous 
chapters of this work), any of each could be mediating the interaction between both proteins. 
Interestingly, some of these shared interactors can also provide clues on the APP ability to 
modulate EGFR expression levels and trafficking, as the previously discussed interaction with the 
Rab5 effector APPL1 (or DCC-interacting protein 13-alpha); the interaction with Grb2, LRP1, or 
c-Src that could modulate, in turn, the interaction of the ubiquitin-protein ligase CBL with EGFR; 
and the interaction with the deubiquitinating enzyme UCH-L1. There are several other possibilities 
(see Figure  C.2) since APP can be trafficked in the same population of endosomes/MVBs that 
delivers EGFR to the lysosome for degradation, as shown by our results and results from other 
[17]. Based on our results with the APP-S655E phosphomutant, it would be interesting to 
investigate if APP can be also recycled in the same vesicles as EGFR. 
In our APP S655 phosphorylation interactome we detected the protein optineurin (OPTN) as a 
potential APP phosphoS655 exclusive protein interactor (on the earlier differentiation phase, at day 
3). Interestingly, OPTN has been extensively related to membrane trafficking events, namely in 
post-Golgi membrane trafficking to the plasma membrane, membrane trafficking at the RE, and 
lysosome function, especially by its ability to interact with huntingtin, myosin IV, and Rab8 and its 
GTPase-activating protein, TBC1D17 [18-20]. The fact that OPTN is present in the RE, is able to 
bind both Rab8 (a regulator of the endocytic traffic to the RE) and Rab11 (regulator of the transport 
of cargo from the RE to plasma membrane) [21], and the results showing that the interaction 
TBC1D17:OPTN regulates the Rab8-mediated endocytic recycling of transferrin receptor [22], 
provide a molecular hypothesis on how the APP-S655E could be promoting (as we propose) EGFR 
recycling. Noteworthy, OPTN was already implicated in the polarized distribution of EGFR at the 
plasma membrane [23]. 
The biological importance of APP and proEGF should be also pursued, including if APP is also 
able to interact with the mature EGF, and what protein domains are involved in such interactions. 
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There are a considerable amount of evidences showing how EGF affects APP processing, and it 
would be noteworthy to test how APP affects EGF. Since EGF is part of a large family of ligands, 
it would be interesting to also test the ability of APP to interact with other EGF family members. 
Data from our lab shows that APP also interacts with HB-EGF. 
 
Figure  C.2 - APP and EGFR common interactors implicated in intracellular trafficking events. Interactors shared 
by APP and EGFR were retrieved from the HIPPIE database (March 2017). Functional enrichment analysis was 
performed using the Cytoscape app ClueGO, and restricted to p< 0.05. Functional terms of interest to intracellular 
trafficking and the respective proteins were selected. Ontologies' sources included the Reactome and Gene Ontology 
Biological Process. Interactors are represented by their gene symbol (white nodes, grey outlined) and functions by 
coloured nodes. Nodes are configured by size accordingly to degree (low values to small sizes). ESCRT: Endosomal 
Sorting Complex Required for Transport; ER: endoplasmic-reticulum; TGN: trans-Golgi network; MT: microtubules. 
 
Regarding ERK1/2 activation, its involvement in APP-induced neurite outgrowth must be 
confirmed in the presence of a specific inhibitor of the ERK1/2 pathway, like the commonly used 
MEK (mitogen-activated protein kinase kinase or ERK activator kinase) inhibitor and/or under 
knock-down conditions. It should be considered that other upstream effectors could lead to ERK1/2 
activation and/or other signaling pathways could be leading to neurite outgrowth, under the APP 
modulation. For instance, APP has been shown to be a positive modulator of the Wnt-PCP pathway 
required for axonal outgrowth [24], and our lab has gathered evidences that the interaction between 
APP and Gαo can influence neuritogenesis via modulation of the STAT3 and ERK signaling (Dias 
R et al, submitted). 
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During this work, we have faced reproducible problems when translating SH-SY5Y differentiation 
studies to mice cortical primary neurons. While in SH-SY5Y cells APP seems to have a synergistic 
effect with the EGF-EGFR signaling to promote cell differentiation, in cortical primary cultures the 
combination of APP overexpression and EGF stimulation seems detrimental. We are currently 
analyzing data on identical studies using a different growth factor (NGF). Nevertheless, in cortical 
primary neurons we were able to demonstrate that APP overexpression tends to induce increases in 
the number of primary dendrites and dendritic branches, in a S655 phosphorylation-dependent 
manner. The APP-S655A overexpression was always associated with decreased neuronal 
differentiation parameters, while the APPWt overexpression and the phosphomimetic mutant APP-
S655E presented similar neuritogenic results.  
A detailed study of the endogenous APP S655 phosphorylation during neuronal differentiation 
events is, at this point, imperative. This is of most importance since our studies stem from APP 
transient overexpression using cDNAs under the control of a strong promoter, what may induce 
overwhelmed and dysregulated APP processing and/or localization [25], and may also affect 
protein folding and protein interactions [26]. Furthermore, the phosphomimetic mutants generated 
can only mimic to some extent the mechanism of phosphorylation, a biological process that in vivo 
most certainly occurs as dynamic cycles of phosphorylation and dephosphorylation. In addition, a 
phosphate group imposes to the local protein backbone two negative charges and a high electronic 
density, while glutamate has only one negative charge and much less valence electrons [27]. It 
would be important to test how APP phosphorylation levels changes in response to specific known 
neurogenic stimulus, for example EGF, or upon specific insults. An increased APP phosphorylation 
at S655 was previously detected in AD brain lysates [28], a likely result of the deregulation of the 
cellular phosphorylation system that has been reported to occur in AD or a result of a 
compensatory response. The difficulty to study endogenous APP S655 phosphorylation levels 
resides in the absence of a specific anti-phospho-S655 APP antibody. Our studies using the unique 
available commercial antibody failed due to lack of specificity in mice. Although this sequence is 
predicted to have high similarity between species, studies with human cell lines could be further 
conducted. Indeed, using the anti-phospho-S655 APP antibody in WB assays, we were able to 
detect increases in the signal of transfected AICD-DsRed peptides (human AICD sequence), in 
cells exposed to the PKC activator PDBu (data not shown). Endogenous APP S655 
phosphorylation could be also pursued by quantitative mass spectrometry proteomics using for 
instance rodent primary neuronal cultures of different differentiation days, and tissue samples from 
different brain areas of different embryonic stages [29, 30]. Nevertheless, one as to expect that 
transduction signals like phosphorylation could operate in an acute and transient mode or could 
function in low levels that would fail to be detected by even the most sensitive proteomic 
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approaches. If such approach proved to be possible, it would be valuable to detect the levels of 
S655 in relation to other described APP phosphosites like T668, Y682 and Y687 [31]. An indirect 
approach using transgenic knock-in mice for these APP phosphomutants could also be of interest 
[32, 33], and would further allow in vivo behavior and functional studies, or other in vitro detailed 
characterizations of neuronal progenitor’s proliferation, migration and differentiation. Ultimately, it 
would be interesting to test the neuroregenerative potential of the APPS655 phosphorylation in 
specific brain injury models. 
App KO mice are viable and fertile indicating that APP is not essential. Only the combined KO of 
all the APP family members (App/Aplp2/Aplp1 triple KO) or the mice haploinsufficient for Aplp2 
are lethal (during gestation period or early postnatal). Although the described phenotypes for App 
KO mice might be considered, in general, subtle, one should consider that in the human brain a 
lack or a dysfunction of APP might have more dramatic implications. For example, animals with 
higher encephalization, and more specifically humans, have more expanded subventricular zones, 
with higher numbers and diversity of intermediate progenitors, which in turn correlate with 
increased number of neurons and thicker cortical layers [34, 35]. Thus, APP can have 
“expanded”/specific effects in human neuronal differentiation events. Additional differences in 
species should also be considered. A study using species-specific genome scale microarrays to 
compare the protein-coding transcriptome of the aging cerebral cortex in mice, rhesus monkeys, 
and humans showed that a relatively small subset of age-regulated gene expression changes are 
conserved from mouse to man. The study also shows that age-related downregulation of neuronal 
genes has increased dramatically from mouse to man, and might be a particularity of humans [36]. 
Furthermore, humans have unique cognitive processes in which APP might be specifically 
involved. The effects of APP will most probable depend on the brain area/cell type and on the brain 
development and maturation stage. Noteworthy, completion of brain development is only 
accomplished around the 3rd decade of life: axon/dendrite outgrowth and synaptogenesis extend 
into early childhood, while the refinement of synaptic connections and dendritic pruning (and, 
curiously, myelination) can last until the 3rd decade of life. On the other hand, the time-course for 
each neuronal differentiation and maturation event, in the human brain, varies enormously by brain 
region [37]. In humans, the degree of vulnerability of a neuronal system seems to correlate with the 
degree of plasticity throughout life, and the last systems to mature - the ones associated with more 
advanced functions – are also among the first to degenerate in disorders such as Alzheimer’s 
disease [38], and might represent areas where APP can be particularly important.  
The molecular mechanisms of APP might include a role in RBP modulation and alternative 
splicing control, so important for neuronal function, and the regulation of gene transcription. It 
might also include modulation of intracellular signaling pathways: as a receptor, APP could trigger 
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signaling cascades in response to specific stimulus; or APP could be functioning as a co-receptor, 
e.g. for EGFR and other growth factor receptors, for integrin, or for GPCRs; APP can be a 
modulator of intermediate signaling cascade steps, sequestering, blocking, or enhancing different 
signaling players. In addition, APP might be an active player in the endocytic pathway. This last 
aspect is of particular interest, since it can relate well with a role in the modulation of signaling 
pathways, a role in neuritogenesis and neurite outgrowth (membrane trafficking events are 
necessary for the increase of the plasma membrane surface area), and a role in modulation of 
synaptogenesis and synaptic plasticity (for example the regulated addition and removal of synaptic 
receptors at the post-synaptic membrane influences synaptic strength).Several studies show that 
APP has a role in endosomal transport, and that increased gene dose for APP (associated to an 
increase in both APP full-length and βCTFs) leads to endosomal abnormalities and reduces the 
endosomal trafficking and signaling of specific cargo, namely of the nerve growth factor leading to 
degeneration of basal forebrain cholinergic neurons, and of the EGFR [39-42]. Furthermore, a 
dysfunction of the neuronal endocytic system has been identified in the earliest stages of sporadic 
AD, before the onset of dementia and before the formation of plaques and tangles, and in Down's 
syndrome [39-42].   
APP studies were for long centered in Aβ production and in the amyloid cascade hypothesis as the 
AD origins. APP involvement in several other human diseases calls for ponderation of important 
physiological functions carried by APP, including in central nervous system development and 
function. APP has been associated, both with the trajectory of brain development in normal 
conditions, and with neurodevelopmental disorders (like schizophrenia, fragile x syndrome, autism) 
and neurodegenerative disorders associated with aging (like Alzheimer’s disease and Parkinson’s 
disease) [43]. Furthermore, the involvement of APP in adult neurogenesis, axonal outgrowth and 
dendritogenesis during neuronal regeneration after brain injury and disease, has also been pointed 
out [44]. The role of APP in such events most probable includes complex interactions with several 
other, functionally related (and probably functionally redundant), molecules. A dysregulation in the 
interaction networks of such molecules might be the common molecular basis of several nervous 
system diseases and mental disorders [45], and might particularly affect the human brain (including 
specific areas and/or brain circuits). It might also implicate that the treatment of such pathologies 
should involve rescue of an entire network of interacting molecules [46].  
Concluding, with the present work we hope to have advanced the knowledge on the physiological 
role of APP, particularly on the functions it plays on neuronal differentiation when phosphorylated 
on its elusive S655 residue, and hope that this knowledge will help to assist future therapies 
targeting neurological diseases and injury. 
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